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Ovarian cancer can no longer be considered one disease entity, but a heterogeneous group
of diseases. Our understanding of its clinical and molecular complexity is improving nota‐
bly over the last decade. This is of utmost importance when it comes to determine the most
adequate treatment strategy for each individual patient. Despite not being the most frequent
tumor, ovarian cancer has the highest mortality rate amongst gynecological cancers. The ab‐
sence of specific symptoms and the lack of a universally and validated screening strategy
leads to a delayed diagnosis, when the tumor has spread beyond the ovaries. Despite most
patients are diagnosed at advanced stages, aggressive cytoreductive surgery and combina‐
tion chemotherapy is recommended. This therapeutic approach may control the disease for
some time, but a great majority of patients experience relapses within the first two years of
primary treatment. Relapsed ovarian cancer is no longer a curable disease and chemothera‐
py is the mainstay of treatment in that scenario. Ovarian cancer has been traditionally con‐
sidered a chemosensitive tumor. However, the development of resistance to cytotoxics is a
major problem. New molecularly targeted agents are actively being investigated in an at‐
tempt to improve the outcome of this patient population.
Stemmed from the complexity of ovarian cancer, high-scale medical specialization is there‐
fore needed. Ideally, ovarian cancer patients should be treated in tertiary institutions, where
higher volumes of complex cytoreductive procedures are performed. It is likely that a strong
link with a clinical research facility may also derive in benefit for patients, having immediate
access to the latest treatment opportunities within clinical trials. Considerable efforts are al‐
so underway in early diagnosis and identification of new biomarkers that may help in pre‐
dicting response to treatment.
The present book encompasses most of the key aspects pertaining the current of diagnosis
and treatment of ovarian cancer. It is intended to cover topics from clinical epidemiology to
the latest advances in biomarker development and new drugs. The present publication has
counted with the valuable contribution of renowned international experts in the field of
ovarian cancer, to whom I want to express my most sincere gratitude. We hope that our
target readership (general gynecologists, medical oncologists, gynecologic oncologists) will
find this book as a useful and valuable reference in their daily practice.
Ivan Diaz-Padilla, M.D.
Consultant Medical Oncologist
Head, Gynecologic Cancer Program
Centro Integral Oncologico Clara Campal
Hospital Universitario HM Sanchinarro
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1. Introduction
In Canada, ovarian cancer affects 2600 women and 1750 women die annually from this dis‐
ease.[1] The case fatality rate for ovarian cancer is quite high at 0.67 because women usually
present with wide-spread disease. Symptoms of ovarian cancer are non-specific, and there is
no effective screening test which identifies ovarian cancer early, when the cure rate is high‐
est.[2] When patients present with advanced disease, long term survival is elusive and the
goals of care focus on increasing duration of survival and improving quality of life by man‐
aging symptoms of disease.
Ovarian cancer is usually managed with a combination of surgery and chemotherapy. The
role of surgery is to make a histologic diagnosis, determine the extent of disease spread
(staging) and remove as much disease as possible (debulking). The role of chemotherapy is
to reverse the vascular permeability of tumour capillaries, thereby decreasing the presence
of ascites and pleural effusions, and to cause cellular apoptosis of tumour cells, resulting in
disease regression.
Evaluation  of  the  patterns  of  care  provided to  patients  with  ovarian  cancer  in  Ontario,
Canada demonstrated a variety of specialists are involved in the delivery of surgery in‐
cluding gynaecologists, general surgeons and gynaecologic oncologists.[3] The delivery of
chemotherapy can  be  provided by  medical  or  gynaecologic  oncologists.  Surgery  and/or
chemotherapy can be delivered in low, medium or high volume centres in rural or urban
settings and by teaching or non-teaching faculty.[3] This paper addresses the question of
whether  the  context  in  which a  woman receives  care  for  her  ovarian cancer  affects  her
outcome.
© 2013 Elit and Reade; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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2. Quality of care
The focus of this chapter falls within the rubric of quality of care. The Institute of Medicine
has defined quality of care as “the degree to which health services for individuals and popu‐
lations increase the likelihood of desired health outcomes and are consistent with current
professional knowledge”.[4] Good quality means providing patients with appropriate serv‐
ices in a technically competent manner, with good communication, shared decision making
and cultural sensitivity.[4] Quality assurance can be defined as all those planned and sys‐
tematic actions necessary to provide adequate confidence that a product or service will satis‐
fy given requirements for quality.[5]
Donabedian originally coined the phrase quality of care.[6,7] He assessed quality of care by
looking at the triad of structures, processes and outcomes.
Structure attributes describe the physical and organizational settings in which care is pro‐
vided and evaluate whether these characteristics are conducive to the kind of care that can
be expected to improve health and to be acceptable to patients and the community. Evalua‐
tion of the adequacy of facilities, qualifications of medical staff, availability of equipment,
and organizational structure and operations of programs within the institution providing
care fall under the category of structure of care. Often-evaluated structural variables include
the demographic characteristics, training and experience of care providers and the environ‐
ment in which they work. Other structural variables of interest include access to specific
technologies, access to intensive care facilities and nurse-to-patient ratios. The most com‐
monly cited variable used as a surrogate for assessing surgical quality is hospital or physi‐
cian case volume.
Process of care describes the care the patient actually receives and evaluates the degree to
which interventions provided to patients correspond to what is known or believed to be
most effective in improving health. This includes: 1) the patient’s activity in seeking care
and carrying it out, and 2) the practitioner’s activities in making a diagnosis and recom‐
mending and implementing therapy. Whether care is effective can be judged according to
the evidence from good studies demonstrating a link between a particular process (ie., de‐
bulking surgery) and better outcomes (ie., prolonged survival). Process indicators are easily
measured in a timely fashion and can provide actionable feedback for quality improvement
initiatives. Other examples of process variables include guidelines for surgery and use of
care pathways. These variables are usually used in the context of quality assessment audits.
Outcomes are the actual changes in health and wellbeing obtained by patients and com‐
munities, and the degree to which the care provided is acceptable. In other words, outcome
is the effect of care on the health status of patients and populations. This may be improve‐
ment in patient knowledge, behaviour and satisfaction. Endpoints of interest in ovarian can‐
cer could include 30-day peri-operative mortality, overall survival, and quality of life.
Overall survival data takes a long time to mature and it reflects a culmination of many proc‐
esses and structures that have contributed to care. There is currently a strong focus on out‐
comes for patients with ovarian cancer, especially in the context of health care payers
obtaining high quality care for the health care dollars spent.[8]
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To demonstrate the concepts of structure, process and outcomes as ways to measure quality
of care in ovarian cancer, we will review population-based studies published over the last 10
years. We have restricted our scope to population-based studies because they provide out‐
comes for the whole population in a region and avoid biases inherent with single institution
studies (ie., related to socioeconomic status, race or comorbidities). As well, population-
based studies allow us the opportunity to identify where variations in care may lead to su‐
perior outcomes for the population. If these processes and/or structures are incorporated
into practice, they may lead to improved health outcomes.
3. Methods
A systematic search of the published English language literature from Jan 1, 2000 to Jun 29,
2012 was undertaken in order to present an unbiased view of the current population-based
literature in the field of quality of care. Several key articles were identified[9-11] and MeSH
terms from these references were used to create a search strategy for PubMed (Figure 1).
http:/ / www.ncbi.nlm.nih.gov/ entrez/ query.fcgi?CMD=search&term=(genital
neoplasms, 
female[mh]+AND+(th[sh]+OR+su[sh]+OR+rt[sh]+OR+dt[sh]+OR+surgery[tiab]+OR+surgi
cal* [tiab]))+AND+(health planning[mh]+OR+”health care quality, access, and 
evaluation”[mh]+OR+”outcome and process assessment (health 
care)”[mh])+AND+(outcome*[ti]+OR+population*[ti]+OR+treatment 
outcome[majr])+AND+2000:2012[dp]+AND+english[la]&db=PubMed
Figure 1. PubMed search strategy
The search yielded 1178 articles of which 172 were identified as potentially relevant by title
and abstract. To be included the article had to include population-based data collection re‐
lated to primary management of ovarian cancer. The article needed to report on structure or
processes of care in relation to outcomes. Articles were excluded if they were reporting on
screening for ovarian cancer, pre-cancerous or benign conditions; if they were focused solely
on quality of life, biologic therapies, biomarkers and personalized medicine, survivorship or
palliative care. We identified two systematic reviews of quality of care indicators.[12,13]
However, in both cases the authors did not restrict their study inclusion to population-based
reports, therefore these studies are not included in our analysis.
4. Results
The 30 population-based studies in this review represent findings from many high-income
countries, including Australia (1), Canada (3), USA (12), Austria (2), Finland (2), Germany
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(1), Netherlands (3), Norway (1), Switzerland (1), UK (3), and Japan (1). Twenty-five unique
studies report the impact of structure on outcomes, and 13 studies report the impact of vari‐
ous processes on outcomes. Included are 91,866 patients.
4.1. Outcomes
The 5-year overall survival rate is the indicator of most interest to clinicians caring for pa‐
tients with ovarian cancer. Other outcomes of interest include quality of life, patient satisfac‐
tion, and cost. However, when 5-year survival rates are so poor, surrogate outcomes,
including progression-free survival (PFS), can be used to reflect small changes in outcomes
that are important to patients and society. Changes in processes or structures that result in
improved surrogate outcomes should eventually be reflected in improved 5-year survival
rates. Surrogate outcomes in ovarian cancer include PFS and 30 or 60-day mortality.
4.2. Structure
In 25 unique population-based studies of quality of care in ovarian cancer, structural varia‐
bles evaluated include a hospital’s annual ovarian cancer surgical volume, physician annual
ovarian cancer surgical volume, hospital type (university affiliated vs community hospital),
and physician type (gynaecologic oncologist, general gynaecologist, or general surgeon).
These studies are listed in Table 1.
Studies evaluating hospital volume demonstrate hospitals with higher volumes of ovarian
cancer surgery per year are often associated with better long-term survival (Table 2). The
improvement in overall survival did not appear to be a reflection of peri-operative deaths,
because the 30 and 60-day mortality was not affected by hospital volume in the studies eval‐
uating those outcomes. The long-term survival advantage produced by high-volume hospi‐
tals is due to other differences in structures and processes of care in these institutions.
Studies evaluating physician volume did not demonstrate a uniform improvement in sur‐
vival when high-volume physicians operated on patients with ovarian cancer (Table 3).
Findings were inconclusive for both shorter and longer-term survival.
In just over half of the studies identified, hospitals classified as teaching facilities or univer‐
sity hospitals were associated with better short and long-term survival outcomes (Table 4).
Usually these specialized facilities provide access to physicians with expertise in complicat‐
ed gynaecologic oncology surgical procedures necessary for appropriate surgical manage‐
ment of ovarian cancer patients.
Studies evaluating physician specialization usually compare outcomes for patients operated
by gynaecologic oncologists versus general gynaecologists versus general surgeons. Opera‐
tion by a gynaecologic oncologist was associated in most studies with better outcomes in
terms of long-term survival (Table 5). It is likely that general surgeons are more likely to per‐
form emergency surgeries in advanced situations like bowel obstruction. However, the dif‐
ference in outcomes persisted even after adjusting for prognostic factors like the Charlson
comorbidity score.
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Stockton 2000[14] UK Retrospective database 989 Yes
Olaitan 2001[15] UK Prospective cohort 595 n/a
Carney 2002[16] USA Retrospective database 734 Yes
Elit 2002[17] Canada Retrospective database 3,815 Yes
Grossi 2002[18] Australia Retrospective database +
chart review
434 No
Kumpulainen 2002[19] Finland Retrospective database 3,851 Yes
Cress 2003[20] USA Retrospective database 1,088 n/a
Harlan 2003[21] USA Retrospective database 1,167 n/a
Ioka 2004[22] Japan Retrospective database 2,450 Yes
Diaz-Montez 2005[23] USA Retrospective database 2,417 n/a
Bailey 2006[24] UK Prospective cohort 361 No*
Earle 2006[25] USA Retrospective database 3,067 Yes
Elit 2006[11] Canada Retrospective database 2,502 No
Engelen 2006[26] Netherlands Retrospective database +
chart review
632 Yes
Goff 2006 and 2007[27,28] USA Retrospective database 10,432 n/a
Kumpulainen 2006 and
2009[29,30]
Finland Prospective cohort 275 Yes
Oberaigner 2006[31] Austria Retrospective database 911 Yes
Paulsen 2006[32] Norway Prospective registry 198 Yes
Schrag 2006[33] USA Retrospective database 2,952 Yes
Elit 2008[34] Canada Retrospective database 1,341 No
Bristow 2009[35] USA Retrospective database 1,894 Yes
Marth 2009[36] Austria Prospective cohort 1,948 Yes
Vernooij 2009[37] Netherlands Retrospective cohort 1,077 Yes
Mercado 2010[38] USA Retrospective cohort 31,897 Yes
Rochon 2011[39] Germany Prospective cohort 476 No
n/a: not applicable—these studies used surrogate outcomes, *the authors of this study reported it was underpowed
to find an association between structure and survival
Table 1. Studies reporting on structural variables in relation to outcomes for ovarian cancer
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Overall survival 7 3 10
DFS 1 0 1
30-day mortality 0 2 2
60-day mortality 0 1 1
DFS: disease-free survival
Table 2. Relationship between hospital volume and patient outcomes
Outcome Number of studies finding an
association between higher
volume and improved outcomes
Number of studies finding no
association between volume and
outcomes
Total
Survival 1 2 3
30-day mortality 1 2 3
60-day mortality 0 1 1
Table 3. Relationship between physician volume and patient outcomes
Outcomes Number of studies finding an
association between specialized
hospitals and improved outcomes




Overall survival 4 3 7
30-day mortality 1 1 2
Table 4. Relationship between hospital type and patient outcomes








Overall survival 6 3 9
30-day mortality 1 1 2
Table 5. Relationship between physician specialization and patient outcomes
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Several studies have reported a link between structural variables (hospital volume, physi‐
cian volume, hospital type and physician specialization) and outcomes. Population-based
studies  published  over  the  past  ten  years  identify  more  consistent  evidence  linking  in‐
creased hospital volume and increased physician specialization with long-term outcomes
than for  other  structural  variables.  Surgery by a  gynecologic  oncologist  appears  to  pro‐
vide superior outcomes in terms of long term survival. These studies pertain to the sur‐
gical  management  of  patients  with  ovarian  cancer.  The  single  study  looking  at
chemotherapy for  ovarian  cancer  patients  found no  association  between oncologist  vol‐
ume  of  chemotherapy  and  outcomes.[11]  Of  note,  no  study  demonstrated  worse  out‐
comes  with  higher  volumes  or  specialization  of  hospitals  or  physicians.  Some
jurisdictions  have  used  these  findings  to  implement  a  strategy  of  centralization  of  sur‐
gery  for  ovarian  cancer  in  an  effort  to  improve  quality  of  surgical  care  and  outcomes.
[40,41]
There are important limitations in this data. Not all studies were able to obtain individu‐
al data to allow adjustment for every important confounding variable which can impact
survival. The majority of these studies were retrospective or dependant on accurate data-
entry into databases.  It  is  possible some of the advantages observed for type or volume
of provider may be due to more diligent data-entry and documentation of patient demo‐
graphics,  stage and treatment received.  For example,  teaching hospitals  may have more
accurate  and  detailed  documentation  of  the  surgical  procedures  provided  to  patients
which may lead to an assumption that they provided more complete surgical care when
in  fact  the  differences  were  in  documentation only.  The use  of  re-operation as  a  surro‐
gate  outcome  is  questionable  when  discussing  physician  type,  since  more  specialized
physicians are typically the ones making the decision to perform a second operation and
this decision is more likely to occur if the primary surgery was performed by a less spe‐
cialized surgeon.
4.3. Process
Evidence-based guidelines on the surgical care of women with ovarian cancer generally rec‐
ommend hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. In early-stage
disease, staging should be performed, including cytology, peritoneal biopsies, and pelvic
and para-aortic lymphadenectomy. In late-stage disease, debulking should be performed,
including the removal of all macroscopic tumour. This sometimes requires the use of bowel
resection, splenectomy, diaphragmatic and peritoneal stripping.[42-44] Adjuvant or neoad‐
juvant chemotherapy with a combination of a platinum and a taxane agent has been the
standard of care for epithelial ovarian cancers over the past ten years.[45] Appropriate sur‐
gery and chemotherapy have a demonstrated impact on outcomes for ovarian cancer pa‐
tients and represent processes of care indicating quality.
Next we look at whether the processes evaluated in the literature are related to the four
structural variables reported, and whether these impact on survival.
In what Setting Should Women with Ovarian Cancer Receive Care?
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including the removal of all macroscopic tumour. This sometimes requires the use of bowel
resection, splenectomy, diaphragmatic and peritoneal stripping.[42-44] Adjuvant or neoad‐
juvant chemotherapy with a combination of a platinum and a taxane agent has been the
standard of care for epithelial ovarian cancers over the past ten years.[45] Appropriate sur‐
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Number of studies finding an
association between higher volume
and improved processes




Adequate surgery 1 1 2
Optimal debulking 5 1 6
LND 3 0 3
Re-operation 2 0 2
Length of Stay 2 0 2
Complications 0 1 1
Adjuvant chemotherapy 1 0 1
LND: lymph node dissection
Table 6. Relationship between hospital volume and evidence-based processes
Higher hospital volumes of ovarian cancer surgery were associated with better compliance
to process steps in the optimal care of women with ovarian cancer (Table 6). These processes
included: surgery according to guidelines (optimal debulking, lymph node dissection) and
use of adjuvant chemotherapy.
Number of studies finding an
association between higher
volume and improved processes




LND 2 0 2
Optimal debulking 1 0 1
Length of stay 1 0 1
Re-operation 2 0 2
Adjuvant chemotherapy 1 0 1
Complications 0 1 1
Length of Stay 1 0 1
LND: lymph node dissection
Table 7. Relationship between physician volume and evidence-based processes
Surgery by physicians with higher volumes of ovarian cancer surgeries was also associated
with better compliance to process steps such as surgery according to guidelines and use of
adjuvant chemotherapy (Table 7).
Ovarian Cancer - A Clinical and Translational Update10
Number of studies finding an
association between specialized
hospitals and improved processes




Optimal debulking 3 0 3
LND 6 0 6
Re-operation 1 0 1
Adjuvant chemotherapy 5 0 5
LND: lymph node dissection
Table 8. Relationship between hospital type and evidence-based processes
Type of hospital (ie. teaching versus non-teaching, academic versus community) where sur‐
gery for ovarian cancer is performed was clearly associated with more appropriate surgery
and adjuvant chemotherapy in accordance with guidelines (Table 8).








Optimal debulking 6 0 6
LND 5 0 5
Re-operation 3 0 3
Adjuvant chemotherapy 4 0 4
LND: lymph node dissection
Table 9. Relationship between physician specialization and evidence-based processes
Physician specialization (ie., gynaecologic oncologist vs general gynaecologist vs general
surgeon) was also associated with appropriate surgery and adjuvant chemotherapy in ac‐
cordance with guidelines (Table 9).
In  summary,  13  population-based  studies  involving  22,255  patients  across  3  continents
linked processes of care to improved survival. The relationship of important processes of
care with survival is so clear that this work that has led to defining quality indicators for
the  treatment  of  ovarian  cancer  care.  In  Ontario,  Canada,  Gagliardi  and  colleagues[40]
used  the  Delphi  technique  to  define  quality  indicators.  More  recently,  Verleye  and  the
EORTC has defined and set surgical benchmarks for quality care in ovarian cancer (Table
11., Appendix).[46]
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Study Country Data Source Number of
patients
Which process variables affected
survival?
Surgery Chemo
Bailey 2006[24] UK Prospective cohort 361 X
Chan 2008[47] USA Retrospective
database
8,372 X
Elit 2006[11] Canada Retrospective
database
2,502 X X
Elit 2008[34] Canada Retrospective
database
1,341 X X




Fairfield 2010[48] USA Retrospective
database
4,589 X









Maas 2005[50] Netherlands Retrospective
database
1,116 X X
Marth 2009[36] Austria Prospective cohort 1,948 X











Table 10. Studies reporting on process variables in relation to outcomes in ovarian cancer
5. Processes or structures of care that require further evaluation
There are many processes considered by experts to be important in the care of women with
ovarian cancer. These process variables have face validity but have not yet been clearly eval‐
uated for their impact on outcomes in ovarian cancer. Additionally, the organizational struc‐
ture for care provision is a complex construct; it is unclear what components contribute
most positively to outcomes. We wish to focus on three variables that may or may not be
related to survival but may impact treatment and decision making.
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5.1. Pathology assessment
When making a diagnosis of ovarian cancer, the histology may be assessed by a pathologist,
a pathologist with interest and experience in gynaecologic malignancies, or a subspecialist
gynaecologic pathologist. Heatley[53] defines a pathologist as someone who has completed
training and passed the appropriate examinations. A pathologist with a special interest (PSI)
is a general pathologist who takes the lead in a subspecialty area within their department
such as gynaecological pathology, attending meetings of specialist societies, participating in
the appropriate subspecialist external quality assurance scheme, providing specialist opin‐
ions for colleagues in the department, and on occasion, neighbouring departments. A sub‐
specialist pathologist is a pathologist with a special interest but who now, possibly after a
period working as a general pathologist, devotes all or the vast majority of their time to one
area of practice.[53] Subspecialisation leads to standardisation of pathology reports and im‐
proved communication of findings, participation in multidisciplinary tumour board meet‐
ings, enhanced knowledge and standards, decreased turnaround times, quality assurance of
diagnoses, improved quality of resident training, ability to distinguish appropriate variation
from the standard of care, and advancement of academic knowledge through participation
in research.[54]
In gynaecologic oncology, there are several studies reporting up to a 16.9% discrepancy with
the referral diagnosis when a PSI or a subspecialist gynaecologic pathologist provides a re‐
view of the original pathology.[55] In 4.7% -12% of cases there is a change in diagnosis
which has a major therapeutic or prognostic implication.[55-58] Although these findings
were from studies including all gynaecologic malignancies rather than ovarian cancer spe‐
cifically, they demonstrate subspecialist pathology review has an important role to play in
the care of patients with ovarian cancer. Verleye and colleagues[59] found that pathology re‐
ports for ovarian cancer surgery originating from high-volume centres and academic hospi‐
tals are of higher quality than those originating from lower volume or non-academic centres.
The availability of subspecialist gynaecologic pathologists may be one structural aspect of
care in these centres leading to better outcomes. The impact of expert pathology review in
ovarian cancer needs to be evaluated as a process step that could impact survival.
5.2. Multidisciplinary care
Multidisciplinary care is an integrated team-based approach to cancer care where medical
and allied health care professionals consider all relevant treatment options and collabora‐
tively develop an individual treatment and care plan for each patient. Evidence in oncolo‐
gy  suggests  that  multidisciplinary  care  leads  to  improved  survival  and  quality  of  life,
satisfaction with treatment, and mental well-being of clinicians.[60] An important compo‐
nent  of  multidisciplinary care is  availability of  regularly scheduled tumour board meet‐
ings[61] with participation of gynaecologic oncologists, pathologists, radiologists, radiation
and medical oncologists, and allied health professionals with a special interest in care of
gynaecologic  oncology  patients.  Tumour  board  conferencing  in  Auckland City  Hospital
from 2005-2006 led to a 5.9% rate of major changes in patient management.[62] This re‐
sulted from radiologic review (major discrepancy rate 1.4%) and pathology review (major
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discrepancy  rate  of  4.5%)  which  led  to  identification  of  major  diagnostic  discrepancies.
However, they could not quantify how the changes in diagnosis and management might
impact patient outcomes. Santoso did a comparison of the initial gynecologic cancer diag‐
nosis and management plan to the diagnosis and management plan after discussion at a
multidisciplinary tumor board meeting. They showed that 6.9% of cases discussed at tu‐
mor  board  had  changes  made  to  the  diagnosis  or  plan,  and  in  5%  there  were  major
changes in treatment.[63] The most convincing research suggesting care by a multidiscipli‐
nary team is a process that improves outcomes was published by Junor and colleagues us‐
ing  population-based data  from Scotland.  In  a  retrospective  analysis  of  all  533  cases  of
ovarian cancer diagnosed in Scotland in 1987, referral to a multidisciplinary team was one
of five factors significantly associated with improved 5 yr survival after adjusting for pa‐
tient and disease characteristics (hazard ratio 0.60, p<0.001).[64]
5.3. Institutional participation in clinical trials
Several studies have identified clinical trial participation as an institutional marker of quali‐
ty care. In 1994, Stiller published a review of several cancer disease sites and found that
across disease sites, patients treated as part of a clinical trial had better outcomes.[65] du
Bois and colleagues evaluated outcomes in a population-based cohort of patients diagnosed
with ovarian cancer in Germany in 2001.[52] After adjusting for disease stage, patients treat‐
ed in an institution participating in multi-centre clinical trials had improved overall survival
(35 months vs 25 months for patients with stage III-IV ovarian cancer treated at participating
vs non-participating hospitals).[39,52] Notably, patients treated in participating hospitals
had better outcomes even if they were not themselves participating in a trial. Patients treat‐
ed in hospitals participating in trials were more likely to receive care in accordance with
clinical practice guidelines including staging, debulking and combination chemotherapy
where appropriate.[39] Trial participation at an individual patient level may indicate good
performance status that can, in and of itself, lead to better outcomes. However, it appears all
patients treated at hospitals participating in trials may benefit from improved outcomes.
This is likely due to differences in processes of care at these institutions.
6. What does all this mean?
When geographic variation in outcomes exist at a population level, there are opportunities
to assess whether changes in structures or processes of care could improve outcomes. There
have been several strategies to improve outcome. One is to standardize care using evidence-
based guidelines and techniques to optimize processes like a structured care path, whether
in a paper chart or as part of an electronic medical record. Another approach to try to im‐
prove outcomes at a population level has been to centralize care. In some situations where
care requires an experienced surgical team and highly developed perio-operative care, such
as for the surgical management of pancreatic cancer, there is evidence that centralization of
care to high-volume centres decreases 30-mortality.[66] However, not all reports are consis‐
tent with this finding.[67] Another strategy to improve outcomes is to focus on improving
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processes by the involvement of highly regarded opinion leaders providing education. More
consistent improvement in processes of care has been noted using the audit and feedback
system.[68] These approaches have been variously referred to as quality assessment, quality
management quality improvement and knowledge translation. In this paper, we refer to
quality assessment as the audit process whereby performance is measured and compared
with a reference standard. Quality improvement includes the steps taken to actively change
practice to improve adherence to processes and to improve outcomes.
7. Quality assurance and monitoring
Quality assurance and monitoring of outcomes is essential to allow for quality improvement
initiatives. Regions, hospitals, and care providers must understand which outcomes are not
reaching a targeted standard in order to identify structures and processes which may im‐
prove outcomes. Initiatives such as the International Cancer Benchmarking Partnership[69]
have used population-based registry data to identify significant discrepancies in survival for
women with ovarian cancer based on geographic location. Striking differences were ob‐
served, with women in Australia and Canada having significantly longer survival than
women in the UK and Denmark after adjusting for stage.[70]
Measuring the quality of surgical procedures has lagged behind quality-assurance initiatives
in other areas because of the difficulty in identifying parameters to evaluate.[71] Early stud‐
ies suggested operative morbidity and mortality, adequacy of resection, local recurrence and
survival as parameters to measure surgical quality.[71] However several of these factors are
also highly influenced by the use of appropriate adjuvant therapy. Several programs have
now begun systematically tracking outcomes for surgical oncology patients in an effort to
identify areas where quality improvement measures should be implemented.
One such program is the American College of Surgeons (ACS) National Surgical Quality
Improvement Program (NSQIP).[72] This is a nationally validated, multi-specialty, risk-ad‐
justed 30-day outcomes measurement  program which originated in the Veterans Health
Administration in 1991.  Since 2004,  NSQIP has been expanding and now includes more
than 400 hospitals in the US, Canada, Lebanon and the UAE. The aim of the program is to
provide institutions and surgeons with 30-day outcomes which can be used to compare
performance to other institutions.  Risk adjustment incorporates pre-operative comorbidi‐
ties and intra-operative risk factors using hierarchical modelling. Twice per year, institu‐
tions  are  given  a  report  with  their  risk-adjusted  outcomes  in  the  form  of  odds  ratios,
which can be used for  bench-marking.  After  implementation of  NSQIP in 10 Tennessee
hospitals,  significantly  fewer  surgical  site  infections,  failed  grafts  and flaps,  episodes  of
acute  renal  failure,  and prolonged ventilation  of  more  than 48  hours  was  achieved.[73]
The ACS evaluated outcomes across all  participating institutions from 2005 to 2007 and
found 66% of  hospitals  showed improvement  in  30-day mortality  and 82% of  hospitals
achieved a reduction in complications after enrollment in the NSQIP program.[74] These
improvements also led to significant cost savings. The remarkable success of this program
will likely lead to further expansion.
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Quality improvement naturally follows from quality assessment. Review of performance in
terms of adherence to best-practices (processes of care) in a methodologically rigorous and
transparent manner (quality assessment) can lead to improvement in outcomes if interven‐
tions are undertaken to improve areas of weakness in performance. Interventions based on
quality assurance data attempt to improve processes of care in order to improve outcomes.
A framework for quality improvement could include the following steps:[75]
1. Debate and select values and goals that will inform the effort
2. Select a clinical area requiring improvement
3. Select team members
4. Select relevant quality markers for improvement
5. Collect data for selected markers
6. Select and operationalize interventions to achieve improvements in markers
7. Re-evaluate, modify and repeat the steps
The American Society of Clinical Oncology (ASCO) initiated the Quality Oncology Practice
Initiative (QOPI)[76] for US-based Hematology-Oncology practices in order to improve
quality of cancer care by using measurement and feedback and by providing improvement
tools. Processes of care indicative of quality were identified by a group of oncologists using
consensus and clinical practice guidelines.[77] QOPI provides individual care providers
with quality of care benchmarking information twice per year, allowing clinicians to make
improvements within their own practices. Implementation of QOPI and sharing results with
physicians at one academic oncology centre in the US led to significant improvements in
several areas of quality.[78] Although this program is only available to medical oncology
practices in the US, it serves as a good example of how measurement and feedback can lead
to improvement in quality of care.
A quality management program was implemented in one German academic oncology cen‐
tre in 2001 with the aim of improving the quality of surgery provided to patients with ovari‐
an cancer.[79] The components of the quality management system included establishment of
a prospective tumour registry, creation and training of dedicated surgical teams operating
on patients with advanced ovarian cancer, inter-disciplinary surgical care, intra-operative
second opinion by another gynecologic oncologist if the first surgeon did not believe de‐
bulking to microscopic residual disease was attainable, interdisciplinary management of
complications, and quality conferences including assessment and benchmarking of morbidi‐
ty and survival outcomes. This effort, along with a significant increase in the volume of
ovarian cancer surgery performed at this centre over time, led to a significant improvement
in processes and outcomes. Debulking to microscopic residual disease increased from 33%
in 1997-2000, and 47% in 2001-2003, to 62% in 2004-2008. This led to median survival of 26
months for patients treated in 1997-2000, 37 months in 2000-2003 and to 45 months in
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2004-2008 and 5-year survival in 24%, 34% and 36% of patients in the three time periods.
Changes in both structures and processes of care were achieved using this quality manage‐
ment system, leading to improved survival for patients.[79]
A quality improvement program for the surgical care of patients with advanced ovarian
cancer was implemented at the Mayo Clinic using an audit and feedback approach, with the
aim of increasing the proportion of patients debulked to microscopic residual disease.[44] A
surgical complexity score was developed to categorize the aggressiveness of the surgical ap‐
proach.[80] The quality improvement program consisted of weekly conferences where pa‐
tient outcomes and treatment approaches were discussed, confidential benchmarking
allowing individual surgeons to see their rates of complete surgical debulking in compari‐
son to peers, teaching fellows and staff how to perform techniques needed for complete de‐
bulking, and intra-operative mentoring of staff and fellows by surgeons experienced in
advanced procedures. After the quality improvement program was implemented, rates of
debulking to microscopic disease increased from 31% to 43%.
9. Knowledge translation
Knowledge translation is the science of moving knowledge into action.[81] Several studies
across various disciplines in medicine have demonstrated many patients do not receive care
known to improve outcomes.[81,82] One of the first groups to show this in ovarian cancer
was Munstedt and colleagues who found a large proportion of patients treated in Hesse,
Germany between 1997 and 2001 did not receive care recommended in national guidelines.
[83] Knowledge translation aims to bridge the gap between what is known from research,
and implementation of this knowledge in an effort to improve outcomes for patients and ef‐
ficiency for the health care system.[81]
Knowledge translation has been described as a cycle, where a clinical problem is identified
(possibly by quality assurance or monitoring efforts), processes of care are identified from
research to address the problem, these processes are adapted to the local context and any
barriers to implementation are identified and addressed, and the new processes are imple‐
mented. After implementation, adherence to the process is monitored, and final patient out‐
comes are evaluated.[81] Evaluation of outcomes and monitoring of processes may then
identify additional clinical problems. If no evidence-based solution to the problem is identi‐
fied, this leads to a need for additional research. In this way, new research informs clinical
practice, and problems from clinical practice help to identify research priorities.[82]
A major focus of knowledge translation research is finding ways to change clinician and pa‐
tient behaviour given the results of research. Simply publishing new findings in peer-re‐
viewed journals, a method termed ‘diffusion’, is not adequate for wide-spread adoption of
new processes.[84] Other methods that have been investigated include audit and feedback,
[85] educational outreach by local opinion leaders,[86] and clinical decision support and re‐
minder systems which can be integrated into computer-based patient-care platforms.[87]
Audit and feedback, such as the ACS NSQIP or ASCO QOPI programs, are one of the most
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effective methods for behaviour change in clinicians.[68,88] An excellent overview of these
methods has been published by Brouwers and colleagues, who performed a review of sys‐
tematic reviews on knowledge translation interventions used in cancer control.[68] The sci‐
ence of knowledge translation is relatively new. As research methods continue to improve,
strategies are expected to be refined.
Figure 2. Flow diagram for study selection
10. Conclusion
Women with ovarian cancer should be treated in institutions providing high quality care.
Quality of care can be evaluated by examining the processes and structures of care leading
to improved outcomes such as survival and quality of life.
In the US, there is a trend to link reimbursement for hospitals and care providers to clinical
outcomes in an effort to improve quality of care.[72] Because of financial pressures in the
health care system, this trend is expected to continue, since improvement in several metrics
used to identify quality surgical care (such as decreased surgical site infections) can save a
significant amount of money. Whether health systems are achieving value for money can
only be assessed if performance is measured in a systematic way. Tracking outcomes with
the use of population-based registries is an essential component of quality assurance, which
allows for comparison of outcomes across jurisdictions.[71] Identifying variations in out‐
comes can then trigger specific quality improvement initiatives. Knowledge translation is
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the science of moving knowledge into action, and encompasses both quality assurance and
quality improvement. The concepts underlying quality of care are essential information for
health care providers caring for women with ovarian cancer given the current global focus
on outcomes and value for money in health care systems.
Appendix
Early-stage epithelial ovarian cancer -Percent of patients with a suspicious ovarian mass undergoing staging
laparotomy within 1 month after decision to treat or documented clinical or
patient-related reason for delay
-Percent of performed staging laparotomies for an ovarian mass suspected to
be malignant performed through a vertical incision
Percent of performed staging laparotomies in which all of the following
procedures are included: total hysterectomy, bilateral salpingo-oophorectomy,
cytology of the peritoneal cavity, infracolic omentectomy, random peritoneal
biopsies and systematic pelvic and para-aortic lymphadenectomy if medium or
high risk features
Percent of surgery reports with documented presence or absence of cyst
rupture before or during surgery
Percent of surgery reports with documented presence or absence of dense
adhesions, percent of dense adhesions biopsied
Primary debulking surgery in
advanced-stage epithelial ovarian
cancer
Percent of patients with advanced-stage ovarian cancer undergoing debulking
laparotomy within 31 days after decision to treat or documented clinical or
patient-related reason for delay
Percent of patients undergoing debulking surgery with the spread of disease
fully assessed for operability at the start of study and initial findings
documented in the operation notes
Percent of debulking operations including a hysterectomy, bilateral salpingo-
oophorectomy and infracolic omentectomy when the surgeon considers
optimal debulking feasible
Percent of debulking operations for advanced ovarian cancer at the end of
which complete cytoreduction, defined as no macroscopic residual disease at
the end of the operation, was achieved
Percent of debulking operations including a pelvic and para-aortic
lymphadenectomy when otherwise complete debulking has been achieved
percent of debulking operations for which the size and location of residual
disease at the end of the operation is documented in the operation notes
Table 11. EORTC benchmarks for quality surgical care in ovarian cancer[46]
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1. Introduction
The past two decades have witnessed an unprecedented level of attention devoted to the as‐
sessment of Quality of Life (QOL) in cancer patients. This is a result of a major change that
occurred in the way cancer management and its impact has been understood and practiced.
Contrary to earlier views, which focused primarily on prolonging the quantity of life of the
patient, cancer management recognizes now the potential effects of the diagnosis and treat‐
ment on the overall functioning and well-being of the patient. QOL issues and its measure‐
ment became particularly important in oncology throughout the different phases of the
cancer trajectory. In this context, the National Cancer Institute (NCI) has recommended that
cancer research focus on both survival and QOL [1]. Many instruments have been devel‐
oped and used in clinical and research settings. It is noteworthy the inclusion of QOL as one
of the main endpoints in important randomized clinical trials [2]. The benefits of studying
QOL outcomes are evident. Primarily, QOL measurement has the potential to provide infor‐
mation to guide clinical decision making [3]. The knowledge about the impact of the illness
and its treatment on cancer patients can help clinicians and patients to make decisions re‐
garding treatment options and choose appropriate supportive therapy adjusted to the pa‐
tient's needs. The toxicity and tolerability of a given treatment can be as important as its
efficacy, as is the ability to help decrease or prevent associated toxicities that have a negative
impact on QOL [4]. Furthermore, QOL data can foster patient-clinician interactions in rou‐
tine practice, identify problems that have a significant impact on QOL, prioritize problems,
develop interventions to deal with these problems and evaluate the impact of palliative and
rehabilitative efforts [5]. Additionally, it can help to shape public policy and health care de‐
cisions made by governmental and private institutions [6] and allow the economic evalua‐
tion of healthcare provision [7].
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When considering ovarian cancer in particular, researchers follow the general trend by re‐
garding QOL as one of the most important outcomes. Several reasons make the study of
QOL in ovarian cancer patients especially worthy and relevant. First, ovarian cancer is an
aggressive illness which is associated with very poor survival and high recurrence rates. It is
the most fatal malignancy of the female genital tract and the fourth most common cause of
female cancer death [8]. Generally, it is detected at an advance stage, with a 5-year survival
rate of 46% for all the stages and 31% for advanced stages [8]. The management of ovarian
cancer normally includes radical pelvic surgery and multiple aggressive courses of chemo‐
therapy. The stress of receiving the diagnosis of such an aggressive and life threatening ill‐
ness, which can be unexpected for many women, may be associated with uncertainty and
anxiety about the future. This may be regarded as an immediate threat to a woman's life and
an associated fear of death. Additionally, women may suffer disease-related symptoms,
which may be very difficult to cope with. These include weight loss, bloating and ascites,
fatigue and pain. Women may also experience a wide range of sequalae related to their
treatment that do not dissipate with time and may persist for a long-term period [9, 10]. Ex‐
amples include neutropenia, body distortion, hair loss, bowel and bladder incontinence, loss
of taste and appetite, premature menopause, infertility, decrease physical functioning, poor
sleep, edema and sexual problems [9, 10]. Another burden involves the amount of time
spend in treatments that is lost from family and work [11]. Second, research carried out, spe‐
cifically, with ovarian cancer patients has shown that a substantial proportion of women ex‐
perience psychological disorders. Anxiety, depression [9, 12-16] and Post-Traumatic Stress
Disorder (PTSD) [17] have been found among different studies. Reports have also highlight‐
ed the occurrence of impairments in physical, vocational, social, familial and sexual func‐
tioning. Those are not confined to the diagnosis and treatment periods, but have been also
observed in short and long-term ovarian cancer survivors. Lastly, advances in Medicine fu‐
elled the development of new treatments for ovarian cancer. However, these treatments
have associated side-effects and toxicities that may impact on the QOL of the women. There‐
fore, when considering a treatment plan, risks and benefits must be balanced in order to
achieve an optimal QOL [11]. Improvements in survival in ovarian cancer have been rela‐
tively reduced [18]. The ability of chemotherapeutic regimens in slowing the progression of
disease to prolong life with active disease has been responsible for those improvements in
survival [19]. Undoubtedly, QOL is a fundamental consideration for patients with ovarian
cancer.
This chapter addresses the most recent knowledge regarding the impact of the treatment
on QOL of ovarian cancer patients. Additionally, QOL in ovarian cancer survivors is al‐
so discussed.
2. Quality of life: Brief overview
Central to this particular subject, is the question: What is QOL? Although, it is somehow
consensual by the clinical and research communities the importance of studying QOL, it is
much less consensual what exactly QOL means. This lack of consensus fuels the appearance
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of different definitions and, inevitably, means of measurement. This makes difficult the
comparison of findings among studies and to establish more definite conclusions. Issues of
definition and measurement continue to be, in fact, the subject of ongoing debate. Despite
lack of consensus in its definition, it is widely accepted that QOL is a multidimensional con‐
struct that includes several important dimensions (any area of behavior or experience) [4, 7,
20, 21]. These encompass physical functioning (physical well-being, mobility, ability to per‐
form self-care activities, physical activities, role activities such as work or housework, appe‐
tite, comorbidities, fatigue/sleep, symptoms, side-effects), cognitive and psychological
functioning (emotional well-being, anxiety, depression, coping, perceptions, prior experi‐
ence, enjoyment, optimism), social functioning (family interactions, time with friends, lei‐
sure activities), disease and treatment related symptoms (such as pain and fatigue), spiritual
or existential concerns, sexual functioning, body image, patient's satisfaction with health
care, control of the disease [7, 21]. According to the WHO [22], QOL is defined as 'an indi‐
vidual's perception of their position in life in the context of the culture and value systems in
which they live and in relation to their goals, expectations, standards and concerns. It is a
broad ranging concept affected in a complex way by the person's physical health, psycho‐
logical state, level of independence, social relationships, and their relationships to salient
features of their environment". Following these lines, QOL includes all aspects of the indi‐
vidual well-being and must be evaluated from the individual's perspective.
When QOL is considered in the context of health, it is often referred to as health-related
QOL (HRQOL). HRQOL is a more specific concept, which reflects the effect of the illness
and illness treatment on general well-being. Bowling defined HRQOL as ‘optimum levels
of mental,  physical,  role (e.g.  work, parent,  career,  etc) and social functioning, including
relationships, and perceptions of health, fitness, life satisfaction and well-being. It should
also  include  some assessment  of  patient´s  level  of  satisfaction  with  treatment,  outcome
and health status and with future prospects.  It  is  distinct  from QOL as a whole,  which
would also include adequacy of housing, income and perceptions of immediate environ‐
ment’ [23]. HRQOL is a dynamic concept, as health status deteriorates, experiences, roles
and  relationships  change  [24].  Furthermore,  It  may  be  modified  by  impairments,  func‐
tional  status,  perceptions,  and  social  opportunities  and  may  be  influenced  by  disease,
treatment, and policy [25].
Particularly in ovarian cancer literature, the term QOL is much more extensively used in‐
stead of HRQOL. In general, QOL assessment in ovarian cancer patients has been focusing
more on the acute phase of the treatment. Of interest is the evaluation of QOL under treat‐
ment conditions in randomized clinical trials, focusing on different treatment options. The
measurement of QOL in screening and early diagnosis of ovarian cancer is very scarce. It of
note that, in fact, screening and early detection of ovarian cancer are very limited in clinical
practice, existing narrow useful technologies to assist in early diagnosis. The majority of the
QOL measurement in ovarian cancer screening evaluates populations at high risk, such as
women with genetic mutations undergoing risk-reducing salpingo-oophorectomy [26].
However, for individuals undergoing risk-reducing salpingo-oophorectomy, screening is
more a process of early detection or diagnosis rather than a true screening test [26]. Regard‐
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ing survivorship, recently, there is a growing interest in the study of QOL in ovarian cancer
survivors. The following section focuses on the instruments designed to capture QOL that
are more commonly used in this specific population.
3. Measurement of QOL in patients with ovarian cancer
Many instruments have been developed and validated to capture important QOL issues in
cancer patients. These instruments comprise four main groups: generic measures of QOL
(used to assess non-cancer medical patients), cancer condition-specific (used in general can‐
cer populations), cancer site and treatment-specific instruments. QOL measures are often
supplemented by questionnaires designed to evaluate specific dimensions of QOL, for ex‐
ample depression. The use of generic questionnaires allows comparisons of QOL among
conditions [7]; however, they lack specificity necessary to understand particular problems
inherent to a specific condition, such as cancer. This specificity can be found when disease –
and site-specific instruments are used. These are more likely to be responsive to change but
are not comprehensive [7]. The Medical Outcome Study (Short Form) MOS SF-36 [27] is an
example of a QOL generic instrument used in oncology. The European Organization for Re‐
search and Treatment of Cancer QOL Core Questionnaire (EORTC QOL-C30) [28] and the
Functional Assessment of Cancer Therapy – General (FACT-G) [20] are examples of condi‐
tion (cancer) specific instruments. All are self-administered questionnaires, multidimension‐
al, relatively brief, acceptable to patients and have good psychometric properties [7]. The
EORTC QOL-C30 and the FACT-G comprise ovarian cancer modules that constitute exam‐
ples of site specific QOL instruments.
Particularly in ovarian cancer, the most commonly used measures are the EORTC QOL-C30
and the FACT-G [18]. The EORTC QOL-C30 and the FACT-G have a similar format: a core
QOL questionnaire applicable to cancer patients in general and specific modules, applicable
to specific cancer sites. These instruments have been developed primarily from research en‐
vironments; however, they will be extremely helpful if they assist physicians in detecting
clinically significant differences or changes in a patient condition.
3.1. EORTC QOL-C30
This cancer-specific questionnaire was developed by the Study Group on Quality of Life
from the European Organization for Research on Treatment of Cancer comprising a core set
of questions applicable to all cancer patients and modules to be used to specific cancer sides,
such as ovarian cancer [28, 29]. This instrument was designed to be used in international
randomized clinical trials. It is based on a multidimensional model of QOL, covering cancer-
specific symptoms of the disease, psychological distress, treatment side-effects, social inter‐
action, physical functioning, body image, sexuality, global health and QOL, and satisfaction
with medical care. The core QOL instrument is composed by 30 items, comprising nine
scales of QOL: one global QOL scale (2 items), five functional scales (physical functioning,
role functioning, cognitive functioning, emotional functioning, social functioning) (15 iems),
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three symptom scales (fatigue, pain, nausea and vomiting) (7 items), and six single items,
assessing additional symptoms commonly reported by cancer patients (breathlessness, diffi‐
culty sleeping, appetite loss, constipation, diarrhea, and financial difficulties). Each scale is
scored separately. Seven questions have a dichotomous yes/no response. For the two global
QOL items, respondents have to answer by using a 7-point scale, where '1 = very poor' and
'7 = excellent'. The remaining questions have a four-point Likert scale, ranging from '1 = Not
at all' to '4 = Very much'. No timeframe is specified in the seven dichotomous questions. In
the remaining questions, the patient has to answer according to the past week. Each dimen‐
sion score for each patient is the sum of that patient's item responses for that dimension,
transformed, so that the minimum possible value is zero and the maximum possible value is
100. Each scale has a limited set of possible values, determined by the number of items and
the range of response options for each item. For the functional scales and the global QOL
scale, a higher score corresponds to a better QOL. For the symptom scales and the single
items, a higher score indicates more frequent and/or intense symptom experience and thus a
lower QOL. Finally, there are two items that ask respondents to rate their overall physical
condition. The EORTC QOL-C30 has established reliability and validity [28]. This scale is
easy to complete, acceptable to patients and has been translated into several languages. The
EORTC QOL-OV28 is the ovarian cancer module designed to supplement the EORTC QOL-
C30, for the assessment of QOL in ovarian cancer patients in clinical trials and related stud‐
ies. It consists of 7 subscales and a total of 28 items, which assess abdominal symptoms
(abdominal pain, feeling bloated, clothes too tight, changed bowel habit, flatulence, fullness
when eating, indigestion), peripheral neuropathy (tingling, numbness, and weakness), other
chemotherapy related side effects (hair loss and upset by hair loss, taste change, muscle
pain, hearing problem, urinary frequency, and skin problem), hormonal/menopausal symp‐
toms (hot flushes and night sweat), body image (less attractive, dissatisfied with body), atti‐
tude to disease and treatment (disease burden, treatment burden, and worry about future)
and sexual functioning (interest in sex, sexual activity, enjoyment of sex and dry vagina) [29,
30]. Each scale is scored separately. For symptom scales, a higher score means a lower QOL,
while for function scales, such as body image and sexual function, a higher score means a
better QOL. The EORTC QOL-OV28 is a valid and reliable measure to be used in ovarian
cancer populations [30].
3.2. FACT-G
The FACT-G was developed by Cella et al to evaluate QOL in oncology settings [20]. This is
the core scale of the instrument system and consists of four dimensions, comprising a total
of 27 items. The dimensions include functional well-being (7 questions), emotional well-be‐
ing (6 questions), social/family well-being (7 questions) and physical well-being (7 ques‐
tions). These four dimensions can be analyzed separately or aggregated to produce a total
QOL score. Response categories for all items range from 0 (not at all) to 4 (very much).
Higher scores are associated with increased satisfaction with QOL. The timeframe for this
instrument is the past 7 days. FACT-G is tested and validated in large international samples,
showing reliability, validity and responsiveness to change over time [20]. This instrument is
commonly used in ovarian cancer clinical trials and it is available in many languages. The
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ing survivorship, recently, there is a growing interest in the study of QOL in ovarian cancer
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three symptom scales (fatigue, pain, nausea and vomiting) (7 items), and six single items,
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toms (hot flushes and night sweat), body image (less attractive, dissatisfied with body), atti‐
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30]. Each scale is scored separately. For symptom scales, a higher score means a lower QOL,
while for function scales, such as body image and sexual function, a higher score means a
better QOL. The EORTC QOL-OV28 is a valid and reliable measure to be used in ovarian
cancer populations [30].
3.2. FACT-G
The FACT-G was developed by Cella et al to evaluate QOL in oncology settings [20]. This is
the core scale of the instrument system and consists of four dimensions, comprising a total
of 27 items. The dimensions include functional well-being (7 questions), emotional well-be‐
ing (6 questions), social/family well-being (7 questions) and physical well-being (7 ques‐
tions). These four dimensions can be analyzed separately or aggregated to produce a total
QOL score. Response categories for all items range from 0 (not at all) to 4 (very much).
Higher scores are associated with increased satisfaction with QOL. The timeframe for this
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supplement of the FACT-G with a set of twelve items specific to ovarian cancer is referred as
the Functional Assessment of Cancer Therapy – Ovarian (FACT-O). Items include stomach
swelling, losing weight, bowels control, vomiting, hair loss, appetite, appearance, getting
around, feeling like a woman, stomach cramping, interest in sex and concerns about ability
to have children. The ovarian cancer specific subscale assesses severity of problems that can
be targeted by proper disease management. The FACT-O is a valid instrument to be used in
ovarian cancer patients [31]. This questionnaire has been commonly used in clinical trials
and other descriptive studies. The FACT-O can be used alone or in combination with other
scales or subscales of the FACT, such as the FACT/GOG neurotoxicity subscale, or the Ane‐
mia (FACT-An) or Fatigue (FACT-F) subscale, if the research interest is these specific issues.
The physical well-being and the functional well-being scales of the FACT-G plus the ovarian
cancer subscale can be combined to represent the Trial Outcome Index (TOI). This index has
excellent psychometric properties [31].
4. Quality of life in ovarian cancer patients
How is the QOL of ovarian cancer patients? Do patients with ovarian cancer experience a
good QOL? These are questions that researchers have been attempting to answer in the
many studies available dedicated to this subject. The number of studies carried out in‐
creased significantly in recent years [18], and collectively, these studies captured ongoing is‐
sues and concerns resulting from the ovarian cancer diagnosis and treatment [9]. However,
there is a difficulty in drawing definite conclusions to answer the above questions. This is
due to the lack of consistency in the types and format of QOL data collected in ovarian can‐
cer patients [18]. The accumulated knowledge about QOL issues in patients undergoing
treatment and in survivors of ovarian cancer is presented below.
4.1. QOL during ovarian cancer treatment
The management of ovarian cancer generally requires a multimodal approach. Surgery has
always been the cornerstone, which plays an essential role in both diagnosis and treatment.
The aim of which is to leave no residual deposits greater than 1–2 cm in diameter. In cases of
apparent early stage disease, proper surgical management involves comprehensive surgical
staging. Advanced-stage disease frequently requires aggressive surgical debulking [32]. The
standard approach is to follow surgery by either intravenous or intraperitoneal chemothera‐
py. Two classes of cytotoxic components, the plantinums and the taxanes are key compo‐
nents of chemotherapeutic regimens for advanced disease [33]. Both treatment modalities
can impact negatively on the QOL of patients [34]. In recurrent disease, a variety of treat‐
ment regimens are used, including re-treatment with a platinum and/or taxane agent, and
second line agents such as liposomal doxorubicin, topotecan, and gemcitabine. Chemothera‐
py side effects may be temporary (e.g. hair loss, nausea and vomiting) or cumulative and/or
permanent (e.g. fatigue, neurotoxicity) [34].
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It is paramount to understand how ovarian cancer and its treatment may disrupt the overall
well-being and QOL of patients. A recent systematic review and meta-analysis, carried out
to assess and summarize QOL data before, during and after chemotherapy among ovarian
cancer patients, found that baseline QOL may significantly improve, particularly after com‐
pletion of chemotherapy treatment [18]. Authors identified a total of 139 studies; of those, 48
were randomized clinical trials. However, it was only possible to synthesize data from a
subset of studies, due to inconsistencies in the way the data was reported across studies.
Pooled data showed that QOL as measured by the EORTC QOL C-30 was found to improve
during the treatment period and ovarian cancer specific concerns as measured by the FACT-
O subscale, were improved during the treatment period [18]. The EORTC QOL C-30, FACT-
G and FACT-O found significant improvements in QOL after completion of primary
therapy, despite the lack of measurable improvements during treatment as measured by the
FACT-G [18]. Following these lines, a recent longitudinal study evaluated the course of
QOL, depressive symptoms, anxiety symptoms and fatigue over the course of chemothera‐
py until 6 months follow-up [35]. Results demonstrated a significant improvement of QOL,
as measured by the EORTC QOL C-30 and EORTC QOL OV-28, from the start of chemother‐
apy and post-surgery period (QOL was severely impaired and high levels of anxiety symp‐
toms, depressive symptoms and fatigue were found), until after care (symptoms reach
nearly general population symptom levels). Although, this was a small study of 23 patients,
it highlighted the importance of understanding QOL over the course of treatment [35]. Simi‐
lar results were obtained by other investigators, reporting improvements of QOL in ovarian
cancer during chemotherapy until one year follow-up. Von Gruenigen et al [36] in a sample
of 42 ovarian cancer patients found that QOL, as measured by the FACT-G and SF-36, mark‐
edly decreased after surgery with a slow improvement during adjuvant chemotherapy,
mainly in the physical, functional and fatigue domains. Physical functioning decreased dur‐
ing chemotherapy but increased to perioperative levels following treatment. Functional
well-being increased following chemotherapy, while emotional and social scores did not
change over time [36]. Collectively, these findings highlight that, in addition to chemothera‐
peutic treatments, surgery may have a negative impact on QOL. Although several factors
may influence this impact, tumour stage, and therefore, the extent of the surgical interven‐
tion and the existence of intra – or postoperative complications may be crucial [35]. Minig et
al [37] found in a study of 181 women with gynaecological cancers, of which 116 had ovari‐
an cancer, that postoperative complications, surgical complexity, advanced stage were asso‐
ciated with lower levels of postsurgical QOL specifically in ovarian cancer patients. The
strongest predictor of postsurgical QOL was preoperative QOL, closely followed by surgical
complications. Investigators stressed that postoperative complications may be difficult to
avoid due to the aggressiveness of the surgery performed in order to achieve maximum cy‐
toreduction in ovarian cancer; however, attention needs to be paid intraoperatively and
postoperatively to the early detection of complications to optimize QOL whenever possible
in this group of patients [37]. Consequences of surgery are well documented, including loss
of fertility, sexual dysfunction, surgical menopause and bowel obstruction. For women at re‐
productive age, premature menopause and loss of fertility may be devastating [34].
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many studies available dedicated to this subject. The number of studies carried out in‐
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sues and concerns resulting from the ovarian cancer diagnosis and treatment [9]. However,
there is a difficulty in drawing definite conclusions to answer the above questions. This is
due to the lack of consistency in the types and format of QOL data collected in ovarian can‐
cer patients [18]. The accumulated knowledge about QOL issues in patients undergoing
treatment and in survivors of ovarian cancer is presented below.
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The management of ovarian cancer generally requires a multimodal approach. Surgery has
always been the cornerstone, which plays an essential role in both diagnosis and treatment.
The aim of which is to leave no residual deposits greater than 1–2 cm in diameter. In cases of
apparent early stage disease, proper surgical management involves comprehensive surgical
staging. Advanced-stage disease frequently requires aggressive surgical debulking [32]. The
standard approach is to follow surgery by either intravenous or intraperitoneal chemothera‐
py. Two classes of cytotoxic components, the plantinums and the taxanes are key compo‐
nents of chemotherapeutic regimens for advanced disease [33]. Both treatment modalities
can impact negatively on the QOL of patients [34]. In recurrent disease, a variety of treat‐
ment regimens are used, including re-treatment with a platinum and/or taxane agent, and
second line agents such as liposomal doxorubicin, topotecan, and gemcitabine. Chemothera‐
py side effects may be temporary (e.g. hair loss, nausea and vomiting) or cumulative and/or
permanent (e.g. fatigue, neurotoxicity) [34].
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apy and post-surgery period (QOL was severely impaired and high levels of anxiety symp‐
toms, depressive symptoms and fatigue were found), until after care (symptoms reach
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it highlighted the importance of understanding QOL over the course of treatment [35]. Simi‐
lar results were obtained by other investigators, reporting improvements of QOL in ovarian
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edly decreased after surgery with a slow improvement during adjuvant chemotherapy,
mainly in the physical, functional and fatigue domains. Physical functioning decreased dur‐
ing chemotherapy but increased to perioperative levels following treatment. Functional
well-being increased following chemotherapy, while emotional and social scores did not
change over time [36]. Collectively, these findings highlight that, in addition to chemothera‐
peutic treatments, surgery may have a negative impact on QOL. Although several factors
may influence this impact, tumour stage, and therefore, the extent of the surgical interven‐
tion and the existence of intra – or postoperative complications may be crucial [35]. Minig et
al [37] found in a study of 181 women with gynaecological cancers, of which 116 had ovari‐
an cancer, that postoperative complications, surgical complexity, advanced stage were asso‐
ciated with lower levels of postsurgical QOL specifically in ovarian cancer patients. The
strongest predictor of postsurgical QOL was preoperative QOL, closely followed by surgical
complications. Investigators stressed that postoperative complications may be difficult to
avoid due to the aggressiveness of the surgery performed in order to achieve maximum cy‐
toreduction in ovarian cancer; however, attention needs to be paid intraoperatively and
postoperatively to the early detection of complications to optimize QOL whenever possible
in this group of patients [37]. Consequences of surgery are well documented, including loss
of fertility, sexual dysfunction, surgical menopause and bowel obstruction. For women at re‐
productive age, premature menopause and loss of fertility may be devastating [34].
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Several clinical trials evaluating ovarian cancer treatments have been carried out, in which
QOL is one of the outcomes evaluated. Table 1 describes recent clinical trials that have in‐
cluded QOL as an outcome. QOL measurement in clinical trials has been useful to argue in
favor or against novel therapies. Furthermore, there is some evidence demonstrating that
QOL is a prognostic indicator for treatment outcomes [26] and future survival [38-41].
Study Comparison Group QOL measures QOL findings
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disease
EORTC QOL-C30 QOL decreased shorter in
the early treatment arm;
significant disadvantages in
role, emotional, social and
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Table 1. Some recent clinical trials that have included QOL as an outcome
The aggressiveness of  treatments  in advanced ovarian cancer patients  place more atten‐
tion upon their QOL than patients diagnosed at an early stage. Several randomized clini‐
cal trials have been conducted in the first-line treatment of ovarian cancer. Clinical trials
focus in important issues concerning the combination of surgery and chemotherapy, the
identification of new targeted therapeutics and the route and timing of chemotherapy ad‐
ministration  [48].  Paclitaxel  in  combination  with  a  platinum compound is  considered  a
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standard care as first-line chemotherapy for advanced ovarian cancer. However, paclitax‐
el  is  associated  with  several  toxicities  (e.g.  anemia,  thrombocytopenia)  that  overlap  the
toxicities of the plantinums, and the co-administration of paclitaxel and a platinum com‐
pound can potentially  increase  the  frequency and/or  severity  of  shared toxicities.  By it‐
self,  paclitaxel  is  associated  with  peripheral  neuropathy  that  can  add  to  the  disease
burden of the patient [4].  Therefore,  studies have been conducted to find the least toxic
combination of medications used in chemotherapy in order to improve treatment tolera‐
bility and QOL [49]. For example, a Phase III Trial conducted by the Scotish Gynaecolog‐
ical  Cancer  Trials  Group  (SCOTROC  Trial),  which  included  1077  patients,  compared
carboplatin  docetaxel  with  carboplatin  paclitaxel  for  first  line  therapy.  Results  demon‐
strated  a  clear  advantage  for  docetaxel  in  terms  of  neurotoxicity  [43].  Concurrent  with
the  developments  in  intravenous  treatment,  intraperitoneal  treatment  has  also  been
shown  a  valuable  strategy.  The  Gynecologic  Oncology  Group  published  data  from  the
GOG  randomized  phase  III  trial  (GOG  172)  pertaining  QOL  outcomes  associated  with
the use of  intravenous paclitaxel  plus intraperitoneal  cisplatin plus paclitaxel,  versus in‐
travenous  paclitaxel  plus  cisplatin,  for  advanced  stage  cancer  [42].  This  was  the  first
Phase III GOG ovarian cancer that proposed a change in route for the administration of
front-line  chemotherapy.  In  the  intraperitoneal  arm,  overall  survival  was  improved  by
approximately  16  months;  however,  during  active  treatment,  patients  reported  more
QOL disruptions, abdominal discomfort and neurotoxicity compared to those patients re‐
ceiving  conventional  intravenous  chemotherapy.  However,  only  neurotoxicity  remained
significantly higher for patients in the intraperitoneal arm 12 months post-treatment. Fu‐
ture studies to lessen the added burden associated with intraperitoneal therapy are going
[42].  Recently,  Vergote  et  al.  [44]  reported  the  results  of  a  Gynaecologic  Cancer  Inter‐
group Collaboration Trial which compared upfront debulking followed by chemotherapy
to neoadjuvant chemotherapy. This was the first  randomized Phase III  Trial  of neoadju‐
vant chemotherapy in ovarian cancer using QOL as an endpoint. The two groups report‐
ed similar survival outcomes. QOL scores did not differ among the two groups [44].
The majority of ovarian cancer patients will eventually relapse. In fact, it is not uncommon
for ovarian cancer patients to undergo numerous chemotherapeutics treatments. In this con‐
text, the evaluation of QOL is of utmost importance. In the management of recurrent ovari‐
an cancer, tumour control without compromising QOL should be the goal of the therapy
[50]. However, there are deficits in the measurement of general QOL data in the recurrent
setting, in terms of QOL disruptions and number of studies including QOL measurements
[26]. A recent trial published data pertaining the impact of early versus delayed treatment of
recurrent ovarian cancer based on Ca125 measurements exceeding twice the upper limit of
normal. Results showed that women did not live longer if chemotherapy was initiated earli‐
er based on Ca125, as opposed to delaying treatment until symptoms developed. In addi‐
tion, QOL was higher in women who underwent treatment at the time of clinical recurrence
[47]. Despite the limitations of this study, these findings may have potential impact on clini‐
cal practice.
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an cancer, tumour control without compromising QOL should be the goal of the therapy
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4.2. QOL in ovarian cancer survivors
Despite the considerable increase in the number of QOL studies carried out in ovarian can‐
cer patients, few studies have focused, particularly, in assessing QOL in ovarian cancer sur‐
vivors. Although, ovarian cancer patients do not belong to the most prevalent survivor
population due to the aggressiveness of the disease and relatively low survival rates, it is of
utmost importance to understand the QOL of those women who live years after the diagno‐
sis without symptoms of the disease [9, 51, 52]. QOL has been evaluated namely among
small samples of survivors by using mostly the EORTC QOL-C30, EORTC QOL-OV28 and
supplemented by several other questionnaires to assess specific dimensions of QOL.
Overall, with the exception of the study conducted by Liaavaaq et al [53], available data sug‐
gests that ovarian cancer survivors have generally good QOL; however, specific deficits are
reported and these are more prevalent in ovarian cancer survivors that in women without a
history of cancer [52, 54-57]. Results concerning psychological functioning are inconsistent,
ranging from good emotional status to psychological distress, including PTSD and depres‐
sion. Below are described with more detail findings from recent studies examining QOL in
ovarian cancer survivors.
Results from the study conducted by Steward et al [54] support the view that this group of
survivors experiences overall good QOL. These investigators assessed 200 ovarian cancer
survivors, who were at the time of the study without active disease and not on treatment, on
physical, psychological and social well-being. On average, women had been diagnosed with
ovarian cancer in the previous 7 years. Results showed that the majority of the survivors
(89%) regarded their health as good or excellent. Participants also reported a better mental
health and equivalent energy levels comparing to the general population. However, the ma‐
jority of the women suffered from pelvic pain and discomfort (54%). Study findings also
demonstrated that although 57% of the survivors referred that their sexual life had been
negatively affected by the cancer and its treatment, their general sense of loss regarding sex‐
ual functioning was perceived as moderate to low. Unsurprisingly, women under 55 years
of age reported a greater sense of loss about sexual functioning and fertility. According to
these authors, the experience of surviving ovarian cancer appeared to have enriched these
women, altering their life priorities and developing on them an impressive resilience [54].
Furthermore, authors highlighted that these survivors showed in general a great pleasure in
life and relationships [54]. Similar findings were obtained in the study conducted by Wenzel
et al [55], who examined 49 early stage ovarian cancer survivors (> 5 years). Findings re‐
vealed that survivors enjoyed a good QOL, with physical, emotional and social well-being
comparable to other survivors and same aged samples without a history of cancer. Few defi‐
cits were reported, such as problems related to abdominal and gynaecological symptoms,
and neurotoxicity. In the emotional domain, scores were more variable, with only one third
of the survivors experiencing an excellent emotional well-being. Fears of future diagnostic
tests (30%) and recurrence (20%) were also found. Investigators emphasised the resilience
and growth that survivors reported in their study as a result of their ovarian cancer experi‐
ence [55]. Another attempt to understand QOL in ovarian cancer survivors was carried out
by Matulonis et al [56], who evaluated 55 early stage survivors. Findings demonstrated that
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survivors had good physical QOL, with few long-term physical symptoms (such as abdomi‐
nal complaints and neurotoxicity) and few unmet needs. However, survivors reported emo‐
tional problems, such as psychological distress (40%), anxiety about Ca125 testing (54%),
fear of recurrence (56%) and 26% had scores suggestive of PTSD. Better mental health was
associated with less fatigue and pain, fewer stressful life events and higher social support.
The authors reported as well sexual problems, namely pain during sexual intercourse (52%).
Less than 10% of participants were interested in sex or were sexually active. Additionally, it
was noted that younger survivors presented greater sexual problems. Similarly, Mirabeau-
Beale et al [57] who conducted the first comparison between early stage (58 women) and ad‐
vanced stage (42 women) survivors on QOL (> 3 years), physical, sexual and mental
function, reported that survivors experienced positive overall QOL and long-term adjust‐
ment. Investigators reported no differences between early stage and advanced stage survi‐
vors on overall QOL, unmet needs, social support, complementary therapy use, physical
symptoms (neurotoxicity, fatigue and comorbidities), functioning (cognitive, sexual, physi‐
cal, role, emotional and sexuality), spirituality, hopelessness and psychological state. How‐
ever, advanced stage survivors experienced better social functioning. Although, the majority
of survivors had a good emotional functioning, scores suggestive of PTSD were noted in 7%
of early stage survivors. Diagnosable PTSD scores were not found in the advance stage sur‐
vivors group. Decreased sexual interest attributed to cancer, physical comorbidities, such as
degenerative joint disease, gastrointestinal distress and thyroid disease, fear of recurrence,
use of complementary and alternative medicines (exercise, vitamins, prayer and massage) in
order to improve their QOL were reported by survivors. The most recent account on QOL in
ovarian cancer survivors was given by Greimel et al [52], who attempted to fill a gap in the
literature by conducting a prospective study on QOL in long-term survivors (> 10 years).
This longitudinal study examined survivors at three time points: pre-treatment (baseline), 1-
year after diagnosis and 10 years post-treatment using the EORTC QOL-C30. At the base‐
line, 33 survivors were included; of those, 22 died within 5 years post diagnosis and 11
survived beyond 10 years. In general, results corroborated previous findings reporting that
survivors experienced a good physical, psychological, social and spiritual health. Despite no
differences at baseline in FIGO stage, residual tumour, performance status and treatment
characteristics between short-term and long-term survivors, the latter group experienced
better physical functioning, role functioning, cognitive functioning and less symptoms than
short-term survivors. Higher levels of symptoms and intra operative ascites were also more
prevalent in the short-term survivors group. One year after treatment, the majority of the
QOL dimensions were comparable among the two groups; however, long-term survivors re‐
ported better global QOL but more insomnia. Emotional functioning and global QOL im‐
proved significantly from baseline to 1 year after diagnosis and remained relatively stable in
the 10 year follow-up evaluation. Long-term survivors did not experience more sleeping
problems 10 years after their diagnosis than women from a general population [52].
Contradicting the trend described above, Liaavaaq et al [53] evaluated 189 ovarian cancer
survivors (> 18 months after primary treatment) and found that survivors experienced poor‐
er QOL, had more chronic fatigue and mental morbidity, used more medication and health
services when compared to age-adjusted controls from the general population.
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physical, psychological and social well-being. On average, women had been diagnosed with
ovarian cancer in the previous 7 years. Results showed that the majority of the survivors
(89%) regarded their health as good or excellent. Participants also reported a better mental
health and equivalent energy levels comparing to the general population. However, the ma‐
jority of the women suffered from pelvic pain and discomfort (54%). Study findings also
demonstrated that although 57% of the survivors referred that their sexual life had been
negatively affected by the cancer and its treatment, their general sense of loss regarding sex‐
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survivors had good physical QOL, with few long-term physical symptoms (such as abdomi‐
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associated with less fatigue and pain, fewer stressful life events and higher social support.
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Beale et al [57] who conducted the first comparison between early stage (58 women) and ad‐
vanced stage (42 women) survivors on QOL (> 3 years), physical, sexual and mental
function, reported that survivors experienced positive overall QOL and long-term adjust‐
ment. Investigators reported no differences between early stage and advanced stage survi‐
vors on overall QOL, unmet needs, social support, complementary therapy use, physical
symptoms (neurotoxicity, fatigue and comorbidities), functioning (cognitive, sexual, physi‐
cal, role, emotional and sexuality), spirituality, hopelessness and psychological state. How‐
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of survivors had a good emotional functioning, scores suggestive of PTSD were noted in 7%
of early stage survivors. Diagnosable PTSD scores were not found in the advance stage sur‐
vivors group. Decreased sexual interest attributed to cancer, physical comorbidities, such as
degenerative joint disease, gastrointestinal distress and thyroid disease, fear of recurrence,
use of complementary and alternative medicines (exercise, vitamins, prayer and massage) in
order to improve their QOL were reported by survivors. The most recent account on QOL in
ovarian cancer survivors was given by Greimel et al [52], who attempted to fill a gap in the
literature by conducting a prospective study on QOL in long-term survivors (> 10 years).
This longitudinal study examined survivors at three time points: pre-treatment (baseline), 1-
year after diagnosis and 10 years post-treatment using the EORTC QOL-C30. At the base‐
line, 33 survivors were included; of those, 22 died within 5 years post diagnosis and 11
survived beyond 10 years. In general, results corroborated previous findings reporting that
survivors experienced a good physical, psychological, social and spiritual health. Despite no
differences at baseline in FIGO stage, residual tumour, performance status and treatment
characteristics between short-term and long-term survivors, the latter group experienced
better physical functioning, role functioning, cognitive functioning and less symptoms than
short-term survivors. Higher levels of symptoms and intra operative ascites were also more
prevalent in the short-term survivors group. One year after treatment, the majority of the
QOL dimensions were comparable among the two groups; however, long-term survivors re‐
ported better global QOL but more insomnia. Emotional functioning and global QOL im‐
proved significantly from baseline to 1 year after diagnosis and remained relatively stable in
the 10 year follow-up evaluation. Long-term survivors did not experience more sleeping
problems 10 years after their diagnosis than women from a general population [52].
Contradicting the trend described above, Liaavaaq et al [53] evaluated 189 ovarian cancer
survivors (> 18 months after primary treatment) and found that survivors experienced poor‐
er QOL, had more chronic fatigue and mental morbidity, used more medication and health
services when compared to age-adjusted controls from the general population.
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Recent studies attempted to improve methodological deficits observed in previous research,
for example, by using more standardized and validate measures to assess QOL in this can‐
cer population. However, small sample sizes, heterogeneity of samples, timing of assess‐
ment are among the difficulties posed by current research, which make problematic to reach
definite conclusions. Despite this, collectively, existing studies highlight important issues
and concerns experienced by ovarian cancer survivors. Beyond the expected physical and
sexual sequalaes of the illness and treatment, studies highlighted, particularly, psychological
difficulties faced by survivors, which may adversely affect their psychological adjustment
and well-being. Findings from survivorship research are paramount to provide critical infor‐
mation to guide the development and design of interventions to assist survivors at risk.
The care provided to the cancer patient does not cease when the treatment ends. Survivor‐
ship is now recognized as a phase in the cancer trajectory that requires special attention and
ongoing specialized care. In 2006, the Institute of Medicine (IOM) published a report on can‐
cer survivorship entitled: 'From cancer patient to cancer survivor: Lost in transition' [58],
identifying unique concerns for cancer survivors, recommending the development of a sur‐
vivorship plan to be developed at the end of treatment for all people treated for cancer of
any type. Examples of requirements of the survivorship care plan as recommended by the
IOM include, among others, information on possible late and long term effects of treatments
and symptoms of such effects, information on the possible effects of cancer on marital/part‐
ner relationship, sexual functioning, work and parenting and the potential future need for
psychosocial support, referrals to specific follow-up care providers (e.g. rehabilitation, psy‐
chology), support groups, and/or the patient's primary care provider.
5. QOL in ovarian cancer: The challenges
Definitely, one of the main challenges in QOL research is to translate and apply the findings
obtained in research settings to clinical practice. In fact, in order to fully take advantage of
all the benefits offered by QOL research, it is imperative that QOL research provides health
care professionals with clinically relevant and interpretable information that can guide treat‐
ment decisions. However, routine use of QOL measures has been limited in clinical settings
[6]. Challenges of using QOL data to inform clinical practice may include the use of some‐
what arbitrary cutoff points or magnitude of change in QOL scores to determine when ther‐
apeutic change is needed [26]. To optimize treatment decisions for patients with ovarian
cancer, it is paramount that health care professionals are familiar with differences between
treatment regimens regarding toxicity, dosage and administration but also findings from
QOL measurements [11].
From the research perspective, there is a need for standardized collection and reporting of
QOL data from ovarian cancer patients, such as use of common instruments that demon‐
strate the most sensitivity to the study hypothesis and outcomes of interest, common data
collection time points, minimum expectations for data analysis and publication reporting
guidelines. These would allow comparative effectiveness research to be carried out [18]. Fur‐
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ther larger and rigorous studies are needed to fully understand QOL issues in ovarian can‐
cer patients. Longitudinal studies examining QOL across the different phases of ovarian
cancer trajectory would give valuable insights into the QOL of these patients.
As new treatment regimens for ovarian cancer continue to be developed and investigated in
the hope of improving survival of patients, it is paramount that QOL is regarded as one of
the most important endpoints in clinical trials. However, this is not sufficient. It is as well
important to routinely assess QOL disruptions in patients in clinical settings in order to
screen and identify patients at risk. Therefore, efforts should also be targeted to the develop‐
ment of interventions to be used in women at need, to prevent or ameliorate the negative
impact of the illness on QOL. The assessment of QOL in clinical settings also allows the
identification of QOL needs throughout the cancer trajectory.
6. Conclusion
Ovarian cancer patients may experience QOL disruptions and a wide range of sequalae that
do not dissipate with time and may persist for a long-term period. Measuring QOL in ovari‐
an cancer patients during the illness trajectory is of utmost importance. This is of great value
to develop and design interventions to assist ovarian cancer patients at need, and as well to
assist in the therapeutic decision process.
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1. Introduction
According to the American Cancer Society, in 2012 ovarian cancer is expected to account for
3% (22,280) of all new cases and 6% (15,500) of all female cancer deaths in the United States.
The proportion of ovarian cancer among gynaecological cancers is increasing, also because of
the decrease in cervical cancer as a result of pap smear screening programmes. On the other
hand, survival from ovarian cancer is the poorest of all gynaecological cancers, with a five-
year relative survival rate of 44% for all stages [1,2]. The main reasons for this poor survival
are the lack of early detection strategies and an unfavourable anatomical situation. Thus, the
vast majority of ovarian cancer is diagnosed at an advanced stage and therapy for this
pathology is very complex [3-5]. Reduction in mortality rates could be gained both with new
screening strategies and with ameliorations in surgical and medical treatments. However,
neither of these approaches will affect cancer incidence, thus, it is clear that the prospects for
making a major impact on the mortality from ovarian cancer lie more in the area of prevention.
The purpose of this chapter is to identify the evidence for the appropriate practical strategies
to prevent ovarian cancer or the detection of cancer in the early stages in order to improve the
overall survival. The search was restricted to full reports and guidelines published in English
between 2000 and May 2012, in an attempt to summarize the principal findings regarding
primary and secondary ovarian cancer prevention.
2. Primary prevention for ovarian cancer in general population
Primary prevention aims to prevent the disease before its biological onset, thus it is based on
avoiding risk factors and increasing protective factors.
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A summary of the most significant risk and protective factors, with relative hazard ratio, for
epithelial ovarian cancer is summarized in Tables 1a and1b,
AUTHORS RISK FACTORS RR (95% CI)
Schorge JO et al. [6] White race 1.35 (1.08-1.50)
Schouten LJ et al. [7] Height≥160 cm 1.38 (1.16-1.65)
Lahmann PH et al. [8] BMI≥25 1.33 (1.05-1.68)
Camargo MC et al. [9] Asbestos exposure 1.77 (1.37-2.28)
Cramer DW [10] early age at menarche 1.74 (1.28-2.18)
Cramer DW [10] late menopause 1.61 (1.15-2.08)
Beral V et al. [11] HRT 1.20 (0.98-1.32)
Melin A et al. [12] Endometriosis 1.43 (1.19-1.71)





Watson P et al. [14] MMR 19 (5.0-30.0)
(a)
AUTHORS PROTECTIVE FACTORS HR (95% CI)
Trudel D et al. [15] green tea components 0.66 (0.54-0.80)
Collaborative Group on
Epidemiological Studies of Ovarian
Cancer [16]
hormonal contraceptive use 0.73 (0.70-0.76)
Ness RB et al. [17] Multiparity(≥ 4 pregnancies) 0.40 (0.30-0.50)
Danforth KN et al. [18] breastfeeding
0.98 per month
( 0.97-1.00)
Hankinson SE et al. [19] bilateral tube ligation 0.33 (0.16-0.64)
Hankinson SE et al. [19] hysterectomy 0.67 (0.45-1.00)
(b)
Table 1. (a) Main significant risk factors for ovarian cancer. (b) Main significant protective factors for ovarian cancer.
The average age at diagnosis is approximately 60 years, but the overall incidence of ovarian
cancer rises with increasing age up to 75-84 years, due to the accumulation of random genetic
alterations, before declining slightly among women beyond 84 years [20]. Women residing in
North America, Northern Europe or in any industrialized Western country have a higher risk
of developing ovarian cancer. Conversely, women residing in developing countries have
shown the lowest rate [6]. The exact reasons for this distribution are unknown but discrepan‐
cies in parity, rates of gynaecologic surgery and dietary habits may account for some differ‐
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ences [21]. In particular, regarding dietary habits, a comprehensive meta-analysis of the
observational studies published up to September 2011 provided no evidence of a material
association between alcohol drinking and epithelial ovarian cancer risk [22]. Finally, a recent
study provided some suggestion that soy and phytoestrogen consumption may decrease
ovarian cancer risk, although the results did not reach statistical significance [23].
Exposure to radiation may increase the risk of ovarian cancer and the risk increases with
increasing dose. The Life Span Study incidence data for ovarian cancer demonstrated a
borderline significant association [24], and mortality data showed a significant positive
association between exposure to radiation and ovarian cancer [25].
With regards to reproductive factors, early age at menarche and late menopause have been
consistently associated with an increased risk of ovarian cancer, likely due to an increase in
ovulation and in oestrogen exposure [26]. The effect of combined hormonal contraceptive use
on the risk of ovarian cancer has been long discussed. In 2007, the IARC review concluded that
women who had at least for a period used combined hormonal contraceptives orally had an
overall reduced risk for ovarian cancer, which persists for at least 20 years after cessation of
use, and an inverse relationship was observed with duration of use [27]. These results have
been confirmed by the Collaborative Group on Epidemiological Studies of Ovarian Cancer [16]
that reported an overall reduction in ovarian cancer risk in users versus non-users of 27%,
which was not confined to any particular type of oral formulation nor to any histological type
of ovarian cancer, although it was less consistent for mucinous than for other types of ovarian
cancer. On this basis, the “incessant menstruation” hypothesis was postulated, which con‐
cludes that the use of oral contraceptives (OC) should be favoured for prolonged periods of
time, especially in women with endometriosis, a population at doubled risk of ovarian cancer
[28]. On the other hand, in the Million Women Study HRT after menopause was shown to
increase the risk of ovarian cancer [11].
Women who have never had children are at increased risk of developing ovarian cancer [29].
Regarding fertility drug use, previous studies have provided conflicting results. Recent data
demonstrated that fertility drug use does not significantly contribute to ovarian cancer risk
among the majority of women. However, women who despite their use remain nulliparous
may have an increased risk [30]. The role of breastfeeding as a protective factor against ovarian
cancer has been long discussed. Finally, the risk of ovarian cancer decreases in women who
underwent bilateral tube ligation or hysterectomy, probably because these surgical interven‐
tions do not allow the carcinogenic agents to enter the body from the vagina and reach the
ovaries [19, 31]. For instance, a number of observational studies (largely case-control) con‐
ducted over the last two decades suggested an association between use of talc powders on the
female perineum and increased risk of ovarian cancer, although the weak statistical associa‐
tions observed in a number of epidemiological studies do not support a causal association
between cosmetic talc use and ovarian cancer [32,33].
Endometriosis represents another considerable risk factor for epithelial ovarian cancer. In
particular, self-reported endometriosis was associated with a significantly increased risk of
clear-cell, low-grade serous and endometrioid invasive ovarian cancers. No association was
noted between endometriosis and risk of mucinous or high-grade serous invasive ovarian
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A summary of the most significant risk and protective factors, with relative hazard ratio, for
epithelial ovarian cancer is summarized in Tables 1a and1b,
AUTHORS RISK FACTORS RR (95% CI)
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Schouten LJ et al. [7] Height≥160 cm 1.38 (1.16-1.65)
Lahmann PH et al. [8] BMI≥25 1.33 (1.05-1.68)
Camargo MC et al. [9] Asbestos exposure 1.77 (1.37-2.28)
Cramer DW [10] early age at menarche 1.74 (1.28-2.18)
Cramer DW [10] late menopause 1.61 (1.15-2.08)
Beral V et al. [11] HRT 1.20 (0.98-1.32)
Melin A et al. [12] Endometriosis 1.43 (1.19-1.71)





Watson P et al. [14] MMR 19 (5.0-30.0)
(a)
AUTHORS PROTECTIVE FACTORS HR (95% CI)
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Collaborative Group on
Epidemiological Studies of Ovarian
Cancer [16]
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Ness RB et al. [17] Multiparity(≥ 4 pregnancies) 0.40 (0.30-0.50)
Danforth KN et al. [18] breastfeeding
0.98 per month
( 0.97-1.00)
Hankinson SE et al. [19] bilateral tube ligation 0.33 (0.16-0.64)
Hankinson SE et al. [19] hysterectomy 0.67 (0.45-1.00)
(b)
Table 1. (a) Main significant risk factors for ovarian cancer. (b) Main significant protective factors for ovarian cancer.
The average age at diagnosis is approximately 60 years, but the overall incidence of ovarian
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ences [21]. In particular, regarding dietary habits, a comprehensive meta-analysis of the
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Exposure to radiation may increase the risk of ovarian cancer and the risk increases with
increasing dose. The Life Span Study incidence data for ovarian cancer demonstrated a
borderline significant association [24], and mortality data showed a significant positive
association between exposure to radiation and ovarian cancer [25].
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use, and an inverse relationship was observed with duration of use [27]. These results have
been confirmed by the Collaborative Group on Epidemiological Studies of Ovarian Cancer [16]
that reported an overall reduction in ovarian cancer risk in users versus non-users of 27%,
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tions observed in a number of epidemiological studies do not support a causal association
between cosmetic talc use and ovarian cancer [32,33].
Endometriosis represents another considerable risk factor for epithelial ovarian cancer. In
particular, self-reported endometriosis was associated with a significantly increased risk of
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cancers or borderline tumours of either subtype [34]. Also, pelvic inflammatory disease has
been suggested to double the risk of epithelial ovarian cancer [35], but few studies have been
done and the conclusions are inconsistent.
The most important risk factor still remains a family history of breast or ovarian cancer. Up to
10% of ovarian cancer patients may have inherited a germline mutation that places them at in‐
creased risk of the disease. Mutations in the breast and ovarian cancer-susceptibility genes
BRCA1 and BRCA2 confer an increased lifetime risk of ovarian cancer. BRCA1 and BRCA2 are
tumour suppressor genes involved in many cellular functions to prevent carcinogenesis [Fig.1].
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[40]. To date, at least 16 genes have been associated with hereditary ovarian cancer, most‐
ly involved in the FA-BRCA  pathway and the mismatch repair  system. However,  many
families with suspicious pedigrees do not have a specific mutation identified through clin‐
ical testing, due to a currently undetectable BRCA1/2  mutation or a mutation in another
susceptibility  gene.  Although  their  cancer  risks  are  not  as  well  defined,  these  families
should be considered as part of the hereditary breast and/or ovarian cancer spectrum [13].
However, most of the common risk and protective factors only slightly influence the risk of
developing ovarian cancer, thus, to date; the knowledge of these factors has still not been
translated into practical strategies to prevent ovarian cancer.
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cancers or borderline tumours of either subtype [34]. Also, pelvic inflammatory disease has
been suggested to double the risk of epithelial ovarian cancer [35], but few studies have been
done and the conclusions are inconsistent.
The most important risk factor still remains a family history of breast or ovarian cancer. Up to
10% of ovarian cancer patients may have inherited a germline mutation that places them at in‐
creased risk of the disease. Mutations in the breast and ovarian cancer-susceptibility genes
BRCA1 and BRCA2 confer an increased lifetime risk of ovarian cancer. BRCA1 and BRCA2 are
tumour suppressor genes involved in many cellular functions to prevent carcinogenesis [Fig.1].
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3. Primary prevention for ovarian cancer in high risk women
Some women have a high risk of developing ovarian cancer due to hereditary conditions
associated to BRCA syndrome and Lynch syndrome. Thus, when one of these forms of
hereditary or familial breast and/or ovarian cancer is suspected in clinical practice, the general
practitioner should refer the patient to a cancer centre specialising in cancer-specific genetic
counselling for the identification, definition and management of risk. Genetic counselling,
defined by the American Society of Human Genetics as ‘a communication process which deals
with the human problems associated with the occurrence or risk of occurrence of a genetic
disorder in a family’, involves one or more professional figures to help the affected individuals
or families [41-44]. Genetic counselling in the oncological setting (cancer-specific genetic
counselling) should also provide sufficient information to enable the user to make a fully
informed choice as to course of action, particularly with regards to prevention, in the case of
the identification of a mutation or of a familial cancer risk [45, 46].
A recent review investigated the impact of cancer genetic risk assessment on outcomes,
including perceived risk of inherited cancer and psychological distress. The review found
favourable outcomes for patients after risk assessment for familial breast cancer, suggesting
that cancer-specific genetic risk assessment services help to reduce distress, improve the
accuracy of the perception of risk of ovarian cancer, and increase the knowledge of ovarian
cancer and genetics. However, there were too few papers to make any significant conclusions
on how best to deliver cancer genetic risk assessment services. Further research is needed,
assessing the best means of delivering cancer risk evaluation, by different health professionals,
in different ways and in alternative locations [47].
Women at increased risk of breast and ovarian cancer are advised to consider risk-reducing
strategies; however, such methods vary in their effectiveness. These strategies include
chemoprevention and prophylactic surgery (risk-reducing salpingo-oophorectomy, RRSO).
Risk-reducing strategies have been shown to have associations with a lengthening of life
expectancy in BRCA1/2 carriers.
3.1. Risk-reducing salpingo-oophorectomy (RRSO)
Women who have inherited mutations in the BRCA1 or BRCA2 genes have substantially
elevated risks of breast and ovarian cancer, with a lifetime risk of breast cancer of 56%–84%
[48-51]. Breast cancer in BRCA1/2 mutation carriers also occurs at an earlier age, particularly
among the BRCA1 mutation carriers, than in non-carriers. The risk for ovarian cancer depends
on whether the mutation has occurred in BRCA1 or BRCA2, with estimated risks ranging from
34% to 44% for BRCA1 mutation carriers and from 12% to 25% for BRCA2 mutation carriers
[48, 49, 52-54]. Carriers of BRCA1/2 mutations are counselled to help them interpret the
implications of these elevated risks, choose strategies to reduce these risks, and maximize early
detection of cancers. The risk of breast cancer can be reduced either with RRSO and/or
mastectomy or non-surgically (i.e. with chemoprevention). However, due to the lack of
effective screening for ovarian cancer, RRSO is usually strongly recommended to BRCA1/2
mutation carriers once childbearing is complete.
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RRSO has also been demonstrated to decrease the risk of both breast and ovarian cancer in
BRCA1/2 mutation carriers [55-60]. However, the studies examining the extent of risk reduction
have used different designs; some are retrospective case–control studies, while others used a
prospective cohort design. In a large, retrospective analysis of 551 BRCA carriers, RRSO was
found to reduce the risk of ovarian cancer by 96% and breast cancer by 53% at a mean follow-
up of 9 years [55]. A multicentre prospective study, Kauff et al. [56] found that, during a 3-year
follow-up, RRSO was associated with an 85% reduction in BRCA1-associated gynaecologic
cancer risk and a 72% reduction in BRCA2-associated breast cancer risk. Although protection
against BRCA1-associated breast cancer and BRCA2-associated gynaecologic cancer was
suggested, neither effect reached statistical significance. The authors postulate that the
protection conferred by RRSO against breast and gynaecologic cancers may differ between the
carriers of BRCA1 and BRCA2 mutations.
Similar findings were observed in a prospective study of 170 BRCA carriers. During a mean fol‐
low-up of 2 years, the incidence of ovarian or peritoneal cancer and breast cancer was significant‐
ly greater amongst those women who selected surveillance than amongst those who chose to
undergo RRSO [59.] Even among prospective studies, the inclusion criteria and the definitions of
follow-up time differ. In some studies, only unaffected mutation-positive women are included
and followed up. In others, particularly when examining ovarian cancer risk, women with breast
cancer are included. Such differences in study design can introduce biases (such as the survival
bias) and can have an impact on risk reduction estimates. For example, the reported efficacy of
RRSO in reducing the risk of ovarian/fallopian tube cancers varies from 71% to 96% [55-61]. Al‐
though these estimates imply a substantial reduction in risk, this variability may affect the deci‐
sions of premenopausal women who are making a decision about whether to undergo a
treatment that will cause abrupt and premature menopause. Patients and their physicians need
as much information as possible regarding the efficacy of RRSO in reducing cancer risk to bal‐
ance this benefit with the health risks caused by premature entry into menopause.













Rebbeck et al., 2002 [55] RC 261/292 8.5 96 53
Kauff et al., 2008 [56] PC 509/283 3.2 85 72
Finch et al., 2006 [57] RC 1041/779 3.5 80 NA
Chang-Claude et al., 2007 [58] RC 55/1601 65,675 PY NA 44
Rutter et al., 2003 [60] RC 5/223 NA 67 NA
Kauff et al., 2002 [61] PC 98/72 2.0 85 68
PC = prospective cohort; RC = retrospective cohort; MYFU = mean years of follow-up; PY = person-years; NR = not reported;
and NA = not applicable; RRSO = risk-reducing salpingo-oophorectomy.
Table 2. Published studies on risk-reducing salpingo-oophorectomy in BrCa1and/ or BrCa2 mutation carriers.
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Table 3. Synopsis of different prevention strategies for BRCA1 and BRCA2 mutation carriers.
The National Comprehensive Cancer Network (NCCN) guidelines and other institutions
concerning this method, recommend RRSO “for women with a known BRCA1/2 mutation,
ideally between 35 and 40 years or upon completion of child bearing” or at an adjusted age
based on earliest age of ovarian cancer diagnosis in the family” [62].
Also ACOG, the Committee on Genetics and the Society of Gyneacologic Oncologists,
recommends RRSO for women with BRCA1/2 mutations, by the age of 40 years or when
childbearing is complete [63].
The National Cancer Institute (NCI) [64] on the clinical management of BRCA mutation carriers
considers, besides salpingo-oophorectomy, bilateral salpingectomy as an interim procedure
to reduce risk in BRCA mutation carriers. There are no data available on the efficacy of
salpingectomy as a risk-reducing procedure. The procedure preserves ovarian function and
spares the premenopausal patient the adverse effects of a premature menopause. It can be
performed using a minimally invasive approach, and a subsequent bilateral oophorectomy
could be deferred until the patient approaches menopause. While the data make the compel‐
ling argument that some pelvic serous cancers in BRCA mutation carriers originate in the
fallopian tube, clearly, some cancers arise in the ovary. Furthermore, bilateral salpingectomy
could give patients a false sense of security that they have eliminated their cancer risk as
completely as if they had undergone a bilateral salpingo-oophorectomy. A small study of 14
young BRCA mutation carriers documented the procedure as feasible [65]. However, efficacy
and impact on ovarian function was not assessed in this study. Future prospective trials are
needed to establish the validity of the procedure as a risk-reducing intervention.
For the European Society of Medical Oncology ESMO [66], RRSO is associated with a reduction
in risk of breast cancer in premenopausal BRCA mutation carriers, a reduction in risk of ovarian
cancer, and there is evidence of a reduction in overall mortality [67]. RRSO is recommended
after the age of 35 and when childbearing decisions are complete.
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The significantly reduced risk of breast cancer by RRSO seems to be higher in BRCA2 mutation
carriers than in BRCA1 carriers. Several reports have addressed this question although
additional research is required [56]. Short-term HRT after RRSO seems not to decrease the
overall benefit of this strategy for breast cancer risk reduction [68].
However, it should be noted that the NCCN and other institutions couch these recommenda‐
tions within a multidisciplinary consultative process in which reproductive desires, assess‐
ment of cancer risk, and the pros and cons of surgery along with the potential sequelae of
surgery are fully discussed.
The recommendations of different organizations regarding surgical primary prevention for
BRCA1/2 mutation carriers are shown in Table 4.
Management options NCCN [62]
ACOG Committee





























Table 4. Recommendations of several organizations regarding primary prevention for BRCA mutation carriers.
3.2. Chemoprevention
Women at increased risk, based on their personal or family history of breast and/or ovarian
cancer including BRCA1/2 mutation carriers, may join a cancer prevention clinical trial or a
chemoprevention trial. OC have been the most widely studied chemopreventive agents in
ovarian cancer. Recently, Iodice et al. conducted a meta-analysis updated to March 2010 on the
association between OC use and breast or ovarian cancer in BRCA1/2 mutation carriers [69].
Based on 18 studies a total of 2855 breast cancer cases and 1503 ovarian cancer cases carrying
an ascertained BRCA1/2 mutation were included. As previously noted, use of OC at any point
during one’s life was associated with a 50% reduction in relative risk of developing ovarian
cancer for BRCA1/2 mutation carriers. Looking specifically at duration of use, each 10-year
period of OC use resulted in a 36% relative risk reduction in the development of ovarian cancer.
However, the meta-analysis showed no evidence of a significant association between OC use
and breast cancer risk. Notably, formulations used before 1975 correlated with an increased
risk of breast cancer, but there was no correlation with the use of more recent formulations. A
summary of the association between OC use and ovarian cancer risk in mutation carriers is
shown in Table 5.
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could be deferred until the patient approaches menopause. While the data make the compel‐
ling argument that some pelvic serous cancers in BRCA mutation carriers originate in the
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could give patients a false sense of security that they have eliminated their cancer risk as
completely as if they had undergone a bilateral salpingo-oophorectomy. A small study of 14
young BRCA mutation carriers documented the procedure as feasible [65]. However, efficacy
and impact on ovarian function was not assessed in this study. Future prospective trials are
needed to establish the validity of the procedure as a risk-reducing intervention.
For the European Society of Medical Oncology ESMO [66], RRSO is associated with a reduction
in risk of breast cancer in premenopausal BRCA mutation carriers, a reduction in risk of ovarian
cancer, and there is evidence of a reduction in overall mortality [67]. RRSO is recommended
after the age of 35 and when childbearing decisions are complete.
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additional research is required [56]. Short-term HRT after RRSO seems not to decrease the
overall benefit of this strategy for breast cancer risk reduction [68].
However, it should be noted that the NCCN and other institutions couch these recommenda‐
tions within a multidisciplinary consultative process in which reproductive desires, assess‐
ment of cancer risk, and the pros and cons of surgery along with the potential sequelae of
surgery are fully discussed.
The recommendations of different organizations regarding surgical primary prevention for
BRCA1/2 mutation carriers are shown in Table 4.
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Table 4. Recommendations of several organizations regarding primary prevention for BRCA mutation carriers.
3.2. Chemoprevention
Women at increased risk, based on their personal or family history of breast and/or ovarian
cancer including BRCA1/2 mutation carriers, may join a cancer prevention clinical trial or a
chemoprevention trial. OC have been the most widely studied chemopreventive agents in
ovarian cancer. Recently, Iodice et al. conducted a meta-analysis updated to March 2010 on the
association between OC use and breast or ovarian cancer in BRCA1/2 mutation carriers [69].
Based on 18 studies a total of 2855 breast cancer cases and 1503 ovarian cancer cases carrying
an ascertained BRCA1/2 mutation were included. As previously noted, use of OC at any point
during one’s life was associated with a 50% reduction in relative risk of developing ovarian
cancer for BRCA1/2 mutation carriers. Looking specifically at duration of use, each 10-year
period of OC use resulted in a 36% relative risk reduction in the development of ovarian cancer.
However, the meta-analysis showed no evidence of a significant association between OC use
and breast cancer risk. Notably, formulations used before 1975 correlated with an increased
risk of breast cancer, but there was no correlation with the use of more recent formulations. A
summary of the association between OC use and ovarian cancer risk in mutation carriers is
shown in Table 5.












5 1503 0.50 (0.33-0.75)
BRCA 1 5 1251 0.51 (0.40-0.65)
BRCA 2 4 286 0.52 (0.31-0.87)




5 years 0.80 (0.73-0.88)
10 years 0.64 (0.53-0.78)
Table 5. Summary of the association between OC use and ovarian cancer risk in mutation carriers
Another meta-analysis of cohort, case-control and case-case studies published in English up
to December 2009 confirmed a significantly decreased ovarian cancer risk in BRCA1/2 mutation
carriers associated with the use of OC, while a significantly increased risk in breast cancer was
only shown in a subset of cohort studies on BRCA1 mutation carriers. To conclude, OC use
can be considered as an alternative strategy in the chemoprevention of ovarian cancer in
BRCA1 mutation carriers who do not accept RRSO above the age of 30 years [70].
Other chemopreventative agents such as retinoids, vitamin D, cyclo-oxygenase inhibitors and
peroxisome proliferator activated receptor-gamma ligands have shown promise in early
investigations of disease prevention [71].
Retinoids, a class of compounds comprising vitamin A, its natural derivatives, and synthetic
analogs, have been extensively studied in both the prevention and treatment of gynaecologic
malignancies [72]. One of the most promising retinoids to be used in chemoprevention trials
is the synthetic amide of retinoic acid fenretinide, N-4-hydroxyphenyl retinamide (4-HPR). 4-
HPR has been found to have significant chemopreventive action in a large variety of in vitro
and in vivo systems. Since both fenretinide and its major metabolite, 4-metoxyphenyl retina‐
mide (MPR), selectively accumulate in the human breast, evaluation of 4-HPR as a chemopre‐
ventive agent in breast cancer has been particularly attractive [73]. The most important clinical
trials with 4-HPR are mentioned in Table 6.
The most important study where 4-HPR was administrated was a multicentric phase III
randomized trial, coordinated by the Istituto Nazionale dei Tumori in Milan, which started in
1987. Most notably, the younger the women were, the greater the benefit of 4-HPR. Such a
benefit was associated with a remarkable 50% risk reduction in women aged 40 years or
younger, whereas it disappeared after 55 years of age. Interestingly, the incidence of ovarian
cancer during the 5-year intervention period was significantly lower in the treatment arm [74].
The role of analgesic drug use in the development of ovarian cancer is still widely discussed.
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Table 6. Clinical trials with 4-HPR [74].
A recent population-based case-control study, carried out in Denmark in the period 1995-1999,
analysed the association between analgesic drug use and ovarian cancer risk using multiple
logistic regression models. The study showed that regular use of non-aspirin non-steroidal
anti-inflammatory drugs (NA-NSAID), paracetamol or other analgesics did not decrease
ovarian cancer risk. In contrast, use of any analgesics (OR = 0.72; 95% CI 0.53-0.98) or aspirin
(OR = 0.60; 95% CI 0.36-1.00) resulted in a statistically significant decreased risk of serous
ovarian cancer but not mucinous or other ovarian tumours [79]. On the other hand, recent data
reported by the Multiethnic Cohort Study did not find compelling evidence to support an
association between use of NSAID and risk of ovarian and endometrial cancers in a multiethnic
population. The RR (95% CI) for ovarian cancer associated with aspirin, non-aspirin NSAID,
and acetaminophen were 0.87 (0.68, 1.14), 0.97 (0.74, 1.26), and 0.86 (0.67, 1.12), respectively.
No heterogeneity across ethnic groups (P's ≥0.29) or dose-response relation with increased
duration of use (P's for trend ≥0.16) was observed [80]. Finally, in an attempt to review and
summarize the evidence provided by longitudinal studies on the association between NSAID
use and ovarian cancer risk, a comprehensive literature search for articles published up to
December 2011 was performed (Table 7). The meta-analysis found no evidence of an associa‐
tion between aspirin or NA-NSAID use and ovarian cancer risk, based on a random-effects
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Another meta-analysis of cohort, case-control and case-case studies published in English up
to December 2009 confirmed a significantly decreased ovarian cancer risk in BRCA1/2 mutation
carriers associated with the use of OC, while a significantly increased risk in breast cancer was
only shown in a subset of cohort studies on BRCA1 mutation carriers. To conclude, OC use
can be considered as an alternative strategy in the chemoprevention of ovarian cancer in
BRCA1 mutation carriers who do not accept RRSO above the age of 30 years [70].
Other chemopreventative agents such as retinoids, vitamin D, cyclo-oxygenase inhibitors and
peroxisome proliferator activated receptor-gamma ligands have shown promise in early
investigations of disease prevention [71].
Retinoids, a class of compounds comprising vitamin A, its natural derivatives, and synthetic
analogs, have been extensively studied in both the prevention and treatment of gynaecologic
malignancies [72]. One of the most promising retinoids to be used in chemoprevention trials
is the synthetic amide of retinoic acid fenretinide, N-4-hydroxyphenyl retinamide (4-HPR). 4-
HPR has been found to have significant chemopreventive action in a large variety of in vitro
and in vivo systems. Since both fenretinide and its major metabolite, 4-metoxyphenyl retina‐
mide (MPR), selectively accumulate in the human breast, evaluation of 4-HPR as a chemopre‐
ventive agent in breast cancer has been particularly attractive [73]. The most important clinical
trials with 4-HPR are mentioned in Table 6.
The most important study where 4-HPR was administrated was a multicentric phase III
randomized trial, coordinated by the Istituto Nazionale dei Tumori in Milan, which started in
1987. Most notably, the younger the women were, the greater the benefit of 4-HPR. Such a
benefit was associated with a remarkable 50% risk reduction in women aged 40 years or
younger, whereas it disappeared after 55 years of age. Interestingly, the incidence of ovarian
cancer during the 5-year intervention period was significantly lower in the treatment arm [74].
The role of analgesic drug use in the development of ovarian cancer is still widely discussed.
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Table 6. Clinical trials with 4-HPR [74].
A recent population-based case-control study, carried out in Denmark in the period 1995-1999,
analysed the association between analgesic drug use and ovarian cancer risk using multiple
logistic regression models. The study showed that regular use of non-aspirin non-steroidal
anti-inflammatory drugs (NA-NSAID), paracetamol or other analgesics did not decrease
ovarian cancer risk. In contrast, use of any analgesics (OR = 0.72; 95% CI 0.53-0.98) or aspirin
(OR = 0.60; 95% CI 0.36-1.00) resulted in a statistically significant decreased risk of serous
ovarian cancer but not mucinous or other ovarian tumours [79]. On the other hand, recent data
reported by the Multiethnic Cohort Study did not find compelling evidence to support an
association between use of NSAID and risk of ovarian and endometrial cancers in a multiethnic
population. The RR (95% CI) for ovarian cancer associated with aspirin, non-aspirin NSAID,
and acetaminophen were 0.87 (0.68, 1.14), 0.97 (0.74, 1.26), and 0.86 (0.67, 1.12), respectively.
No heterogeneity across ethnic groups (P's ≥0.29) or dose-response relation with increased
duration of use (P's for trend ≥0.16) was observed [80]. Finally, in an attempt to review and
summarize the evidence provided by longitudinal studies on the association between NSAID
use and ovarian cancer risk, a comprehensive literature search for articles published up to
December 2011 was performed (Table 7). The meta-analysis found no evidence of an associa‐
tion between aspirin or NA-NSAID use and ovarian cancer risk, based on a random-effects
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model or a fixed-effects model. Furthermore, the analysis did not show strong association
between frequency or duration of NA-NSAID use and ovarian cancer, leading to the conclu‐




Fixed-effects model Random-effects model
P-value
RR (95% CI) RR (95% CI)
ASPIRIN USE
All studies 17 0,94 (0,87-1,01) 0,91 (0,82-1,01) 0,046
C-C studies 14 0,94 (0,87-1,02) 0,90 (0,79-1,03) 0,015
Cohort studies 3 0,92 (0,77-1,09) 0,92 (0,77-1,10) 0,456
Regular Use 7 0,86 (0,73-1,03) 0,83 (0,65-1,05) 0,119
Irregular Use 7 1,07 (0,96-1,20) 1,07 (0,96-1,21) 0,421
Duration > 5 yrs 5 0,91 (0,67-1,24) 0,89 (0,63-1,25) 0,332
NA-NSAID use
All studies 7 0,86 (0,76-0,98) 0,89 (0,74-1,08) 0,089
C-C studies 4 0,88 (0,75-1,03) 0,97 (0,73-1,28) 0,042
Cohort studies 3 0,82 (0,64-1,04) 0,89 (0,74-1,08) 0,283
Regular Use 3 1,45 (1,07-1,98) 1,47 (0,95-2,27) 0,153
Irregular Use 3 0,96 (0,69-1,33) 0,93 (0,49-1,76) 0,038
Duration > 5 yrs 3 1,65 (1,13-2,41) 1,56 (0,92-2,65) 0,21
NA-NSAID: non aspirin- non-steroidal anti-inflammatory drugs
Table 7. Metanalysis of longitudinal studies on the association between NSAID use and ovarian cancer risk
4. Secondary prevention for ovarian cancer
This is based on diagnosing and treating extant disease in the early stages before it causes signif‐
icant morbidity. CA125 (or MUC16) glycoprotein is the most studied tumour marker, alone
and/or in combination with other biomarkers, for ovarian cancer screening. However, false pos‐
itive CA125 levels can occur in women with benign conditions, including menstruation, appen‐
dicitis, benign ovarian cysts, endometriosis and pelvic inflammatory disease, as well as with
other malignancies, including breast, lung, endometrial and pancreatic cancers. Thus, a large
number of false-positive screening tests can occur, potentially leading to unnecessary surgeries
and subsequent issues of morbidity and cost [82]. Consequently, multimodal strategies, in par‐
ticular the combination of CA125 with pelvic ultrasound, have been examined, in order to im‐
prove sensitivity and positive predictive value of ovarian cancer screening.
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4.1. Transvaginal ultrasound
In the general population, TVUS appears to be superior to transabdominal ultrasound in the pre‐
operative diagnosis of adnexal masses. Both techniques have lower specificity in premenopaus‐
al  women  than  in  postmenopausal  women  due  to  the  cyclic  menstrual  changes  in
premenopausal ovaries (e.g., transient corpus luteum cysts) that can cause difficulty in the inter‐
pretation. The randomized prospective Prostate, Lung, Colorectal, and Ovarian Cancer Screen‐
ing Trial found no reduction in mortality with the annual use of combined TVUS and CA125 in
screening asymptomatic, postmenopausal women at average risk of ovarian cancer [83].
Data are limited regarding the potential benefit of TVUS in screening women at inherited risk
of ovarian cancer. A number of retrospective studies have reported experiments with ovarian
cancer screening in high-risk women using TVUS with or without CA125 [84-90].
However, there is little uniformity in the definition of high-risk criteria and compliance with
screening, and in whether the cancers detected were incident or prevalent. One of the largest re‐
ported studies included 888 BRCA1/BRCA2 mutation carriers who were annually screened
with TVUS and CA125. Ten women developed ovarian cancer; five of the ten developed inter‐
val cancers after normal screening results within 3 to 10 months before diagnosis. Five of the ten
ovarian cancers were screen-detected incident cases, which had had normal screening results
within 6 to 14 months before diagnosis. Out of these five cases, four were stage IIIB or IV [85].
A similar study reported the results of annual TVUS and CA125 combined-screening in a
cohort of 312 high-risk women (152 BRCA1/BRCA2 mutation carriers) [86]. Out of four cancers
detected because of abnormal TVUS and CA125, all cases were symptomatic, and three had
an advanced-stage disease. Annual screening of BRCA1/BRCA2 mutation carriers with pelvic
ultrasound, TVUS, and CA125 failed to detect early-stage ovarian cancer among 241 women
in a study from the Netherlands [87]. Three cancers were detected over the course of the study,
all advanced stage IIIC disease. Finally, a study of 1,100 moderate- and high-risk women who
underwent annual TVUS and CA125 combined screening reported that ten out of 13 ovarian
tumours were detected due to screening. Only five out of ten were stage I or II [88]. There are
limited data related to the efficacy of semiannual screening with TVUS and CA125 [89].
The first prospective study of TVUS and CA125 with survival as the primary outcome was com‐
pleted in 2009. Out of 3,532 high-risk women screened, 981 were BRCA mutation carriers, of
which 49 developed ovarian cancer. The 5- and 10-year survival was 58.6% (95% CI, 50.9–66.3)
and 36% (95% CI, 27–45), respectively, and there was no difference in survival between carriers
and non-carriers. A major limitation of the study was the absence of a control group. Despite
these limitations, this study suggests that annual surveillance by TVUS and CA125 level appears
to be ineffective in detecting tumours at an early stage to substantially influence survival [90].
4.2. Serum CA125
Serum  CA125  screening  for  ovarian  cancer  in  high-risk  women  has  been  evaluated  in
combination with TVUS in a number of retrospective studies, as described in the previous
section [84-90].
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model or a fixed-effects model. Furthermore, the analysis did not show strong association
between frequency or duration of NA-NSAID use and ovarian cancer, leading to the conclu‐
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Table 7. Metanalysis of longitudinal studies on the association between NSAID use and ovarian cancer risk
4. Secondary prevention for ovarian cancer
This is based on diagnosing and treating extant disease in the early stages before it causes signif‐
icant morbidity. CA125 (or MUC16) glycoprotein is the most studied tumour marker, alone
and/or in combination with other biomarkers, for ovarian cancer screening. However, false pos‐
itive CA125 levels can occur in women with benign conditions, including menstruation, appen‐
dicitis, benign ovarian cysts, endometriosis and pelvic inflammatory disease, as well as with
other malignancies, including breast, lung, endometrial and pancreatic cancers. Thus, a large
number of false-positive screening tests can occur, potentially leading to unnecessary surgeries
and subsequent issues of morbidity and cost [82]. Consequently, multimodal strategies, in par‐
ticular the combination of CA125 with pelvic ultrasound, have been examined, in order to im‐
prove sensitivity and positive predictive value of ovarian cancer screening.
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In the general population, TVUS appears to be superior to transabdominal ultrasound in the pre‐
operative diagnosis of adnexal masses. Both techniques have lower specificity in premenopaus‐
al  women  than  in  postmenopausal  women  due  to  the  cyclic  menstrual  changes  in
premenopausal ovaries (e.g., transient corpus luteum cysts) that can cause difficulty in the inter‐
pretation. The randomized prospective Prostate, Lung, Colorectal, and Ovarian Cancer Screen‐
ing Trial found no reduction in mortality with the annual use of combined TVUS and CA125 in
screening asymptomatic, postmenopausal women at average risk of ovarian cancer [83].
Data are limited regarding the potential benefit of TVUS in screening women at inherited risk
of ovarian cancer. A number of retrospective studies have reported experiments with ovarian
cancer screening in high-risk women using TVUS with or without CA125 [84-90].
However, there is little uniformity in the definition of high-risk criteria and compliance with
screening, and in whether the cancers detected were incident or prevalent. One of the largest re‐
ported studies included 888 BRCA1/BRCA2 mutation carriers who were annually screened
with TVUS and CA125. Ten women developed ovarian cancer; five of the ten developed inter‐
val cancers after normal screening results within 3 to 10 months before diagnosis. Five of the ten
ovarian cancers were screen-detected incident cases, which had had normal screening results
within 6 to 14 months before diagnosis. Out of these five cases, four were stage IIIB or IV [85].
A similar study reported the results of annual TVUS and CA125 combined-screening in a
cohort of 312 high-risk women (152 BRCA1/BRCA2 mutation carriers) [86]. Out of four cancers
detected because of abnormal TVUS and CA125, all cases were symptomatic, and three had
an advanced-stage disease. Annual screening of BRCA1/BRCA2 mutation carriers with pelvic
ultrasound, TVUS, and CA125 failed to detect early-stage ovarian cancer among 241 women
in a study from the Netherlands [87]. Three cancers were detected over the course of the study,
all advanced stage IIIC disease. Finally, a study of 1,100 moderate- and high-risk women who
underwent annual TVUS and CA125 combined screening reported that ten out of 13 ovarian
tumours were detected due to screening. Only five out of ten were stage I or II [88]. There are
limited data related to the efficacy of semiannual screening with TVUS and CA125 [89].
The first prospective study of TVUS and CA125 with survival as the primary outcome was com‐
pleted in 2009. Out of 3,532 high-risk women screened, 981 were BRCA mutation carriers, of
which 49 developed ovarian cancer. The 5- and 10-year survival was 58.6% (95% CI, 50.9–66.3)
and 36% (95% CI, 27–45), respectively, and there was no difference in survival between carriers
and non-carriers. A major limitation of the study was the absence of a control group. Despite
these limitations, this study suggests that annual surveillance by TVUS and CA125 level appears
to be ineffective in detecting tumours at an early stage to substantially influence survival [90].
4.2. Serum CA125
Serum  CA125  screening  for  ovarian  cancer  in  high-risk  women  has  been  evaluated  in
combination with TVUS in a number of retrospective studies, as described in the previous
section [84-90].
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The National Institutes of Health (NIH) Consensus Statement on Ovarian Cancer recommend‐
ed against routine screening of the general population for ovarian cancer with serum CA125.
The NIH Consensus Statement did, however, recommend that women at inherited risk of
ovarian cancer undergo TVUS and serum CA125 screening every 6 to 12 months, beginning
at the age of 35 years [91]. The Cancer Genetics Studies Consortium task force recommends
that female carriers of a deleterious BRCA1 mutation undergo annual or semi-annual screening
using TVUS and serum CA125 levels, beginning at age of 25 to 35 years [92]. Both recommen‐
dations are based solely on expert opinion and best clinical judgment.
NCCN for those patients who have not chosen RRSO, consider concurrent TVUS (preferably
day 1-10 menstrual cycle women in premenopausal women) + CA125 (preferably after day 5
of menstrual cycle women in premenopausal women) every 6 months starting at the age of 30
years or 5-10 years before the earliest age of first diagnosis of ovarian cancer in the family [93].
Although there are retrospective data indicating that annual ovarian cancer screening using
TVUS and measurement of serum CA125 levels is neither an effective strategy for the early
detection of ovarian tumours nor a reasonable substitute for a bilateral RRSO, the effectiveness
of these interventions is limited to six-monthly screening. Investigational imaging and
screening studies may be considered for this population.
4.3. Proton Magnetic Resonance Spectroscopy (MRS)
MRS has proved to be a reliable technique for probing metabolic patterns, biochemical effects
of tumour microenvironment, and the action of therapy in cancer cells, both in vivo and in
vitro [94]. In particular, an increase in the total choline-containing compounds (tCho) content
allows to distinguish malignant from benign lesions in the breast [95].
Moreover, some studies have also shown alterations of the phospholipid metabolism in vitro
using epithelial ovarian carcinoma cell lines [96,97], and demonstrated the feasibility of 3D CSI
MRS to detect a choline peak in ovarian lesions in vivo at 1.5 T.
Then, the metabolic meaning of a high concentration of choline in ovarian tumours merits
some consideration. This topic has been extensively reviewed by Podo et al. in 2007 [98]. The
high choline concentration of ovarian tumours can be considered as the result of an inappro‐
priate storage attributable to metabolic deregulation associated with clinical indicators of
increased malignancy. The possibility of using a spatially resolved approach for MRS of
ovarian masses opens an intriguing prospect for the diagnosis of early-stage tumours, with
potential impact on the overall survival. This is especially true for carriers of a BRCA mutation,
with a lifetime risk of 39% to 46% among women with the BRCA1 mutation and a risk of 12%
to 20% among those with the BRCA2 mutation [99].
Based on peer-reviewed published data, several institutions established the Guidelines to
facilitate clinical management of patients with a suggestive personal or family history of breast
and/or ovarian cancer, in particular individuals from a family with a known deleterious
BRCA1/2 mutation. Screening options include transvaginal ultrasonography (TVUS), and
serum CA125, while prevention options include medical therapy with drugs and surgery such
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as RRSO. The guidelines, summarized in Table 8, include age ranges for which these options
should be begun and how often screening should take place. [53].
Management options NCCN [62]
ACOG Committee on Genetics








Every 6 months starting
at age 30 years
Periodic screening beginning
between the ages 30 years and
35years
Every 6 to 12
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Chemoprevention Considered Considered Considered Not considered
Investigational imaging
and screening studies
Considered Considered Considered Not considered
Table 8. Published Guidelines/Consensus Statements for the management of BRCA mutation carriers.
4.4. Human Epididymis Protein 4 (HE4)
Additional potential serum biomarkers have been studied for the detection of ovarian cancer.
For instance, human epididymis protein 4 (HE4) is a secreted glycoprotein over-expressed by
serous and endometrioid ovarian cancers and expressed by 32% of ovarian cancers lacking
CA125 expression.
To define the clinical utility of HE4, a comprehensive assessment of HE4 protein expression
in benign and malignant ovarian and non-ovarian tissues by immunohistochemistry was
performed and published in 2005. In comparison with normal surface epithelium, which does
not express the protein, HE4 was widely found in cortical inclusion cysts lined by metaplastic
Mullerian epithelium. These findings suggested that the formation of Mullerian epithelium is
a prerequisite step in the development of some types of epithelial ovarian cancer. Moreover,
the expression was restricted to certain histologic subtypes: 93% of serous and 100% of
endometrioid epithelial ovarian cancers expressed HE4, while only 50% and 0% of clear cell
carcinomas and mucinous tumours, respectively, were positive. HE4 protein expression is
restricted in normal tissue to the reproductive tracts and respiratory epithelium. In fact, tissue
microarrays revealed that the majority of non-ovarian carcinomas do not express HE4 [100].
In 2008 the Food and Drug Administration (FDA) approved HE4 to monitor disease recurrence
and this marker was recently incorporated into the clinical evaluation of ovarian cancer
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patients. Recently, Moore et al. published a series of papers that used a combination of CA125,
HE4 and menopausal status to predict the presence of a malignant ovarian tumour and
developed the Risk of Ovarian Malignancy Algorithm (ROMA), a simple biomarker based
algorithm, which requires US [101, 102].
In the last few years, several multi-modal screenings of women at high risk, combining
different approaches, were carried out to improve ovarian cancer diagnostic test performance
[103,104]. In 2010, a prospective case-control study was designed to evaluate the independent
contributions of HE4, CA125 and the Symptom Index (SI) to predict ovarian cancer status in
a multivariate model [105]. The SI is a screening tool that evaluates specific symptoms in
conjunction with their frequency and duration to identify women who are at risk of ovarian
cancer [106]. The SI, HE4 and CA125 all made significant independent contributions to ovarian
cancer prediction. A rule for the positive cut-off based on anyone of the three tests being
positive had a sensitivity of 95% with specificity of 80%. A rule based on any two of the three
tests being positive had a sensitivity of 84% with a specificity of 98.5%. The SI alone had
sensitivity of 64% with specificity of 88%. If the SI index is used to select women for CA125
and HE4 testing, specificity is 98.5% and sensitivity is 58% using the 2-of-3-positive positive
cut-off rule. A comparison between different markers in ovarian cancer early diagnosis is




CA125 was dichotomized at 95th percentile in the control group. Subjects with a
marker value above that threshold were considered to be positive for CA125.
HE4
HE4 was dichotomized at 95th percentile in the control group. Subjects with a marker
value above that threshold were considered to be positive for HE4.
Symptom Index (SI)
The SI was considered to be positive if the patient had at least one of the following
symptoms for less than one year but more than 12 times per month: bloating or
increased abdominal size, abdominal or pelvic pain, difficulty eating or feeling full
quickly.
Marker Combinations
CA125 or HE4 Screen considered positive if CA125, HE4 or both were positive.
SI or CA125
Screen considered positive if either the SI or CA125 was positive, or if both were
positive.
SI or HE4 Screen considered positive if either the SI or HE4 was positive, or if both were positive.
Any 1 of 3 tests positive
Screen considered positive if any one of the SI or CA125 or HE4 was positive, or if two
or more tests were positive.
Any 2 of 3 tests positive
Screen considered positive if both the SI and CA125 were positive, or if both the SI
and HE4 were positive, or if both CA125 and HE4 were positive, or if all three tests
were positive.
SI and at least 1 additional test
positive
Classified as positive if SI was positive in addition to either a positive CA125 or a
positive HE4, or if all three tests were positive.
Table 9. Description of screening tests and biomarker combinations.
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4.5. Proteomic profiling of ovarian cancer for biomarker discovery
Unfortunately, current diagnostic tools have had very limited success in early detection. The
search for an ovarian cancer screening method with improved specificity and sensitivity has
led to the examination of serum biomarker patterns using new ‘omic’ technologies [107-110].
In recent years, the advancing techniques for proteomics have accelerated the research for
ovarian cancer biomarkers. Numerous proteomics-based molecular biomarkers/panels have
been identified and hold great potential for diagnostic applications, but they need further
development and validation.
Several studies have analysed the proteomic profiles of ovarian tumour tissue, cell lines, urine,
ascites fluid and blood samples from ovarian cancer patients (Table 10) [111- 114].





Ferritin light chain ↑
Proteasome alpha-6 ↑
NAGK (N-acetyl glucosamine kinase) ↑
Petri et al., (2009) [112]
fibrinogen alpha fragment ↑
collagen alpha 1 (III) fragment ↑
fibrinogen beta NT fragment ↑





mitochondrial short-chain enoyl-CoA hydratase ↑
Prohibitin ↑
Cortesi et al.,(2011) [114]
Annexin-5 (ANXA5) ↓
Phosphatidylethanolamine-biding protein 1 (PEBP) ↓
glutathione S-transferase A2 (GSTA2) ↓
galectin-3 (LEG3) ↓
protein S100-A8-calgranulin A (S100A8) ↑
retinol binding protein (RET1) ↓
Table 10. Promising biomarkers discovered by proteomic technology for ovarian cancer diagnosis.
An et al. [111] identified that different histologic subtypes of ovarian malignant epithelial
tumours showed distinctly different protein expression profiles. The potential candidate
biomarkers screened in ovarian tumours and found to be significantly up-regulated in
comparison to normal tissues were: NM23, annexin-1, protein phosphatase-1, ferritin light
chain, proteasome R-6, and NAGK (N-acetylglucosamine kinase). More recently, Petri et al.
[112] examined whether urine could be used to measure specific ovarian cancer proteomic
Preventive Strategies for Ovarian Cancer
http://dx.doi.org/10.5772/54686
61
patients. Recently, Moore et al. published a series of papers that used a combination of CA125,
HE4 and menopausal status to predict the presence of a malignant ovarian tumour and
developed the Risk of Ovarian Malignancy Algorithm (ROMA), a simple biomarker based
algorithm, which requires US [101, 102].
In the last few years, several multi-modal screenings of women at high risk, combining
different approaches, were carried out to improve ovarian cancer diagnostic test performance
[103,104]. In 2010, a prospective case-control study was designed to evaluate the independent
contributions of HE4, CA125 and the Symptom Index (SI) to predict ovarian cancer status in
a multivariate model [105]. The SI is a screening tool that evaluates specific symptoms in
conjunction with their frequency and duration to identify women who are at risk of ovarian
cancer [106]. The SI, HE4 and CA125 all made significant independent contributions to ovarian
cancer prediction. A rule for the positive cut-off based on anyone of the three tests being
positive had a sensitivity of 95% with specificity of 80%. A rule based on any two of the three
tests being positive had a sensitivity of 84% with a specificity of 98.5%. The SI alone had
sensitivity of 64% with specificity of 88%. If the SI index is used to select women for CA125
and HE4 testing, specificity is 98.5% and sensitivity is 58% using the 2-of-3-positive positive
cut-off rule. A comparison between different markers in ovarian cancer early diagnosis is




CA125 was dichotomized at 95th percentile in the control group. Subjects with a
marker value above that threshold were considered to be positive for CA125.
HE4
HE4 was dichotomized at 95th percentile in the control group. Subjects with a marker
value above that threshold were considered to be positive for HE4.
Symptom Index (SI)
The SI was considered to be positive if the patient had at least one of the following
symptoms for less than one year but more than 12 times per month: bloating or
increased abdominal size, abdominal or pelvic pain, difficulty eating or feeling full
quickly.
Marker Combinations
CA125 or HE4 Screen considered positive if CA125, HE4 or both were positive.
SI or CA125
Screen considered positive if either the SI or CA125 was positive, or if both were
positive.
SI or HE4 Screen considered positive if either the SI or HE4 was positive, or if both were positive.
Any 1 of 3 tests positive
Screen considered positive if any one of the SI or CA125 or HE4 was positive, or if two
or more tests were positive.
Any 2 of 3 tests positive
Screen considered positive if both the SI and CA125 were positive, or if both the SI
and HE4 were positive, or if both CA125 and HE4 were positive, or if all three tests
were positive.
SI and at least 1 additional test
positive
Classified as positive if SI was positive in addition to either a positive CA125 or a
positive HE4, or if all three tests were positive.
Table 9. Description of screening tests and biomarker combinations.
Ovarian Cancer - A Clinical and Translational Update60
4.5. Proteomic profiling of ovarian cancer for biomarker discovery
Unfortunately, current diagnostic tools have had very limited success in early detection. The
search for an ovarian cancer screening method with improved specificity and sensitivity has
led to the examination of serum biomarker patterns using new ‘omic’ technologies [107-110].
In recent years, the advancing techniques for proteomics have accelerated the research for
ovarian cancer biomarkers. Numerous proteomics-based molecular biomarkers/panels have
been identified and hold great potential for diagnostic applications, but they need further
development and validation.
Several studies have analysed the proteomic profiles of ovarian tumour tissue, cell lines, urine,
ascites fluid and blood samples from ovarian cancer patients (Table 10) [111- 114].





Ferritin light chain ↑
Proteasome alpha-6 ↑
NAGK (N-acetyl glucosamine kinase) ↑
Petri et al., (2009) [112]
fibrinogen alpha fragment ↑
collagen alpha 1 (III) fragment ↑
fibrinogen beta NT fragment ↑





mitochondrial short-chain enoyl-CoA hydratase ↑
Prohibitin ↑
Cortesi et al.,(2011) [114]
Annexin-5 (ANXA5) ↓
Phosphatidylethanolamine-biding protein 1 (PEBP) ↓
glutathione S-transferase A2 (GSTA2) ↓
galectin-3 (LEG3) ↓
protein S100-A8-calgranulin A (S100A8) ↑
retinol binding protein (RET1) ↓
Table 10. Promising biomarkers discovered by proteomic technology for ovarian cancer diagnosis.
An et al. [111] identified that different histologic subtypes of ovarian malignant epithelial
tumours showed distinctly different protein expression profiles. The potential candidate
biomarkers screened in ovarian tumours and found to be significantly up-regulated in
comparison to normal tissues were: NM23, annexin-1, protein phosphatase-1, ferritin light
chain, proteasome R-6, and NAGK (N-acetylglucosamine kinase). More recently, Petri et al.
[112] examined whether urine could be used to measure specific ovarian cancer proteomic
Preventive Strategies for Ovarian Cancer
http://dx.doi.org/10.5772/54686
61
profiles and whether one peak alone or in combination with CA125 or other peaks had the
sensitivity and specificity to discriminate between ovarian cancer pelvic mass and benign
pelvic mass. Twenty-one significantly different peaks (p<0.001) were examined and the three
most significant peaks were identified as fibrinogen alpha fragment, collagen alpha 1 (III)
fragment and fibrinogen beta NT fragment. These results supported the feasibility of using
urine as a diagnostic tool and suggested the enhanced prediction performance of combined
marker analysis. Li et al. [113] performed a comparative proteomic study of normal ovarian
epithelial and ovarian epithelial serous cystadenocarcinoma tissue and identified six proteins
significantly differentially expressed. In particular, Prx-II expression was found to be linearly
decreased from normal ovarian tissue, to benign ovarian lesions, and ovarian malignancies.
No statistical difference between carcinoma groups in different clinical stages, differentiation
status, and histological type was seen, suggesting that the decreased level of Prx-II is a common
marker for ovarian malignancies. This was the first report on the altered expression of Prx-II
in ovarian cancer.
A recent comparative proteomic study investigated and defined protein expression patterns
associated with advanced stage ovarian cancer, to define a panel of diagnostic and/or prog‐
nostic markers. The study also investigated proteins secreted by the cancer cell into the
interstitial fluid, as cancer growth and progression also depends on stromal factors present in
the tumour microenvironment. Moreover, many biomarkers present in biopsied cancer tissues
can also be found in blood serum, representing potential biomarkers of the disease. Proteomic
profiling of differentially expressed proteins in cancer ovarian tissue, tumoral interstitial fluid
(TIF) and ascitic fluid, compared with healthy tissue samples and normal interstitial fluid
(NIF), allowed the identification of protein spots consistently differentially expressed between
normal and cancer samples. Protein expression/identification was evaluated by 2-DE (two-
dimensional gel electrophoresis) and MS (mass spectrometry) analysis and was confirmed by
immunohistochemistry. Six proteins showed differential expression in tumoral interstitial
fluid and tumour tissue compared to normal interstitial fluid and healthy tissue. Differential








ANXA5 -1,88 ± -0,48 <0,0001 -5,605 ± -3,29 <0,01
PEBP -4,21 ± -2,90 <0,01 -2,82 ± -0,69 <0,0001
GSTA2 -4,67 ± -1,88 <0,0001 -27,39 ± -21,24 <0,01
LEG3 -2,19 ± -0,69 <0,0001 -5,10 ± -4,42 <0,05
S100A8 3,67 ± 1,50 <0,001 3,58 ± 1,11 <0,0001
RET1 -6,33 ± -3,30 <0,001 -5,01 ± -4,28 <0,05
The fold change indicates the direction and the magnitude of the change in expression level. Data are expressed as mean
± standard deviation.
Table 11. Modification in protein expression in tumoral tissue and interstitial fluid
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Five were found to be down-regulated and identified as galectin 3, glutathione S-transferase
A-2, retinol binding protein 1, phosphatidylethanolamine-binding protein and annexin 5,
while the calgranulin, was significantly up-regulated in all pathological samples, including
the ascitic fluid. This is the first study to report an over-expression of calgranulin by 2-DE
analysis combined with MS/MS on surgical biopsy. As previously reported, the reduced
expression of galectin 3 and retinol binding protein 1 in cystic fluid and serum of patients with
early stage disease is confirmed in this study. The results highlight alterations in proteins that
control cell-cycle progression and apoptosis, as well as factors that modulate the activity of
signal transduction pathways. Moreover, this study suggests that calgranulin expression may
be used as a diagnostic and/or prognostic biomarker [114].
However, critical assessment of the results has shown significant shortcomings and uncer‐
tainties with regard to the reproducibility of the findings and identity of the proteins behind
the peak patterns, thus, the validation of the newly discovered biomarkers still remains the
most challenging aspect of clinical proteomics. The advancing techniques for proteomics have
shown promise in a variety of studies and have provided new insights into ovarian cancer
diagnosis, but few have turned out to be useful in the clinic. At present, the development of
an effective strategy for early detection of ovarian cancer is still a work in progress [110].
5. Discussion
Primary and secondary prevention of ovarian cancer play a crucial role in the attempt to
improve the overall survival from the disease. In particular, primary prevention is based on
avoiding risk factors and increasing protective factors. Despite the identification of several risk
and protective factors among the general population, most of the common factors described
to date only slightly influence the risk of developing ovarian cancer, thus, the knowledge of
these factors has still not been translated into practical strategies to prevent ovarian cancer.
On the other hand, primary prevention could represent a good opportunity for high-risk
women. Women who inherit a mutation in either the BRCA1 or BRCA2 gene have greatly
elevated lifetime risks of ovarian cancer, fallopian tube cancer and breast cancer. Surveillance
for ovarian and fallopian tube cancer has not been proven to be effective. For this reason,
preventive surgical removal of the ovaries and fallopian tubes (salpingo-oophorectomy) is
actively recommended to these women by the age of 35 or 40 years, often prior to natural
menopause, to prevent cancer. Moreover, women at increased risk may join a cancer preven‐
tion clinical trial or a chemoprevention trial. In particular, oral contraceptive use can be
considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1
mutation carriers who do not accept RRSO above the age of 30 years. Other chemopreventive
agents such as retinoids, analgesic drugs, vitamin D, cyclo-oxygenase inhibitors and peroxi‐
some proliferator activated receptor-gamma ligands have shown promise in early investiga‐
tions of disease prevention.
Regarding radiological methods to investigate ovaries and their adnexes, new techniques
besides TVUS need to be explored. Pelvic Magnetic Radiological Imaging could be of interest
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even if it is difficult to imagine such an expensive technique being employed in the screening
of high-risk women. For high-risk women, recommended cancer screening strategies, which
need to be adjusted depending on the earliest age of onset in a family, have not been assessed
by randomized trials or case-control studies. Ovarian cancer screening relies on a combination
of annual or semi-annual pelvic examination, annual or semi-annual transvaginal ultrasound
examination with colour Doppler, and annual measurement of serum CA125 concentrations.
Current approaches are a futile attempt to detect ovarian cancer in the early stages, but future
research should be directed to better characterizing critical pathways in ovarian carcinogenesis
and to identifying appropriate surveillance programs based on biomarker tests and/or
radiological investigations, in order to improve overall survival, which dramatically decreases
in the first 5 years. Due to the fact that an analysis of potentially thousands of proteins which
could be simultaneously altered is necessary, comparative proteomics is a promising mode of
potential biomarker discovery for cancer detection and monitoring. A better estimation of the
biological importance of certain proteins with regard to the progression from pre-neoplastic
tissue alterations to malignant tumours, as well as the prediction of the metastasis-forming
potential by biomarkers, will be a necessary prerequisite to provide a more detailed insight
and understanding of tumour progression.
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even if it is difficult to imagine such an expensive technique being employed in the screening
of high-risk women. For high-risk women, recommended cancer screening strategies, which
need to be adjusted depending on the earliest age of onset in a family, have not been assessed
by randomized trials or case-control studies. Ovarian cancer screening relies on a combination
of annual or semi-annual pelvic examination, annual or semi-annual transvaginal ultrasound
examination with colour Doppler, and annual measurement of serum CA125 concentrations.
Current approaches are a futile attempt to detect ovarian cancer in the early stages, but future
research should be directed to better characterizing critical pathways in ovarian carcinogenesis
and to identifying appropriate surveillance programs based on biomarker tests and/or
radiological investigations, in order to improve overall survival, which dramatically decreases
in the first 5 years. Due to the fact that an analysis of potentially thousands of proteins which
could be simultaneously altered is necessary, comparative proteomics is a promising mode of
potential biomarker discovery for cancer detection and monitoring. A better estimation of the
biological importance of certain proteins with regard to the progression from pre-neoplastic
tissue alterations to malignant tumours, as well as the prediction of the metastasis-forming
potential by biomarkers, will be a necessary prerequisite to provide a more detailed insight
and understanding of tumour progression.
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1. Introduction
Borderline ovarian tumors (BOT) were first described in 1929 by Taylor, which, due to the
characteristics of the tumor, called it “semi malignant” or “borderline” [1]; subsequently, this
group of tumors of the ovary were classified in 1973 by the World Health Organization as “low
malignant potential ovarian tumor” [2] and, finally, in 2003 WHO separates them from
carcinomas and call them borderline tumors. [3]
Another term accepted to designate these independent ovarian neoplasms is “atypical
proliferating (or atypical proliferative) tumor”. [4]
Borderline ovarian tumors represent 10-20% of epithelial ovarian neoplasm’s [5] with an
incidence of 1.8-4.8 out of 100.000 women per year [6] and typically have an excellent prognosis.
Unlike the invasive carcinomas, borderline ovarian tumors are characterized by cytoplasmic
and nuclear atypia, (element of differential diagnosis with benign tumors), absence of stromal
invasion, (element of differential diagnosis with malignant tumors), unusual degree of
proliferation of the epithelial cells with cellular stratification including remarkable architec‐
tural atypia and the formation of papillary protuberances. The absence of obvious stromal
invasion is a principal diagnostic criterion for BOTs. Histologically, most of them are serous
or mucinous, but endometrioid, clear cell, Brenner (transitional cell) or mixed histotypes can
be also seen. [7]
To date, there are still no prospective randomized trials to clinical management, although they
have an excellent prognosis, with a 5-year overall survival rate of almost 100% in early-stage
disease (stage I-II) and between 86% and 92% in more advanced disease (stage III-IV). [8]
© 2013 Cormio et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
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2. Classification, pathology and clinical behavior
Although they might occur in every age, most of the cases are diagnosed in pre-menopausal
women between 34 and 40 years [9], while malignant ovarian cancer usually is diagnosed in
patients between 50 and 70 years.
Risk factors for the development of BOTs are absolutely similar to those known for ovarian
cancer, menarche, age at first pregnancy, age at first delivery, menstrual history, smoking
history and family history of ovarian cancer, except that BOTs seem to have a lower frequency
of BRCA mutations.
Borderline ovarian tumors are staged according to the FIGO classification of ovarian cancer.
In 80% of cases patients with BOTs are in FIGO stage I at the time of diagnosis, about 30% of
patients are in stage II-III in the same percentages each, while stage IV BOTs are very rare. [10]
2.1. Serous borderline tumors
They represent the 70% of BOTs, and 9-15% of all serous neoplasms [11,12] the mean age at
presentation is 38 years old (range 17-77). [13] According to the FIGO staging system, [14] 68%
are Stage I, 11% Stage II, 21% Stage III and less than 1% Stage IV. [15]
These neoplasms can be divided in two subtypes:
• APTSs, Atypical proliferative serous tumors, behave in a benign way and show a papillary
architecture with a hierarchical pattern
• Non-invasive MPSCs, micopapillary serous borderline tumors, with a non hierarchical
pattern, characterized by the presence of micropapilla, they are more associated with
invasive implants and a worse prognosis than APTSs.
APTSs in 25-30% of cases they are bilateral, macroscopically they appear as cysts with serous
contents with friable and exuberant papillary projections. (Figure 1) These papillae are mostly
observed on the inner surface of the cyst, but in 70% of cases also in the external one. Rarely
these serous BOTs show solid components.
Histologically APTSs show the presence of papillae with extensive epithelial stratification and
budding, the epithelial cells have low or moderate atypias, in the fluid a detachment of single
cells can be seen, there must not be any sign of invasion (Figure 2), but microinvasion (not
more than 10 mm2) can be present in up to 15% of cases. F [13, 16, 17] Some patients with stage
I microinvasive tumors have developed progressive disease and microinvasion for some
authors can be considered as risk factor for patients with high-stage disease. [18]
The cells in APTS can show an epithelial and occasionally a mesothelial differentiation. The
nuclei of these cells present more atypia than those seen in benign cystoadenomas, the nuclei
are usually basally located and ovoid or rounded, the nucleoli are only occasionally prominent
and the mitosis are not so common (usually less than four per ten high-power fields, HPF). [4]
APTSs are occasionally also associated to the presence of endosalpingiosis or non invasive
peritoneal implants, referred as the phenomenon of autoimplantation can be observed as the
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presence of foci resembling non invasive desmoplastic peritoneal implants with a well-
delineated border on the ovarian surface, this phenomenon does not have any clear known
pathogenesis nor clinical significance. [13, 19, 20, 16, 17] Signs of necrosis are very rare. [4]
APTSs are usually positive for CK7, OC-125 and cytokeratin and express estrogen and
progesterone receptors. [4]
Non-invasive MPSCs, are serous borderline tumors characterized by the presence of micro‐
papillae arising from central papilla, when this specific pattern constitutes either a 5 mm or
grater area or 10% or greater proportion.
In invasive MPSCs (synonymous of low-grade serous carcinoma) the stromal invasion must
exceed 5 mm.
Non-invasive MPSCs represent 14% of all BOTs. The mean age at diagnosis is about 42 years,
in 70% of cases they are bilateral and 50% of patients are in stage I at the time of diagnosis,
while the other 50% are in stage II or III.
On gross appearance, non-invasive MPSC s look like cysts with papillae without or with little
necrosis just like APSTs but in contrast to them they present mostly with peritoneal implant
and bilaterality; the mean size is about 8 cm.
Histologically they are neoplasm with high degree of epithelial proliferation in a non hier‐
archical branching architecture, with micropapillary and cribriform patterns. [4]
The differential diagnosis should be done with serous cystadenomas, serous mucinous or
endometrioid borderline tumors and with malignant neoplasm.
Survival in serous BOTs differs significatively from serous invasive ovarian cancer and is
characterized by an excellent prognosis.
Figure 1. Serous borderline ovarian tumor
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Figure 2. Serous borderline ovarian tumors
2.2. Mucinous borderline tumors
Mucinous BOTs are less common than their serous counterparts. They are also called “atypical
proliferative mucinous tumor” (APMT) or “mucinous tumor of low malignant potential”. They
are often associated to pseudomyxoma peritonei (PMP) a condition characterized by the
presence of mucinous ascites and mucoid peritoneal implant
They can be divided into two subtypes:
• Gastrointestinal type
• Endocervical-like type (müllerian or seromucinous)
The first type in 95% of cases is unilateral and appears macroscopically as a multicystic large
neoplasm (mean size of about 20 cm) with a smooth capsule.
The cysts contain inside a mucinous material and their surfaces very rarely show the presence
of papillary projections.
Histologically, the stromal invasion is absent, the epithelium is stratified, mucinous gastroin‐
testinal-type, with villoglandular of papillary intraglandular growth; the cells show moderate
atypia in their nuclei. [4]
Their biological behaviour is very benign with a survival rate of nearly in early stages 100%.
The tumors in advanced stage have a mortality of 50%, but mostly are associated with
pseudomyxoma peritonei and probably all these case can be considered of primary gastroin‐
testinal and not ovarian origin (usually appendix but also pancreas and biliary tract). For this
reason is generally accepted that the true primary APMT in advanced stage do not really exist
and that those cases with mucin or benign mucinous epithelium implant on the peritoneum
can be explained by the rupture of the cyst and should not be classified as PMP or as APMT
with peritoneal implants. [4]
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Atypical proliferative mucinous tumors of endocervical-like type are more frequently bilateral,
smaller and are often associated with endometriosis. Macroscopically and microscopically
they resemble APTS with a combination of endocervical mucinous and serous epithelium.
These neoplasms very rarely present with peritoneal implants or signs of microinvasion
(defined as the presence of single or small cluster of cells within the stroma) and have a benign
behaviour.
In same cases these tumors can show a severe atypia and epithelial overgrowth still without
any sign of stromal invasion, these cases are referred to “non invasive or intraepithelial
carcinoma” and have still an excellent prognosis in stage I. [4]
The immunohistochemistry pattern of mucinous BOTs is characterized by the expression of
cytokeratin (CK) 7 and 20, but no positivity for estrogen and progesterone receptors and Ca125;
in the differential diagnosis with intestinal tract tumors this can be very helpful (the neoplasms
of intestinal tract origin express CK20 but not CK 7). [4]
The differential diagnosis should be done with metastatic mucinous carcinomas to the ovary
and benign or invasive mucinous neoplasms of ovarian origin.
2.3. Endometrioid borderline tumors
Endometrioid tumors of the ovary are usually carcinomas, while borderline forms are very
rare; they can arise from endometriosis and can also be associated to endometrial hyperplasia.
Endometrioid BOTs, also called Atypical Proliferative Endometrioid Tumors (APET), account
for the 0,2% of ovarian epithelial neoplasms. [4]
Macroscopically they appear as cyst sometimes with solid compounds with hemorrhagic
brown fluid inside, in about 60% of cases endometriotic foci are also associated. [4]
Figure 3. Endometrioid borderline ovarian tumor
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Atypical proliferative mucinous tumors of endocervical-like type are more frequently bilateral,
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(defined as the presence of single or small cluster of cells within the stroma) and have a benign
behaviour.
In same cases these tumors can show a severe atypia and epithelial overgrowth still without
any sign of stromal invasion, these cases are referred to “non invasive or intraepithelial
carcinoma” and have still an excellent prognosis in stage I. [4]
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Figure 3. Endometrioid borderline ovarian tumor
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Histologically they have glandular and papillary proliferation with different grade of com‐
plexity, with moderate or mild atypia in their cells, sometimes they show also squamous
metaplasia and necrosis (Figure 3). A microinvasive APET can also be described if the glan‐
dular proliferation becomes confluent and the confluent area is less than 5 mm (otherwise it
becomes a carcinoma) and this does not seem to be a negative prognostic factors.
Also in case of APET with intraepithelial carcinoma (referred to the presence of severely
atypical cells, but without any sign of invasion) the prognosis remains benign.
The immunohistochemistry pattern of endometrioid BOTs is characterized by the expression
of CK7, CK20 and p16 only focally. [4, 21]
2.4. Clear cell borderline tumors
Clear cell tumors of the ovary are usually carcinomas, while borderline forms are very rare;
they are usually associated to endometriosis and sometimes to endometrial disorders.
Clear cell BOTs, also called Atypical Proliferative Clear Cell Tumors (APCCT), represent the
0,2% of ovarian epithelial neoplasm, their incidence is higher in elder people than other BOTs
(mean age 60-70 years).
Macroscopically, they usually appear as cyst with a smooth lobulated surface, clear fluid inside
and the cut surface has minute cyst in a rubbery stroma (honeycomb appearance). Microscop‐
ically, they are characterized by the presence of tubular glands lined by more layers of hobnail
cells, with a more crowded architecture, more epithelial proliferation and more atypia in their
cells, when compared to their benign counterparts (clear cell adenofibromas). [4]
As for other BOTs microinvasive APCCT or APCCT with intraepithelial carcinoma can be
described, but they are actually very rare, while peritoneal implants have not been described.
The prognosis of these forms of BOTs in early stage is also very benign. [4, 22]
2.5. Borderline brenner (transitional cell) tumors
Transitional cell tumors of the ovary account for 10% of all the epithelial ovarian neoplasm,
they are usually benign while malignant and borderline forms have been described but are
very uncommon.
Borderline Brenner (Transitional cell) tumors are also called Atypical Proliferative Brenner
(Transitional cell) tumors, the mean age at presentation is about 69 years; they are usually
unilateral and in stage I at the moment of diagnosis.
Macroscopically, they are cystic, quite large (mean diameter of about 20 cm) with papillary
projections in the inner surface.
Histologically, they are characterized by a transitional urothelial like epithelium, with benign
areas and parts with proliferation and atypia. No cases of intraepithelial carcinoma or
microinvasion have been described in literature.
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In immunohistochemistry these neoplasms are usually positive for CEA, EGFR, Ras and
negative for p16, p53 and cyclin d.
The prognosis is very good, with only one lethal case of recurrence occurred 50 months after
the primary surgery reported in literature. [4, 23]
3. Diagnosis
The only certain diagnosis of BOT can be done by pathologists on the histological examina‐
tions, despite this, better understanding before surgery if an adnexal mass is benign, borderline
or malignant is very important to decide if surgery is required and the surgical approach. The
diagnosis of BOT can be suggested by the presence of certain symptoms, serum markers and
image techniques patterns.
3.1. Symptoms
The range and type of symptoms claimed by BOT patients are similar to invasive cancer
patients,
Most commonly [80%) patients with Borderline tumors of the ovary complain of abdominal
symptoms like abdominal pain or increased abdominal size, discomfort, tense abdomen;
10-35% of these patients complain of gastrointestinal symptomatology like changes in bowel
habits, nausea or constipation; 15% complain of gynaecological symptoms like abnormal
vaginal bleeding and dyspareunia (more patients when compared with invasive cancer); 5-26%
complain of urinary symptoms especially urinary frequency or urgency; 5-7% present with
weight loss and malaise and increased urinary urgency or frequency, very few patients
(around3%) complain chest pain or breathing problems. Some studies demonstrated that
patients with borderline ovarian tumour are more likely to have no symptoms than patient
with invasive cancer. [24, 25, 26, 27, 28, 29, 30, 31]
Olsen et al compared symptoms of women with benign, borderline and invasive ovarian
tumors, and demonstrated that patients with invasive cancer reported a greater number of
symptoms (3.1 and 3.6 for Stages I-II and III-IV, respectively) than women with borderline or
benign tumors. (2.8 and 2.2 respectively; p < 0.0001). [31]
3.2. Serum markers
Many studies tried to identify a serum marker that could distinguish BOT from invasive and
benign ovarian tumors.
Ca-125 increases in BOT patients, less than in women with invasive cancer; anyway this marker
is not so useful in the diagnosis especially because it can overlap between patients with stage
I ovarian carcinoma or benign adnexal masses like endometriomas, abscesses or myomas and
BOT patients. [27, 32, 33]
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Ca-125 can instead, be used in the follow up and to primarily assess the severity of the disease
because several studies demonstrated that it increases more in advanced stage BOT than early
ones. [34, 35, 36, 37, 38]
Ca-19.9 increases in 18,8 – 48,8% of patients, probably more in serous hystotype, [35, 39], while
Carcinoembryonic antigen (CEA) levels increases in 17% of patients and more in mucinous
tumor. [35, 39, 40]
Ca 72-4 increases in BOT with no differences within the hystotypes, anyway the levels of this
serum marker are similar in patients with ovarian cancer. [35, 41]
3.3. Ultrasound
Transvaginal ultrasound is well known to be an effective primary screening imaging technique
in patients with adnexal masses to distinguish benign from malignant conditions.
Up to 63% of patients with BOT present on the ultrasound a cyst with papillae inside, but
without solid patterns, septa or any other sign of complexity. [42, 43]
BOTs appears on ultrasound images usually as:
• unilocular cyst with solid papillary projections (defined as any projections with a height
greater than or equal to 3 mm) arising from the inner wall and with a positive ovarian
crescent sign (Figure 4, 5)
• cyst with a “honeycomb nodule”, defined as a multilocular nodule mostly with a solid
pattern with cystic areas arising from the inner cyst wall. (Figure 6) [42, 43, 44, 45]
Figure 4. Unilocular cyst with solid papillary projections in BOTs
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Figure 5. Papillary projections in BOTs
Figure 6. Honeycomb nodule in BOTs
11% of these tumors can appear as simple anechoic cysts without any papillae, and up to 30%
as cysts with septa. (Figure 7) [42, 43, 45]. For these reasons, neither the presence of papillae
nor septa can be considered as sensitive sonographic markers of borderline tumors, in fact it
has been shown that also benign tumors can contain papillae or septa. [42, 46]
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Figure 7. Cyst with septa in BOTs
The ovarian crescent sign is defined as the presence of healthy ovarian tissue adjacent to the
cyst wall seen on the ultrasound images as an hypoechogenic area with or without ovarian
follicles that cannot be separated from the mass when applying pressure with the transvaginal
probe; it has been shown that the presence of this sign can be used to exclude the diagnosis of
invasive ovarian cancer. [47]
Yazbek et al demonstrated that the presence of papillae and crescent signs are suggestive of a
serous or endocervical hystotype while the presence of thick echogenic fluid and honeycomb
nodules are suggestive of gastrointestinal hystotype, moreover Exacoustos et al found that the
serous types seem to be smaller than mucinous. [43, 45]
Yazbek et al conclude that the diagnosis of BOT with ultrasound can be achieved in 68.6%,
more in serous or endocervical (75%) than in gastrointestinal hystotype (60%). [45]
The role of Doppler ultrasound is still not clear in the diagnosis of BOTs, some authors found
a difference in the resistance index and pulsatility index between BOT, benign tumors and
invasive cancers, these indexes seem to gradually decrease with the grade of malignancy of
the condition. [48, 49, 50]
Otherwise, Tekay et al found no statistically significative differences in the resistance and
pulsatility indexes values between invasive, borderline and benign ovarian tumors. [51]
The vessel distribution within the tumor tissue has also been studied deeply but there are not
still any clear conclusions, some authors demonstrated that BOT show similar vascular
patterns to benign or malignant conditions. [42, 43, 49, 52]
Exacoustos et al found that the flow was present respectively in benign, borderline and
malignant tumors in 80, 97 and 100% of cases and that usually a peripheral vascularization is
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present mostly in benign masses, while intramural or intrapapillae flow is present mostly in
borderline or malignant conditions. (Figure 8, 9) [43]
The study of the distribution of the flow or the resistance and pulsatility indexes cannot be
considered effective neither in the differential diagnosis between the different histotypes. [53]
Figure 8. Flow distribution in BOTs
The use of contrast medium injected intravenously has been also suggested as a technique able
to discriminate benign from borderline and malignant condition, a multicentre study including
10 cases of BOT and totally 89 patients with ovarian masses concluded that the use of second
generation contrast agent like Sono Vue, Bracco, Netherland can be useful in the differential
diagnosis between benign and malignant condition but not between borderline and benign
ovarian masses. [54]
3.4. Computerized tomography, magnetic resonance and positron emission tomography
Computerized tomography seems not to discriminate BOT from malignant ovarian tumors, it
can recognize the complex architecture of BOT, but the tissue contrast is limited so that it is
not so clear the contrast between the solid and cystic components of these tumors; the role of
CT scan is then mostly limited to detect the presence of metastases and to estimate the FIGO
stage. [55, 56]
Magnetic Resonance is the best image technique to characterize borderline ovarian tumors.
Bent et al described the appearance of BOT on MR images, and identified four morphological
categories: unilocular cysts (19%), minimally septate cysts with papillae (19%), markedly
septate lesions with plaque-like excrescences (45%) and predominantly solid with exophytic
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papillary projections (16%); they also concluded that MRI can be helpful in the differential
diagnosis of BOT and in surgical planning. [57]
In T1- and T2-weighted images BOTs solid tissues are usually intermediate in signal intensity
and they demonstrate also enhancement after the administration of gadolinium-based contrast
media. [57, 58, 59, 60] The enhancement pattern seems to be useful in the differential diagnosis
between benign, borderline and invasive ovarian tumors. [61]
In a series of 168 ovarian masses (23 BOT) Bazot et al estimated that the sensitivity and
specificity of MRI for the diagnosis of BOT are 45.5% and 96.1%, respectively. [62]
Positron emission tomography can increase the accuracy of other imaging techniques in the
diagnosis of BOT.
Malignant cells use glucose to survive, for this reason invasive cancer are characterized on PET
images by a higher uptake of 18F-fluorodeoxyglucose than both BOT and benign tumors that
do not have a high glycolitic rate. [64, 65, 66, 67]
Nam et al investigated the role of combined 18F-fluorodeoxyglucose positron emission
tomography/computerized tomography (FDG-PET/CT) and found that it can be more accurate
than ultrasound, CT and MRI in the differential diagnosis between BOT, benign and malignant
ovarian cancer. [68]
4. Treatment and follow up
Surgery represents the gold standard treatment and a complete surgical staging is mandatory
and very important. Lin et al found out that only in 12% of cases the primary surgical stadiation
is actually right. Moreover, BOTs are also difficult to diagnosed in frozen section, many
apparent BOTs on frozen section are found to be frankly malignant in permanent sections (the
correct diagnosis is achieved in 58-86%) of patients and it depends especially on the experience
of the pathologists.
The surgical approach in the management of BOT is similar to the one used in the malignant
forms and includes: total abdominal hysterectomy, bilateral salpinogo-oophorectomy,
omentectomy, peritoneal washings, and multiple biopsies, including pelvic and pariaortic
lymph nodes sampling for the stadiation.
In mucinous BOTs is strongly recommended to perform appendectomy and to carefully
analyze the entire intestinal tract to exclude a gastrointestinal tumor.
Because of the excellent prognosis and the young age of these women the treatment is
becoming always more conservative and fertility sparing surgery can be considered [69, 70],
it consists in ovariectomy or simple cystectomy.
Because 15% of patients who undergone unilateral salpingo oophorectomy develop a primary
tumor in the preserved ovary [13, 71] the conservative approach should be considered
carefully. In all cases a carefully inspection of the capsule to find any sign of rupture should
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be performed in case of fertility sparing surgery. Several reports suggest that the overall
disease-specific survival rates between the radical e the fertility sparing surgical approaches
are not different. [70, 72] Thus, it appears that young women who desire future fertility can be
safety treated with fertility-sparing surgery without compromising their overall survival.
Barnhill DA et al suggested that a simple cystectomy should be performed only in selected
cases if the tumor is in stage I, can be removed completely and is loosely attached. [73]
The contralateral ovary must be carefully macroscopically inspected, but performing a biopsy
is not recommended in order to avoid the occurrence of adhesions that can affect the future
fertility capacity of the patient. Some surgeon suggest to women with BOTs who had under‐
gone fertility sparing surgery to complete the radical surgery after the completion of child‐
bearing.
BOTs in advanced stage should be treated with debulking surgery.
The role of adjuvant therapy is still not clear. At this time, there is no proven benefit from adju‐
vant therapy, even in advanced-stage disease and with the presence of invasive implants. [74]
Generally, in absence of invasive implants, watchful expectancy should be considered, while
adjuvant chemotherapy (usually platin based chemotherapy) should be offered to patients
with invasive implants, with the persistence of residual tumor after surgery and in clinically
progressive disease.
The follow up of these patients must be performed for more than 10 years after the primary
treatment since long term recurrence (even after 20 years) have been observed especially in
women who underwent a conservative surgical approach. The follow up should include pelvic
and gynecological examinations, ultrasound and measurement of serum markers.
5. Our experience: 55 cases
Fifty-five women with borderline ovarian tumors were identified a tour institution from 1991
to 2011, median age at diagnosis was 40 years (range 13-79). The most common symptoms
complained by patients at the moment of diagnosis were abdominal-or pelvic pain and
discomfort. The tumor diameter ranged between 0.5 and 10 cm and 5.4% of patients presented
ascites at the time of diagnosis.
Only in the 47% patients, [26] tumor markers were evaluated before primary surgery, specif‐
ically CA125 was higher in 13 (23.6%), CA19.9 in 2 (3.6%) and 4 patients (7.3%) presented with
both of these markers increased.
Our expert pathologist in Gynecological oncology pathology found 33 serous, 18 mucinous, 1
endometrioid and 3 mixed borderline ovarian tumors.
All women underwent surgery as primary treatment, 72,8% with laparotomic approach,
whereas 13 women (23.6%) underwent a laparoscopic one; in particular 20 patients (36.4%)
had a total abdominal hysterectomy with bilateral salpingo-oophorectomy, 2 patients (3.6%)
Borderline Epithelial Tumors of the Ovary
http://dx.doi.org/10.5772/54828
89
papillary projections (16%); they also concluded that MRI can be helpful in the differential
diagnosis of BOT and in surgical planning. [57]
In T1- and T2-weighted images BOTs solid tissues are usually intermediate in signal intensity
and they demonstrate also enhancement after the administration of gadolinium-based contrast
media. [57, 58, 59, 60] The enhancement pattern seems to be useful in the differential diagnosis
between benign, borderline and invasive ovarian tumors. [61]
In a series of 168 ovarian masses (23 BOT) Bazot et al estimated that the sensitivity and
specificity of MRI for the diagnosis of BOT are 45.5% and 96.1%, respectively. [62]
Positron emission tomography can increase the accuracy of other imaging techniques in the
diagnosis of BOT.
Malignant cells use glucose to survive, for this reason invasive cancer are characterized on PET
images by a higher uptake of 18F-fluorodeoxyglucose than both BOT and benign tumors that
do not have a high glycolitic rate. [64, 65, 66, 67]
Nam et al investigated the role of combined 18F-fluorodeoxyglucose positron emission
tomography/computerized tomography (FDG-PET/CT) and found that it can be more accurate
than ultrasound, CT and MRI in the differential diagnosis between BOT, benign and malignant
ovarian cancer. [68]
4. Treatment and follow up
Surgery represents the gold standard treatment and a complete surgical staging is mandatory
and very important. Lin et al found out that only in 12% of cases the primary surgical stadiation
is actually right. Moreover, BOTs are also difficult to diagnosed in frozen section, many
apparent BOTs on frozen section are found to be frankly malignant in permanent sections (the
correct diagnosis is achieved in 58-86%) of patients and it depends especially on the experience
of the pathologists.
The surgical approach in the management of BOT is similar to the one used in the malignant
forms and includes: total abdominal hysterectomy, bilateral salpinogo-oophorectomy,
omentectomy, peritoneal washings, and multiple biopsies, including pelvic and pariaortic
lymph nodes sampling for the stadiation.
In mucinous BOTs is strongly recommended to perform appendectomy and to carefully
analyze the entire intestinal tract to exclude a gastrointestinal tumor.
Because of the excellent prognosis and the young age of these women the treatment is
becoming always more conservative and fertility sparing surgery can be considered [69, 70],
it consists in ovariectomy or simple cystectomy.
Because 15% of patients who undergone unilateral salpingo oophorectomy develop a primary
tumor in the preserved ovary [13, 71] the conservative approach should be considered
carefully. In all cases a carefully inspection of the capsule to find any sign of rupture should
Ovarian Cancer - A Clinical and Translational Update88
be performed in case of fertility sparing surgery. Several reports suggest that the overall
disease-specific survival rates between the radical e the fertility sparing surgical approaches
are not different. [70, 72] Thus, it appears that young women who desire future fertility can be
safety treated with fertility-sparing surgery without compromising their overall survival.
Barnhill DA et al suggested that a simple cystectomy should be performed only in selected
cases if the tumor is in stage I, can be removed completely and is loosely attached. [73]
The contralateral ovary must be carefully macroscopically inspected, but performing a biopsy
is not recommended in order to avoid the occurrence of adhesions that can affect the future
fertility capacity of the patient. Some surgeon suggest to women with BOTs who had under‐
gone fertility sparing surgery to complete the radical surgery after the completion of child‐
bearing.
BOTs in advanced stage should be treated with debulking surgery.
The role of adjuvant therapy is still not clear. At this time, there is no proven benefit from adju‐
vant therapy, even in advanced-stage disease and with the presence of invasive implants. [74]
Generally, in absence of invasive implants, watchful expectancy should be considered, while
adjuvant chemotherapy (usually platin based chemotherapy) should be offered to patients
with invasive implants, with the persistence of residual tumor after surgery and in clinically
progressive disease.
The follow up of these patients must be performed for more than 10 years after the primary
treatment since long term recurrence (even after 20 years) have been observed especially in
women who underwent a conservative surgical approach. The follow up should include pelvic
and gynecological examinations, ultrasound and measurement of serum markers.
5. Our experience: 55 cases
Fifty-five women with borderline ovarian tumors were identified a tour institution from 1991
to 2011, median age at diagnosis was 40 years (range 13-79). The most common symptoms
complained by patients at the moment of diagnosis were abdominal-or pelvic pain and
discomfort. The tumor diameter ranged between 0.5 and 10 cm and 5.4% of patients presented
ascites at the time of diagnosis.
Only in the 47% patients, [26] tumor markers were evaluated before primary surgery, specif‐
ically CA125 was higher in 13 (23.6%), CA19.9 in 2 (3.6%) and 4 patients (7.3%) presented with
both of these markers increased.
Our expert pathologist in Gynecological oncology pathology found 33 serous, 18 mucinous, 1
endometrioid and 3 mixed borderline ovarian tumors.
All women underwent surgery as primary treatment, 72,8% with laparotomic approach,
whereas 13 women (23.6%) underwent a laparoscopic one; in particular 20 patients (36.4%)
had a total abdominal hysterectomy with bilateral salpingo-oophorectomy, 2 patients (3.6%)
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had a bilateral salpingo-oophorectomy with uterus sparing and the remaining 33 women [60%)
performed a procedure strictly interested the ovary. Omentectomy was performed in 32
patients [58%) whereas para aortic lymph node dissection in only 1 patient and appendectomy
in 17 patients (31%). Peritoneal biopsies were performed in 27 women (49%), peritoneal
cytology in 29 cases (53%) and positive in only 2 (7%).
Forty-seven patients were in FIGO stage I (85.4%), most of these in IA stage (41 patients, 74.5%),
4 patients were in stage II (7.3%) and the last 4 patients in stage III (7.3%).
Fifty-four patients (98.2%) had no residual tumor after surgical procedure, while 1 patient
(1.8%) had macroscopic residual tumor ≤2 cm in the ovary and peritoneal carcinomatosis.
After surgery only 2 patients (3.7%) were treated with adjuvant platinum-based combination
chemotherapy for their stage IIC and IIIC; both patients achieved a complete response after
treatment.
The other patients did not received any other treatment.
The median disease free survival and the 5-year survival rate of our patient population were
42 months (range 16-84) and 97%, respectively.
The statistical analysis performed with Kaplan Meier method and log rank test showed that
the survival in patients who underwent fertility-sparing surgery did not differ from those who
had a complete surgical staging (p=0.08). No significative differences were observed when
comparing the different stages (Stage I-II vs Stage III; p=0.7), histological type (serous versus
mucinous, endometrioid and mixed tumor; p=0.15), tumor size (> 10 cm vs < 10 cm; p=0.39),
surgical approach (laparotomy vs laparoscopy; p=0.56), elevation of CA125 at diagnosis
(positive vs negative marker; p=0.55).
Six patients developed a recurrence of the disease. All of them underwent a secondary
laparotomy, four with a conservative approach and two with a complete surgical staging
because of the presence of invasive implants. These two patients received then also chemo‐
therapy. All the six women were alive with no evidence of disease with a median survival of
39 months.
We were able to obtain the fertility status of 16 patients who underwent a fertility-sparing
surgery. Four of these women became pregnant and the rest of them had not a desire of
childbearing at the time of their last follow up. One of these pregnancies was obtained by in
vitro fertilization techniques, while the rest of them were spontaneous.
6. Conclusions
In conclusion, BOTs have an excellent prognosis of nearly 100% of survival rate.
Conservative fertility sparing surgery should be considered for women in the reproductive
age group who desire preservation of fertility.
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In any case, a long-term follow-up is highly recommended for these tumors because recur‐
rences can occur several years after primary treatment.
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1. Introduction
The incidence of ovarian cancer in 2008 was projected to be 225,500 new cases and 140,200
deaths worldwide, representing 3.7% of all female cancers and 4.2% of all cancer deaths in
women [1]. Ovarian cancer, one of the major causes of death from cancer in women, is
commonly diagnosed at an advanced stage. Cytoreductive surgery followed by chemotherapy
combining platinum and taxane is currently the standard treatment for ovarian cancer [2].
Ovarian cancer is one of the most sensitive solid tumors, with objective responses ranging from
60 to 80% even in patients with advanced stage. However, most patients ultimately recur and
develop resistance to platinum and taxane.
Resistance to chemotherapy presents a major obstacle in attempting to improve the prognosis
of patients with ovarian cancer. Accordingly, it is important to elucidate the mechanisms of
chemoresistance to manage ovarian cancer. Recently, the biological characteristics of ovarian
cancer have been clarified. It has long been known that ovarian cancers of serous histology
appear to be more sensitive to chemotherapy than other histological subtypes. Patients with
clear cell carcinoma or mucinous adenocarcinoma of the ovary showed a significantly worse
prognosis in a retrospective review of several Gynecologic Oncology Group (GOG) trials [3].
Therefore, it is important to determine optimal regimens based on histological subtype. In this
chapter, clear cell carcinoma and mucinous adenocarcinoma of the ovary are discussed.
2. Clear cell carcinoma
Clear cell carcinoma (CCC) has unique clinical and biological features [4]. In North America and
Europe, CCC is the third most common histological subtype of epithelial ovarian cancer (EOC),
with an estimated prevalence of 1-12% [5, 6]. For unknown reason, CCC comprises more than
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20% of such cancers in Japan [7-9]. Interestingly, among Asian women living in the United States,
CCC was diagnosed twice as frequently (11.1%) compared to Caucasians (4.8%) [10].
Several studies have analyzed the risk factors for ovarian cancer by histologic subtype. CCC
was associated (odds ratio: 2.2-2.3) with an increased body mass index (BMI 30) [11, 12].
However, in the NIH-AARP Diet and Health Study BMI was correlated only with endome‐
trioid histology [13].
It has long been recognized that CCC often is associated with endometriosis (22-70%), where‐
as hobnail cells bear a very strong morphological resemblance to endometrial Aria-Stella cells
[14, 15]. Several studies have reported that endometriosis frequently shows a sequential change
to EOC, including CCC. Therefore, atypical endometriosis is considered to be a precancerous
change. Ovarian cancers associated with endometriosis tend to occur in younger women, and
present 5-6 years earlier, on average, than high-grade serous carcinoma (HGSC) [16]. In National
Cancer Institute Surveillance, Epidemiology and End Results (SEER) data, women with CCC
were younger than patients with serous adenocarcinoma (SAC) (55 vs. 64 years; median age) [10].
An increased incidence of vascular thromboembolic complications is seen in patients with CCC
[17, 18]. Up to 40% of patients with CCC may develop thromboembolic disease and this rate
is double that in matched non-CCC controls with ovarian cancers [19].
3. Clinicopathological features
Ovarian CCC usually presents as a large pelvic mass [20, 21]. The size of masses range from 3
to 20 cm, with most tumors detected preoperatively either by clinical examination or imaging.
Recent reports involving large institutional cohorts compared early-stage (I/II) to advanced-
stage ovarian cancers (III/IV) and showed that 57-81% of CCC were diagnosed at an early stage
[9, 22]. In SEER data, 56% of CCC were stage I, compared to 19% for SAC [10]. Combining the
low overall incidence of CCC and their early stage propensity, CCC may make up only 1-5%
of advanced stage patients in chemotherapy trials, largely due to their overall low incidence
and tendency for early stage distribution at the time for initial diagnosis [6].
Sugiyama, et al. [9] retrospectively reviewed 101 patients with CCC in Japan who underwent
complete surgical staging to determine clinicopathological features of CCC. Histologic
evaluation was performed under central pathological review. Tumors were diagnosed as CCC
if the following appeared in 90% or more of all specimens: a small to large sheet of polyhedral
clear cells with delicate fibrovascular septa, tubules and papillae, clear or hobnail, or eosino‐
philic cells of organoid appearance, or clear cells with coalescent vacuoles containing "targe‐
toid" eosinophilic PAS-positive globules. Of the 662 patients with EOC, 101 (15.3%) had CCC
and 235 (35.5%) SAC. All patients underwent complete surgical staging, including intraperi‐
toneal cytology, bilateral salpingo-oophorectomy, hysterectomy, omentectomy, pelvic-/
paraaortic lymphadenectomy, and aggressive cytoreductive surgery for advanced cases.
Ninety-seven (96%) of 101 patients with CCC and 229 (97%) of 235 with SAC underwent
platinum-based chemotherapy after initial surgery.
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The median age did not differ between patients with CCC and those with SAC. The percentage
of patients at stage I was significantly higher in CCC than SAC (16.6%), while significantly
fewer patients were at stage III had CCC than SAC (61.7%). By contrast, the incidence of stage
III was significantly lower in CCC than in SAC. Recurrence in patients with CCC occurred in
29% of stage I patients, 30% of stage II, 62% of stage III, and 73% at stage IV. Although none
of the patients with stage Ia CCC relapsed, 14 of 38 patients (37%) with stage Ic did relapse.
In stage III disease the median survival time was significantly shorter for patients with CCC
than those with SAC. The survival rate for patients at stage III was significantly lower in the
CCC group than in the SAC group. Although estimated survival rates at 3 and 5 years in
patients with no gross tumor did not differ significantly between CCC and SAC, survival rates
in both patients with <2 cm and >2 cm residual disease were significantly lower in CCC than
in SAC. Jenison, et al. [23] showed that the survival rates for CCC were consistently lower in
each of the FIGO stages compared with SAC, although there was no statistical significance. In
their study, median survival time for stage I patients with CCC was significantly shorter than
that for those with SAC. Similarly, the survival rate for patients with stage Ic CCC was lower
compared with patients with stage Ic SAC. Additionally, the median survival time for stage I
patients with CCC was worse than those with SAC (31.8 months vs 42.3 months) and the time
to recurrence in patients with stage I/II CCC was definitely shorter (12.2 months) [9]. Twenty-
seven patients with stage III/IV CCC had measurable disease after initial surgery. The overall
clinical response rate for SAC was 72.5%. In contrast, only three (11.1%) of 27 patients re‐
sponded to platinum-based chemotherapy in CCC. Patients with CCC showed a very low rate
of response and a high incidence of progressive disease. Another authors demonstrated that
platinum-based chemotherapy did not appear to improve the survival of patients with CCC,
compared with survival after non-platinum-based chemotherapy [24]. Additionally, CCC
patients with residual tumor showed a high recurrence rate (Fig 1). CCC has a more aggressive
course and a more malignant behavior than SAC. Therefore, new treatment strategies for CCC,
including alternative regimens of chemotherapy, should be established.
4. Mechanisms of platinum resistance in CCC of the ovary
There is general acceptance of CCC that is insensitive to conventional platinum-based
chemotherapy lead to a poor prognosis. Resistance to cisplatin (CDDP) is an important factor
in the poor prognosis of patients with CCC. Several mechanisms involved in drug resistance
have been proposed as explanations, including decreased drug accumulation, increased drug
detoxification, increased DNA repair activity, and activation of receptor tyrosine kinases and
its downstream signaling pathways [25-29].
Adenosine 5’-triphosphate (ATP)-binding cassette (ABC) transporters, such as ABCB1 (also
known as P glycoprotein), ABCC1 (multidrug resistance associated protein-1) and ABCC3, are
known to lower intracellular drug concentrations and are important multidrug resistance
factors [30]. An immunohistochemical study of ABCB1 and ABCC1 in CCC and SAC tumors
revealed that their expression of these transporters did not differ between CCC and SAC [31].
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In addition, no significant differences were observed in the expression of ABCB1 and ABCC1
between responders and non-responders to platinum-based chemotherapy in both tumor
types. These results suggest that multidrug resistance proteins do not contribute to chemore‐
sistance in CCC. Ohishi, et al. [32] examined the expression of mRNA by ABCC superfamily
members, ABCC1, ABCC2, and ABCC3, in CCC and SAC tumors. They found that only ABCC3
genes were expressed significantly more in CCC than SAC. Therefore, they concluded that
increased expression of ABCC3 may, at least in part, be associated with the chemoresistant
phenotype of CCC.
Several drug detoxification systems also can diminish intracellular drug activity. Cellular
detoxification via the glutathione system is known to be involved in the metabolism of various
cytotoxic agents, including the platinum agents, etoposide (VP-16), and mitomycin C (MMC)
[27, 28, 33, 34]. Indeed, the glutathione concentrations in CCC cell lines increased significantly
after exposure to CDDP or MMC [35]. A gene expression study showed that glutathione
peroxidase 3 (GPx3), glutaredoxin (GLRX), and superoxide dismutase (SOD2) were expressed
highly in CCC tumors and that the elevated levels of these, and perhaps other, antioxidant
proteins may render the tumors more resistant to chemotherapy [36].
Nucleotide excision repair (NER) is a multienzyme DNA repair pathway in eukaryotes that
has been implicated in drug resistance in human tumor cells [37]. Reed, et al. [38] examined
the mRNA expression of two key genes, excision repaircross-complementing rodent repair
deficiency, complementation group 1 (ERCC1) and xeroderma pigmentosum group B (XPB),
that are involved in the NER pathway of EOC tumors. Expression of ERCC1 and XPB were
higher in CCC tumors than in other histological tumor types. This phenomenon may be related
to de novo drug resistance against chemotherapeutic agents in CCC. DNA mismatch repair
systems (MMR), which correct errors that occur during DNA replication, also play a critical
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Figure 1. Progression free survival rate for stage III and IV patients, and residual tumor diameter. Progression free sur‐
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MMR are highly tolerant to the methylating chemotherapeutic drugs streptozocin and
temozolomide and, to a lesser extent, CDDP and doxorubicin [39]. Loss of MMR may be caused
either by a germline mutation of two major MMR genes, hMLH1 or hMSH2, or by somatic
MMR gene inactivation through epigenetic silencing via methylation of the hMLH1 promoter.
Cai, et al. [40] reported that elevated expression of hMLH1 and hMSH2 proteins are involved
in the development of a subset of CCC, and that there is a strong correlation between alterations
in the expression of hMLH1 and hMSH2 and the presence of MSI in CCC tumors.
Epidermal growth-factor receptor (EGFR) and v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2 (ERBB2; HER2) are cell-surface-receptor tyrosine kinases and can activate both the
signaling pathways of mitogen-activated protein kinase and phosphatidylinositol 3’-kinase
(PI3K)-Akt [41]. Activating these pathways leads to phosphorylated Bc1-2 antagonist cell death
(BAD) and B-cell leukemia/lymphoma (Bcl)-2, thereby inhibiting chemotherapy-induced
apoptosis [42]. An immunohistochemical study showed found EGFR in 61% of CCC tumors
[43]. Molecular analyzes of various types of ovarian tumors showed HER2 to be overexpressed
in CCC relative to other major histological types of EOC [44]. In ovarian cancer, the HER2
protein is overexpressed as a consequence of HER2 gene amplification in 20 to 25% of cases
and predicts a poor prognosis [45, 46].
Cell proliferation is controlled by cyclin-dependent kinases (CDK), which are regulated by
cyclin binding, phosphorylation, and CDK inhibitors (e.g. p16, p21, and p27) [47]. p53, known
as a tumor suppressor protein, also up-regulates expression of p21 and causes cell the cycle to
arrest at G1. Changes in the p53 gene are seen in 50 to 70% of cases of advanced serous
adenocarcinoma [48, 49]. In contrast, the p53 mutation is rare in CCC, and immunohistochem‐
ical staining shows that CCC tends to express little or no p53 protein [50]. Cytotoxic drugs are
primarily effective against proliferating cells; therefore, quiescent cells show a degree of
resistance relative to cycling cells [51]. Dimanche-Boitrel, et al. [52] reported that less intracel‐
lular drug accumulates in resting cells. Itamochi et al. examined the proliferation activity and
CDDP sensitivity of 11 CCC and 5 SAC cell lines, and this found that the doubling time for
CCC cells was significantly longer than for SAC (61.4 vs 29.8 h) [7]. There was a significant
reverse correlation between the S-phase fraction and the response to CDDP. These findings
may relate to the high incidence of stage I patients with CCC, and also suggests that the
resistance of CCC to CDDP may be caused by low cell proliferation. In addition, Ki-67, a
nuclear antigen expressed in all states of the cell cycle except in resting cells in G0, has a
significantly lower labeling index in CCC than in SAC [31]. Furthermore, a significantly higher
Ki-67 labeling index (LI) is observed in responders than in non-responders in both CCC and
SAC tumors.
The 5-year survival rate for high LI patients (over 18.4%; mean value for CCC) was significantly
greater than that for low LI (less than 18.4%) ( 46.3% vs. 9.2%, p<0.05) (Fig. 2). A multivariable
analysis revealed that the Ki-67 labeling index and residual tumor size were independent
prognostic factors. Other authors have reported that immunohistochemical staining of CCC
reveals a low expression of Ki-67, p53, and cyclin A, and significantly increased expression of
both p21 and cyclin E, which are other histological subtypes [53]. These results suggest that
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[27, 28, 33, 34]. Indeed, the glutathione concentrations in CCC cell lines increased significantly
after exposure to CDDP or MMC [35]. A gene expression study showed that glutathione
peroxidase 3 (GPx3), glutaredoxin (GLRX), and superoxide dismutase (SOD2) were expressed
highly in CCC tumors and that the elevated levels of these, and perhaps other, antioxidant
proteins may render the tumors more resistant to chemotherapy [36].
Nucleotide excision repair (NER) is a multienzyme DNA repair pathway in eukaryotes that
has been implicated in drug resistance in human tumor cells [37]. Reed, et al. [38] examined
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deficiency, complementation group 1 (ERCC1) and xeroderma pigmentosum group B (XPB),
that are involved in the NER pathway of EOC tumors. Expression of ERCC1 and XPB were
higher in CCC tumors than in other histological tumor types. This phenomenon may be related
to de novo drug resistance against chemotherapeutic agents in CCC. DNA mismatch repair
systems (MMR), which correct errors that occur during DNA replication, also play a critical
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MMR are highly tolerant to the methylating chemotherapeutic drugs streptozocin and
temozolomide and, to a lesser extent, CDDP and doxorubicin [39]. Loss of MMR may be caused
either by a germline mutation of two major MMR genes, hMLH1 or hMSH2, or by somatic
MMR gene inactivation through epigenetic silencing via methylation of the hMLH1 promoter.
Cai, et al. [40] reported that elevated expression of hMLH1 and hMSH2 proteins are involved
in the development of a subset of CCC, and that there is a strong correlation between alterations
in the expression of hMLH1 and hMSH2 and the presence of MSI in CCC tumors.
Epidermal growth-factor receptor (EGFR) and v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2 (ERBB2; HER2) are cell-surface-receptor tyrosine kinases and can activate both the
signaling pathways of mitogen-activated protein kinase and phosphatidylinositol 3’-kinase
(PI3K)-Akt [41]. Activating these pathways leads to phosphorylated Bc1-2 antagonist cell death
(BAD) and B-cell leukemia/lymphoma (Bcl)-2, thereby inhibiting chemotherapy-induced
apoptosis [42]. An immunohistochemical study showed found EGFR in 61% of CCC tumors
[43]. Molecular analyzes of various types of ovarian tumors showed HER2 to be overexpressed
in CCC relative to other major histological types of EOC [44]. In ovarian cancer, the HER2
protein is overexpressed as a consequence of HER2 gene amplification in 20 to 25% of cases
and predicts a poor prognosis [45, 46].
Cell proliferation is controlled by cyclin-dependent kinases (CDK), which are regulated by
cyclin binding, phosphorylation, and CDK inhibitors (e.g. p16, p21, and p27) [47]. p53, known
as a tumor suppressor protein, also up-regulates expression of p21 and causes cell the cycle to
arrest at G1. Changes in the p53 gene are seen in 50 to 70% of cases of advanced serous
adenocarcinoma [48, 49]. In contrast, the p53 mutation is rare in CCC, and immunohistochem‐
ical staining shows that CCC tends to express little or no p53 protein [50]. Cytotoxic drugs are
primarily effective against proliferating cells; therefore, quiescent cells show a degree of
resistance relative to cycling cells [51]. Dimanche-Boitrel, et al. [52] reported that less intracel‐
lular drug accumulates in resting cells. Itamochi et al. examined the proliferation activity and
CDDP sensitivity of 11 CCC and 5 SAC cell lines, and this found that the doubling time for
CCC cells was significantly longer than for SAC (61.4 vs 29.8 h) [7]. There was a significant
reverse correlation between the S-phase fraction and the response to CDDP. These findings
may relate to the high incidence of stage I patients with CCC, and also suggests that the
resistance of CCC to CDDP may be caused by low cell proliferation. In addition, Ki-67, a
nuclear antigen expressed in all states of the cell cycle except in resting cells in G0, has a
significantly lower labeling index in CCC than in SAC [31]. Furthermore, a significantly higher
Ki-67 labeling index (LI) is observed in responders than in non-responders in both CCC and
SAC tumors.
The 5-year survival rate for high LI patients (over 18.4%; mean value for CCC) was significantly
greater than that for low LI (less than 18.4%) ( 46.3% vs. 9.2%, p<0.05) (Fig. 2). A multivariable
analysis revealed that the Ki-67 labeling index and residual tumor size were independent
prognostic factors. Other authors have reported that immunohistochemical staining of CCC
reveals a low expression of Ki-67, p53, and cyclin A, and significantly increased expression of
both p21 and cyclin E, which are other histological subtypes [53]. These results suggest that
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CCC has low tumor proliferation activity and that this low proliferation activity in CCC could
be associated with chemoresistance.
Figure 2. Estimated survival rates for patient with clear cell carcinoma. When the cut-off value of Ki-67 labeling index
(LI) was set at 18.4% (the mean value of clear cell carcinoma), the estimated 5-year survival rate for elevated Ki-67 LI
patients was significantly greater than that for low Ki-67 LI (46.3% vs. 9.2%).
5. Future directions
The clinicopathological features of CCC suggest that a new strategy for chemotherapy in CCC
should be adopted, focusing on new agents without cross-resistance to platinum agents.
Several anticancer agents with no cross-resistance to platinum analogues, such as paclitaxel
(PTX), VP-16, and camptothecin (CPT-11) have been developed.
Activating the PI3K/Akt pathway and its downstream signaling mammalian target of rapa‐
mycin (mTOR) seems to indicate drug resistance and poor prognosis in many cancers. It has
been reported that CCC has a high frequency of activating mutations of PIK3CA [54]. Because
it is known well that activation of Akt signaling results in hypersensitivity to mTOR inhibition,
CCC may be a good candidate for therapy with an mTOR inhibitor. Several clinical trials have
shown potential antitumor activities for mTOR inhibitors (everolimus, deforolimus, and
temsirolimus) in solid tumors. Temsirolimus (CCI779, a synthetic, ester analog of rapamycin)
is indicated to treat advanced renal cell carcinoma. A phase II study is ongoing to evaluate the
safety and efficacy of temsirolimus in combination with carboplatin and PTX followed by
temsirolimus consolidation as first-line therapy for patients with stage III-IV CCC in the ovary
(NCT01196429, ClinicalTrials.gov). We hope this combination therapy will improve the
survival of patients with ovarian CCC.
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6. Mucinous adenocarcinoma
Ovarian mucinous adenocarcinoma (MAC) is divided into intraepithelial and invasive
carcinomas (Fig. 3). Intraepithelial mucinous carcinoma is characterized by marled epithelial
atypia in the absence of stromal invasion. Invasive mucinous carcinoma is diagnosed once
stromal invasion measuring more than 5 mm or more than 10 mm2 is detected. Two types of
invasive mucinous caricinoma are recognized: expansile and infiltrative. The former is
characterized by conflicted glandular growth uninterrupted by normal ovarian parenchyma,
while the latter demonstrates a presence of small glands, nests or individual cells infiltrating
the stroma.
Figure 3. Criteria for central pathological review.
Intraepithelial mucinous carcinoma, FIGO stage I, has a recurrence rate of 5.8% [55]. Invasive
mucinous carcinoma, FIGO stage I, has a 5-year survival rate of 91%. Patients with advanced
tumors usually die of the disease [56]. Invasive mucinous carcinoma with an infiltrative pattern
has a more aggressive course than mucinous carcinoma with an expansile pattern. Interest‐
ingly, invasive mucinous caricinoma of the ovary often coexistes alongside areas of mucinous
borderline lesions and benign mucinous cystadenomas, suggesting that these lesions may be
precursors to invasive tumors [57].
Winter, et al. [3] reviewed the data from 6 GOG phase III trials of adjuvant chemotherapy with
CDDP and PTX in women with stage III EOC after primary debulking surgery, both optimal
and suboptimal. Of the 1,895 patients included in these 6 studies, 74% had SAC, while only
2% had MAC. The authors found that women with mucinous tumors had a progression-free
survival of 10.5 months, compared to 16.9 months for women with serous tumors. Women
with MAC had a relative risk of progression of 2.18 compared their serous counterparts
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CDDP and PTX in women with stage III EOC after primary debulking surgery, both optimal
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2% had MAC. The authors found that women with mucinous tumors had a progression-free
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(p<0.001) [69]. The relative risk of death from MAC for compared to SAC was 4.14 (p<0.001).
Shimada, et al. [58] compared 24 women with primary MAC to 189 women with SAC and
found response rates to platinum-based regimens of 12.5 % and 37.7% respectively. Pectasides,
et al. [59] compared 47 women with advanced stage primary MAC to 94 with advanced-stage
SAC, all of whom had received a platinum-based regimen in 1 of 9 Hellenic Cooperative
Oncology Group studies. The authors found a better response rate in women with SAC (70%
for serous vs 38.5 % for mucinous), although this did not translate into survival differences
between the 2 groups.
7. Clinicopathological features
Seidman, et al. [60] carefully reviewed the pathology of 220 consecutive cases of epithelial
ovarian cancer. After excluding carcinosarcomas and primary peritoneal cancers, they found
the incidence of primary MAC to be 3.4%. Other authors reviewed 1400 cases of EOC from 14
centers in Japan [58]. In this large group, 16% patients had an initial diagnosis of invasive
primary mucinous ovarian cancer. However, after a careful pathologic review, only 4.9% had
invasive primary ovarian cancer, with the remainder reclassified as either mucinous intraepi‐
thelial carcinoma, mucinous borderline tumors, or metastases from another site. Seidman and
colleagues argue that these lower estimates are likely a more accurate reflection of the incidence
of mucinous ovarian cancer because the following problems were likely in the literature: (1)
misclassification of a gastrointestinal primary tumor as an ovarian primary tumor (80% of
mucinous epithelial tumors found in the ovary are extraovarian in origin); (2) misclassification
of a mucinous borderline tumor as an invasive cancer; and (3) classification of pseudomyxoma
peritoneii as being of ovarian origin when it is now standard to consider all such cases as
intestinal in origin.
Mutations in KRAS, BRCA, and p53 are the most frequently studied single gene alterations in
ovarian cancer pathogenesis. Some investigators have gone beyond analysis of single gene
mutations and have used gene expression analysis to evaluate differences between serous and
mucinous ovarian carcinomas. Marchini, et al.[61] carried out genomic analyses using a
microarray chip with 16,000 genes and found that serous and mucinous tumors were easily
distinguished on the basis of expression profiles. Using a probe set of 59,000 genes, Heinzel‐
mann-Schwarz, et al. [62] likewise found clear separation in expression profiles between serous
and mucinous tumors of the ovary.
The role of the KRAS oncogene has been explored extensively in EOC. The RAS family of G
proteins is part of the pathway that signals cell division. Mutations in the RAS genes have been
found to stimulate cell growth [63]. In the literature, 50% of MAC had KRAS mutations,
compared to only 5% of SAC, 10% of endometrioid ovarian caricinomas, and no CCC [64].
Interestingly, the same KRAS mutations found in invasive mucinous tumors also are found in
adjacent borderline and benign mucinous lesions in the same specimens [65].
Mutations of BRCA1 and BRCA2 are thought to play a significant role in developing SAC but
not MAC. BRCA1 and BRCA2 are tumor suppressor genes that help to repair damaged DNA
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and are commonly mutated not only in inherited SAC but also in many cases of sporadic SAC.
Tonin, et al. [66] reviewed the histopathologic subtypes of ovarian carcinomas in 58 families
with hereditary breast and ovarian carcinomas. In those patients with known BRCA mutations,
64% had SAC, and only 2% had MAC. In contrast, among women with ovarian cancer negative
for BRCA mutation, 29% had MAC, and this proportion was significantly higher than among
women with BRCA mutation. Similarly, in a review of the literature that included 636 BRCA
mutation-positive women with ovarian cancer, only 2% were found to have mucinous
subtypes. p53 also seems to play a prominent role in carcinogenesis of serous ovarian tumors
but not mucinous ovarian tumors [70]. Mutations in p53 have been found in almost 60% of
serous tumors but in only 16% of mucinous tumors.
The expression of multiple individual proteins has been examined in serous and mucinous
tumor specimens using immunohistochemical stains. Compared to serous tumors, mucinous
tumors are more likely to express E-cadherin (62% vs. 4%, p<0.001) and less likely to stain
positive for N-cadherin (8% vs. 68%, p<0.001). The cadherin family of glycoproteins helps cells
establish contact with other cells and stabilize tissue architecture. The matrix metalloprotei‐
nases, which also play a role on cell migration and adhesion, have also been found to be
expressed differently between serous and mucinous tumors. Kobel, et al. evaluated 21 proteins
with immunohistochemistry in 500 ovarian cancer specimens. They found different expression
between serous and mucinous subtypes in 20 of the 21 biomarkers they examined, including
p53, cadherin, metalloproteinase, CA125, and WT-1. Collectively, these and other molecular
studies point toward a distinct pathogenesis of MAC compared to other histological subtypes
of ovarian cancer.
The majority of MAC are either well or moderately differentiated and this contributes to the
low risk of relapse for FIGO stage I tumors. It also is known that patients at an early stage show
good outcomes. On the other hand, patients with advanced mucinous adenocarcinoma are
recognized to have poorer outcomes. There was no significant difference in survival between
mucinous invasive adenocarcinoma and SAC in patients with optimal surgical management
[58]. In contrast, patients with suboptimal therapy showed a significantly worse prognosis
than those with SAC (Fig 4).
When a mucinous tumor is grossly limited to the ovary, there is little chance of occult lymph node
metastasis. Cho, et al. [71] reviewed 26 cases of MAC noted to be grossly stage I intraoperative‐
ly. All of these patients underwent lymphadenectomy as part of their staging procedures, and
none were found to have lymph node disease. In contrast, 10% of patients with apparent stage I
SAC of the ovary have been reported to have occult nodal metastasis at the time of diagnosis.
Using the Swedish Family Canter Database of over 6,000 women with a diagnosis of ovarian
cancer showed that the average overall survival was 34 months in women with serous sub‐
types, compared to 70 months for women with mucinous subtypes [72]. In addition, the hazard
ratio for cause-specific survival from MAC compared to SAC was 0.49 (95% confidence inter‐
val, 0.41-0.57); the corresponding hazard ratio for overall survival was 0.56 (95% confidence
interval, 0.48-0.64).
Patients with advanced-stage MAC had a worse prognosis than women with nonmucinous
EOC [73]. The authors matched 27 patients with MAC to 54 patients with nonmucinous ovarian
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The majority of MAC are either well or moderately differentiated and this contributes to the
low risk of relapse for FIGO stage I tumors. It also is known that patients at an early stage show
good outcomes. On the other hand, patients with advanced mucinous adenocarcinoma are
recognized to have poorer outcomes. There was no significant difference in survival between
mucinous invasive adenocarcinoma and SAC in patients with optimal surgical management
[58]. In contrast, patients with suboptimal therapy showed a significantly worse prognosis
than those with SAC (Fig 4).
When a mucinous tumor is grossly limited to the ovary, there is little chance of occult lymph node
metastasis. Cho, et al. [71] reviewed 26 cases of MAC noted to be grossly stage I intraoperative‐
ly. All of these patients underwent lymphadenectomy as part of their staging procedures, and
none were found to have lymph node disease. In contrast, 10% of patients with apparent stage I
SAC of the ovary have been reported to have occult nodal metastasis at the time of diagnosis.
Using the Swedish Family Canter Database of over 6,000 women with a diagnosis of ovarian
cancer showed that the average overall survival was 34 months in women with serous sub‐
types, compared to 70 months for women with mucinous subtypes [72]. In addition, the hazard
ratio for cause-specific survival from MAC compared to SAC was 0.49 (95% confidence inter‐
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cancer (2:1), all of whom had stage III or IV disease and had undergone primary therapy. There
was no difference between patients with the mucinous tumors and nonmucinous with regard
to histological grade, stage, optimal or suboptimal debulking, chemotherapy regimen, or
length of follow-up. Patients with advanced MAC had a progression-free survival of 5.7
months, compared to 14.1 for patients with nonmucinous ovarian cancer, and an overall
survival of 12.0 compared to 36.7 months.
8. Pathological diagnosis for MAC
Most MAC involving the ovary prove to be metastases, as opposed to ovarian primary
carcinomas. Therefore, surgeons and pathologists must have a high suspicion toward meta‐
static disease when considering the origin of MAC found in the ovary. Seidman, et al.[74] found
that only 23% of invasive mucinous carcinomas of the ovary were primary ovarian cancer.
Most clinicians assume that metastases to the ovary have a gastrointestinal origin. However,
although gastrointestinal tract tumors are the most common source of ovarian metastases,
accounting for 45% of such tumors, they also see ovarian metastases from primary tumors of
the pancreas (accounting for 20% of ovarian metastases), cervix (13%), breast (8%), and uterus
(5%). The remaining 10% of ovarian metastases are from unknown primary tumors [68].
At surgical exploration a working differential diagnosis can be developed on the basis of tumor
size and laterality. Among unilateral tumors, more than 80% of those larger than 10 cm are
ovarian primary tumors, while 88% of those smaller than 10 cm are metastases. This division
has been retrospectively validated by other investigators, who showed it to be correct 84% of
the time in differentiating primary from metastatic mucinous carcinomas of the ovary [74].
Other authors also have found this algorithm is useful in predicting the site of origin for ovarian
carcinomas [75, 76]. In addition, primary ovarian carcinomas tend to have a smooth capsule,
while ovarian metastases often involve the gross ovarian surface. However, the algorithm














Figure 4. Overall survival and residual tumor in mucinous adenocarcinoma (MAC). There was no significant difference
in survival between mucinous invasive adenocarcinoma and serous adenocarcinoma (SAC) in patients with optimal
surgical management. In contrast, patients with suboptimal surgery showed a significantly worse prognosis than
those with serous adenocarcinoma.
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presented above and the status of the ovarian surface should be used clinically with caution:
in one study, up to 24 % of the cases of colonic adenocarcinoma metastatic to the ovary showed
unilateral ovarian involvement with tumor measurements of at least 10 cm [77]. In the same
study, 46% of the cases with available information on gross intraoperative appearance had a
smooth capsule.
Although gross examination of the adnexae can often predict the site of origin, both ovarian
and extraovarian sources of primary disease should be explored. Intraoperatively, the surgeon
should perform a careful exploration of potential gatrointestinal sources, including palpating
the pancreas and running the entire small and large bowel. Postoperatively, the surgeon
should consider a colonoscopy and mammogram if these screening tests have not been
performed within the year prior to diagnosis.
Although the presence of certain histological features can favor a diagnosis of primary MAC
over metastasis, there are cases where a definitive diagnosis cannot be provided due to the
presence of discordant or overlapping features. Microscopic features that favor the diagnosis
of primary ovarian MAC include a coexisting borderline and benign mucinous components,
an expansile pattern of invasion, and a coexisting ovarian teratoma, Brenner tumor, or mural
nodule. In contrast, the following microscopic features favor the diagnosis of metastatic
adenocarcinoma to the ovary: (1) prominent desmoplastic response, (2) nodular pattern of
invasion (i.e., tumor nodules among structures indigenous to the ovarian parenchyma), (3)
small clusters of tumor cell within the corpora lutea or albicantia, (4) numerous pools of mucin
dissecting the ovarian stroma (i.e., pseudomyxoma ovarii) in the absence of a coexistent
ovarian teratoma, (5) an extensive signet ring cell pattern, (6) ovarian surface involvement, (7)
vascular invasion, (8) hilar involvement, and (9) an extensive infiltrative pattern of invasion.
Immunohistochemistry may help determine the primary site of a mucinous carcinoma.
Primary ovarian mucinous carcinomas tend to be positive for CK7 and CK20 with a predom‐
inance of CK7 expression, while colorectal primaries tend to express CK20 only. In addition,
colorectal cancers usually express racemase and beta-catenin while primary mucinous ovarian
cancers do not. In regard to other gynecological primaries metastatic to the ovary, it is worth
mentioning that Human Papilloma Virus (HPV) in situ hybridization can confirm an endo‐
cervical origin because most of the endocervical adenocarcinoma are related to HPV. p16
immunostagining is useful only in well differentiated adenocarcinoma cases where a diffuse
staining will be in keeping with an endocercvical origin.
Attention must be paid to the fact that high-grade ovarian mucinous or endometrioid adeno‐
carcinomas can be positive for p16. Estrogen and progesterone receptors usually are expressed
in endometrioid carcinomas, metastasizing from the endometrium or primary to the ovary.
Metastatic endocervical adenocarcinomas in ovaries cannot be distinguished from a primary
mucinous carcinoma of the ovary because both tumors are progesterone receptor negative and
usually negative for estrogen receptors, although they can have variable expression for the
latter (weak/diffuse or strong/focal staining) [78]. The presence of mesothelin, fascin, and
prostate stem cell antigen (PSCA) favor a pancreatic primary, while the presence of expressed
Dpc4 favors an ovarian primary for differentiating primary ovarian tumors from metastasis
from the pancreas [79]. Most breast cancers are CK7-positive/CK20-negative, unlike ovarian
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should consider a colonoscopy and mammogram if these screening tests have not been
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nodule. In contrast, the following microscopic features favor the diagnosis of metastatic
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invasion (i.e., tumor nodules among structures indigenous to the ovarian parenchyma), (3)
small clusters of tumor cell within the corpora lutea or albicantia, (4) numerous pools of mucin
dissecting the ovarian stroma (i.e., pseudomyxoma ovarii) in the absence of a coexistent
ovarian teratoma, (5) an extensive signet ring cell pattern, (6) ovarian surface involvement, (7)
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inance of CK7 expression, while colorectal primaries tend to express CK20 only. In addition,
colorectal cancers usually express racemase and beta-catenin while primary mucinous ovarian
cancers do not. In regard to other gynecological primaries metastatic to the ovary, it is worth
mentioning that Human Papilloma Virus (HPV) in situ hybridization can confirm an endo‐
cervical origin because most of the endocervical adenocarcinoma are related to HPV. p16
immunostagining is useful only in well differentiated adenocarcinoma cases where a diffuse
staining will be in keeping with an endocercvical origin.
Attention must be paid to the fact that high-grade ovarian mucinous or endometrioid adeno‐
carcinomas can be positive for p16. Estrogen and progesterone receptors usually are expressed
in endometrioid carcinomas, metastasizing from the endometrium or primary to the ovary.
Metastatic endocervical adenocarcinomas in ovaries cannot be distinguished from a primary
mucinous carcinoma of the ovary because both tumors are progesterone receptor negative and
usually negative for estrogen receptors, although they can have variable expression for the
latter (weak/diffuse or strong/focal staining) [78]. The presence of mesothelin, fascin, and
prostate stem cell antigen (PSCA) favor a pancreatic primary, while the presence of expressed
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from the pancreas [79]. Most breast cancers are CK7-positive/CK20-negative, unlike ovarian
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primaries which typically express both. In addition, breast cancers almost always express
estrogen receptors as well as gross cystic disease fluid protein (GCDFP)- 15 [80]. Mucinous
ovarian carcinomas are unlikely to express these markers.
Carcinoembryonic antigen (CEA) is a well known serum tumor marker for gastrointestinal
carcinomas. CEA has been noted to be elevated in almost one third of all ovarian carcinomas.
However, CEA is much more likely to be elevated in mucinous ovarian carcinomas than in
nonmucinous ovarian carcinomas (88% vs 19%) [81, 82]. Nolen, et al. [83] compared the levels
of 58 serum biomarkers in serous ovarian carcinomas to mucinous, clear cell, and endoterioid
ovarian carcinomas. Using immunoassays, they found significant differences between the 2
groups for 10 of the biomarkers examined. SAC had significantly higher levels of CA125,
follicle-stimulating hormone, luteinizing hormone, and SMRP. Mucinous tumors had higher
levels of CA72-4, matrixmetalloproteinase-9, CD40L, insulin-like growth factor-binding
protein-1, myeloperoxidase, and tissue plasminogen activator-1.
9. Future directions
Realizing that MAC is a disease distinct from SAC, several collaborative groups have proposed
innovative prospective chemotherapy protocols for patients with advanced or recurrent MAC.
Sato, et al. [84] evaluated 6 different cytotoxic agents in 5 different primary mucinous ovarian
cancer cell lines. All 5 cell lines resisted platinum agents and taxanes given as single agents.
However, 2 of the 5 cell lines were sensitive to oxaliplatin, VP-16, and 5-fluorouracil (5-FU) as
single agents. The investigators then treated the cell lines with oxaliplatin plus VP-16 and
oxaliplatin plus 5-FU. They found that oxaliplatin with 5-FU had was significant inhibition in
4 of the 5 cell lines, whereas the combination of oxaliplatin plus VP-16 was active in only 1 of
the 5 cell lines. Moreover, the combination of oxaliplatin plus 5-FU appeared to be synergistic
by providing significantly more inhibition than either drug alone. The authors then applied
the cell line results to a mouse model of mucinous ovarian cancer xenograft and found that
mice treated with oxaliplatin plus 5-FU survived significantly longer than mice treated with
either agent alone or control mice treated with placebo (Fig 5).
These basic studies led to a single-arm phase II trial of S-1 and oxaliplatin that currently is
enrolling women with advanced or recurrent mucinous ovarian cancer in. S-1 is an orally active
drug made by Taiho Pharmaceuticals that combines 3 separate molecules. The first is tegafur,
a prodrug that is converted to fluorouracil in cells. Next is gimeracil, an inhibitor of dihydro‐
purimidine dehydrogenase, an enzyme that degrades fluorouracil. The third component is
oteracil, a molecule that inhibits the phosphorylation of fluorouracil in the gastrointestinal
tract, reducing gastrointestinal toxicities. The primary endpoint of the study is response rate;
secondary endpoints are toxicity, progression-free survival, and overall survival.
The GOG and the Gynecologic Cancer Intergroup (GCIG) are about to begin accrual to a 4-
arm, phase III, randomized study comparing carboplatin and PTX with and without bevaci‐
zumab to oxaliplatin and capecitabine with and without bevacizumab in women with stage
II-IV or recurrent, untreated, stage I, primary, mucinous ovarian or fallopian tube cancer. The
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primary endpoint will be overall survival; secondary endpoints will be progression-free
survival, response rate, toxicity, and quality of life. The study also assesses the translational
endpoint, KRAS mutations and expression of vascular endothelial growth factor and epider‐
mal growth factor. The targeted accrual for the study is 322 patients.
Based on the similarity of biological characteristics, the standard chemotherapy regimen for
colorectal cancer has been given in patients with MAC. Therefore, the first phase-II chemo‐
therapy study of oral S-1, a 5FU derivative, combined with oxaliplatin (SOX) for advanced or
recurrent patients with MAC was conducted in the Japan ovarian mucinous adenocarcinoma
study group.
We hope that future research in this field will enable to develop an effective strategy for
conquest of chemoresistance in EOC.
Clear cell Serous
No 101 235
Median age 51 (31-72) 54 (23-82)
FIGO stage
Ia 49 (48.5%) 39 (16.6%)
Ib 11 (10.9%) 15 ( 6.5%)
Ic 0 2 ( 0.9%)
II 38 (37.6%) 22 (9.4%)
III 10 (9.9%) 145 (61.7%) P<0.0001
IV 31 (30.7%) 38 (16.2%)
Table 1. Patients Characteristics
Figure 5. Survival in mice with mucinous adenocarcinoma cells (TU-OM-1 cell). Mice treated with oxaliplatin and 5-FU
survived significantly longer than mice treated with either agent alone or control mice.
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1. Introduction
Ovarian cancer is the fifth leading cause of cancer death in the United States, and contrib‐
utes significantly to the worldwide cancer burden [1]. The lack of gynecologic-specific
symptoms and effective early detection methods for ovarian cancer leads to a preponder‐
ance of late-stage diagnoses. Ovarian cancer is a surgically-staged and treated disease, and
the application of appropriate, guidelines-based treatment is currently the only option to re‐
duce ovarian cancer mortality [2].
The National Comprehensive Cancer Network (NCCN) [3] and the National Institutes of
Health (NIH) [4] publish widely used treatment guidelines for ovarian cancer cases in the
United States. Both NCCN and NIH’s Physician Data Query (PDQ) incorporate tumor his‐
tology into treatment guidelines. While the NCCN publishes guidelines for the three main
types of ovarian cancer, epithelial, sex cord-stromal, and germ cell tumors [5]; the PDQ of‐
fers guidelines only for the most common epithelial tumors. While epithelial tumors account
for about 90% of all ovarian neoplasms, they are not a homogenous group [5]. The four main
epithelial subtypes (serous, mucinous, clear cell, and endometrioid) can have very different
clinical and pathologic patterns.
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1. Introduction
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United States. Both NCCN and NIH’s Physician Data Query (PDQ) incorporate tumor his‐
tology into treatment guidelines. While the NCCN publishes guidelines for the three main
types of ovarian cancer, epithelial, sex cord-stromal, and germ cell tumors [5]; the PDQ of‐
fers guidelines only for the most common epithelial tumors. While epithelial tumors account
for about 90% of all ovarian neoplasms, they are not a homogenous group [5]. The four main
epithelial subtypes (serous, mucinous, clear cell, and endometrioid) can have very different
clinical and pathologic patterns.
Among  epithelial  ovarian  cancer  subtypes  is  mucinous  epithelial  ovarian  cancer
(mEOC), a relatively rare subtype accounting for approximately 14% of invasive ovarian
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cancer  cases  [6].  mEOC has  a  distinct  natural  history compared to  other  epithelial  sub‐
types, especially the most common serous subtype. mEOCs are more often diagnosed in
younger women [6] than other epithelial tumors, and epidemiologic studies have shown
a lack of protective effect from parity and oral contraceptive use [7-11]. Pathologic stud‐
ies  have determined that  mutations in the K-ras  oncogene are  more common in mEOC
compared to other subtypes [12],  while mutations in the BRCA1 tumor suppressor gene
are  less  common  [13].  Despite  their  distinctive  nature,  mEOCs  are  included  in  overall
epithelial  ovarian  cancer  treatment  guidelines,  as  standard  care  for  all  epithelial  sub‐
types is defined in the same manner [3,4].
Because of the differences in risk factors and presentation, a few studies have examined dif‐
ferences in outcomes of mEOC compared to other epithelial subtypes. Many have found
lower response rates to chemotherapy and inferior outcomes compared to other subtypes
[14-16]. Based on these results, it has been suggested that mEOC be treated as a different en‐
tity and not grouped along with epithelial tumors in standard treatment and also in clinical
trials for epithelial ovarian cancer [17]; however, these suggestions have yet to be widely
adopted or implemented. While the existing evidence seems consistent, studies producing
this evidence have contained small numbers and generally represent the experience of indi‐
vidual institutions.
1.1. Objectives
The objective of this chapter is to fully characterize mEOC using a population-based ap‐
proach. We add to the paucity of existing literature on mEOC with an analysis that utilizes
ovarian cancer medical record data from two large populations in the United States, New
York and Northern California. We comprehensively examine demographics, pathologic
characteristics, and the outcomes of treatment for mEOC. We compare these characteristics
to other epithelial subtypes in order to determine whether clinical presentation or outcomes
differ among epithelial subtypes. Finally, we discuss the results of this research in the con‐
text of published studies on mEOC.
2. Study design
2.1. Setting and population
The data presented and analyzed here are from the Ovarian Cancer Treatment Patterns and
Outcomes (OCTPO) study, funded by the Centers for Disease Control and Prevention
(CDC), and conducted by the New York State and the California Cancer Registries [18-20].
The New York State Cancer Registry (NYSCR) conducts surveillance on all 19 million New
York state residents, and the two components of the California Cancer Registry (CCR) that
were funded for this study serve the contiguous geographical area of Greater San Francisco-
San Jose and Sacramento regions, providing surveillance for a population of 9 million resi‐
dents in California. Both the NYSCR and the CCR conduct high quality, population-based
cancer surveillance, and routinely review medical records to abstract demographics, tumor
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characteristics and treatment data as part of state-mandated cancer surveillance. For this ret‐
rospective study, additional detailed patient, tumor, and treatment data were collected by
these registries from multiple sources including hospital, outpatient facility and physician
records. Vital status was determined by linkage with the National Death Index http://
www.cdc.gov/nchs/ndi.htm. The study population included patients with invasive epithe‐
lial ovarian cancer diagnosed between 1998 and 2000. Only invasive cases of epithelial ovari‐
an cancer were included; benign and low malignant potential tumors were excluded.
Primary peritoneal cancers and fallopian tube cancers were also excluded. Subjects diag‐
nosed at autopsy or by death certificate were ineligible. All cases included were histological‐
ly confirmed. Cases were followed up for six years for vital status information.
2.2. Data classification
Histology was collected according to World Health Organization International Classification
of Diseases for Oncology, third edition (ICD-O-3) morphology codes [21]. All epithelial his‐
tologies collected were collapsed into categories for analysis according to Table 1.
Epithelial Ovarian Cancer (EOC) Subtype ICD-O-3 Codes
Mucinous (mEOC) 8470, 8471, 8480, 8481
Serous 8441,8442,8460,8461,8462
Other
(includes endometrioid, clear cell, Brenner, mixed,




Table 1. Histologic definitions by epithelial ovarian cancer subtype
Race and ethnicity was categorized as white non-Hispanic, black non-Hispanic, Asian non-
Hispanic, and Hispanic. A total of 34 cases were excluded from the analysis on the basis of
race or ethnicity data. Three of the 34 cases were classified as American Indian/Alaska Na‐
tive race; these were excluded because of the inability to draw any conclusions from this
race because of the very small number. The remaining 31 cases were excluded because race
or ethnicity information was unspecified or missing. Stage was defined using the Interna‐
tional Federation of Gynecology and Obstetrics (FIGO) system, with categories I, II, III IV, or
unknown. Grade was collapsed into four categories defined as Grade I (well differentiated
tumors), Grade II (moderately differentiated tumors), Grade III/IV (poorly differentiated
and undifferentiated tumors) and unknown grade. Laterality was collapsed into unilateral
(single ovary involved at diagnosis: right, left, or unspecified), or bilateral (both ovaries in‐
volved at diagnosis) categories. Comorbidity was defined using the Deyo-Charlson Comor‐
bidity Index [22, 23], a commonly used measure of disease burden. Comorbidity
information was collected via linkage with state hospital discharge data. Any comorbidity
present in the 12 months prior to or 4 months following an ovarian cancer diagnosis was
included. Type of treatment was defined to distinguish patients who received various com‐
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an cancer were included; benign and low malignant potential tumors were excluded.
Primary peritoneal cancers and fallopian tube cancers were also excluded. Subjects diag‐
nosed at autopsy or by death certificate were ineligible. All cases included were histological‐
ly confirmed. Cases were followed up for six years for vital status information.
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information was collected via linkage with state hospital discharge data. Any comorbidity
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binations of surgery and chemotherapy. In descriptive analyses, chemotherapy was further
categorized by receipt of specific agents. These categories consisted of surgery and platinum
agent (cisplatin or carboplatin) receipt, surgery and platinum agent and paclitaxel receipt
(standard treatment for EOC) [24], and surgery and any chemotherapy agent or combination
of agents other than cisplatin, carboplatin, or paclitaxel.
2.3. Analyses
Statistical testing was performed using the likelihood ratio chi-square test for discrete varia‐
bles. The Kruskal-Wallis test was used to test for differences among continuous variables. A
generalized logits model was fit to determine the characteristics associated with epithelial
subtype. Variables included in the model were age, race/ethnicity, stage, grade, and laterali‐
ty. Age was transformed in all models using restricted cubic spline functions to allow for
nonlinearity [25]. Due to the lack of availability of grade and stage information for some cas‐
es (31% for grade; 15% for stage), missing indicator variables were included for each varia‐
ble in all models. Because of potential issues with using missing indicator variables, separate
models that imputed missing data were fit (data not shown) [26,27]. These models yielded
consistent results with the un-imputed models. Six-year survival curves are presented as
Kaplan-Meier estimates. Statistical testing for differences in unadjusted survival rates across
epithelial subtypes was performed using the log-rank test. For adjusted survival, a time-de‐
pendent Cox model was used to determine the predictors of six-year survival. Age, race/
ethnicity, stage, grade, epithelial subtype, comorbidity, laterality, surgery, and chemothera‐
py were included as covariates in the survival model. Time-dependent covariates for sur‐
gery and chemotherapy were used to prevent an artificial inflation of the association
between treatment and survival. Cases were considered as not receiving treatment until the
date of the procedure; they were considered as having received treatment after the date of
the procedure. Interactions between epithelial subtype and treatment were included to de‐
termine if the effects of surgery and chemotherapy varied across subtypes. The proportional
hazards assumption was assessed using time-dependent covariates and the Schoenfeld re‐
sidual correlation test. Laterality was found to violate the proportional hazards (PH) as‐
sumption. Stratified log[-log S(t)] plots were used to help determine time intervals within
which the PH assumption held. An interaction between laterality and time was included in
the final model to satisfy the PH assumption.
3. Results
3.1. Demographic and clinical characteristics of mucinous epithelial ovarian cancer
The characteristics of ovarian cancer cases in New York and Northern California are pre‐
sented by epithelial subtype in Table 2. Overall, 230 (8.7%) tumors were mEOC, 1195 (45.3%)
tumors were serous EOC, and 1211 (45.9%) were other EOC. mEOCs were diagnosed at
younger ages (57 years) compared to other subtypes (62 years for serous, 63 years for other
EOCs). Relatively higher percentages of mEOCs were found among black non-Hispanic
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(8.0% vs. 5.9 and 6.7%) and Asian non-Hispanic (14.2% vs. 5.4 and 9.8%) populations com‐
pared to serous and other EOCs. Lower percentages of mEOCs (5.8%) were found among
Hispanics compared to serous and mEOCs (7.5 and 7.7%). mEOCS were more likely to be
diagnosed at FIGO stage I (45.2%) compared to serous (10.0%) and other mEOCs (24.9%).
Higher percentages of low grade tumors and unilateral ovarian involvement at diagnosis
were also present with mEOCs compared to other EOC types. A little under half of mEOC
patients (46.3%) were treated with surgery only and 39.0% were treated with surgery plus a









Age at diagnosis* 57 (45, 72) 62 (52, 72) 63 (51, 75) <0.001
Race/Ethnicity <0.001
White Non-Hispanic 162 (72.0%) 956 (81.3%) 910 (75.8%)
Black Non-Hispanic 18 (8.0%) 69 (5.9%) 80 (6.7%)
Asian Non-Hispanic 32 (14.2%) 63 (5.4%) 118 (9.8%)
Hispanic 13 (5.8%) 88 (7.5%) 93 (7.7%)
FIGO Stage <0.001
I 104 (45.2%) 119 (10.0%) 302 (24.9%)
II 26 (11.3%) 66 (5.5%) 125 (10.3%)
III 62 (27.0%) 747 (62.5%) 380 (31.4%)
IV 19 (8.3%) 153 (12.8%) 225 (18.6%)
Unknown 19 (8.3%) 110 (9.2%) 179 (14.8%)
Grade <0.001
I 73 (31.7%) 80 (6.7%) 92 (7.6%)
II 69 (30.0%) 223 (18.7%) 193 (15.9%)
III/IV 30 (13.0%) 730 (61.1%) 493 (40.7%)
Unknown 58 (25.2%) 162 (13.6%) 433 (35.8%)
Laterality <0.001
Unilateral 167 (77.7%) 410 (36.7%) 634 (67.7%)
Bilateral 48 (22.3%) 707 (63.3%) 302 (32.3%)
Comorbidity 0.0257
None 161 (74.5%) 847 (77.6%) 814 (74.9%)
1 38 (17.6%) 181 (16.6%) 170 (15.6%)
2 or more 17 (7.9%) 63 (5.8%) 103 (9.5%)
Demographic and Clinical Characteristics of Mucinous Epithelial Ovarian Cancer, and…
http://dx.doi.org/10.5772/53740
121
binations of surgery and chemotherapy. In descriptive analyses, chemotherapy was further
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(standard treatment for EOC) [24], and surgery and any chemotherapy agent or combination
of agents other than cisplatin, carboplatin, or paclitaxel.
2.3. Analyses
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between treatment and survival. Cases were considered as not receiving treatment until the
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tumors were serous EOC, and 1211 (45.9%) were other EOC. mEOCs were diagnosed at
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Hispanics compared to serous and mEOCs (7.5 and 7.7%). mEOCS were more likely to be
diagnosed at FIGO stage I (45.2%) compared to serous (10.0%) and other mEOCs (24.9%).
Higher percentages of low grade tumors and unilateral ovarian involvement at diagnosis
were also present with mEOCs compared to other EOC types. A little under half of mEOC
patients (46.3%) were treated with surgery only and 39.0% were treated with surgery plus a
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Surgery only 95 (46.3%) 132 (12.2%) 196 (17.9%)
Surgery+Platinum 7 (3.4%) 46 (4.3%) 28 (2.6%)
Surgery+Platinum+ Paclitaxel 80 (39.0%) 826 (76.5%) 565 (51.6%)
Surgery+other chemotherapy 2 (1.0%) 21 (1.9%) 12 (1.1%)
Chemotherapy only 12 (5.9%) 32 (3.0%) 169 (15.4%)
No surgery/no chemotherapy 9 (4.4%) 23 (2.1%) 124 (11.3%)
Table 2. Demographic and clinical characteristics of invasive epithelial ovarian cancer cases by subtype, New York and
Northern California. * Continuous variable presented as median (25th percentile, 75th percentile).
Figure 1. Adjusted relationship between age and risk of mucinous epithelial compared to serous epithelial ovarian
cancer. Solid line indicates log-odds ratio, dotted lines indicated confidence intervals.
Table 3, Figure 1 and Figure 2 show the demographic and clinical characteristics significant‐
ly associated with mEOCs compared to other epithelial ovarian cancers, after adjusting for
other factors. mEOCs were more often associated with Asian non-Hispanic race/ethnicity
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compared to serous tumors (odds ratio [OR] 1.94, 95% confidence interval [CI] 1.13-3.35).
The relationship between age and epithelial subtype was nonlinear; ages 55 years and
younger were more often associated with mEOC compared to both serous and other EOCs
(Figures 1 and 2). Less advanced stage was associated with mEOCs compared to serous
EOC (OR 0.29, 95% CI 0.18-0.47 for stage III and 0.39, 0.19-0.78 for stage IV). mEOCs were
less likely to be grade III/IV compared to serous (OR 0.11, 95% CI 0.07-0.20) and other EOC
(OR 0.10, 95% CI 0.06-0.16). Bilateral ovarian cancer at diagnosis was less often associated





Mucinous vs. Other Epithelial
Odds Ratio
95% CI
Age at diagnosis* 0.0008 Nonlinear Nonlinear
Nonlinear 0.0002
Race/Ethnicity 0.0723
White non-Hispanic 1.00 1.00
Black non-Hispanic 1.36 (0.73-2.54) 1.52 (0.82-2.80)
Asian non-Hispanic 1.94 (1.13-3.35) 1.17 (0.72-1.90)
Hispanic 0.77 (0.40-1.50) 0.76 (0.40-1.44)
FIGO Stage <.0001
I 1.00 1.00
II 0.89 (0.50-1.60) 0.96 (0.57-1.63)
III 0.29 (0.18-0.47) 1.10 (0.70-1.72)
IV 0.39 (0.19-0.78) 0.68 (0.35-1.32)
Unknown 0.41 (0.21-0.83) 0.80 (0.41-1.57)
Grade <.0001
I 1.00 1.00
II 0.62 (0.38-1.00) 0.49 (0.31-0.77)
III/IV 0.11 (0.07-0.20) 0.10 (0.06-0.16)
Unknown 0.92 (0.55-1.55) 0.31 (0.19-0.49)
Laterality <.0001
Unilateral 1.00 1.00
Bilateral 0.32 (0.22-0.49) 0.80 (0.53-1.21)
Table 3. Adjusted odds ratios and 95% confidence intervals for demographic and clinical characteristics of invasive
epithelial ovarian cases by subtype, New York and Northern California. *The relationship between age and histologic
subtype is shown in Figures 1 and 2.CI=confidence interval
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Table 3, Figure 1 and Figure 2 show the demographic and clinical characteristics significant‐
ly associated with mEOCs compared to other epithelial ovarian cancers, after adjusting for
other factors. mEOCs were more often associated with Asian non-Hispanic race/ethnicity
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compared to serous tumors (odds ratio [OR] 1.94, 95% confidence interval [CI] 1.13-3.35).
The relationship between age and epithelial subtype was nonlinear; ages 55 years and
younger were more often associated with mEOC compared to both serous and other EOCs
(Figures 1 and 2). Less advanced stage was associated with mEOCs compared to serous
EOC (OR 0.29, 95% CI 0.18-0.47 for stage III and 0.39, 0.19-0.78 for stage IV). mEOCs were
less likely to be grade III/IV compared to serous (OR 0.11, 95% CI 0.07-0.20) and other EOC
(OR 0.10, 95% CI 0.06-0.16). Bilateral ovarian cancer at diagnosis was less often associated





Mucinous vs. Other Epithelial
Odds Ratio
95% CI
Age at diagnosis* 0.0008 Nonlinear Nonlinear
Nonlinear 0.0002
Race/Ethnicity 0.0723
White non-Hispanic 1.00 1.00
Black non-Hispanic 1.36 (0.73-2.54) 1.52 (0.82-2.80)
Asian non-Hispanic 1.94 (1.13-3.35) 1.17 (0.72-1.90)
Hispanic 0.77 (0.40-1.50) 0.76 (0.40-1.44)
FIGO Stage <.0001
I 1.00 1.00
II 0.89 (0.50-1.60) 0.96 (0.57-1.63)
III 0.29 (0.18-0.47) 1.10 (0.70-1.72)
IV 0.39 (0.19-0.78) 0.68 (0.35-1.32)
Unknown 0.41 (0.21-0.83) 0.80 (0.41-1.57)
Grade <.0001
I 1.00 1.00
II 0.62 (0.38-1.00) 0.49 (0.31-0.77)
III/IV 0.11 (0.07-0.20) 0.10 (0.06-0.16)
Unknown 0.92 (0.55-1.55) 0.31 (0.19-0.49)
Laterality <.0001
Unilateral 1.00 1.00
Bilateral 0.32 (0.22-0.49) 0.80 (0.53-1.21)
Table 3. Adjusted odds ratios and 95% confidence intervals for demographic and clinical characteristics of invasive
epithelial ovarian cases by subtype, New York and Northern California. *The relationship between age and histologic
subtype is shown in Figures 1 and 2.CI=confidence interval
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Figure 2. Adjusted relationship between age and risk of and mucinous epithelial ovarian cancer compared to other
epithelial ovarian cancer. Solid line indicates log-odds ratio, dotted lines indicated confidence intervals.
3.2. Survival following a mucinous ovarian cancer diagnosis
Unadjusted Kaplan-Meier estimates showed that survival following an epithelial ovarian
cancer diagnosis was initially worse for mEOC and other EOC compared to serous EOC
(Figure 3). At approximately 38-40 months post-diagnosis, mEOC and other EOC tumor sur‐
vival rates stabilized, whereas survival from serous EOC continually decreased. At the end
of the 6 year follow-up period, survival was significantly different among the epithelial sub‐
types (log rank p<0.001). Unadjusted survival was 49.8% among women with mEOC, 39.0%
among women with other EOC, and 30.8% among women serous EOC.
The results of the multivariable Cox model predicting 6-year survival are shown in Table 4
and Figure 4. After adjustment, black race, advanced stage, higher grade, and the presence
of comorbidities were all associated with increased mortality from EOC (Table 4), as was in‐
creasing age (especially age > 60, Figure 4). By epithelial subtype, mEOC conferred a worse
prognosis and was associated with increased mortality compared to both serous EOC (Haz‐
ard ratio [HR] 0.51, 95% CI 0.40-0.65), and other EOC (HR 0.56, 95% CI 0.44-0.72). Significant
interactions were found between epithelial subtype and both surgery (p=0.0064) and chemo‐
therapy (p=0.0340). In all cases, mEOC was associated with increased mortality. Significant
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associations occurred among those who received both surgery and chemotherapy; women
with serous EOC and other EOC had better survival than those with mEOC in this group
(serous HR 0.45, 05% CI 0.33-0.62; other EOC HR 0.44, 95% CI 0.32-0.61). This was also the
case for women who were treated with chemotherapy alone (serous EOC HR 0.16, 95% CI
0.07-0.38; other EOC HR 0.40, 95% CI 0.20-0.81). In women who received only surgery or did
not receive treatment, those with serous EOC had better survival than those with mEOC
(HR 0.65, 95% CI 0.42-1.00, HR 0.23, 95% CI 0.10-0.53, respectively).
Figure 3. Six-year survival following an invasive epithelial ovarian cancer diagnosis by subtype, New York and North‐
ern California
Characteristic Wald χ2 DF* P-value
Hazard Ratio
(95% CI)
Age at diagnosis* 99.68 2 <0.0001
Nonlinear 10.75 1 0.0010
Race/Ethnicity 26.63 3 <0.0001
White non-Hispanic 1.00
Black non-Hispanic 1.47 (1.17-1.86)
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not receive treatment, those with serous EOC had better survival than those with mEOC
(HR 0.65, 95% CI 0.42-1.00, HR 0.23, 95% CI 0.10-0.53, respectively).
Figure 3. Six-year survival following an invasive epithelial ovarian cancer diagnosis by subtype, New York and North‐
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Characteristic Wald χ2 DF* P-value
Hazard Ratio
(95% CI)
Age at diagnosis* 99.68 2 <0.0001
Nonlinear 10.75 1 0.0010
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White non-Hispanic 1.00
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Characteristic Wald χ2 DF* P-value
Hazard Ratio
(95% CI)
Asian non-Hispanic 0.62 (0.45-0.84)
Hispanic 0.76 (0.59-0.98)
FIGO Stage 239.24 4 <0.0001
I 1.00
II 1.40 (0.96- 2.04)
III 4.96 (3.77- 6.51)
IV 8.02 (5.93-10.84)
Unknown 5.36 (3.93- 7.31)





Laterality 38.41 2 <0.0001
0 – 2 years
Bilateral vs. Unilateral 1.04 (0.87-1.23)
"/>2 years – 6 years
Bilateral vs. Unilateral 1.86 (1.53-2.27)
Comorbidity 20.04 2 <0.0001
0 1.00
1 1.26 (1.08-1.48)
2 or more 1.59 (1.26-2.01)
Epithelial subtype** 48.68 6 <0.0001
Mucinous 1.0
Serous 0.51 (0.40-0.65)
Other Epithelial 0.56 (0.44-0.72)
Surgery+Chemotherapy
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Other Epithelial 0.40 (0.20-0.81)
No Surgery/ No Chemotherapy
Mucinous 1.0
Serous 0.23 (0.10-0.53)
Other Epithelial 0.75 (0.38-1.49)
Surgery (Yes vs. No) 34.93 3 <0.0001
Mucinous 0.38 (0.20-0.75)
Serous 1.06 (0.63-1.79)
Other Epithelial 0.42 (0.31-0.58)
Chemotherapy (Yes vs. No) 11.05 3 0.0115
Mucinous 1.25 (0.79-1.97)
Serous 0.88 (0.68-1.14)
Other Epithelial 0.67 (0.51-0.87)
Table 4. Multivariate proportional hazards results of invasive epithelial ovarian cancer cases, New York and Northern
California. *The relationship between age and risk of death is shown in Figure 4. **The overall epithelial subtype
comparisons are from a model excluding the subtype and treatment interactions. These are presented to show the
“average” effect across treatments. All other hazard ratios in the model are calculated from the model including the
interactions.
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Characteristic Wald χ2 DF* P-value
Hazard Ratio
(95% CI)
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This large, population-based study adds further, definitive evidence for demographic and
clinical characteristics previously associated with mEOC: Asian race, early stage, low grade,
and unilateral ovarian involvement at diagnosis [9,16,28]. Regardless of the large proportion
of stage I diagnoses (about 45%), mEOC appears to be a particularly deadly subtype of ovar‐
ian cancer. These patterns seen in mEOC are consistent with clear cell EOC, which also
tends to be diagnosed at early stages [29], and has poor overall survival compared to other
EOCs [29,30]. Patterns of other epithelial subtypes vary: endometrioid EOC is often diag‐
nosed at early stages, but generally has better overall survival compared to other EOCs [31];
serous EOC is most often diagnosed at late stages (stage III and IV), and survival from these
tumors appears to be significantly associated with grade [32]. These divergent patterns sug‐
gest that EOC is an extremely heterogeneous group, and histologic subtype should be con‐
sidered in addition to stage before and during treatment.
Figure 4. Adjusted relationship between age and risk of death within six years following an epithelial ovarian cancer
diagnosis. Solid line indicates log-hazard ratio, dotted lines indicate 95% confidence intervals.
The  poor  survival  from  mEOC  shown  here  is  consistent  with  other  studies  [14,16,33]
and may be due to a decreased response to chemotherapy. Our study results are consis‐
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tent with these findings, in that chemotherapy did not appear to have a beneficial effect
in women with mEOC. Evidence suggests  that  mEOC response rates  to platinum-based
chemotherapy are low overall (13-26%) [14,34]. This decreased response could be related
to  a  lack  of  sensitivity  of  mEOCs  to  standard  platinum-containing  chemotherapy  regi‐
mens [17].  It  is  well-established that  platinum sensitivity varies by pathologic and clini‐
cal  characteristics  including  tumor  type  [34,35].  Relatively  recently,  some groups  in  the
United States have suggested that different treatment strategies should be considered for
mEOC,  and  that  future  clinical  trials  should  be  redesigned  to  1)  exclude  women  with
mEOC  and  other  rare  EOC  types  [36],  and  2)  assist  with  the  development  of  novel
agents more targeted to mEOC that can be used in the front-line and recurrent settings
[17,  37].  Several  barriers  exist  to  such  clinical  trials,  including  decreased  availability  of
funding [38],  as  well  as  potential  lack of  enrollment  and participation due to the rarity
and deadly nature of mEOC. Despite these limitations however,  a phase III  clinical trial
comparing standard carboplatin and paclitaxel regimen (with and without bevacizumab)
to oxalitlatin and capecitabine (with and without bevacizumab) in women with stages II-
IV or recurrent untreated stage I primary mEOC was recently announced [39].
Some groups have suggested additional chemotherapeutic agents that may be more effec‐
tive in the treatment of mEOC. Based on studies with mEOC cell lines, combination chemo‐
therapy consisting of oxaliplatin and 5-fluorouracil may be beneficial for mEOCs [40]. The
suggested use of fluorouracil, a chemotherapy agent used in the treatment of colon cancer
[41], has gained additional support because of the similarities between mEOC and mucinous
tumors of the colon [16,42]. A recent review comparing characteristics of these two tumor
types concluded that there are multiple similarities with respect to mutational patterns, clin‐
ical presentation, therapy response, and outcomes [43]. The review further proposes that the
search for new and more effective chemotherapeutic agents for mucinous tumors might be
more successful if comparisons are made across organs [43]. However, there are clear differ‐
ences in the cellular localization of mucin in these two types, and further research is needed
to substantiate the usefulness of this approach.
Regardless of the availability of and evidence for alternative treatment regimens, the results
presented here underscore the need for precise pathologic assessment of all EOCs with re‐
spect to site of tumor origin, histologic type and subtype, behavior and grade. The vast ma‐
jority of histologic-specific analyses using medical record data (including this one) are
limited by the fact that there is no central pathology review of included cases. Because of
this, a few studies have retrospectively reviewed stored specimens and medical records to
examine concordance of pathologic characteristics of ovarian cancer. In a population-based
study using Surveillance Epidemiology and End Results (SEER) data, there was 98% con‐
cordance on site of origin, and 97% concordance on overall epithelial histologic type [44].
Concordance varied by histologic subtype; it was 100% for clear cell EOC, 87% for mEOC,
80% for serous EOC, and 73% for endometrioid EOC. For tumor behavior, there was 85%
concordance for invasive ovarian tumors. In most cases (90%), tumors originally diagnosed
as invasive were thought to be low malignant potential upon review. Another study exam‐
ining pathology in the Gilda Radner Familial Ovarian Cancer Tumor Registry reported
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tent with these findings, in that chemotherapy did not appear to have a beneficial effect
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chemotherapy are low overall (13-26%) [14,34]. This decreased response could be related
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comparing standard carboplatin and paclitaxel regimen (with and without bevacizumab)
to oxalitlatin and capecitabine (with and without bevacizumab) in women with stages II-
IV or recurrent untreated stage I primary mEOC was recently announced [39].
Some groups have suggested additional chemotherapeutic agents that may be more effec‐
tive in the treatment of mEOC. Based on studies with mEOC cell lines, combination chemo‐
therapy consisting of oxaliplatin and 5-fluorouracil may be beneficial for mEOCs [40]. The
suggested use of fluorouracil, a chemotherapy agent used in the treatment of colon cancer
[41], has gained additional support because of the similarities between mEOC and mucinous
tumors of the colon [16,42]. A recent review comparing characteristics of these two tumor
types concluded that there are multiple similarities with respect to mutational patterns, clin‐
ical presentation, therapy response, and outcomes [43]. The review further proposes that the
search for new and more effective chemotherapeutic agents for mucinous tumors might be
more successful if comparisons are made across organs [43]. However, there are clear differ‐
ences in the cellular localization of mucin in these two types, and further research is needed
to substantiate the usefulness of this approach.
Regardless of the availability of and evidence for alternative treatment regimens, the results
presented here underscore the need for precise pathologic assessment of all EOCs with re‐
spect to site of tumor origin, histologic type and subtype, behavior and grade. The vast ma‐
jority of histologic-specific analyses using medical record data (including this one) are
limited by the fact that there is no central pathology review of included cases. Because of
this, a few studies have retrospectively reviewed stored specimens and medical records to
examine concordance of pathologic characteristics of ovarian cancer. In a population-based
study using Surveillance Epidemiology and End Results (SEER) data, there was 98% con‐
cordance on site of origin, and 97% concordance on overall epithelial histologic type [44].
Concordance varied by histologic subtype; it was 100% for clear cell EOC, 87% for mEOC,
80% for serous EOC, and 73% for endometrioid EOC. For tumor behavior, there was 85%
concordance for invasive ovarian tumors. In most cases (90%), tumors originally diagnosed
as invasive were thought to be low malignant potential upon review. Another study exam‐
ining pathology in the Gilda Radner Familial Ovarian Cancer Tumor Registry reported
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95.3% concordance on primary site [45]. The agreement by histologic subtype was lower,
with disagreement on 38.3% of cases. The vast majority of differences were related to differ‐
ences in classification of serous EOC, either by the initial or reviewing pathologist. Concord‐
ance by grade was slightly better than that by histologic subtype, with disagreement on
31.2% of cases. The majority of differences centered on the differential assignment of grade
II versus grade III. Few cases (a total of 7.6%) were upgraded or downgraded in a way that
would have potential implications for treatment. While these pathologic review findings are
encouraging overall and provide support for analyses of mEOC such as this one, they may
not be exact enough to support the prescription of alternative treatment regimens based
solely on histologic subtype.
5. Conclusions
The results presented here provide definitive evidence that mEOC is associated with differ‐
ent demographic and clinical characteristics than other EOC subtypes, and women diag‐
nosed with mEOC have worse adjusted survival compared to those with other EOC
subtypes. A particular strength of this study is the population-based approach, which re‐
flects the experience of two U.S. populations of women with ovarian cancer, as opposed to
that of a single institution or those participating in clinical research. This study yields sever‐
al implications for future research. First and foremost, the continued characterization of the
heterogeneity of ovarian cancer through basic, clinical, and population research is necessary.
Second, the need for precision in pathologic assessments is paramount, and pathologists, on‐
cologists and scientists all have a role in assisting with this through research and education.
Finally, assessment of provider knowledge and awareness regarding treatment recommen‐
dations, and proposed or enacted changes to these recommendations, would be beneficial
for ensuring appropriate use of evidence-based practices in the treatment of ovarian cancer.
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1. Introduction
Health Care providers managing patients with Epithelial Ovarian Cancer (EOC) must be fa‐
miliar not only with the diagnosis, staging, treatment and follow-up of this disease, but also
with the current knowledge on carcinogenesis, genetics and prevention/early diagnosis. This
knowledge is needed in order to provide the best possible care to the patients and at the
same time to provide the best possible advice to their relatives.
For the general population of women, the lifetime risk of developing ovarian cancer is 1.4%,
which means that a woman's average risk of developing ovarian cancer during her lifetime
is about one in 70. The lifetime risk of dying from ovarian cancer is 1.04%. Ovarian Cancer
can be called a rare disease but at the same time it is the ninth most common cancer in the
USA, with an estimated 22,280 new cases in 2012, and the fifth most deadly, with an estimat‐
ed 15,500 deaths in 2012.The median age at diagnosis is 63 years. The poor ratio of survival
to incidence in EOC results from the high percentage of cases diagnosed at an advanced
stage. It is hard to find ovarian cancer early, as it may not cause any symptoms. When
symptoms do appear, disease is often advanced and it is well known that the prognosis
largely depends on its extent at diagnosis. Less than one-fourth of women present with lo‐
calized disease. Despite advances in surgery and chemotherapy, survival of patients with
EOC stands at about 31-45% at 5 years. Despite the efficacy of platinum-based chemothera‐
py, over 75% of women with stage III/IV EOC ultimately relapse and die from their disease.
Median survival for women whose disease does not respond or in whom duration of re‐
sponse is short is less than 12 months. Although new drugs hold the potential of improved
responses in advanced and recurrent EOC, a greater impact could be made by recognition of
high-risk patients and by offering the proper advice and risk-reducing surgery when indi‐
cated. It is important that health care professionals can recognize women with possible he‐
reditary Ovarian Cancer and have the basic knowledge to inform them of their management
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options. Details about the Genetics of Breast and Ovarian Cancer are available at the Nation‐
al Cancer Institute site and other relevant sites and publications [1-6].
2. The pathogenesis of ovarian cancer – The role of genes
The pathogenesis of ovarian carcinoma remains unclear and represents a fascinating re‐
search area. It is possible that several pathways lead to ovarian cancer. Certain theories have
been proposed to explain its epidemiology including the theory of incessant ovulation, go‐
nadotropin stimulation, excess androgenic stimulation, and inflammation. Associated risk
factors for ovarian cancer support some or all of these hypotheses. Multiparity, oral contra‐
ceptive use, and breastfeeding are associated with a decreased risk of ovarian cancer.
Oophorectomy reduces but does not completely eliminate the risk of ovarian cancer. A his‐
tory of tubal ligation or hysterectomy with ovarian conservation is also associated with a de‐
creased risk of ovarian cancer. Risk is increased in women with a family history of ovarian
cancer, with the postmenopausal use of hormone therapy, and among women who have
used fertility drugs. Obesity, tall height, and high body mass index have also been associat‐
ed with increased risk of ovarian cancer. Perineal exposure to talcum powder has been in‐
vestigated as possible risk factor for ovarian cancer. It is very important to note that some
women are at an increased risk due to an inherited susceptibility to ovarian cancer with the
magnitude of that risk depending on the affected gene and specific mutation [1-5,7,8].
There is significant heterogeneity within the EOC group. Histologically defined subtypes
such as serous, endometrioid, mucinous, and low- and high-grade malignancies all have
variable  clinical  manifestations  and underlying  molecular  signatures.  Substantial  advan‐
ces  have  been  made  in  understanding  the  genetic  alterations  and  biologic  processes  in
ovarian cancer;  however,  the etiology remains poorly understood. According to a recent
publication by S Vaughan et al the term ovarian cancer is misleading. Ovarian Cancer is
not a single disease, and a considerable proportion of tumors do not arise from ovarian
tissue.  “The unifying clinical  feature of  all  ovarian cancers is  frequent loco-regional  dis‐
semination  to  the  ovary  and  related  pelvic  organs.  We  considered  whether  the  term
ovarian cancer should be replaced with the terms pelvic or peritoneal cancer but we rec‐
ognized the confusion that might ensue for patients and physicians, as well as in the sci‐
entific  literature,  especially during a transition period. Before the term ovarian cancer is
abandoned, the disparate origins of  this disease need to be more widely understood by
patients, physicians and scientists.”[1-5, 7, 8]
While approximately 90% of ovarian cancers occur sporadically, 10% of women with ovari‐
an cancer have inherited genetic changes that predisposed them to ovarian cancer. It is very
important to identify these persons and properly manage them. The following information
is very useful for the candidates of genetic testing: Genes carry information in the form of
DNA within each cell of the human body. There are 30,000 different genes in each cell’s
chromosomes and there are 23 pairs of chromosomes in each cell. One chromosome of each
pair is inherited from the person's father and one from the person's mother. Genes control
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how a cell functions, including how quickly it grows, how often it divides, and how long it
lives. To control these functions, genes produce proteins that perform specific tasks and act
as messengers for the cell. Therefore, it is essential that each gene have the correct instruc‐
tions or "code" for making its protein so that the protein can perform the proper function for
the cell [1-5].
Many cancers begin when one or more genes in a cell are mutated creating an abnormal pro‐
tein or no protein at all. The information provided by an abnormal protein is different from
that of a normal protein, which can cause cells to multiply uncontrollably and become can‐
cerous. A person may either be born with the genetic mutation in all of their cells (germline
mutation) or acquire a genetic mutation in a single cell during his or her lifetime. An ac‐
quired mutation is passed on to all cells that develop from that single cell (somatic muta‐
tion). A germline mutation or a hereditary mutation, according to the NCI definition, is a
gene change in a body's reproductive cell that becomes incorporated into the DNA of every
cell in the body of the offspring. Germline mutations are passed on from parents to off‐
spring. Somatic mutations, according to the NCI, are alterations in DNA that occur after
conception. Somatic mutations can occur in any of the cells of the body except the germ cells
and therefore are not passed on to children. These alterations can (but do not always) cause
cancer or other diseases. If the mutant cell continues to divide, the individual will come to
contain a patch of tissue of genotype different from the cells of the rest of the body. So this is
a change in the genetic structure that is neither inherited nor passed to offspring. These
changes can be caused by environmental factors such as ultraviolet radiation from the sun
and cigarette smoke or can occur if a mistake is made as DNA copies itself during cell divi‐
sion. Mutations may also occur in a single cell within an early embryo. As all the cells divide
during growth and development, the individual will have some cells with the mutation and
some cells without the genetic change. This situation is called mosaicism. Some genetic
changes are very rare; others are common in the population. Genetic changes that occur in
more than 1 percent of the population are called polymorphisms. They are common enough
to be considered a normal variation in the DNA. Polymorphisms are responsible for many
of the normal differences between people such as eye color, hair color, and blood type. Al‐
though many polymorphisms have no negative effects on a person’s health, some of these
variations may influence the risk of developing certain disorders [1-5, 9-17].
Most ovarian cancers (about 85% to 90%) are considered sporadic, meaning that the damage
to the genes occurs by chance after a person is born and there is no risk of passing on the
gene to a person’s children. Inherited ovarian cancers are less common (about 10% to 15%)
and occur when gene mutations are passed within a family, from one generation to the next.
Every cell usually has two copies of each gene: one inherited from a person’s mother and
one inherited from a person’s father. Most types of hereditary ovarian cancer follow an au‐
tosomal dominant inheritance pattern, in which a mutation needs to happen in only one
copy of the gene for the person to have an increased risk of getting the disease. This means
that a parent with a gene mutation may pass on a copy of the normal gene or a copy of the
gene with a mutation. Therefore, a child who has a parent with a mutation has a 50% chance
of inheriting that mutation. A brother, sister, or parent of a person who has a gene mutation
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options. Details about the Genetics of Breast and Ovarian Cancer are available at the Nation‐
al Cancer Institute site and other relevant sites and publications [1-6].
2. The pathogenesis of ovarian cancer – The role of genes
The pathogenesis of ovarian carcinoma remains unclear and represents a fascinating re‐
search area. It is possible that several pathways lead to ovarian cancer. Certain theories have
been proposed to explain its epidemiology including the theory of incessant ovulation, go‐
nadotropin stimulation, excess androgenic stimulation, and inflammation. Associated risk
factors for ovarian cancer support some or all of these hypotheses. Multiparity, oral contra‐
ceptive use, and breastfeeding are associated with a decreased risk of ovarian cancer.
Oophorectomy reduces but does not completely eliminate the risk of ovarian cancer. A his‐
tory of tubal ligation or hysterectomy with ovarian conservation is also associated with a de‐
creased risk of ovarian cancer. Risk is increased in women with a family history of ovarian
cancer, with the postmenopausal use of hormone therapy, and among women who have
used fertility drugs. Obesity, tall height, and high body mass index have also been associat‐
ed with increased risk of ovarian cancer. Perineal exposure to talcum powder has been in‐
vestigated as possible risk factor for ovarian cancer. It is very important to note that some
women are at an increased risk due to an inherited susceptibility to ovarian cancer with the
magnitude of that risk depending on the affected gene and specific mutation [1-5,7,8].
There is significant heterogeneity within the EOC group. Histologically defined subtypes
such as serous, endometrioid, mucinous, and low- and high-grade malignancies all have
variable  clinical  manifestations  and underlying  molecular  signatures.  Substantial  advan‐
ces  have  been  made  in  understanding  the  genetic  alterations  and  biologic  processes  in
ovarian cancer;  however,  the etiology remains poorly understood. According to a recent
publication by S Vaughan et al the term ovarian cancer is misleading. Ovarian Cancer is
not a single disease, and a considerable proportion of tumors do not arise from ovarian
tissue.  “The unifying clinical  feature of  all  ovarian cancers is  frequent loco-regional  dis‐
semination  to  the  ovary  and  related  pelvic  organs.  We  considered  whether  the  term
ovarian cancer should be replaced with the terms pelvic or peritoneal cancer but we rec‐
ognized the confusion that might ensue for patients and physicians, as well as in the sci‐
entific  literature,  especially during a transition period. Before the term ovarian cancer is
abandoned, the disparate origins of  this disease need to be more widely understood by
patients, physicians and scientists.”[1-5, 7, 8]
While approximately 90% of ovarian cancers occur sporadically, 10% of women with ovari‐
an cancer have inherited genetic changes that predisposed them to ovarian cancer. It is very
important to identify these persons and properly manage them. The following information
is very useful for the candidates of genetic testing: Genes carry information in the form of
DNA within each cell of the human body. There are 30,000 different genes in each cell’s
chromosomes and there are 23 pairs of chromosomes in each cell. One chromosome of each
pair is inherited from the person's father and one from the person's mother. Genes control
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how a cell functions, including how quickly it grows, how often it divides, and how long it
lives. To control these functions, genes produce proteins that perform specific tasks and act
as messengers for the cell. Therefore, it is essential that each gene have the correct instruc‐
tions or "code" for making its protein so that the protein can perform the proper function for
the cell [1-5].
Many cancers begin when one or more genes in a cell are mutated creating an abnormal pro‐
tein or no protein at all. The information provided by an abnormal protein is different from
that of a normal protein, which can cause cells to multiply uncontrollably and become can‐
cerous. A person may either be born with the genetic mutation in all of their cells (germline
mutation) or acquire a genetic mutation in a single cell during his or her lifetime. An ac‐
quired mutation is passed on to all cells that develop from that single cell (somatic muta‐
tion). A germline mutation or a hereditary mutation, according to the NCI definition, is a
gene change in a body's reproductive cell that becomes incorporated into the DNA of every
cell in the body of the offspring. Germline mutations are passed on from parents to off‐
spring. Somatic mutations, according to the NCI, are alterations in DNA that occur after
conception. Somatic mutations can occur in any of the cells of the body except the germ cells
and therefore are not passed on to children. These alterations can (but do not always) cause
cancer or other diseases. If the mutant cell continues to divide, the individual will come to
contain a patch of tissue of genotype different from the cells of the rest of the body. So this is
a change in the genetic structure that is neither inherited nor passed to offspring. These
changes can be caused by environmental factors such as ultraviolet radiation from the sun
and cigarette smoke or can occur if a mistake is made as DNA copies itself during cell divi‐
sion. Mutations may also occur in a single cell within an early embryo. As all the cells divide
during growth and development, the individual will have some cells with the mutation and
some cells without the genetic change. This situation is called mosaicism. Some genetic
changes are very rare; others are common in the population. Genetic changes that occur in
more than 1 percent of the population are called polymorphisms. They are common enough
to be considered a normal variation in the DNA. Polymorphisms are responsible for many
of the normal differences between people such as eye color, hair color, and blood type. Al‐
though many polymorphisms have no negative effects on a person’s health, some of these
variations may influence the risk of developing certain disorders [1-5, 9-17].
Most ovarian cancers (about 85% to 90%) are considered sporadic, meaning that the damage
to the genes occurs by chance after a person is born and there is no risk of passing on the
gene to a person’s children. Inherited ovarian cancers are less common (about 10% to 15%)
and occur when gene mutations are passed within a family, from one generation to the next.
Every cell usually has two copies of each gene: one inherited from a person’s mother and
one inherited from a person’s father. Most types of hereditary ovarian cancer follow an au‐
tosomal dominant inheritance pattern, in which a mutation needs to happen in only one
copy of the gene for the person to have an increased risk of getting the disease. This means
that a parent with a gene mutation may pass on a copy of the normal gene or a copy of the
gene with a mutation. Therefore, a child who has a parent with a mutation has a 50% chance
of inheriting that mutation. A brother, sister, or parent of a person who has a gene mutation
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also has a 50% chance of having the same mutation. Autosomal dominant inheritance of
breast/ovarian cancer is characterized by transmission of cancer predisposition from genera‐
tion to generation, through either the mother’s or the father’s side of the family, with an in‐
heritance risk of 50%. Although the risk of inheriting the predisposition is 50%, not everyone
with the predisposition will develop cancer because of incomplete penetrance and/or gen‐
der-restricted or gender-related expression. Both males and females can inherit and transmit
an autosomal dominant cancer predisposition. A male who inherits a cancer predisposition
can still pass the altered gene on to his sons and daughters [1-5, 9-17].
3. The BRCA1 and BRCA2 genes
Breast and ovarian cancer are components of several autosomal syndromes but most strong‐
ly associated with both cancers are the BRCA1 or BRCA2 mutation syndromes, which ac‐
count for about 90% of hereditary cases. The BRCA1 gene is located on chromosome 17q21,
while BRCA2 is located on chromosome 13q12. BRCA1 and BRCA2 play major roles in the
repair of DNA doublestrand breaks by homologous recombination. Homologus recombina‐
tion repairs doublestrand breaks that occur in late S and G2 phase of the cell cycle and also
has a key role in repairing doublestrand breaks that result from unrepaired single-strand
break. BRCA1 signals the presence of doublestrand breaks, while BRCA2 is directly in‐
volved in the mechanism of homologous recombination. So the BRCA1 and BRCA2 proteins
are considered caretakers of the genome, and play key roles in the signaling of DNA dam‐
age, the activation of DNA repair, the induction of apoptosis, and the monitoring of cell cy‐
cle checkpoints. Cells that lack functional BRCA have increased aneuploidy, centrosome
amplification, and chromosomal aberrations, which make them susceptible to further muta‐
tions. BRCA appears to function as a cofactor for a variety of transcription factors, and the
associated ovarian cancers are more likely to be high grade and of serous histopathology. In
the absence of BRCA1 or BRCA2, alternative DNA repair pathways are used, which result in
chromosomal instability and cell death. Normal cell of carriers are usually heterozygote
with loss of the second allele occurring during tumorigenesis in the tumor cells of these
women. [1-5, 7,8].
There are several genetic conditions linked to an increased risk of ovarian cancer involving
mutations in several other genes, including TP53, PTEN, STK11/LKB1, CDH1, CHEK2,
ATM, MLH1, and MSH2.Some of the most common hereditary cancer syndromes associated
with ovarian cancer risk are the following:
1. Hereditary breast and ovarian cancer syndrome. This syndrome is associated with mu‐
tations in the BRCA1 or BRCA2 genes (BRCA stands for BReast CAncer) and it is relat‐
ed with an increased risk of breast cancer and ovarian cancer. There have also been
reports of a small number of families with an excess of ovarian cancer, but no breast
cancer, called site-specific ovarian cancer families. These families have been linked to
mutations in BRCA1 and are thought to represent a unique phenotype of the hereditary
breast-ovarian syndrome. The majority of hereditary breast cancers can be accounted
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for by inherited mutations in BRCA1 and BRCA2. Overall, it has been estimated that
inherited BRCA1 and BRCA2 mutations account for 5 to 10 percent of breast cancers
and 10 to 15 percent of ovarian cancers among white women in the United States. When
examining consecutive series of patients with ovarian cancer who have been unselected
for family history, approximately 10% to 15% of patients have a deleterious mutation in
either of these genes. When studying patients with ovarian cancer who have a family
history of ovarian cancer or early onset breast cancer, the likelihood of finding a BRCA1
or BRCA2 mutation rises considerably. In fact, it is generally stated that the majority of
hereditary ovarian cancer is explained by BRCA1 or BRCA2 abnormalities. The Gyneco‐
logic Oncology Group conducted a prospective study of women with ovarian cancer
and a positive family history. Specifically, they enrolled patients with ovarian cancer
who had any of the following features: a first degree relative with ovarian cancer, a sec‐
ond-degree relative with ovarian cancer plus a first-degree relative with early-onset
breast cancer (defined as younger than 50 years), or a first- and second-degree relative
with early onset breast cancer. Of 26 eligible patients screened for mutations, 12 had
deleterious alterations, eight in BRCA1 and four in BRCA2 [1-5, 7, 8]. Although repro‐
ductive, demographic, and lifestyle factors affect risk of ovarian cancer, the single most
important ovarian cancer risk factor is a family history of the disease. A large meta-
analysis of 15 published studies estimated an odds ratio of 3.1 for the risk of ovarian
cancer associated with at least one first degree relative with ovarian cancer. The family
characteristics that suggest hereditary breast and ovarian cancer predisposition include
the following: 1) Multiple cancers within a family. 2) Cancers that are usually diagnosed
at an earlier age than in sporadic. 3) History of two or more primary cancers in a single
particular individual. The Claus and the Gail models are widely used in research stud‐
ies and clinical counseling. Both have limitations, and the risk estimates derived from
the two models may differ for an individual patient. Several other models, which in‐
clude more detailed family history information, are also in use. The use of these models
requires specific knowledge and expertise. 4) Cases of male breast cancer are definitely
indications for genetic testing [1-5, 9-17].
2. Lynch syndrome or hereditary nonpolyposis colon cancer (HNPCC). Lynch syndrome
increases a woman’s risk of ovarian cancer. It is caused by mutations in several differ‐
ent genes and it also increases the risk of colorectal cancer, as well as cancers of the
stomach, small intestine, liver, bile duct, urinary tract, endometrium, the brain and cen‐
tral nervous system, and possibly breast cancer. Defects in mismatch repair in patients
with Lynch syndrome account for approximately 10% of hereditary ovarian cancers and
for 1% to 2% of overall cases. Patients with this syndrome, however, individually carry
an approximately 12% risk of developing ovarian cancer. The mechanism of increased
risk is through defects in the mismatch-repair machinery and its resulting genetic insta‐
bility that places cells at risk of multiple mutations; however, carcinogenesis in ovarian
cancer has not been well studied beyond a description of mismatch repair defects.
Genetic conditions that are also associated with a small increased risk of ovarian cancer are
the following:
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also has a 50% chance of having the same mutation. Autosomal dominant inheritance of
breast/ovarian cancer is characterized by transmission of cancer predisposition from genera‐
tion to generation, through either the mother’s or the father’s side of the family, with an in‐
heritance risk of 50%. Although the risk of inheriting the predisposition is 50%, not everyone
with the predisposition will develop cancer because of incomplete penetrance and/or gen‐
der-restricted or gender-related expression. Both males and females can inherit and transmit
an autosomal dominant cancer predisposition. A male who inherits a cancer predisposition
can still pass the altered gene on to his sons and daughters [1-5, 9-17].
3. The BRCA1 and BRCA2 genes
Breast and ovarian cancer are components of several autosomal syndromes but most strong‐
ly associated with both cancers are the BRCA1 or BRCA2 mutation syndromes, which ac‐
count for about 90% of hereditary cases. The BRCA1 gene is located on chromosome 17q21,
while BRCA2 is located on chromosome 13q12. BRCA1 and BRCA2 play major roles in the
repair of DNA doublestrand breaks by homologous recombination. Homologus recombina‐
tion repairs doublestrand breaks that occur in late S and G2 phase of the cell cycle and also
has a key role in repairing doublestrand breaks that result from unrepaired single-strand
break. BRCA1 signals the presence of doublestrand breaks, while BRCA2 is directly in‐
volved in the mechanism of homologous recombination. So the BRCA1 and BRCA2 proteins
are considered caretakers of the genome, and play key roles in the signaling of DNA dam‐
age, the activation of DNA repair, the induction of apoptosis, and the monitoring of cell cy‐
cle checkpoints. Cells that lack functional BRCA have increased aneuploidy, centrosome
amplification, and chromosomal aberrations, which make them susceptible to further muta‐
tions. BRCA appears to function as a cofactor for a variety of transcription factors, and the
associated ovarian cancers are more likely to be high grade and of serous histopathology. In
the absence of BRCA1 or BRCA2, alternative DNA repair pathways are used, which result in
chromosomal instability and cell death. Normal cell of carriers are usually heterozygote
with loss of the second allele occurring during tumorigenesis in the tumor cells of these
women. [1-5, 7,8].
There are several genetic conditions linked to an increased risk of ovarian cancer involving
mutations in several other genes, including TP53, PTEN, STK11/LKB1, CDH1, CHEK2,
ATM, MLH1, and MSH2.Some of the most common hereditary cancer syndromes associated
with ovarian cancer risk are the following:
1. Hereditary breast and ovarian cancer syndrome. This syndrome is associated with mu‐
tations in the BRCA1 or BRCA2 genes (BRCA stands for BReast CAncer) and it is relat‐
ed with an increased risk of breast cancer and ovarian cancer. There have also been
reports of a small number of families with an excess of ovarian cancer, but no breast
cancer, called site-specific ovarian cancer families. These families have been linked to
mutations in BRCA1 and are thought to represent a unique phenotype of the hereditary
breast-ovarian syndrome. The majority of hereditary breast cancers can be accounted
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for by inherited mutations in BRCA1 and BRCA2. Overall, it has been estimated that
inherited BRCA1 and BRCA2 mutations account for 5 to 10 percent of breast cancers
and 10 to 15 percent of ovarian cancers among white women in the United States. When
examining consecutive series of patients with ovarian cancer who have been unselected
for family history, approximately 10% to 15% of patients have a deleterious mutation in
either of these genes. When studying patients with ovarian cancer who have a family
history of ovarian cancer or early onset breast cancer, the likelihood of finding a BRCA1
or BRCA2 mutation rises considerably. In fact, it is generally stated that the majority of
hereditary ovarian cancer is explained by BRCA1 or BRCA2 abnormalities. The Gyneco‐
logic Oncology Group conducted a prospective study of women with ovarian cancer
and a positive family history. Specifically, they enrolled patients with ovarian cancer
who had any of the following features: a first degree relative with ovarian cancer, a sec‐
ond-degree relative with ovarian cancer plus a first-degree relative with early-onset
breast cancer (defined as younger than 50 years), or a first- and second-degree relative
with early onset breast cancer. Of 26 eligible patients screened for mutations, 12 had
deleterious alterations, eight in BRCA1 and four in BRCA2 [1-5, 7, 8]. Although repro‐
ductive, demographic, and lifestyle factors affect risk of ovarian cancer, the single most
important ovarian cancer risk factor is a family history of the disease. A large meta-
analysis of 15 published studies estimated an odds ratio of 3.1 for the risk of ovarian
cancer associated with at least one first degree relative with ovarian cancer. The family
characteristics that suggest hereditary breast and ovarian cancer predisposition include
the following: 1) Multiple cancers within a family. 2) Cancers that are usually diagnosed
at an earlier age than in sporadic. 3) History of two or more primary cancers in a single
particular individual. The Claus and the Gail models are widely used in research stud‐
ies and clinical counseling. Both have limitations, and the risk estimates derived from
the two models may differ for an individual patient. Several other models, which in‐
clude more detailed family history information, are also in use. The use of these models
requires specific knowledge and expertise. 4) Cases of male breast cancer are definitely
indications for genetic testing [1-5, 9-17].
2. Lynch syndrome or hereditary nonpolyposis colon cancer (HNPCC). Lynch syndrome
increases a woman’s risk of ovarian cancer. It is caused by mutations in several differ‐
ent genes and it also increases the risk of colorectal cancer, as well as cancers of the
stomach, small intestine, liver, bile duct, urinary tract, endometrium, the brain and cen‐
tral nervous system, and possibly breast cancer. Defects in mismatch repair in patients
with Lynch syndrome account for approximately 10% of hereditary ovarian cancers and
for 1% to 2% of overall cases. Patients with this syndrome, however, individually carry
an approximately 12% risk of developing ovarian cancer. The mechanism of increased
risk is through defects in the mismatch-repair machinery and its resulting genetic insta‐
bility that places cells at risk of multiple mutations; however, carcinogenesis in ovarian
cancer has not been well studied beyond a description of mismatch repair defects.
Genetic conditions that are also associated with a small increased risk of ovarian cancer are
the following:
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1. Peutz - Jeghers syndrome. This syndrome is caused by a specific genetic mutation in
the STK11 gene and is associated with multiple polyps in the digestive tract that be‐
come noncancerous tumors, increased pigmentation on the face and hands and with an
increased risk of ovarian, breast, uterine, and lung cancers.
2. Nevoid basal cell carcinoma syndrome or Gorlin syndrome is associated with a muta‐
tion in PTCH and a 20% life time risk of developing stromal tumors and fibromas of the
ovaries. There is a small risk that these fibromas could develop into fibrosarcoma. Peo‐
ple with Gorlin syndrome often have multiple basal cell carcinomas and jaw cysts and
may develop medulloblastoma in childhood.
3. Li-Fraumeni syndrome. The Li-Fraumeni syndrome is a rare condition associated with
a specific genetic mutation. People with Li-Fraumeni syndrome have a higher risk of
developing osteosarcoma, soft tissue sarcoma, leukemia, breast cancer, brain cancer,
and adrenal cortical tumors.
4. Ataxia telangiectasia. Ataxia telangiectasia is a rare disorder associated with a specific
genetic mutation. It causes progressive neurological problems and an increased risk of
leukemia, lymphoma, and possibly sarcoma, breast, ovarian and stomach cancer. Germ‐
line mutations in the genes responsible for those syndromes produce different clinical
phenotypes of characteristic malignancies and, in some instances, associated nonmalig‐
nant abnormalities.
A study of genetic disorders can provide great insight into the etiology and early events in
carcinogenesis. Evaluation of BRCA1 and BRCA2 mutant and sporadic tumors with gene
expression profiling has demonstrated that the greatest contrast in expression patterns was
between that of BRCA1 and BRCA2 mutant tumors and that sporadic tumors shared charac‐
teristics of both. This intriguing finding suggests that BRCA1 and BRCA2 tumors may have
variable pathways in carcinogenesis and that even sporadic tumors may develop as a result
of alterations in either pathway. Ovarian carcinogenesis, as in most cancers, involves multi‐
ple genetic alterations. A great deal has been learned about proteins and pathways impor‐
tant in the early stages of malignant transformation and metastasis, as derived from studies
of individual tumors, microarray data, animal models, and inherited disorders that confer
susceptibility. However, a full understanding of the earliest recognizable events in epithelial
ovarian carcinogenesis is limited by the lack of a well-defined premalignant state common
to all ovarian subtypes and by the paucity of data from early-stage cancers. Evidence sug‐
gests that ovarian cancers can progress both through a stepwise mutation process (low-
grade pathway) and through greater genetic instability that leads to rapid metastasis
without an identifiable precursor lesion (high-grade pathway). In an interesting review, CN
Landen et al. discuss many of the genetic and molecular disorders in each key process that is
altered in cancer cells, and present a model of ovarian pathogenesis that incorporates the
role of tumor cell mutations and factors in the host microenvironment important to tumor
initiation and progression [1-5, 9-17]. Borderline tumors have a much less frequent incidence
of BRCA mutations, which also suggests a different molecular origin. Other than in heredi‐
tary syndromes, BRCA genes are rarely mutated in sporadic ovarian cancers, although epi‐
Ovarian Cancer - A Clinical and Translational Update140
genetic changes alternate splicing, and other genetic factors may affect BRCA function in as
many as 82% of sporadic occurrences.
An  analysis  of  genomic  changes  in  ovarian  cancer  has  provided  the  most  comprehen‐
sive and integrated view of cancer genes for any cancer type to date. Ovarian serous ad‐
enocarcinoma  tumors  from  500  patients  were  examined  by  The  Cancer  Genome  Atlas
(TCGA)  Research  Network  and  analyses  were  reported  in  2011.These  findings  confirm
that  mutations  in  a  single  gene,  TP53,  are  present  in  more  than  96  percent  of  all  such
cancers.  TP53 encodes a tumor suppressor protein that normally prevents cancer forma‐
tion.  Mutations  in  the  gene disrupt  this  protein’s  function,  which contributes  to  uncon‐
trolled growth of ovarian cells.  Several  less-frequent mutations in other genes have also
been  identified  and  was  also  established  how sets  of  genes  are  expressed  in  a  fashion
that can predict patient survival, identifying patterns for 108 genes associated with poor
survival  and  85  genes  associated  with  better  survival.  Patients  whose  tumors  had  a
gene-expression  signature  associated  with  poor  survival  lived  for  a  period  that  was  23
percent  shorter  than patients  whose  tumors  did  not  have  such a  signature.  To  identify
opportunities  for  targeted  treatment,  the  investigators  searched  for  existing  drugs  that
might  inhibit  amplified  or  over-expressed  genes  that  were  suggested  to  play  a  role  in
ovarian cancer. Sixty-eight genes have been identified that could be targeted by existing
or  experimental  therapeutic  compounds.  One  type  of  drug,  a  PARP  (Poly  ADP  ribose
polymerase) inhibitor, might be able to counteract the DNA repair gene observed in half
of  the  ovarian  tumors  studied.  These  drugs  could  be  effective  against  the  disease,  this
study revealed that  50 percent  of  tumors might  be responsive to  drugs that  exploit  the
genetic  instability  of  the  tumors  and  induce  the  cancer  cells  to  die.  The  results  of  this
study  support  the  existence  of  four  distinct  subtypes  of  the  disease,  based  on  the  pat‐
terns  seen  in  the  transcription  of  RNA  from  DNA.  They  also  support  the  existence  of
four related subtypes based on the patterns of DNA methylation—a chemical reaction in
which a  small  molecule  called a  methyl  group is  added to  DNA, changing the  activity
of  individual  genes.  These  patterns  likely  reflect  the  functional  changes  associated with
ovarian  serous  adenocarcinoma,  but  are  not  strongly  associated  with  survival  duration.
In this study, approximately 21 percent of the tumors showed mutations in BRCA1 and
BRCA2 genes. Analysis of these tumors confirmed observations that patients with mutat‐
ed BRCA1 and BRCA2 genes have better survival odds than patients without mutations
in these genes.  If  either of  the BRCA1 and BRCA2 genes is  mutated,  there is  improved
survival  duration.  However,  if  BRCA1 activity  is  instead reduced by methylation,  there
is no improved survival duration [1-5, 9-17].
4. Genetic testing
Only genetic testing can determine whether a person has a genetic mutation. Most experts
strongly recommend that people considering genetic testing first consult a genetic counselor
if possible. Genetic counselors are trained to explain the risks and benefits of genetic testing.
If a Genetic counselor is not available the clinician treating a patient with Ovarian Cancer
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1. Peutz - Jeghers syndrome. This syndrome is caused by a specific genetic mutation in
the STK11 gene and is associated with multiple polyps in the digestive tract that be‐
come noncancerous tumors, increased pigmentation on the face and hands and with an
increased risk of ovarian, breast, uterine, and lung cancers.
2. Nevoid basal cell carcinoma syndrome or Gorlin syndrome is associated with a muta‐
tion in PTCH and a 20% life time risk of developing stromal tumors and fibromas of the
ovaries. There is a small risk that these fibromas could develop into fibrosarcoma. Peo‐
ple with Gorlin syndrome often have multiple basal cell carcinomas and jaw cysts and
may develop medulloblastoma in childhood.
3. Li-Fraumeni syndrome. The Li-Fraumeni syndrome is a rare condition associated with
a specific genetic mutation. People with Li-Fraumeni syndrome have a higher risk of
developing osteosarcoma, soft tissue sarcoma, leukemia, breast cancer, brain cancer,
and adrenal cortical tumors.
4. Ataxia telangiectasia. Ataxia telangiectasia is a rare disorder associated with a specific
genetic mutation. It causes progressive neurological problems and an increased risk of
leukemia, lymphoma, and possibly sarcoma, breast, ovarian and stomach cancer. Germ‐
line mutations in the genes responsible for those syndromes produce different clinical
phenotypes of characteristic malignancies and, in some instances, associated nonmalig‐
nant abnormalities.
A study of genetic disorders can provide great insight into the etiology and early events in
carcinogenesis. Evaluation of BRCA1 and BRCA2 mutant and sporadic tumors with gene
expression profiling has demonstrated that the greatest contrast in expression patterns was
between that of BRCA1 and BRCA2 mutant tumors and that sporadic tumors shared charac‐
teristics of both. This intriguing finding suggests that BRCA1 and BRCA2 tumors may have
variable pathways in carcinogenesis and that even sporadic tumors may develop as a result
of alterations in either pathway. Ovarian carcinogenesis, as in most cancers, involves multi‐
ple genetic alterations. A great deal has been learned about proteins and pathways impor‐
tant in the early stages of malignant transformation and metastasis, as derived from studies
of individual tumors, microarray data, animal models, and inherited disorders that confer
susceptibility. However, a full understanding of the earliest recognizable events in epithelial
ovarian carcinogenesis is limited by the lack of a well-defined premalignant state common
to all ovarian subtypes and by the paucity of data from early-stage cancers. Evidence sug‐
gests that ovarian cancers can progress both through a stepwise mutation process (low-
grade pathway) and through greater genetic instability that leads to rapid metastasis
without an identifiable precursor lesion (high-grade pathway). In an interesting review, CN
Landen et al. discuss many of the genetic and molecular disorders in each key process that is
altered in cancer cells, and present a model of ovarian pathogenesis that incorporates the
role of tumor cell mutations and factors in the host microenvironment important to tumor
initiation and progression [1-5, 9-17]. Borderline tumors have a much less frequent incidence
of BRCA mutations, which also suggests a different molecular origin. Other than in heredi‐
tary syndromes, BRCA genes are rarely mutated in sporadic ovarian cancers, although epi‐
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genetic changes alternate splicing, and other genetic factors may affect BRCA function in as
many as 82% of sporadic occurrences.
An  analysis  of  genomic  changes  in  ovarian  cancer  has  provided  the  most  comprehen‐
sive and integrated view of cancer genes for any cancer type to date. Ovarian serous ad‐
enocarcinoma  tumors  from  500  patients  were  examined  by  The  Cancer  Genome  Atlas
(TCGA)  Research  Network  and  analyses  were  reported  in  2011.These  findings  confirm
that  mutations  in  a  single  gene,  TP53,  are  present  in  more  than  96  percent  of  all  such
cancers.  TP53 encodes a tumor suppressor protein that normally prevents cancer forma‐
tion.  Mutations  in  the  gene disrupt  this  protein’s  function,  which contributes  to  uncon‐
trolled growth of ovarian cells.  Several  less-frequent mutations in other genes have also
been  identified  and  was  also  established  how sets  of  genes  are  expressed  in  a  fashion
that can predict patient survival, identifying patterns for 108 genes associated with poor
survival  and  85  genes  associated  with  better  survival.  Patients  whose  tumors  had  a
gene-expression  signature  associated  with  poor  survival  lived  for  a  period  that  was  23
percent  shorter  than patients  whose  tumors  did  not  have  such a  signature.  To  identify
opportunities  for  targeted  treatment,  the  investigators  searched  for  existing  drugs  that
might  inhibit  amplified  or  over-expressed  genes  that  were  suggested  to  play  a  role  in
ovarian cancer. Sixty-eight genes have been identified that could be targeted by existing
or  experimental  therapeutic  compounds.  One  type  of  drug,  a  PARP  (Poly  ADP  ribose
polymerase) inhibitor, might be able to counteract the DNA repair gene observed in half
of  the  ovarian  tumors  studied.  These  drugs  could  be  effective  against  the  disease,  this
study revealed that  50 percent  of  tumors might  be responsive to  drugs that  exploit  the
genetic  instability  of  the  tumors  and  induce  the  cancer  cells  to  die.  The  results  of  this
study  support  the  existence  of  four  distinct  subtypes  of  the  disease,  based  on  the  pat‐
terns  seen  in  the  transcription  of  RNA  from  DNA.  They  also  support  the  existence  of
four related subtypes based on the patterns of DNA methylation—a chemical reaction in
which a  small  molecule  called a  methyl  group is  added to  DNA, changing the  activity
of  individual  genes.  These  patterns  likely  reflect  the  functional  changes  associated with
ovarian  serous  adenocarcinoma,  but  are  not  strongly  associated  with  survival  duration.
In this study, approximately 21 percent of the tumors showed mutations in BRCA1 and
BRCA2 genes. Analysis of these tumors confirmed observations that patients with mutat‐
ed BRCA1 and BRCA2 genes have better survival odds than patients without mutations
in these genes.  If  either of  the BRCA1 and BRCA2 genes is  mutated,  there is  improved
survival  duration.  However,  if  BRCA1 activity  is  instead reduced by methylation,  there
is no improved survival duration [1-5, 9-17].
4. Genetic testing
Only genetic testing can determine whether a person has a genetic mutation. Most experts
strongly recommend that people considering genetic testing first consult a genetic counselor
if possible. Genetic counselors are trained to explain the risks and benefits of genetic testing.
If a Genetic counselor is not available the clinician treating a patient with Ovarian Cancer
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has the duty to take its role. He/she must consider if each patient with ovarian cancer is a
candidate for genetic testing. Hereditary cancer syndromes have a major ethical, legal and
psychological impact on the individual as well as family members and the caring physician.
As a result, a careful counseling before, during and after the testing is necessary. There are
many issues that one has to know before proceeding with the genetic testing.
Criteria for recommending genetic testing: Currently, there are no standard criteria for rec‐
ommending or referring someone for BRCA1 orBRCA2 mutation testing American Society
of Clinical Oncology (ASCO) has published some guidelines for Genetic Testing of cancer
patients and their families. ASCO also encourages Oncologists to assume the responsibility
of genetics counseling with patients and their families. ASCO General recommendation as
to indications for genetic testing in generally are the following: 1) When a person has a
strong family history of cancer or very early age of onset of disease. 2) Test can be adequate‐
ly interpreted. 3) Result will influence medical management of the patient/family member.
In a family with a history of breast and/or ovarian cancer, it may be most informative to first
test a family member who has breast or ovarian cancer. If that person is found to have a
harmful BRCA1 or BRCA2 mutation, then other family members can be tested to see if they
also have the mutation. Women who have a relative with a harmful BRCA1 or BRCA2 mu‐
tation and women who appear to be at increased risk of breast and/or ovarian cancer be‐
cause of their family history should consider genetic counseling to learn more about their
potential risks and about BRCA1 and BRCA2 genetic tests.
ASCO Recommendation as to indications for genetic testing for Breast and Ovarian cancers
are the following: 1) Family with more than two breast cancer cases and one or more cases
of ovarian cancer diagnosed at any age. 2) Family with more than three breast cancer cases
diagnosed before age 50. 3) Sister pairs with two of the following cancers diagnosed before
age 50: two breast cancers; two ovarian cancers; or a breast and ovarian cancer.4) Relatives
of individuals with breast cancer diagnosed before the age of 30.Despite the above recom‐
mendations, there are individuals who do not fit any of the above categories and yet like to
be tested. Such individuals need to be counseled to determine the appropriateness of genetic
testing [1-5, 9-17].
Genetic counseling: Genetic counseling is generally recommended before and after a genet‐
ic test. This counseling should be performed by a health care professional experienced in
cancer genetics. Genetic counseling usually involves a risk assessment based on the individ‐
ual’s personal and family medical history and discussions about the appropriateness of ge‐
netic testing, the specific test(s) that might be used and the technical accuracy of the test(s),
the medical implications of a positive or a negative test result, the possibility that a test re‐
sult might not be informative (an ambiguous result), the psychological risks and benefits of
genetic test results, and the risk of passing a mutation to children. In case genetic testing
turns positive health care professional must explain to her that a positive test result indi‐
cates that a person has inherited a known harmful mutation in BRCA1 or BRCA2 and, there‐
fore, has an increased risk of developing cancer. Women considering genetic testing must
know in advance certain facts about the risk to develop Ovarian Cancer if the tests are posi‐
tive as well as the available prevention options. The lifetime risk for women who are BRCA1
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carriers is about 40-50% and for BRCA2 carriers about 10-20%. The following information
must be provided to genetic testing candidates according to the NCI. Women must know
that in addition to family history, other environmental and lifestyle factors may increase
their risk of ovarian cancer. Discussing their family history and personal risk factors with a
doctor helps them to better understand their risk. People with a higher than average risk
may benefit from genetic counseling, and the implementation of early detection and preven‐
tion strategies.
There can be benefits to genetic testing, whether a person receives a positive or a nega‐
tive  result.  The  potential  benefits  of  a  negative  result  include  a  sense  of  relief  and the
possibility  that  special  preventive  checkups,  tests,  or  surgeries  may  not  be  needed.  A
positive test result can bring relief from uncertainty and allow people to make informed
decisions about  their  future,  including taking steps to reduce their  cancer  risk.  In addi‐
tion, many people who have a positive test result may be able to participate in medical
research that  could,  in  the  long run,  help  reduce  deaths  from breast  cancer.  The  direct
medical  risks,  or  harms,  of  genetic  testing are  very small,  but  test  results  may have an
effect  on a person’s emotions,  social  relationships,  finances,  and medical  choices.  People
who  receive  a  positive  test  result  may  feel  anxious,  depressed,  or  angry.  They  may
choose to undergo preventive measures,  such as prophylactic surgery,  that have serious
long-term implications and whose effectiveness is uncertain. People who receive a nega‐
tive test result may experience “survivor guilt,” caused by the knowledge that they like‐
ly do not have an increased risk of developing a disease that affects one or more loved
ones.  Because genetic  testing can reveal  information about  more than one family  mem‐
ber,  the  emotions  caused by  test  results  can  create  tension  within  families.  Test  results
can also  affect  personal  choices,  such as  marriage  and childbearing.  Issues  surrounding
the privacy and confidentiality of genetic test results are additional potential risks.
Ovarian cancer may run in the family if first-degree relatives (mother, sisters, daughters) or
many other family members (grandmothers, aunts, nieces, granddaughters) have had ovari‐
an cancer. If a woman's first-degree relatives developed ovarian cancer, her risk of ovarian
cancer is about three times higher than the average woman's risk of ovarian cancer. The risk
increases if other close relatives have had ovarian cancer. When using family history to as‐
sess risk, the accuracy and completeness of family history data must be taken into account.
A reported family history may be erroneous, or a person may be unaware of relatives affect‐
ed with cancer. In addition, small family sizes, premature deaths, immigration and poor
medical records may limit the information obtained from a family history. Breast or ovarian
cancer on the paternal side of the family usually involves more distant relatives than on the
maternal side and thus may be more difficult to obtain. When comparing self-reported in‐
formation with independently verified cases, the sensitivity of a history of breast cancer is
relatively high, at 83% to 97%, but lower for ovarian cancer, at 60%. [1-5, 10,11]
However, a positive test result provides information only about a person’s risk of develop‐
ing cancer. It cannot tell whether an individual will actually develop cancer or when. It must
be stressed that not all women who inherit a harmful BRCA1 or BRCA2 mutation will devel‐
op breast or ovarian cancer. A positive genetic test result may have important health and
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has the duty to take its role. He/she must consider if each patient with ovarian cancer is a
candidate for genetic testing. Hereditary cancer syndromes have a major ethical, legal and
psychological impact on the individual as well as family members and the caring physician.
As a result, a careful counseling before, during and after the testing is necessary. There are
many issues that one has to know before proceeding with the genetic testing.
Criteria for recommending genetic testing: Currently, there are no standard criteria for rec‐
ommending or referring someone for BRCA1 orBRCA2 mutation testing American Society
of Clinical Oncology (ASCO) has published some guidelines for Genetic Testing of cancer
patients and their families. ASCO also encourages Oncologists to assume the responsibility
of genetics counseling with patients and their families. ASCO General recommendation as
to indications for genetic testing in generally are the following: 1) When a person has a
strong family history of cancer or very early age of onset of disease. 2) Test can be adequate‐
ly interpreted. 3) Result will influence medical management of the patient/family member.
In a family with a history of breast and/or ovarian cancer, it may be most informative to first
test a family member who has breast or ovarian cancer. If that person is found to have a
harmful BRCA1 or BRCA2 mutation, then other family members can be tested to see if they
also have the mutation. Women who have a relative with a harmful BRCA1 or BRCA2 mu‐
tation and women who appear to be at increased risk of breast and/or ovarian cancer be‐
cause of their family history should consider genetic counseling to learn more about their
potential risks and about BRCA1 and BRCA2 genetic tests.
ASCO Recommendation as to indications for genetic testing for Breast and Ovarian cancers
are the following: 1) Family with more than two breast cancer cases and one or more cases
of ovarian cancer diagnosed at any age. 2) Family with more than three breast cancer cases
diagnosed before age 50. 3) Sister pairs with two of the following cancers diagnosed before
age 50: two breast cancers; two ovarian cancers; or a breast and ovarian cancer.4) Relatives
of individuals with breast cancer diagnosed before the age of 30.Despite the above recom‐
mendations, there are individuals who do not fit any of the above categories and yet like to
be tested. Such individuals need to be counseled to determine the appropriateness of genetic
testing [1-5, 9-17].
Genetic counseling: Genetic counseling is generally recommended before and after a genet‐
ic test. This counseling should be performed by a health care professional experienced in
cancer genetics. Genetic counseling usually involves a risk assessment based on the individ‐
ual’s personal and family medical history and discussions about the appropriateness of ge‐
netic testing, the specific test(s) that might be used and the technical accuracy of the test(s),
the medical implications of a positive or a negative test result, the possibility that a test re‐
sult might not be informative (an ambiguous result), the psychological risks and benefits of
genetic test results, and the risk of passing a mutation to children. In case genetic testing
turns positive health care professional must explain to her that a positive test result indi‐
cates that a person has inherited a known harmful mutation in BRCA1 or BRCA2 and, there‐
fore, has an increased risk of developing cancer. Women considering genetic testing must
know in advance certain facts about the risk to develop Ovarian Cancer if the tests are posi‐
tive as well as the available prevention options. The lifetime risk for women who are BRCA1
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carriers is about 40-50% and for BRCA2 carriers about 10-20%. The following information
must be provided to genetic testing candidates according to the NCI. Women must know
that in addition to family history, other environmental and lifestyle factors may increase
their risk of ovarian cancer. Discussing their family history and personal risk factors with a
doctor helps them to better understand their risk. People with a higher than average risk
may benefit from genetic counseling, and the implementation of early detection and preven‐
tion strategies.
There can be benefits to genetic testing, whether a person receives a positive or a nega‐
tive  result.  The  potential  benefits  of  a  negative  result  include  a  sense  of  relief  and the
possibility  that  special  preventive  checkups,  tests,  or  surgeries  may  not  be  needed.  A
positive test result can bring relief from uncertainty and allow people to make informed
decisions about  their  future,  including taking steps to reduce their  cancer  risk.  In addi‐
tion, many people who have a positive test result may be able to participate in medical
research that  could,  in  the  long run,  help  reduce  deaths  from breast  cancer.  The  direct
medical  risks,  or  harms,  of  genetic  testing are  very small,  but  test  results  may have an
effect  on a person’s emotions,  social  relationships,  finances,  and medical  choices.  People
who  receive  a  positive  test  result  may  feel  anxious,  depressed,  or  angry.  They  may
choose to undergo preventive measures,  such as prophylactic surgery,  that have serious
long-term implications and whose effectiveness is uncertain. People who receive a nega‐
tive test result may experience “survivor guilt,” caused by the knowledge that they like‐
ly do not have an increased risk of developing a disease that affects one or more loved
ones.  Because genetic  testing can reveal  information about  more than one family  mem‐
ber,  the  emotions  caused by  test  results  can  create  tension  within  families.  Test  results
can also  affect  personal  choices,  such as  marriage  and childbearing.  Issues  surrounding
the privacy and confidentiality of genetic test results are additional potential risks.
Ovarian cancer may run in the family if first-degree relatives (mother, sisters, daughters) or
many other family members (grandmothers, aunts, nieces, granddaughters) have had ovari‐
an cancer. If a woman's first-degree relatives developed ovarian cancer, her risk of ovarian
cancer is about three times higher than the average woman's risk of ovarian cancer. The risk
increases if other close relatives have had ovarian cancer. When using family history to as‐
sess risk, the accuracy and completeness of family history data must be taken into account.
A reported family history may be erroneous, or a person may be unaware of relatives affect‐
ed with cancer. In addition, small family sizes, premature deaths, immigration and poor
medical records may limit the information obtained from a family history. Breast or ovarian
cancer on the paternal side of the family usually involves more distant relatives than on the
maternal side and thus may be more difficult to obtain. When comparing self-reported in‐
formation with independently verified cases, the sensitivity of a history of breast cancer is
relatively high, at 83% to 97%, but lower for ovarian cancer, at 60%. [1-5, 10,11]
However, a positive test result provides information only about a person’s risk of develop‐
ing cancer. It cannot tell whether an individual will actually develop cancer or when. It must
be stressed that not all women who inherit a harmful BRCA1 or BRCA2 mutation will devel‐
op breast or ovarian cancer. A positive genetic test result may have important health and
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social implications for family members, including future generations. Unlike most other
medical tests, genetic tests can reveal information not only about the person being tested but
also about that person’s relatives. Both men and women who inherit harmful BRCA1 or
BRCA2 mutations, whether they develop cancer themselves or not, may pass the mutations
on to their sons and daughters. However, not all children of people who have a harmful mu‐
tation will inherit the mutation. How a negative test result will be interpreted depends on
whether or not someone in the tested person’s family is known to carry a harmful BRCA1 or
BRCA2 mutation. If someone in the family has a known mutation, testing other family mem‐
bers for the same mutation can provide information about their cancer risk. If a person tests
negative for a known mutation in his or her family, it is unlikely that they have an inherited
susceptibility to cancer associated with BRCA1 orBRCA2. Such a test result is called a “true
negative.” On the other hand having a true negative test result does not mean that a person
will not develop cancer; it means that the person’s risk of cancer is probably the same as that
of people in the general population. In cases in which a family has a history of breast and/or
ovarian cancer and no known mutation in BRCA1 or BRCA2 has been previously identified,
a negative test result is not informative. It is not possible to tell whether an individual has a
harmful BRCA1 or BRCA2 mutation that was not detected by testing and this is called a
“false negative test” or whether the result is a true negative. In addition, it is possible for
people to have a mutation in a gene other than BRCA1 or BRCA2 that increases their cancer
risk but is not detectable by the test(s) used. If genetic testing shows a change in BRCA1 or
BRCA2 that has not been previously associated with cancer in other people, the person’s test
result may be interpreted as “ambiguous” and the result is considered as uncertain. It is es‐
timated that 10 percent of women who underwent BRCA1 and BRCA2 mutation testing had
this type of ambiguous result. Because everyone has genetic differences that are not associat‐
ed with an increased risk of disease, it is sometimes not known whether a specific DNA
change affects a person’s risk of developing cancer. As more research is conducted and more
people are tested for BRCA1 or BRCA2 changes, we expect to learn more about these
changes and cancer risk [1-5, 9-17].
Genetic tests: Several methods are available to test for BRCA1 and BRCA2 mutations. Most
of these methods look for changes in BRCA1 and BRCA2 DNA. At least one method looks
for changes in the proteins produced by these genes. Frequently, a combination of methods
is used. A blood sample is needed for these tests. The blood is drawn in a laboratory, doc‐
tor's office, hospital, or clinic and then sent to a laboratory that specializes in the tests. It usu‐
ally takes several weeks or longer to get the test results. Genetic tests are expensive and this
represents a major problem in every day practice.
5. Management of women with mutated genes
The  options  available  today  for  women  who  have  tested  positive  can  be  divided  into
secondary  and  primary  prevention.  Methods  of  secondary  prevention,  such  as  surveil‐
lance,  attempt to diagnose cancers at  an early stage,  while primary prevention prevents
cancer  development.  Chemoprevention and prophylactic  oophorectomy are  examples  of
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primary  prevention.  Not  all  methods  are  appropriate  for  all  patients,  and potential  ad‐
verse effects,  complications,  cost,  and efficacy of these interventions must be considered
and  reviewed  with  patients  before  implementation.  It  must  be  stressed  that  having  a
particular  genetic  mutation  linked  to  ovarian  cancer  cannot  predict  that  a  person  will
develop cancer. [1-5, 18-29].
Cancer prevention is action taken to lower the chance of getting cancer. By preventing can‐
cer, the number of new cases of cancer in a group or population is lowered. Hopefully, this
will lower the number of deaths caused by cancer. To prevent new cancers from starting, we
must consider risk and protective factors. Anything that increases one person’s chance of
developing cancer is called a cancer risk factor; anything that decreases the chance of devel‐
oping cancer is called a cancer protective factor. Some risk factors for cancer can be avoided,
but many cannot. For example, both smoking and inheriting certain genes are risk factors
for some types of cancer, but only smoking can be avoided. Regular exercise and a healthy
diet may be protective factors for some types of cancer. Avoiding risk factors and increasing
protective factors may lower the risk but it does not mean that cancer will be avoided. Dif‐
ferent ways to prevent cancer are being studied, including: Changing lifestyle or eating hab‐
its, avoiding things known to cause cancer or taking medicines to treat a precancerous
condition or to keep cancer from starting[1-5,18-29]. According to the NCI’s PDQ cancer in‐
formation about Ovarian cancer prevention the following risk factors may increase the risk
of ovarian cancer: Family history of ovarian cancer, inherited risk, hormone replacement
therapy, fertility drugs, talc and obesity. Factors associated with a decreased risk of ovarian
cancer include: (a) using oral contraceptives, (b) having and breastfeeding children, (c) hav‐
ing a bilateral tubal ligation or hysterectomy, and (d) having a prophylactic oophorectomy.
Multiple studies have consistently demonstrated a decrease in ovarian cancer risk in women
who take oral contraceptives. The protective association increases with the duration of oral
contraceptive use and persists up to 25 years after discontinuing oral contraceptives. A re‐
view of the literature demonstrated a 10% to 12% decrease in risk associated with use for 1
year and an approximate 50% decrease after 5 years of use. This reduced risk was present
among both nulliparous and parous women. A protective association between oral contra‐
ceptives and risk of ovarian cancer has been observed in most studies among women who
carry a mutation in BRCA1 and BRCA2 genes but a population-based study did not observe
an association between oral contraceptives and ovarian cancer, while parity was protective.
There may be a slight increase in a woman’s risk of breast cancer during the time she is tak‐
ing oral contraceptives. This risk decreases over time. Pregnancy and breastfeeding are
linked to a decreased risk of ovarian cancer. Ovulation stops or occurs less often in women
who are pregnant or breastfeeding and women who ovulate less often have a decreased risk
of ovarian cancer. Factors that increase risk for ovarian cancer include increasing age and
nulliparity, while those that decrease risk include surgical history and use of Oral contracep‐
tives. Relatively few studies have addressed the effect of these risk factors in women who
are genetically susceptible to ovarian cancer. Ovarian cancer incidence rises in a linear fash‐
ion from age 30 years to age 50 years and continues to increase, though at a slower rate,
thereafter. Before age 30 years, the risk of developing epithelial ovarian cancer is remote,
even in hereditary cancer families. Nulliparity is consistently associated with an increased
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social implications for family members, including future generations. Unlike most other
medical tests, genetic tests can reveal information not only about the person being tested but
also about that person’s relatives. Both men and women who inherit harmful BRCA1 or
BRCA2 mutations, whether they develop cancer themselves or not, may pass the mutations
on to their sons and daughters. However, not all children of people who have a harmful mu‐
tation will inherit the mutation. How a negative test result will be interpreted depends on
whether or not someone in the tested person’s family is known to carry a harmful BRCA1 or
BRCA2 mutation. If someone in the family has a known mutation, testing other family mem‐
bers for the same mutation can provide information about their cancer risk. If a person tests
negative for a known mutation in his or her family, it is unlikely that they have an inherited
susceptibility to cancer associated with BRCA1 orBRCA2. Such a test result is called a “true
negative.” On the other hand having a true negative test result does not mean that a person
will not develop cancer; it means that the person’s risk of cancer is probably the same as that
of people in the general population. In cases in which a family has a history of breast and/or
ovarian cancer and no known mutation in BRCA1 or BRCA2 has been previously identified,
a negative test result is not informative. It is not possible to tell whether an individual has a
harmful BRCA1 or BRCA2 mutation that was not detected by testing and this is called a
“false negative test” or whether the result is a true negative. In addition, it is possible for
people to have a mutation in a gene other than BRCA1 or BRCA2 that increases their cancer
risk but is not detectable by the test(s) used. If genetic testing shows a change in BRCA1 or
BRCA2 that has not been previously associated with cancer in other people, the person’s test
result may be interpreted as “ambiguous” and the result is considered as uncertain. It is es‐
timated that 10 percent of women who underwent BRCA1 and BRCA2 mutation testing had
this type of ambiguous result. Because everyone has genetic differences that are not associat‐
ed with an increased risk of disease, it is sometimes not known whether a specific DNA
change affects a person’s risk of developing cancer. As more research is conducted and more
people are tested for BRCA1 or BRCA2 changes, we expect to learn more about these
changes and cancer risk [1-5, 9-17].
Genetic tests: Several methods are available to test for BRCA1 and BRCA2 mutations. Most
of these methods look for changes in BRCA1 and BRCA2 DNA. At least one method looks
for changes in the proteins produced by these genes. Frequently, a combination of methods
is used. A blood sample is needed for these tests. The blood is drawn in a laboratory, doc‐
tor's office, hospital, or clinic and then sent to a laboratory that specializes in the tests. It usu‐
ally takes several weeks or longer to get the test results. Genetic tests are expensive and this
represents a major problem in every day practice.
5. Management of women with mutated genes
The  options  available  today  for  women  who  have  tested  positive  can  be  divided  into
secondary  and  primary  prevention.  Methods  of  secondary  prevention,  such  as  surveil‐
lance,  attempt to diagnose cancers at  an early stage,  while primary prevention prevents
cancer  development.  Chemoprevention and prophylactic  oophorectomy are  examples  of
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primary  prevention.  Not  all  methods  are  appropriate  for  all  patients,  and potential  ad‐
verse effects,  complications,  cost,  and efficacy of these interventions must be considered
and  reviewed  with  patients  before  implementation.  It  must  be  stressed  that  having  a
particular  genetic  mutation  linked  to  ovarian  cancer  cannot  predict  that  a  person  will
develop cancer. [1-5, 18-29].
Cancer prevention is action taken to lower the chance of getting cancer. By preventing can‐
cer, the number of new cases of cancer in a group or population is lowered. Hopefully, this
will lower the number of deaths caused by cancer. To prevent new cancers from starting, we
must consider risk and protective factors. Anything that increases one person’s chance of
developing cancer is called a cancer risk factor; anything that decreases the chance of devel‐
oping cancer is called a cancer protective factor. Some risk factors for cancer can be avoided,
but many cannot. For example, both smoking and inheriting certain genes are risk factors
for some types of cancer, but only smoking can be avoided. Regular exercise and a healthy
diet may be protective factors for some types of cancer. Avoiding risk factors and increasing
protective factors may lower the risk but it does not mean that cancer will be avoided. Dif‐
ferent ways to prevent cancer are being studied, including: Changing lifestyle or eating hab‐
its, avoiding things known to cause cancer or taking medicines to treat a precancerous
condition or to keep cancer from starting[1-5,18-29]. According to the NCI’s PDQ cancer in‐
formation about Ovarian cancer prevention the following risk factors may increase the risk
of ovarian cancer: Family history of ovarian cancer, inherited risk, hormone replacement
therapy, fertility drugs, talc and obesity. Factors associated with a decreased risk of ovarian
cancer include: (a) using oral contraceptives, (b) having and breastfeeding children, (c) hav‐
ing a bilateral tubal ligation or hysterectomy, and (d) having a prophylactic oophorectomy.
Multiple studies have consistently demonstrated a decrease in ovarian cancer risk in women
who take oral contraceptives. The protective association increases with the duration of oral
contraceptive use and persists up to 25 years after discontinuing oral contraceptives. A re‐
view of the literature demonstrated a 10% to 12% decrease in risk associated with use for 1
year and an approximate 50% decrease after 5 years of use. This reduced risk was present
among both nulliparous and parous women. A protective association between oral contra‐
ceptives and risk of ovarian cancer has been observed in most studies among women who
carry a mutation in BRCA1 and BRCA2 genes but a population-based study did not observe
an association between oral contraceptives and ovarian cancer, while parity was protective.
There may be a slight increase in a woman’s risk of breast cancer during the time she is tak‐
ing oral contraceptives. This risk decreases over time. Pregnancy and breastfeeding are
linked to a decreased risk of ovarian cancer. Ovulation stops or occurs less often in women
who are pregnant or breastfeeding and women who ovulate less often have a decreased risk
of ovarian cancer. Factors that increase risk for ovarian cancer include increasing age and
nulliparity, while those that decrease risk include surgical history and use of Oral contracep‐
tives. Relatively few studies have addressed the effect of these risk factors in women who
are genetically susceptible to ovarian cancer. Ovarian cancer incidence rises in a linear fash‐
ion from age 30 years to age 50 years and continues to increase, though at a slower rate,
thereafter. Before age 30 years, the risk of developing epithelial ovarian cancer is remote,
even in hereditary cancer families. Nulliparity is consistently associated with an increased
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risk of ovarian cancer, including among BRCA1/BRCA2mutation carriers. Risk may also be
increased among women who have used fertility drugs, especially those who remain nulli‐
gravid. Evidence is growing that the use of menopausal HRT is associated with an increased
risk of ovarian cancer, particularly in long-time users and users of sequential estrogen-pro‐
gesterone schedules [1-5].
Surveillance means cancer screening, or a way of detecting the disease early. Screening
does not, however, change the risk of developing cancer. The goal is to find cancer early,
when it may be most treatable. Screening, looking for cancer before a person has any symp‐
toms, can help find cancer at an early stage and increase the chances for cure or prolong sur‐
vival. By the time symptoms appear, the disease may have begun to spread and treatment
results are usually disappointing. Before recommending screening it is important to esti‐
mate women who have increased risk to develop ovarian cancer in order to suggest the
proper screening tests, when to start screening and how often to repeat it. If screening tests
are abnormal then the physician has to proceed to diagnostic tests. There are unfortunately
no satisfactory standard screening tests for ovarian cancer. Family members of ovarian can‐
cer patients must be informed that tests that may detect ovarian cancer are the following:
Pelvic examination, transvaginal ultrasound and CA-125 assay. Although screening for
ovarian cancer has not been proven to decrease the death rate from the disease, this ap‐
proach is the only available screening today for the possible early diagnosis for Ovarian
Cancer and this is what we must follow. Several biomarkers with potential application to
ovarian cancer screening are under development but have not yet been validated or evaluat‐
ed for efficacy in early detection and mortality reduction. The Pap test, which is considered
by many women as the “screening for Gynecological Cancer”, may occasionally detect ma‐
lignant ovarian cells, but it is not sensitive, the reported sensitivity is about 10%–30%, and
has not been evaluated for the early detection of ovarian cancer. Other methods of detection,
including cytologic examination of peritoneal lavage obtained by culdocentesis and proteo‐
mics used to identify patterns or specific serum markers that may be used in place of, or in
conjunction with, CA 125 measurements remain under study. Given the low incidence of
ovarian cancer in the general population, the use of these modalities has not been adopted
for screening purposes in the general population. To be cost effective and avoid unnecessary
surgical interventions, the use of transvaginal ultrasound and CA-125 would need to be
nearly 100% specific and sensitive. Premenopausal women in particular have a high inci‐
dence of benign ovarian cysts. Although CA-125 can be a reliable marker for recurrence in
women with a previous diagnosis of ovarian cancer, only 50% of early-stage ovarian cancers
are associated with an abnormal CA-125. It must be noted that CA-125 can also show spuri‐
ous elevations in association with any process, which irritates the peritoneal or pleural cavi‐
ty, such as endometriosis, pneumonia, pulmonary embolism, or even normal menses.
Prospective screening trials, using ultrasound and CA-125, in women in the general popula‐
tion have resulted in approximately 30 surgeries for every cancer diagnosed and have failed
to detect disease at an early stage. Given the higher prevalence of ovarian cancer in patients
with BRCA mutations, there has been speculation that pelvic ultrasound and CA-125 may
be useful screening strategies for these patients. In fact, annual or semiannual screening
with pelvic examination, transvaginal ultrasonography, and serum CA-125 was recom‐
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mended as appropriate interventions for women at high risk of ovarian cancer in a National
Institutes of Health consensus conference although they did concede that there was no evi‐
dence of efficacy. Indeed, multiple investigations have been performed that cast doubt on
the efficacy of these interventions. For example, a recent study prospectively screened 1,110
women with increased risk of ovarian cancer with pelvic ultrasound and CA-125 measure‐
ments. About half of patients were at moderate risk of developing ovarian cancer, with a 4%
to 10% lifetime risk and half were at high risk with more than 10% lifetime risk. Invasive
ovarian cancer was diagnosed in 12 patients. Two patients had stage I disease, one had stage
II, four had stage III, and one had stage IV. These screening techniques missed an additional
two patients with stage III disease and one patient with stage IV ovarian cancer. Based on
abnormal ultrasound findings, 29 additional women underwent surgery for what turned
out to be benign processes. The positive predictive value was 17%, and the sensitivity was
less than 50%. These screening techniques are especially problematic for premenopausal
women (the cohort with BRCA mutations is of highest interest) in which the false-positive
rate was 79%. The conclusion is that the use of pelvic ultrasound and CA-125 does not meet
World Health Organization screening standards for women with an increased risk for ovari‐
an cancer. The advantages of surveillance include avoidance of premature menopause and
the fact that there is no intervention for those without disease. It allows management with
other techniques, which may be available in the future. However, surveillance does not pre‐
vent disease, and an objective assessment of the data on screening for ovarian cancer does
not support the use of these modalities, even in patients at elevated risk. For women who
have not finished childbearing or are deferring prophylactic oophorectomy for other rea‐
sons, current practice guidelines from the National Comprehensive Cancer Network recom‐
mends concurrent transvaginal ultrasound and CA-125 every 6 months starting at age 35 or
5 to 10 years earlier than the earliest ovarian cancer diagnosis in the family (and preferably
days 1 to 10 of cycle for premenopausal women). If initiated, it is important for these women
to understand the shortcomings of surveillance. They should be aware of the high likelihood
of an abnormal scan in ovulating women, and also understand that a normal scan does not
guarantee absence of disease, even in the advanced stages [1-5, 18-29].
Chemoprevention involves the use of natural or synthetic substances to reduce the risk of
developing cancer or to reduce the chance that cancer will come back. It has been postulated
that incessant ovulation may be one mechanism by which ovarian cancer develops. Consis‐
tent with this theory is the observation that parity is associated with a reduction in risk. The
use of oral contraceptives has also been shown to reduce ovarian cancer risk by as much as
50% in the general population. However, there have been relatively few investigations
studying the effect of oral contraceptive use on ovarian cancer risk in women with BRCA
mutations. Unfortunately, the available data are conflicting. In one retrospective investiga‐
tion of 451 patients with BRCA mutations, women who used oral contraceptives for 6 or
more years had an odds ratio of ovarian cancer of 0.62 (95% confidence interval [CI], 0.35–
1.09). Although not a statistically significant reduction in risk, this study suggests that oral
contraceptives may be an effective form of chemoprevention in carriers. In contrast, Modan
et al performed a case-control study of 1,591 Jewish women, 257 of whom underwent genet‐
ic testing and were found to have a BRCA mutation. They did not find clear evidence of a
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risk of ovarian cancer, including among BRCA1/BRCA2mutation carriers. Risk may also be
increased among women who have used fertility drugs, especially those who remain nulli‐
gravid. Evidence is growing that the use of menopausal HRT is associated with an increased
risk of ovarian cancer, particularly in long-time users and users of sequential estrogen-pro‐
gesterone schedules [1-5].
Surveillance means cancer screening, or a way of detecting the disease early. Screening
does not, however, change the risk of developing cancer. The goal is to find cancer early,
when it may be most treatable. Screening, looking for cancer before a person has any symp‐
toms, can help find cancer at an early stage and increase the chances for cure or prolong sur‐
vival. By the time symptoms appear, the disease may have begun to spread and treatment
results are usually disappointing. Before recommending screening it is important to esti‐
mate women who have increased risk to develop ovarian cancer in order to suggest the
proper screening tests, when to start screening and how often to repeat it. If screening tests
are abnormal then the physician has to proceed to diagnostic tests. There are unfortunately
no satisfactory standard screening tests for ovarian cancer. Family members of ovarian can‐
cer patients must be informed that tests that may detect ovarian cancer are the following:
Pelvic examination, transvaginal ultrasound and CA-125 assay. Although screening for
ovarian cancer has not been proven to decrease the death rate from the disease, this ap‐
proach is the only available screening today for the possible early diagnosis for Ovarian
Cancer and this is what we must follow. Several biomarkers with potential application to
ovarian cancer screening are under development but have not yet been validated or evaluat‐
ed for efficacy in early detection and mortality reduction. The Pap test, which is considered
by many women as the “screening for Gynecological Cancer”, may occasionally detect ma‐
lignant ovarian cells, but it is not sensitive, the reported sensitivity is about 10%–30%, and
has not been evaluated for the early detection of ovarian cancer. Other methods of detection,
including cytologic examination of peritoneal lavage obtained by culdocentesis and proteo‐
mics used to identify patterns or specific serum markers that may be used in place of, or in
conjunction with, CA 125 measurements remain under study. Given the low incidence of
ovarian cancer in the general population, the use of these modalities has not been adopted
for screening purposes in the general population. To be cost effective and avoid unnecessary
surgical interventions, the use of transvaginal ultrasound and CA-125 would need to be
nearly 100% specific and sensitive. Premenopausal women in particular have a high inci‐
dence of benign ovarian cysts. Although CA-125 can be a reliable marker for recurrence in
women with a previous diagnosis of ovarian cancer, only 50% of early-stage ovarian cancers
are associated with an abnormal CA-125. It must be noted that CA-125 can also show spuri‐
ous elevations in association with any process, which irritates the peritoneal or pleural cavi‐
ty, such as endometriosis, pneumonia, pulmonary embolism, or even normal menses.
Prospective screening trials, using ultrasound and CA-125, in women in the general popula‐
tion have resulted in approximately 30 surgeries for every cancer diagnosed and have failed
to detect disease at an early stage. Given the higher prevalence of ovarian cancer in patients
with BRCA mutations, there has been speculation that pelvic ultrasound and CA-125 may
be useful screening strategies for these patients. In fact, annual or semiannual screening
with pelvic examination, transvaginal ultrasonography, and serum CA-125 was recom‐
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ments. About half of patients were at moderate risk of developing ovarian cancer, with a 4%
to 10% lifetime risk and half were at high risk with more than 10% lifetime risk. Invasive
ovarian cancer was diagnosed in 12 patients. Two patients had stage I disease, one had stage
II, four had stage III, and one had stage IV. These screening techniques missed an additional
two patients with stage III disease and one patient with stage IV ovarian cancer. Based on
abnormal ultrasound findings, 29 additional women underwent surgery for what turned
out to be benign processes. The positive predictive value was 17%, and the sensitivity was
less than 50%. These screening techniques are especially problematic for premenopausal
women (the cohort with BRCA mutations is of highest interest) in which the false-positive
rate was 79%. The conclusion is that the use of pelvic ultrasound and CA-125 does not meet
World Health Organization screening standards for women with an increased risk for ovari‐
an cancer. The advantages of surveillance include avoidance of premature menopause and
the fact that there is no intervention for those without disease. It allows management with
other techniques, which may be available in the future. However, surveillance does not pre‐
vent disease, and an objective assessment of the data on screening for ovarian cancer does
not support the use of these modalities, even in patients at elevated risk. For women who
have not finished childbearing or are deferring prophylactic oophorectomy for other rea‐
sons, current practice guidelines from the National Comprehensive Cancer Network recom‐
mends concurrent transvaginal ultrasound and CA-125 every 6 months starting at age 35 or
5 to 10 years earlier than the earliest ovarian cancer diagnosis in the family (and preferably
days 1 to 10 of cycle for premenopausal women). If initiated, it is important for these women
to understand the shortcomings of surveillance. They should be aware of the high likelihood
of an abnormal scan in ovulating women, and also understand that a normal scan does not
guarantee absence of disease, even in the advanced stages [1-5, 18-29].
Chemoprevention involves the use of natural or synthetic substances to reduce the risk of
developing cancer or to reduce the chance that cancer will come back. It has been postulated
that incessant ovulation may be one mechanism by which ovarian cancer develops. Consis‐
tent with this theory is the observation that parity is associated with a reduction in risk. The
use of oral contraceptives has also been shown to reduce ovarian cancer risk by as much as
50% in the general population. However, there have been relatively few investigations
studying the effect of oral contraceptive use on ovarian cancer risk in women with BRCA
mutations. Unfortunately, the available data are conflicting. In one retrospective investiga‐
tion of 451 patients with BRCA mutations, women who used oral contraceptives for 6 or
more years had an odds ratio of ovarian cancer of 0.62 (95% confidence interval [CI], 0.35–
1.09). Although not a statistically significant reduction in risk, this study suggests that oral
contraceptives may be an effective form of chemoprevention in carriers. In contrast, Modan
et al performed a case-control study of 1,591 Jewish women, 257 of whom underwent genet‐
ic testing and were found to have a BRCA mutation. They did not find clear evidence of a
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protective effect with oral contraceptive use in BRCA carriers. Given the low incidence of
adverse effects, before more definitive investigations are available, the use of oral contracep‐
tives as a chemopreventive strategy would appear to be a reasonable approach for the pa‐
tient who declines prophylactic salpingo-oophorectomy and for whom prevention of
pregnancy is acceptable. However, the conflicting data should be reviewed with the patient
before initiation [1-5, 18-29].
Prophylactic salpingo-oophorectomy. The use of oral contraceptives, having and breast‐
feeding children do not certainly offer enough protection for BRCA1/BRCA2 carriers. The
removal of the “at-risk” tissue is the most important step to prevent Ovarian Cancer. Wom‐
en who have a high risk of ovarian cancer must be informed about the possibility of a pro‐
phylactic oophorectomy. This includes women who have inherited certain changes in the
BRCA1 and BRCA2 genes or in the genes linked to hereditary nonpolyposis colon cancer
(HNPCC). It is very important to have a cancer risk assessment and counseling before mak‐
ing this decision. These and other factors should be discussed: Early menopause: 90% reduc‐
tion in risk of ovarian cancer observed among women with a BRCA1 or BRCA2 mutation.
BRCA1 or BRCA2 mutations occur in 0.1–0.8% of the general population and are inherited
in an autosomal dominant manner. They are well recognized to have a higher incidence in
certain ethnic groups, such as women of Ashkenazi Jewish descent. S Vaughan Given the
newly appreciated importance of the fallopian tube in the genesis of high-grade serous ovar‐
ian cancer, it is recommended that the complete removal of the fallopian tube should be‐
come standard of care in any woman undergoing hysterectomy and/or removal of the
ovaries (oophorectomy). Oophorectomy in premenopausal women induces early meno‐
pause. As a consequence, and with the changed view of the role of the fallopian tube in
ovarian cancer, some clinicians have recommended that only the fallopian tubes should be
removed (salpingectomy) in women with germline BRCA1 or BRCA2 mutations, or in wom‐
en with a strong family history of breast and/or ovarian cancer34. However, until compre‐
hensive comparative data are available, it is premature to recommend that only the fallopian
tubes are removed in high-risk women [1-5, 30-43].
Women who have completed childbearing are candidates for surgery. For the majority of
women, this surgery can be performed laparoscopically as an outpatient procedure. In con‐
trast to surveillance and chemoprevention, this intervention is very effective in reducing the
risk of ovarian cancer. Bilateral tubal ligation and hysterectomy are associated with reduced
ovarian cancer risk, including in BRCA1/BRCA2 mutation carriers. Ovarian cancer risk is re‐
duced more than 90% in women with documented BRCA1 or BRCA2 mutations who chose
risk-reducing salpingo-oophorectomy. In this same population, prophylactic removal of the
ovaries also resulted in a nearly 50% reduction in the risk of subsequent breast cancer. In a
retrospective analysis of 551 patients, Rebbeck et al showed that women who had under‐
gone prophylactic salpingo-oophorectomy had an odds ratio of 0.04 for ovarian cancer, com‐
pared with carriers without prophylactic salpingo-oophorectomy. Over a median follow-up
of 8.8 years, two primary peritoneal cancers were diagnosed in the 259 women who under‐
went prophylactic salpingo-oophorectomy compared with 58 ovarian/peritoneal cancers in
the 292 women who did not have prophylactic salpingo-oophorectomy. An added benefit
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was a 47% reduction in the risk of breast cancer in premenopausal women who had prophy‐
lactic salpingo-oophorectomy. The effectiveness of prophylactic salpingo-oophorectomy in
reduction of ovarian cancer risk has also been demonstrated in prospective studies. Prophy‐
lactic salpingo-oophorectomy failures may be divided into groups of those patients who are
found to harbor an occult malignancy at the time of surgery and those who go on to develop
carcinoma at a later time. The existence of occult ovarian cancer in BRCA carriers with appa‐
rently healthy ovaries has been documented in small samples for a number of years. In a
recent investigation that included 555 women who underwent prophylactic salpingo-oopho‐
rectomy, the rate of occult fallopian tube or ovarian cancer was 2.2%, consistent with prior
reports. Although a low incidence, this risk should routinely be discussed with patients be‐
fore surgery and highlights the need for an extensive pathologic assessment of the entire ad‐
nexa, including the fallopian tubes [30-43]. Development of primary peritoneal carcinoma
(PPC) represents the vast majority of failures after prophylactic salpingo-oophorectomy. In a
multicenter investigation of 1,828 carriers, the cumulative risk of PPC was 4.3% at 20 years
after prophylactic salpingo-oophorectomy.24 It is hypothesized that PPC arises from the
peritoneal coelomic epithelium, derived from the same embryonic tissue that gives rise to
the epithelial covering of the ovaries. Ovarian and peritoneal epithelium share common em‐
bryonal origin, originating both from the coelomic epithelium (mesodermal origin). Coelo‐
mic epithelium is thought to be of mesonephric origin. With the overall point being that
normal ovarian and peritoneal tissue is derived from the mesonephros. On the contrary, fal‐
lopian tube epithelium, endometrium and endocervix are related to paramesonephros (Mül‐
lerian duct). Surprisingly, epithelial ovarian cancer and primary peritoneal cancer are
histologically similar to the Mullerian epithelium; not their embryonal origin, the meso‐
nephros. Either a metaplasia has occurred or Mullerian remnants have been left behind in
coelemic epithelium, which have turned oncogenic. Although the precise causes are not
known, a link with certain variants of BRCA1/2 has been described. Furthermore, women
with BRCA1/2 mutation have a 5% risk of developing primary peritoneal cancer even after
prophylactic oophorectomy. Primary peritoneal carcinoma shows similar rates of tumor
suppressor gene dysfunction (p53, BRCA, WT1) as ovarian cancer and can also show an in‐
creased expression of HER-2/neu. An association with vascular endothelial growth factor
has been observed. Although the absolute risk of fallopian tube cancer is unknown in pa‐
tients with BRCA mutations, it is agreed that it is substantially elevated, with a relative risk
of 120 in one study. It remains unknown if the 4.3% failure rate found by Finch et al consists
entirely of PPC or if a proportion is in fact peritoneal recurrences of a fallopian tube carcino‐
ma missed at the time of prophylactic salpingo-oophorectomy. Regardless, it is widely ac‐
cepted that removal of the fallopian tubes is essential at the time of prophylactic surgery.
There is an abundance of evidence supporting the efficacy of prophylactic salpingo-oopho‐
rectomy, but less information exists to counsel the clinician as to the optimal timing of pro‐
phylactic surgery. Reasonable guidelines can be inferred from existing data regarding the
onset of ovarian cancer in BRCA carriers. The cumulative incidence of breast cancer is 11.6%
by age 40 for women with BRCA1 mutations. In contrast, the rate is only 2.3% for ovarian
cancer by age 40. By age 45, 6.5% of BRCA1 carriers will be diagnosed with ovarian cancer;
13.2% by age 50. As a result, for BRCA1 carriers, most physicians recommend prophylactic
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protective effect with oral contraceptive use in BRCA carriers. Given the low incidence of
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tient who declines prophylactic salpingo-oophorectomy and for whom prevention of
pregnancy is acceptable. However, the conflicting data should be reviewed with the patient
before initiation [1-5, 18-29].
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en who have a high risk of ovarian cancer must be informed about the possibility of a pro‐
phylactic oophorectomy. This includes women who have inherited certain changes in the
BRCA1 and BRCA2 genes or in the genes linked to hereditary nonpolyposis colon cancer
(HNPCC). It is very important to have a cancer risk assessment and counseling before mak‐
ing this decision. These and other factors should be discussed: Early menopause: 90% reduc‐
tion in risk of ovarian cancer observed among women with a BRCA1 or BRCA2 mutation.
BRCA1 or BRCA2 mutations occur in 0.1–0.8% of the general population and are inherited
in an autosomal dominant manner. They are well recognized to have a higher incidence in
certain ethnic groups, such as women of Ashkenazi Jewish descent. S Vaughan Given the
newly appreciated importance of the fallopian tube in the genesis of high-grade serous ovar‐
ian cancer, it is recommended that the complete removal of the fallopian tube should be‐
come standard of care in any woman undergoing hysterectomy and/or removal of the
ovaries (oophorectomy). Oophorectomy in premenopausal women induces early meno‐
pause. As a consequence, and with the changed view of the role of the fallopian tube in
ovarian cancer, some clinicians have recommended that only the fallopian tubes should be
removed (salpingectomy) in women with germline BRCA1 or BRCA2 mutations, or in wom‐
en with a strong family history of breast and/or ovarian cancer34. However, until compre‐
hensive comparative data are available, it is premature to recommend that only the fallopian
tubes are removed in high-risk women [1-5, 30-43].
Women who have completed childbearing are candidates for surgery. For the majority of
women, this surgery can be performed laparoscopically as an outpatient procedure. In con‐
trast to surveillance and chemoprevention, this intervention is very effective in reducing the
risk of ovarian cancer. Bilateral tubal ligation and hysterectomy are associated with reduced
ovarian cancer risk, including in BRCA1/BRCA2 mutation carriers. Ovarian cancer risk is re‐
duced more than 90% in women with documented BRCA1 or BRCA2 mutations who chose
risk-reducing salpingo-oophorectomy. In this same population, prophylactic removal of the
ovaries also resulted in a nearly 50% reduction in the risk of subsequent breast cancer. In a
retrospective analysis of 551 patients, Rebbeck et al showed that women who had under‐
gone prophylactic salpingo-oophorectomy had an odds ratio of 0.04 for ovarian cancer, com‐
pared with carriers without prophylactic salpingo-oophorectomy. Over a median follow-up
of 8.8 years, two primary peritoneal cancers were diagnosed in the 259 women who under‐
went prophylactic salpingo-oophorectomy compared with 58 ovarian/peritoneal cancers in
the 292 women who did not have prophylactic salpingo-oophorectomy. An added benefit
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lactic salpingo-oophorectomy failures may be divided into groups of those patients who are
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rently healthy ovaries has been documented in small samples for a number of years. In a
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reports. Although a low incidence, this risk should routinely be discussed with patients be‐
fore surgery and highlights the need for an extensive pathologic assessment of the entire ad‐
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bryonal origin, originating both from the coelomic epithelium (mesodermal origin). Coelo‐
mic epithelium is thought to be of mesonephric origin. With the overall point being that
normal ovarian and peritoneal tissue is derived from the mesonephros. On the contrary, fal‐
lopian tube epithelium, endometrium and endocervix are related to paramesonephros (Mül‐
lerian duct). Surprisingly, epithelial ovarian cancer and primary peritoneal cancer are
histologically similar to the Mullerian epithelium; not their embryonal origin, the meso‐
nephros. Either a metaplasia has occurred or Mullerian remnants have been left behind in
coelemic epithelium, which have turned oncogenic. Although the precise causes are not
known, a link with certain variants of BRCA1/2 has been described. Furthermore, women
with BRCA1/2 mutation have a 5% risk of developing primary peritoneal cancer even after
prophylactic oophorectomy. Primary peritoneal carcinoma shows similar rates of tumor
suppressor gene dysfunction (p53, BRCA, WT1) as ovarian cancer and can also show an in‐
creased expression of HER-2/neu. An association with vascular endothelial growth factor
has been observed. Although the absolute risk of fallopian tube cancer is unknown in pa‐
tients with BRCA mutations, it is agreed that it is substantially elevated, with a relative risk
of 120 in one study. It remains unknown if the 4.3% failure rate found by Finch et al consists
entirely of PPC or if a proportion is in fact peritoneal recurrences of a fallopian tube carcino‐
ma missed at the time of prophylactic salpingo-oophorectomy. Regardless, it is widely ac‐
cepted that removal of the fallopian tubes is essential at the time of prophylactic surgery.
There is an abundance of evidence supporting the efficacy of prophylactic salpingo-oopho‐
rectomy, but less information exists to counsel the clinician as to the optimal timing of pro‐
phylactic surgery. Reasonable guidelines can be inferred from existing data regarding the
onset of ovarian cancer in BRCA carriers. The cumulative incidence of breast cancer is 11.6%
by age 40 for women with BRCA1 mutations. In contrast, the rate is only 2.3% for ovarian
cancer by age 40. By age 45, 6.5% of BRCA1 carriers will be diagnosed with ovarian cancer;
13.2% by age 50. As a result, for BRCA1 carriers, most physicians recommend prophylactic
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salpingo-oophorectomy between ages 35 to 40 years. However, performing prophylactic sal‐
pingo-oophorectomy before age 45 must be considered in the context of the potential mor‐
bidity of estrogen deprivation at an early age. Oophorectomy before age 45 has been
associated with a hazard ratio of 1.96 for death from all causes (p 0.002). However, adminis‐
tration of estrogen replacement eliminated this risk. Many physicians consider estrogen
therapy for women without a personal history of breast cancer who undergo prophylactic
salpingo-oophorectomy before the age of 45.29 It should be noted that early prophylactic
salpingo-oophorectomy is less important for BRCA2 carriers who are known to develop
ovarian cancer at approximately the same age as patients with sporadic cancer. Only 1.2% of
BRCA2 carriers will have ovarian cancer by the age of 50, so prophylactic salpingo-oopho‐
rectomy may safely be delayed until these patients are closer to menopause. The disadvan‐
tages of prophylactic salpingo-oophorectomy include the fact that it is an invasive surgical
intervention, there is loss of ovarian tissue with accompanying hormone deprivation, and it
is an irreversible decision. However, in contrast to surveillance and chemoprevention, pro‐
phylactic salpingo-oophorectomy has proven efficacy over an extended time period. Cost
analyses comparing surveillance, oral contraceptives, and prophylactic salpingo-oophorec‐
tomy have shown that although any primary prevention strategy was cost effective, prophy‐
lactic salpingo-oophorectomy dominated all other strategies in women with BRCA
mutations. Consequently, prophylactic salpingo-oophorectomy is recommended for all
BRCA carriers, with timing dependent on the type of BRCA1 or BRCA2 mutation, childbear‐
ing status, and the age of onset of ovarian cancer within the family. The resultant physical
and emotional outcomes of repeated gynecological screening or prophylactic oophorectomy
must be discussed before and after genetic testing. A study of 315 women with documented
HNPCC–associated germline mutations found no ovarian cancer among 47 women who
had bilateral salpingo-oophorectomy and 12 cases (5%) among women with mutations who
had not had surgery for a prevented fraction of 100% (95% CI, 62%–100%).
The degree of  risk of  ovarian cancer,  potential  morbidity and mortality  of  surgery,  and
the risks associated with early menopause, should be taken into account when consider‐
ing prophylactic oophorectomy for high-risk women. Adverse effects of  bilateral  oopho‐
rectomy and  premature  menopause  include  infertility,  vasomotor  symptoms,  decline  in
sexual  interest  and  activity,  cardiovascular  disease,  and  osteoporosis.  Among  women
who have not taken hormone therapy,  women undergoing bilateral  oophorecotmy were
twice as likely to have moderate or severe hot flashes than women who underwent nat‐
ural menopause (odds ratio [OR] = 2.44; 95% CI, 1.03–5.77). Women at increased heredi‐
tary  risk  of  ovarian  cancer  who  underwent  oophorectomy  without  hormone  therapy
reported  statistically  significantly  more  vasomotor  symptoms  than  women  choosing
screening or those using hormone replacement therapy (HRT). These women also report‐
ed  lower  sexual  function  scores  but  the  difference  was  not  statistically  significant.  A
meta-analysis  of  early menopause as  a  risk factor  for  cardiovascular  disease observed a
pooled risk  of  4.55  (95% CI,  2.56–8.01)  among women with bilateral  oophorectomy and
early menopause (defined as younger than 50 years). Early menopause is also associated
with an increased risk of fracture (OR = 1.5; 95% CI, 1.2–1.8).
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6. Treatment
Over the past ten years, the focus of management for BRCA1/2mutation carriers has been on
cancer prevention and early cancer detection. However, despite prophylactic measures to
reduce risk of EOC, many BRCA1/2 carriers have cancer at the time their mutation is diag‐
nosed and more will develop in the future. The treatment of patients with BRCA associated
EOC is so far identical to those with sporadic disease. Data suggested that cancers associat‐
ed with BRCA mutations responded differently to chemotherapy. Tan et al. compared 22
BRCA-positive patients with EOC to 44 nonhereditary EOC controls in a matched case-con‐
trol study. They found that BRCA-positive patients have higher response rates to first line
platinum-based treatment (81.8%versus 43.2%, P =.004) as well as to subsequent lines of
platinum-based treatments (second line, 91.7% versus 40.9%, P =.004), third line, 100% v
14,3% (P<. 002) and time of first relapse (5v 1.6 years; P<. 001). They conclude that BRCA-
positive EOC patients have better outcomes than nonhereditary EOC cases. There exists a
clinical syndrome of BRCAness that includes serous histology, high response rates to first
and subsequent lines of platinum-based treatment, longer tumor free interval between re‐
lapses and improved overall survival [44].
Over recent years the investigation of DNA repair in cancer cells has been a very active area
of translational research. All cells have a number of overlapping pathways to protect the ge‐
nome from DNA damage, which occurs as a result of normal cell cycling, environmental in‐
sults, or cytotoxic chemotherapy. It is well recognized that when mutations occur within
these DNA repair pathways there is an increased risk of malignant transformation and che‐
motherapy resistance. Much research has focused on protecting cells from DNA damage
and/or restoring DNA repair function. However, emerging data suggest that the concept of
“synthetic lethality,” that is, exploiting the vulnerability of cancer cells, which have lost one
mechanism of DNA repair by targeting a second pathway, may be a particularly attractive
therapeutic approach.. Targeting the nuclear enzyme PARP-1 represents a new and novel
approach to the treatment of EOC and appears to be particularly promising for those carry‐
ing mutations in the BRCA1 and 2 genes. Poly(ADPribose) polymerase (PARP) is an en‐
zyme, which plays an important role in the recognition and repair of single-strand DNA
breaks via the base excision repair pathway. Over the last few years it has become apparent
that in cells, which have lost BRCA1 or BRCA2, components of a second DNA repair path‐
way, homologous recombination, are particularly sensitive to PARP inhibition. These data
suggest that PARP inhibitors may be particularly useful for the treatment of women with
hereditary BRCA1/2-associated EOC. Targeted therapy using PARP inhibitors has become
an important novel strategy for treating those with hereditary ovarian cancer. Furthermore
the identification of other subpopulations of women with EOC who may benefit from this
approach is an active area of research. There are currently 17 members of the PARP super‐
family identified. PARP-1 is the most studied enzyme. In the preclinical setting, PARP-1 in‐
hibitors enhance the cytotoxic effects of ionizing radiation and cytotoxic chemotherapy.
Additionally, in the preclinical setting, the use of PARP-1 inhibitors as single agents did not
cause any measurable toxicity, but the combination of PARP-1 inhibitor with temozolomide
in the tumor bearing mice caused significant toxicity. There did not seem to be a correlation,
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salpingo-oophorectomy between ages 35 to 40 years. However, performing prophylactic sal‐
pingo-oophorectomy before age 45 must be considered in the context of the potential mor‐
bidity of estrogen deprivation at an early age. Oophorectomy before age 45 has been
associated with a hazard ratio of 1.96 for death from all causes (p 0.002). However, adminis‐
tration of estrogen replacement eliminated this risk. Many physicians consider estrogen
therapy for women without a personal history of breast cancer who undergo prophylactic
salpingo-oophorectomy before the age of 45.29 It should be noted that early prophylactic
salpingo-oophorectomy is less important for BRCA2 carriers who are known to develop
ovarian cancer at approximately the same age as patients with sporadic cancer. Only 1.2% of
BRCA2 carriers will have ovarian cancer by the age of 50, so prophylactic salpingo-oopho‐
rectomy may safely be delayed until these patients are closer to menopause. The disadvan‐
tages of prophylactic salpingo-oophorectomy include the fact that it is an invasive surgical
intervention, there is loss of ovarian tissue with accompanying hormone deprivation, and it
is an irreversible decision. However, in contrast to surveillance and chemoprevention, pro‐
phylactic salpingo-oophorectomy has proven efficacy over an extended time period. Cost
analyses comparing surveillance, oral contraceptives, and prophylactic salpingo-oophorec‐
tomy have shown that although any primary prevention strategy was cost effective, prophy‐
lactic salpingo-oophorectomy dominated all other strategies in women with BRCA
mutations. Consequently, prophylactic salpingo-oophorectomy is recommended for all
BRCA carriers, with timing dependent on the type of BRCA1 or BRCA2 mutation, childbear‐
ing status, and the age of onset of ovarian cancer within the family. The resultant physical
and emotional outcomes of repeated gynecological screening or prophylactic oophorectomy
must be discussed before and after genetic testing. A study of 315 women with documented
HNPCC–associated germline mutations found no ovarian cancer among 47 women who
had bilateral salpingo-oophorectomy and 12 cases (5%) among women with mutations who
had not had surgery for a prevented fraction of 100% (95% CI, 62%–100%).
The degree of  risk of  ovarian cancer,  potential  morbidity and mortality  of  surgery,  and
the risks associated with early menopause, should be taken into account when consider‐
ing prophylactic oophorectomy for high-risk women. Adverse effects of  bilateral  oopho‐
rectomy and  premature  menopause  include  infertility,  vasomotor  symptoms,  decline  in
sexual  interest  and  activity,  cardiovascular  disease,  and  osteoporosis.  Among  women
who have not taken hormone therapy,  women undergoing bilateral  oophorecotmy were
twice as likely to have moderate or severe hot flashes than women who underwent nat‐
ural menopause (odds ratio [OR] = 2.44; 95% CI, 1.03–5.77). Women at increased heredi‐
tary  risk  of  ovarian  cancer  who  underwent  oophorectomy  without  hormone  therapy
reported  statistically  significantly  more  vasomotor  symptoms  than  women  choosing
screening or those using hormone replacement therapy (HRT). These women also report‐
ed  lower  sexual  function  scores  but  the  difference  was  not  statistically  significant.  A
meta-analysis  of  early menopause as  a  risk factor  for  cardiovascular  disease observed a
pooled risk  of  4.55  (95% CI,  2.56–8.01)  among women with bilateral  oophorectomy and
early menopause (defined as younger than 50 years). Early menopause is also associated
with an increased risk of fracture (OR = 1.5; 95% CI, 1.2–1.8).
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6. Treatment
Over the past ten years, the focus of management for BRCA1/2mutation carriers has been on
cancer prevention and early cancer detection. However, despite prophylactic measures to
reduce risk of EOC, many BRCA1/2 carriers have cancer at the time their mutation is diag‐
nosed and more will develop in the future. The treatment of patients with BRCA associated
EOC is so far identical to those with sporadic disease. Data suggested that cancers associat‐
ed with BRCA mutations responded differently to chemotherapy. Tan et al. compared 22
BRCA-positive patients with EOC to 44 nonhereditary EOC controls in a matched case-con‐
trol study. They found that BRCA-positive patients have higher response rates to first line
platinum-based treatment (81.8%versus 43.2%, P =.004) as well as to subsequent lines of
platinum-based treatments (second line, 91.7% versus 40.9%, P =.004), third line, 100% v
14,3% (P<. 002) and time of first relapse (5v 1.6 years; P<. 001). They conclude that BRCA-
positive EOC patients have better outcomes than nonhereditary EOC cases. There exists a
clinical syndrome of BRCAness that includes serous histology, high response rates to first
and subsequent lines of platinum-based treatment, longer tumor free interval between re‐
lapses and improved overall survival [44].
Over recent years the investigation of DNA repair in cancer cells has been a very active area
of translational research. All cells have a number of overlapping pathways to protect the ge‐
nome from DNA damage, which occurs as a result of normal cell cycling, environmental in‐
sults, or cytotoxic chemotherapy. It is well recognized that when mutations occur within
these DNA repair pathways there is an increased risk of malignant transformation and che‐
motherapy resistance. Much research has focused on protecting cells from DNA damage
and/or restoring DNA repair function. However, emerging data suggest that the concept of
“synthetic lethality,” that is, exploiting the vulnerability of cancer cells, which have lost one
mechanism of DNA repair by targeting a second pathway, may be a particularly attractive
therapeutic approach.. Targeting the nuclear enzyme PARP-1 represents a new and novel
approach to the treatment of EOC and appears to be particularly promising for those carry‐
ing mutations in the BRCA1 and 2 genes. Poly(ADPribose) polymerase (PARP) is an en‐
zyme, which plays an important role in the recognition and repair of single-strand DNA
breaks via the base excision repair pathway. Over the last few years it has become apparent
that in cells, which have lost BRCA1 or BRCA2, components of a second DNA repair path‐
way, homologous recombination, are particularly sensitive to PARP inhibition. These data
suggest that PARP inhibitors may be particularly useful for the treatment of women with
hereditary BRCA1/2-associated EOC. Targeted therapy using PARP inhibitors has become
an important novel strategy for treating those with hereditary ovarian cancer. Furthermore
the identification of other subpopulations of women with EOC who may benefit from this
approach is an active area of research. There are currently 17 members of the PARP super‐
family identified. PARP-1 is the most studied enzyme. In the preclinical setting, PARP-1 in‐
hibitors enhance the cytotoxic effects of ionizing radiation and cytotoxic chemotherapy.
Additionally, in the preclinical setting, the use of PARP-1 inhibitors as single agents did not
cause any measurable toxicity, but the combination of PARP-1 inhibitor with temozolomide
in the tumor bearing mice caused significant toxicity. There did not seem to be a correlation,
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however, between the antitumor activity and the toxicity of the PARP inhibitor-temozolo‐
mide combinations, suggesting that toxicity and chemosensitization were by different mech‐
anisms. In 2005, two preclinical papers demonstrated the sensitivity of BRCA1- and BRCA2-
deficient cell lines to PARP inhibition. The first paper by Bryant et al. demonstrated reduced
survival of BRCA2-deficient cell lines with four PARP inhibitors. They concluded that
BRCA2- deficient cells were sensitive to PARP inhibition, and that monotherapy with one of
these agents could selectively kill cancer cells. In the same year, Farmer et al. demonstrated
how both BRCA1- and BRCA2-deficient cells lines were sensitive to inhibition of PARP-1,
and that BRCA2 deficient cells were more than 1000 times more sensitive to nanomolar con‐
centrations of PARP inhibitor. Both of these papers demonstrated how homozygotes (tumor
cells) are sensitive to the mechanism of PARP inhibition, whereas heterozygotes (the rest of
the patient’s cells) are insensitive to this mechanism and should not exhibit toxicity. These
findings from two independent groups using different chemical classes of PARP inhibitors
on different BRCA deficient cell lines were the first to suggest the potent effect of PARP in‐
hibition. A number of PARP inhibitors have entered the clinic in both intravenous and oral
formulations. The four, which are furthest along in terms of development, are AGO14699
(Pfizer), AZD2281 (AstraZeneca), ABT-888 (Abbott), and BSI-201 (BI Par), and all four of
these compounds demonstrate profound inhibition of PARP-1.Olaparib (AZD2281, KU-
0059436, AstraZeneca) is an oral small-molecule PARP inhibitor. Yap et al. presented the
first clinical evidence demonstrating the sensitivity of BRCA-mutated cancers to PARP in‐
hibitor monotherapy in a study in 2007. This phase I trial included 44 patients, of which 11
patients had a BRCA mutation associated cancer. Dose escalation was guided by toxicity,
pharmacokinetic and pharmacodynamic data. Based on the encouraging antitumor activity,
many in whom had BRCA1/2 mutations, the trial was subsequently expanded to concentrate
on cancers in patients with BRCA mutations. The drug was well tolerated in both BRCA
mutated and normal populations. Most toxicities were grade 1-2 (≥95%), consisting of fati‐
gue (28%), nausea (28%), vomiting (18%), loss of taste (13%), and anorexia (12%). Grade 3-4
toxicities were rare, consisting of myelosuppression (≤5%), nausea and vomiting (2-3%), and
dizziness or mood changes (2- 3%) [27]. Of the 60 patients that were enrolled and treated, 19
of 23 BRCA-positive carriers were evaluable. 12 of the 19 (63%) had a clinical benefit from
olaparib, with radiologic or tumor marker responses, or stable disease for 4 months or more.
Patient response was seen in those receiving a minimum of 100 mg twice daily up to 400 mg
twice daily. Response was the greatest in patients with platinum-sensitive disease, although
duration of response was the same regardless of the platinum-free interval. Recently data
was presented from a phase II study of olaparib in women with advanced EOC with known
mutations in BRCA1/2. Two patient cohorts received continuous oral olaparib in 28-day cy‐
cles; 33 patients received 400 mg orally twice daily, while 24 patients received 100 mg twice
daily. The choice of dosing and schedule was based on the phase I trial above. The objective
response rate measured by RECIST criteria was 33% at the 400 mg dose, and 12.5% at the
100 mg dose, suggesting that there may be a dose response effect. The toxicity profile was
mainly mild, consisting of grade 1 or 2 nausea (44%) and fatigue (35%), with few grade 3 or
4 toxicities. Interestingly, although numbers were low, in this study there appeared to be a
higher response rate in platinum resistant patients (38% versus 14%), which was opposite to
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that observed in the earlier phase I study, where response was the greatest in platinum-sen‐
sitive patients. Laboratory studies have previously suggested that platinum resistant pa‐
tients may reacquire BRCA function thus potentially making them resistant to the effects of
PARP inhibition. Taken together, the clinical data suggest that we still have a lot to learn
with regard to target populations and the role of PARP inhibition. Furthermore, data from
the phase II study appears to give an early indication that response (both RECIST and
CA125) may be greater in those patients with BRCA2 mutations. This would be in line with
the known mechanism of action of the two BRCA proteins as BRCA2 plays a key role in the
repair pathway; whereas BRCA1 functions as a signaling molecule. This phase II study con‐
cluded that oral olaparib is well-tolerated and highly active in advanced, chemotherapy re‐
fractory BRCA-deficient EOC, with greater activity seen at a higher dose of 400 mg twice
daily. The optimal patient group with respect to platinum sensitivity has not been defined.
Reassuringly in the clinical studies there does not appear to be an increase in toxicity be‐
tween BRCA mutation carriers compared to noncarriers, supporting the theory that PARP
inhibitors should not result in increased toxicity to heterozygote cells. These recent phase I
and phase II trials are particularly promising for patients with BRCA-associated EOC. Fur‐
ther phase II trials are currently underway which will help further elucidate the role and po‐
tential for this new targeted therapy. Loss of BRCA1/2 function is not exclusive to inheriting
a mutation in the BRCA1/2 genes. The results seen in known BRCA1 and 2 mutation carriers
may also be relevant to the sporadic EOC patient population. Epigenetic gene inactivation is
a well-recognized phenomenon with 31% of EOC exhibiting aberrant methylation of the
BRCA1 promoter. Furthermore, genetic or epigenetic events occurring in other components
of the HR pathway can be found in sporadic EOC. These tumors seem to be similar to
BRCA1- or BRCA2-mutated tumors, even though they do not have mutations to either of
these genes, a concept called “BRCAness.” One molecular characterization study suggested
that over 50% of patients with high-grade EOC had loss of BRCA function, either by genetic
or epigenetic events [34]. Studies have shown that the loss of functional proteins in the HR
pathway may lead these cells to be sensitive to PARP inhibition. Identification of “BRCA-
like” EOC populations who may benefit from this new therapy through the identification
and validation of biomarkers is an active area of ongoing research. Several PARP inhibitors
are under investigation either as single agents and/or in combination with other agents or
treatment modalities. Phase II studies in women with advanced EOC in both BRCA1/2 mu‐
tation carriers and high-grade EOC of unknown BRCA status are ongoing. Currently, ola‐
parib is being evaluated in a randomized phase II trial comparing this agent with pegylated
liposomal doxorubicin in patients with BRCA-mutated EOC with a platinum-free interval of
0–12 months. More combination studies in women with both hereditary and sporadic EOC
are expected in the future. Further defining the role of PARP inhibitors in the clinic is ongo‐
ing. Olaparib is being evaluated in a randomized placebo-controlled trial as a maintenance
therapy in patients with sporadic EOC at high risk of early recurrence. Furthermore, some
suggest that PARP inhibitors could be used to prevent cancers in patients who are BRCA
mutation carriers. This approach, however, requires careful consideration and some caution
with the potential for the development of drug resistance in long-term use of PARP inhibi‐
tors. Investigation of the PARP inhibitors in the nonhereditary EOC population is very ac‐
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however, between the antitumor activity and the toxicity of the PARP inhibitor-temozolo‐
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anisms. In 2005, two preclinical papers demonstrated the sensitivity of BRCA1- and BRCA2-
deficient cell lines to PARP inhibition. The first paper by Bryant et al. demonstrated reduced
survival of BRCA2-deficient cell lines with four PARP inhibitors. They concluded that
BRCA2- deficient cells were sensitive to PARP inhibition, and that monotherapy with one of
these agents could selectively kill cancer cells. In the same year, Farmer et al. demonstrated
how both BRCA1- and BRCA2-deficient cells lines were sensitive to inhibition of PARP-1,
and that BRCA2 deficient cells were more than 1000 times more sensitive to nanomolar con‐
centrations of PARP inhibitor. Both of these papers demonstrated how homozygotes (tumor
cells) are sensitive to the mechanism of PARP inhibition, whereas heterozygotes (the rest of
the patient’s cells) are insensitive to this mechanism and should not exhibit toxicity. These
findings from two independent groups using different chemical classes of PARP inhibitors
on different BRCA deficient cell lines were the first to suggest the potent effect of PARP in‐
hibition. A number of PARP inhibitors have entered the clinic in both intravenous and oral
formulations. The four, which are furthest along in terms of development, are AGO14699
(Pfizer), AZD2281 (AstraZeneca), ABT-888 (Abbott), and BSI-201 (BI Par), and all four of
these compounds demonstrate profound inhibition of PARP-1.Olaparib (AZD2281, KU-
0059436, AstraZeneca) is an oral small-molecule PARP inhibitor. Yap et al. presented the
first clinical evidence demonstrating the sensitivity of BRCA-mutated cancers to PARP in‐
hibitor monotherapy in a study in 2007. This phase I trial included 44 patients, of which 11
patients had a BRCA mutation associated cancer. Dose escalation was guided by toxicity,
pharmacokinetic and pharmacodynamic data. Based on the encouraging antitumor activity,
many in whom had BRCA1/2 mutations, the trial was subsequently expanded to concentrate
on cancers in patients with BRCA mutations. The drug was well tolerated in both BRCA
mutated and normal populations. Most toxicities were grade 1-2 (≥95%), consisting of fati‐
gue (28%), nausea (28%), vomiting (18%), loss of taste (13%), and anorexia (12%). Grade 3-4
toxicities were rare, consisting of myelosuppression (≤5%), nausea and vomiting (2-3%), and
dizziness or mood changes (2- 3%) [27]. Of the 60 patients that were enrolled and treated, 19
of 23 BRCA-positive carriers were evaluable. 12 of the 19 (63%) had a clinical benefit from
olaparib, with radiologic or tumor marker responses, or stable disease for 4 months or more.
Patient response was seen in those receiving a minimum of 100 mg twice daily up to 400 mg
twice daily. Response was the greatest in patients with platinum-sensitive disease, although
duration of response was the same regardless of the platinum-free interval. Recently data
was presented from a phase II study of olaparib in women with advanced EOC with known
mutations in BRCA1/2. Two patient cohorts received continuous oral olaparib in 28-day cy‐
cles; 33 patients received 400 mg orally twice daily, while 24 patients received 100 mg twice
daily. The choice of dosing and schedule was based on the phase I trial above. The objective
response rate measured by RECIST criteria was 33% at the 400 mg dose, and 12.5% at the
100 mg dose, suggesting that there may be a dose response effect. The toxicity profile was
mainly mild, consisting of grade 1 or 2 nausea (44%) and fatigue (35%), with few grade 3 or
4 toxicities. Interestingly, although numbers were low, in this study there appeared to be a
higher response rate in platinum resistant patients (38% versus 14%), which was opposite to
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that observed in the earlier phase I study, where response was the greatest in platinum-sen‐
sitive patients. Laboratory studies have previously suggested that platinum resistant pa‐
tients may reacquire BRCA function thus potentially making them resistant to the effects of
PARP inhibition. Taken together, the clinical data suggest that we still have a lot to learn
with regard to target populations and the role of PARP inhibition. Furthermore, data from
the phase II study appears to give an early indication that response (both RECIST and
CA125) may be greater in those patients with BRCA2 mutations. This would be in line with
the known mechanism of action of the two BRCA proteins as BRCA2 plays a key role in the
repair pathway; whereas BRCA1 functions as a signaling molecule. This phase II study con‐
cluded that oral olaparib is well-tolerated and highly active in advanced, chemotherapy re‐
fractory BRCA-deficient EOC, with greater activity seen at a higher dose of 400 mg twice
daily. The optimal patient group with respect to platinum sensitivity has not been defined.
Reassuringly in the clinical studies there does not appear to be an increase in toxicity be‐
tween BRCA mutation carriers compared to noncarriers, supporting the theory that PARP
inhibitors should not result in increased toxicity to heterozygote cells. These recent phase I
and phase II trials are particularly promising for patients with BRCA-associated EOC. Fur‐
ther phase II trials are currently underway which will help further elucidate the role and po‐
tential for this new targeted therapy. Loss of BRCA1/2 function is not exclusive to inheriting
a mutation in the BRCA1/2 genes. The results seen in known BRCA1 and 2 mutation carriers
may also be relevant to the sporadic EOC patient population. Epigenetic gene inactivation is
a well-recognized phenomenon with 31% of EOC exhibiting aberrant methylation of the
BRCA1 promoter. Furthermore, genetic or epigenetic events occurring in other components
of the HR pathway can be found in sporadic EOC. These tumors seem to be similar to
BRCA1- or BRCA2-mutated tumors, even though they do not have mutations to either of
these genes, a concept called “BRCAness.” One molecular characterization study suggested
that over 50% of patients with high-grade EOC had loss of BRCA function, either by genetic
or epigenetic events [34]. Studies have shown that the loss of functional proteins in the HR
pathway may lead these cells to be sensitive to PARP inhibition. Identification of “BRCA-
like” EOC populations who may benefit from this new therapy through the identification
and validation of biomarkers is an active area of ongoing research. Several PARP inhibitors
are under investigation either as single agents and/or in combination with other agents or
treatment modalities. Phase II studies in women with advanced EOC in both BRCA1/2 mu‐
tation carriers and high-grade EOC of unknown BRCA status are ongoing. Currently, ola‐
parib is being evaluated in a randomized phase II trial comparing this agent with pegylated
liposomal doxorubicin in patients with BRCA-mutated EOC with a platinum-free interval of
0–12 months. More combination studies in women with both hereditary and sporadic EOC
are expected in the future. Further defining the role of PARP inhibitors in the clinic is ongo‐
ing. Olaparib is being evaluated in a randomized placebo-controlled trial as a maintenance
therapy in patients with sporadic EOC at high risk of early recurrence. Furthermore, some
suggest that PARP inhibitors could be used to prevent cancers in patients who are BRCA
mutation carriers. This approach, however, requires careful consideration and some caution
with the potential for the development of drug resistance in long-term use of PARP inhibi‐
tors. Investigation of the PARP inhibitors in the nonhereditary EOC population is very ac‐
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tive with both the impact of treatment on patients without BRCA defects and the search for
populations of women who have lost functional proteins in the HR pathway. Investigation
of PARP inhibitor resistance and ways to overcome this resistance are emerging fields. The
emerging data regarding the use of PARP inhibitors in patients with BRCA-associated EOC
are encouraging. Identification of further patient groups who will benefit from this ap‐
proach is also indicated. Clinical trials underway will hopefully improve the prognosis of
women with Epithelial Ovarian Cancer [45-53].
7. Conclusions
Genetic testing can identify women with a hereditary increased risk to develop Ovarian
Cancer. This information is extremely useful if the candidate for genetic testing is willing to
accept prophylactic surgery. For patients who already have Ovarian Cancer Genetic testing
will offer useful information for the relatives but it can also help plan their own treatment.
Published data regarding the use of PARP inhibitors in patients with BRCA-associated EOC
are encouraging. Studies in combination with chemotherapy are also producing encourag‐
ing results and there are several ongoing studies in patients with hereditary and sporadic
cancer as well. These studies will clarify the mechanisms of DNA repair and how this can be
exploited to improve treatment results. The development of diagnostic tests in order to se‐
lect patients likely to be sensitive to PARP inhibitors will also be very useful. The combina‐
tion of prevention, early diagnosis and more effective disease management will hopefully
improve EOC prognosis in the near future.
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1. Introduction
Despite great efforts in developing novel screening, diagnosis and therapeutic strategies, the
incidence and mortality of ovarian cancer have not significantly changed in the last 30 years.
[1] It remains the leading cause of death from gynecologic malignancy with a lifetime proba‐
bility of developing the disease of 1 in 59.[1] Worldwide, approximately 200.000 women are
annually diagnosed with ovarian cancer,[2] and almost 70% of them will be diagnosed at ad‐
vanced stage disease.[3] With current treatment modalities, the 5-year survival rate ranges
from 80–95% for those with organ-confined or early stage disease (International Federation of
Gynecology and Obstetrics (FIGO) stage I-II); to 30 – 40% for those women with advanced dis‐
ease, FIGO stage III-IV. Thus, ovarian cancer is a challenging and complex malignancy.[4]
Surgical management of ovarian cancer remains as the cornerstone treatment of this disease.
[5] An adequate full surgical staging in women with early stage disease has demonstrated to
improve oncologic outcome.[6] On the other hand, complete surgical cytoreduction is the
only modifiable prognosis factor for patients with advanced disease. This chapter will de‐
scribe the rationale and surgical steps for an adequate surgical staging for women with early
stage ovarian cancer, and for obtaining the maximal surgical cytoreduction in women affect‐
ed by advanced stage and relapsed disease.
2. Surgical treatment of early stage epithelial ovarian cancer
Approximately 25% of newly diagnosed ovarian cancer will be early stage disease. Progno‐
sis is good with survival rates ranging from 80 % to 95 % when recommended treatment is
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followed.[5] These patients are initially managed by comprehensive surgical staging, which
is relevant not only for identifying women with truly early stage disease, but also to select
patients who will be candidates for adjuvant chemotherapy.
3. Rationale for surgical staging
Adequate surgical staging procedures include: exploration of abdomen/pelvis, peritoneal
washings, bilateral salpingo-oophorectomy, hysterectomy, peritoneal biopsies of Cul-de-sac,
pelvic walls, paracolic gutters, diaphragm, suspicious areas, omentectomy, appendectomy,
as well as pelvic and para-aortic node dissection up to the renal veins. (TABLE 1)[7],[8]
These procedures are needed to find hidden disease in nearly 18% of women[8], which has
implications in the prognosis and subsequent patient treatment.[9] Surgeon expertise is cru‐
cial given that it was correlated with under-staged ovarian cancer. Several studies demon‐
strated that over 30% of patients operated by general gynecologists or general surgeons
were upstaged by gynecologist oncologists by finding disease on pelvic-aortic lymph nodes,
diaphragm biopsies and omentum.[6, 10] Moreover, as it has been demonstrated, inade‐
quate initial surgical staging leads to a higher risk of developing recurrent disease despite
receiving adjuvant chemotherapy.[6] Thus, if the operative risk is not too high, all patients
should be routinely re-staged before starting chemotherapy.
• Peritoneal cytology/ascites drainage
• Careful and systematic abdominal exploration – inspect and palpate all peritoneal surface
• Infracolicomentectomy
• Total abdominal hysterectomy and bilateral salpingo-oophorectomy
• Pelvic and aortic lymphadenectomy
• Random and directed peritoneal biopsies – posterior cul-de-sac, bladder reflection, both pelvic sidewalls and both
paracolic spaces
• Biopsy or scrapings from the undersurface of both diaphragms
• Appendectomy (for mucinous histology)
Table 1. Surgical staging procedures for early stage ovarian cancer
4. Surgical staging procedures
Midline vertical incision is the recommended surgical approach for initial management of
suspected early stage ovarian cancer. The incision is firstly made from the pubis to the um‐
bilicus and then progressed to xifoid appendix, if surgical staging is indicated following the
frozen section diagnosis. The abdominal-pelvic cavity is opened and visualized. If free fluid
is present, a minimum sample of 100 cc[3] should be obtained for cytological examination.
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Peritoneal washing from paracolic gutters, pelvis and abdominal cavity should be done in
the absence of ascites. It is estimated that over 30% of patients with stage I disease have tu‐
moral cells on cytological examination.[11] Careful inspection and palpation is preformed to
detect extra-ovarian implants in a systematic way: starting by right paracolic space, advanc‐
ing the hand to the right kidney, suprahepatic space, the right diaphragm, right hepatic
lobe, gallbladder, Morrison´s pouch, left hemi-diaphragm, left hepatic lobe, spleen, stomach,
transverse colon, left kidney and left paracolic space. The lesser sac is entered on the left side
of the gastrocolic ligament. Both surfaces of the mesentery should be examined and retro‐
peritoneal vascular areas should be palpated as well. The result of this comprehensive pro‐
cedure should be properly described.
The ovaries need to be examined for capsule rupture or external excrescences. The affected
ovary must then be removed for frozen section. Although the influence on the prognosis of
the intraoperative rupture of malignant ovarian tumors is controversial,[12] adnexal masses
should be removed intact. If malignancy is confirmed in the frozen section, full surgical
staging, as previously described, must be performed by the extension of the incision up to
xifoid appendix. Contralateral oophorectomy and total hysterectomy is completed due to
the possibility of synchronous cancer.
Even though controversial, random peritoneal biopsies are indicated in early-stage disease.
A retrospective study demonstrated that less than 4% of patients with ovarian cancer were
upstaged due to positive peritoneal biopsies. No patient, however, had a change in treat‐
ment recommendations based on these biopsies.[13] Infracolic omentectomy should be per‐
formed from the hepatic to splenic flexure. During dissection, the lesser sac is developed
dissecting the posterior and anterior layer of the transverse mesocolon, while preserving the
middle colic artery. The omentum is removed and the pedicles are sequentially sutured –
ligated. Appendectomy is only reserved for mucinous histology.
5. Retropetitoneal lymph node dissection
The incidence of lymph-node involvement in patients with disease confined to the ovary is
5% in only pelvic nodes, 9% in aortic nodes and 6% in both pelvic and aortic nodes.[14] Sys‐
tematic lymphadenectomy as part of surgical staging of apparent early stage ovarian cancer
is associated with a statistically significant increase in median operative time, median blood
loss, and the proportion of patients undergoing blood transfusions.[15] Systematic lympha‐
denectomy, however, significantly improves progression-free survival (PFS) rates, without a
statistically significant impact on overall survival (OS). [14, 15] Lymphatic drainage of the
ovaries is known to follow the gonadal blood supply that reaches the renal vein, on the left
side, and the inferior vena cava, on the right side. Pelvic lymphadenectomy should include
removal of nodes from paravesical and pararectal spaces, including bilateral common iliac
nodes. Aortic nodes should be removed from aortic bifurcation to the renal veins.[14]
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6. Minimally invasive surgery for surgical staging ovarian cancer
Over the last years, laparoscopy has gained an important role for the management of suspect‐
ed adnexal masses. High-volume centers have reported their experience in performing a com‐
prehensive surgical staging by using minimally invasive surgery.[16],[17] Nezhat et al. [16]
reported a case series of 36 patients with early stage invasive ovarian carcinoma managed by
laparoscopy. They showed 100% OS rate with a mean duration of follow-up of 55.9 months.
Chi et al. [17] conducted a case control study by staging 20 patients with early ovarian cancer
with laparoscopy compared with 30 patients staged with laparotomy. There were no differen‐
ces in the omental specimen size or number of lymph nodes removed. Blood loss and hospital
stay were lower for the laparoscopy group, with longer operating time. There were no conver‐
sions to laparotomy or other intraoperative complications in the laparoscopy group.
Despite laparoscopic staging of early ovarian cancer seems to be a safe and feasible proce‐
dure performed by expert surgeons, the possibility of cyst rupture or port-site metastases re‐
main controversial. The immediate effect of tumor rupture is that a patient with a
potentially curable disease will require additional adjuvant chemotherapy. Preoperative
evaluation is essential, as well as the surgical experience and the quality of laparoscopic in‐
struments.[18] Even though there are no specific recommendations, adnexal masses up to
5-6 cm could be reasonably managed by laparoscopy.
The etiology of port-site metastases is uncertain. Several hypotheses include tumor cell en‐
trapment, direct spread from the trocar in which instruments are exchanged, and the ‘‘chim‐
ney effect,’’ which suggests that tumor cells travel along the sheath of the trocars with the
leaking gas. Port-site metastases have been reported in 1% to 2% of patients with ovarian
cancer. However, <5% of port metastases are clinically detected and these sites are likely to
respond to chemotherapy.[9]
Robotic surgery has emerged as an innovative minimally invasive approach in the field of
gynecology. The da Vinci Surgical System (Intuitive Surgical, Inc, Sunnyvale, California,
USA) offers several advantages over conventional laparoscopy including three-dimensional
view, greater dexterity, and tremor filtration. Most of the data regarding the application of
robotic technology for ovarian cancer staging are included in the literature used in the as‐
sessment for its implementation in other gynecologic malignancies, such as cervical and en‐
dometrial cancer.[19] Data are still scarce but promising.
7. Treatment of advanced stage disease: Surgical cytoreduction
Advanced-stage disease means that the disease is extended to pelvic/ aortic lymph nodes,
peritoneum, intra-abdominal organs or disease outside the abdominal cavity.[20] In 1975, a
landmark study quantified residual disease and demonstrated for the first time an inverse
relationship between residual tumor and oncologic outcome. [21] The goal of surgery is to
resect as much tumor as possible obtaining, ideally, a complete resection. The standard
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worldwide recommendation consists of primary maximal surgical cytoreduction followed
by 6 cycles of intravenous carboplatin plus paclitaxel. [5,7] An alternative strategy is re‐
served for selected patients and it includes surgical cytoreduction in between chemotherapy
courses, usually after three or four cycles. This strategy is called neoadjuvant chemotherapy
followed by interval debulking surgery. (fig 1) The appropriate selection of patients for each
modality of treatment will be described below.
Figure 1. Treatment options for advanced stage ovarian cancer
8. Prognostic factors
Prognostic factors in women with advanced stage EOC was described in literature based on
retrospective data.[22] Recently, Du Buois et al., [23] did a combined exploratory analysis of
three prospective randomized phase III multicenter trials, which enrolled 3388 patients with
advanced EOC between 1995 and 2002. Univariate and multivariate analysis revealed non-
modifiable significant prognostic factors for OS and PFS such as: age, performance status
(ECOG 2 versus 0-1), FIGO stage (IIIC-IV versus IIB-IIIB), subtype histology (Mucinous ver‐
sus serous), histology grade (grade 2-3 versus 1), presence of large volume ascites (> 500
mL). The only significant modifiable prognosis factor was postoperative residual tumor (0
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versus >1 mm). (Table 2) This study highlighted the importance of an adequate surgical
management of women affected by ovarian cancer as the key-point for improving oncologic
outcomes given that the quality of surgical cytoreduction was the only modifiable prognosis
factor for survival.
Non-modifiable




• Large volume of ascites
Modifiable
• Post-surgical residual tumor
Table 2. Prognosis factors of overall survival and progression free survival in patients with advanced stage epithelial
ovarian cancer
9. Rationale for primary surgical cytoreduction
1. Improvement of oncologic outcomes: a large body of retrospective and non-random‐
ized prospective studies consistently show an inverse correlation between survival and
the amount of postoperative residual disease [22]. Results of two meta-analysis[22],[24]
evaluated women affected by advanced stage EOC that were treated with primary sur‐
gical cytoreduction and platinum-based neoadjuvant chemotherapy and demonstrated
a mean weighted median survival of 29 and 24 months respectively.
2. Surgical reduction of tumor burden prior to chemotherapy: it has been postulated that
the proportion of tumor cells destroyed with each cycle of chemotherapy is constant.
Thus, in cases of tumor cells not resistant to chemotherapy, fewer cycles would be nec‐
essary to eradicate them if the absolute number were less.[25] In addition, tumor size is
correlated with an increased spontaneous mutation rate of malignant cells.[26] Animal
models have also demonstrated that drug exposure allows the resistant cells to outgrow
the sensitive tumor cells population.[27] Primary surgical cytoreduction, thus, reduces
the number of cancer cells decreasing the chance of inducing drug resistance.
3. Improved drug diffusion: large bulky tumors may have hypoperfused areas where
concentration of chemotherapy agents can be suboptimal, increasing the possibility of
drug resistance.[28]
4. Increased tumor cells growth rate: During initial tumor growth, cancer cell division is
almost exponential. But then, cell growth reaches a plateau. Thus, the great majority of
cells in large tumoral masses are not dividing, being in G0 phase of the cell cycle, which
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are essentially resistant to chemotherapy.[29] Primary surgical cytoreduction may stim‐
ulate G0 residual tumor cells to re-enter in the normal cell cycle, increasing the chemo‐
therapy efficacy.[29]
10. Residual tumor disease: Definition and relevance
Residual tumor disease is commonly described as the diameter, in millimeters, of the biggest
nodule left after surgical debulking. Griffiths et al., first described the importance of residual
disease after surgery in women with ovarian cancer.[21] They demonstrated an inverse rela‐
tionship between residual disease and patient survival. In 1994, the Gynecology Oncology
Group (GOG) published a sub-analysis of two retrospective series (GOG protocol 52 & 97)
of patients affected by advanced stage EOC who underwent primary cytoreduction fol‐
lowed by chemotherapy. The study showed significant differences in OS in women with mi‐
croscopic disease or less than 2 cm in comparison with of residual disease of more than 2 cm
diameter. The maximum diameter of residual disease was firstly found to be an independ‐
ent predictor of OS after controlling other variables. Thus, surgery with residual disease of
less than 2 cm was defined as “optimal” cytoreduction; while more than 2 cm was called
“suboptimal”.[30]
In 2002, a meta-analysis of 6885 patients with stage III or IV ovarian cancer was reported.
[22]The study analyzed 81 cohorts of patients treated in the platinum era to evaluate the ef‐
fect of maximal cytoreductive surgery and other prognostic factors on survival. The investi‐
gators demonstrated that each 10% increase in the proportion of patients undergoing
maximal cytoreduction was associated with a concomitant 5.5% increase in median cohort
survival time. The mean weighted median survival time was 29 months. Thus, for all clinical
trials that followed, the GOG established ≤ 1 cm residual disease as the criterion for optimal
cytoreduction.
Winter III et al. [31] reported the GOG collective experience analyzing the data of seven tri‐
als (GOG 11, 114, 132, 152, 158, 162 and 172) that studied the efficacy of chemotherapy in
1895 stage III and 360 stage IV ovarian cancer patients. All patients underwent primary de‐
bulking surgery followed by 6 courses of cisplatin and paclitaxel. Residual disease after sur‐
gery was an independent prognostic factor. The median OS reported was 79.1, 42.4 and 35
months in patients with microscopic, 1-10 mm and > 10 mm of residual disease, respectively.
The authors suggested a modification of the term “optimal residual disease” from < 1 cm to
microscopic.
These results were confirmed when 3 large phase III randomized trials conducted by the AGO
(AGO-OVAR 3, 5 and 7) of patients with stage IIB-IV ovarian cancer receiving platinum/
taxanes chemotherapy following primary cytoreduction surgery were analyzed. [23] Patients
with microscopic residual disease had significantly longer median OS than those with any re‐
sidual disease, 99.1 months versus less than 36 months, respectively. Thus the current goal of
the surgery in ovarian cancer is to obtain a complete cytoreduction. (Fig 2)
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Figure 2. Goal of the surgery in ovarian cancer
Chang and Bristow in 2012, reported a single institution series and cooperative group trials
since 2003 of patients who underwent primary debulking surgery followed by adjuvant che‐
motherapy. Over 14000 patients in 15 studies were analyzed.[32] A marked inverse correla‐
tion between the maximal diameter of residual tumor and OS was noted. The weighted
median OS for 3593 patients with no gross residual disease was 77.8 months compared to
39.0 months for the 4780 patients with 0.1–1 cm residual disease and 31.1 months for the
3518 patients with residual tumor >1 cm in maximal diameter. The magnitude of the incre‐
mental improvement in OS strongly suggests that complete resection should be the surgical
objective whenever feasible.
11. Feasibility of complete primary cytoreduction
In the presence of a preoperative suspected adnexal mass whit ascites and peritoneal carci‐
nomatosis are present, the feasibility of complete cytoreduction should be determined by ex‐
clusion of multiple liver or pulmonary metastases by imaging studies such as computed
tomography (CT). In the absence of extra-peritoneal lesions and surgical contraindications,
patients should undergo primary debulking surgery. The feasibility of optimal cytoreduc‐
tion depends on the disease distribution, the patient´s overall medical condition and the sur‐
geon’s expertise. However, obtaining an optimal cytoreduction ≤ 1 cm of residual disease is
not an easy task. In highly specialized centers, the rate with optimal primary cytoreduction
is over 75 %. (Fig 3) But this rate falls down to 25% when low-volume ovarian cancer surger‐
ies centers are included in the analysis. (Fig 4) Nevertheless, as it was previously mentioned,
according with collecting data of the latter,[23],[31] primary debulking surgery is beneficial
if complete cytoreduction is achieved. According with the literature, this is achievable in on‐
ly 30% of patients when a gynecologist oncologist performs the surgery, a higher rate when
compared with general gynecologists or general surgeons.[33]-[38]
12. Neoadjuvant chemotherapy followed by interval debulking surgery
Despite upfront primary debulking surgery (PDS) for newly diagnosed patients with ad‐
vanced stage ovarian cancer is considered the standard of care,[5] limitations to this strategy
have been postulated.[39],[40] For instance, patients with incomplete primary cytoreduction
seem to have no meaningful impact on OS.[23],[31] Furthermore, only experienced surgeons
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with extended formal training in cytoreductive techniques obtain an acceptable complete
primary cytoreduction rate.[41]-[43]
Consequently, an alternative approach such as neoadjuvant chemotherapy (NACT) has
been proposed by several authors.[39],[40] This strategy of treatment consists in the admin‐
istration of at least 3 courses of platinum-taxanes chemotherapy followed by an interval de‐
bulking surgery (IDS) and further adjuvant treatment in patients responsive to
chemotherapy. [44] (Figure 1) The goal of this modality is to reduce the extension of the dis‐
ease and, by performing a less radical surgical procedure, to improve the complete cytore‐
duction rate reducing the surgical time and complication rate, while improving the PFS and
OS rate.
Objective indications for neoadjuvant chemotherapy are patients with poor performance
status and with significant medical co-morbidities making them unsuitable for an aggressive
debulking surgery. These indications include, however, the smallest proportion of patients
who underwent neoadjuvant chemotherapy in the series published in the literature. [39],
[40],[45],[46] The majority of women receive either NACT or PDS based on tumor extension
and on estimated tumor resectability.[47] The latter is a subjective and highly surgeon-de‐
pendent indication. [24] Although several criteria have been tested for predicting the surgi‐
cal resectability of ovarian tumors, its accuracy and clinical applicability is still controversial.
[48] Some of these criteria include ascites volume, serum CA 125 values[48] and computer
tomography scan parameters.[49] For example, terms like “dense adhesion between bowel
and omentum”, “large diaphragm disease”, and “large tumor nodules adherent to abdomi‐
nal structures” have been postulated by some authors as criteria of unresectability.[50]
These terms show how subjective is the definition of a patient as debulkable or not. These
criteria are mostly based on CT scan findings but, sometimes, a direct laparoscopic assess‐
ment of is recommended.[51] (Fig. 5)
On the other hand it is a common belief to associate NACT with less complex surgical proce‐
dures, shorter surgical time, and lower incidence of complications after IDS.[44],[46] How‐
ever, this strategy does not exclude the necessity of performing complex surgical procedures
at the time of IDS in order to obtain an optimal cytoreduction. Thus, referring these patients
to a specialized gynecologist is mandatory as well.
Recently, the results of a randomized, controlled, prospective trial conducted by the Europe‐
an Organization for Research and Treatment of Cancer (EORTC) were published.[52] Six
hundred and seventy patients with stage IIIC and IV ovarian cancer were randomly as‐
signed to primary cytoreductive surgery group or neoadjuvant chemotherapy group. There
were no significant differences in OS (29 months for primary cytoreductive surgery group
versus 30 months for neoadjuvant chemotherapy group) between the two groups. Complete
cytoreduction with no gross residual disease was possible in 20% of patients who under‐
went primary cytoreduction and 52% of those who had neoadjuvant chemotherapy. On
multivariate analysis, the strongest independent predictor factor of prolonged survival was
the absence of residual tumor after surgery (p < 0.001). The authors concluded that neoadju‐
vant chemotherapy followed by interval debulking surgery has similar efficacy compared
with primary debulking surgery followed by chemotherapy for patients with stage IIIC or
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IV ovarian cancer and complete resection of all gross lesions remains the objective of the cy‐
toreductive surgery whether performed as primary or after neoadjuvant chemotherapy.
However, optimal cytoreduction (<1 cm residual disease) was achieved in only 41.6% of pa‐
tients in the PDS arm, a substantially lower rate than the published by expert series.[31],[42],
[43] The PFS and OS for patients randomized to the PDS arm were substantially lower than
those reported in previous studies, including prospective trials of the Gynecologic Oncology
Group (GOG) as well.[30],[31],[43]
A recent report from the Memorial Sloan-Kettering Cancer Center contradicts the findings of
the EORTC study and suggests that the strategy of neoadjuvant chemotherapy requires fur‐
ther investigation. A total of 316 stage IIIC–IV ovarian cancer patients were treated at the
institution during the same period in which the EORTC-NCIC trial were evaluated, using
identical inclusion criteria.[53] The optimal cytoreduction rate was 71% and the median OS
time was 50 months. This study suggested that primary cytoreductive surgery should be
considered as t he preferred initial management strategy for patients with this disease.
It seems, therefore, that neoadjuvant chemotherapy should not be performed routinely in
patients with advanced ovarian cancer and be done in selected patients who are at risk of
morbidity associated with primary surgery and less likely to have a complete cytoreduction.
(Fig. 5)
Figure 5. Initial approach of suspected advanced ovarian cáncer
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signed to primary cytoreductive surgery group or neoadjuvant chemotherapy group. There
were no significant differences in OS (29 months for primary cytoreductive surgery group
versus 30 months for neoadjuvant chemotherapy group) between the two groups. Complete
cytoreduction with no gross residual disease was possible in 20% of patients who under‐
went primary cytoreduction and 52% of those who had neoadjuvant chemotherapy. On
multivariate analysis, the strongest independent predictor factor of prolonged survival was
the absence of residual tumor after surgery (p < 0.001). The authors concluded that neoadju‐
vant chemotherapy followed by interval debulking surgery has similar efficacy compared
with primary debulking surgery followed by chemotherapy for patients with stage IIIC or
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IV ovarian cancer and complete resection of all gross lesions remains the objective of the cy‐
toreductive surgery whether performed as primary or after neoadjuvant chemotherapy.
However, optimal cytoreduction (<1 cm residual disease) was achieved in only 41.6% of pa‐
tients in the PDS arm, a substantially lower rate than the published by expert series.[31],[42],
[43] The PFS and OS for patients randomized to the PDS arm were substantially lower than
those reported in previous studies, including prospective trials of the Gynecologic Oncology
Group (GOG) as well.[30],[31],[43]
A recent report from the Memorial Sloan-Kettering Cancer Center contradicts the findings of
the EORTC study and suggests that the strategy of neoadjuvant chemotherapy requires fur‐
ther investigation. A total of 316 stage IIIC–IV ovarian cancer patients were treated at the
institution during the same period in which the EORTC-NCIC trial were evaluated, using
identical inclusion criteria.[53] The optimal cytoreduction rate was 71% and the median OS
time was 50 months. This study suggested that primary cytoreductive surgery should be
considered as t he preferred initial management strategy for patients with this disease.
It seems, therefore, that neoadjuvant chemotherapy should not be performed routinely in
patients with advanced ovarian cancer and be done in selected patients who are at risk of
morbidity associated with primary surgery and less likely to have a complete cytoreduction.
(Fig. 5)
Figure 5. Initial approach of suspected advanced ovarian cáncer
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13. Surgical cytoreduction technique
Women should be placed on supine position with legs spread apart. Vertical midline inci‐
sion is recommended in order to access to the entire abdominal cavity. Ascites is evacuated
and sent for cytological evaluation. As described above, a careful inspection and palpation
of the entire peritoneal cavity and retroperitoneum is carried out in order to assess the ex‐
tent of the primary and metastatic disease. The localization and diameter of the primary tu‐
mor and its extension into surrounding organs is described as the diameter of the larger
metastases. Sometimes, there are regions that cannot be accessed before larger tumor masses
are removed. This careful inspection and palpation is essential in order to establish the feasi‐
bility and extension of surgical cytoreduction. Complete cytoreduction may by difficult in
cases of bulky suprarenal nodes, extensive disease in the liver parenchyma, along the root of
the small bowel mesentery and in the bowel serosa, close to the origin of the superior mes‐
enteric artery, or in the porta hepatis. If complete surgical cytoreduction is not feasible, neo‐
adjuvant chemotherapy is preferred. (Figure 5)
Radical omentectomy use to be the first surgical step because it is the first tumor encoun‐
tered upon entering the peritoneal cavity. The infracolic omentum is separated from the
transverse colon and resected. If the omental metastases involve the gastrocolic omentum, it
is resected as well. The next step is to remove the primary tumor in the pelvis with the other
adnexa and the uterus in the usual fashion if no extension to other pelvic organs is present.
However, advanced ovarian cancer often involves the uterus, rectosigmoid, cecum, ileum
and bladder. Metastases of the pelvic peritoneum sometimes completely obliterate the ante‐
rior and posterior cul-de-sac. In this case, the retroperitoneal approach is the most reasona‐
ble way for removing in block the entire tumor. This procedure is accompanied by
performing a rectosigmoid resection with an end-to end mechanical anastomosis.[54] Tumor
spread to the hilum of the spleen may be carefully inspected as well. Splenectomy may be
sometimes indicated to achieve maximal tumor debulking. Any peritoneal implants should
be removed, particularly if there are large, isolated masses and their removal will render the
patient optimally cytoreduced. Diaphragm peritoneum should be visualized and resected if
the disease is present. Sometimes, it can involve muscle resection that can be sutured with
non-reabsorbed monofilament continuous suture. Pelvic and /or aortic lymph node involve‐
ment is seen is approximately 60% of patient with advanced stage disease. Despite contro‐
versial, pelvic and aortic lymphadenectomy should be completed starting form aortic
bifurcation up to the renal veins. The incidence of complications and morbidity of this ap‐
proach should be also taken into consideration for patient selection. The most common com‐
plications include: infections, cardiac morbidity, pulmonary thromboembolism,
coagulopathy, gastrointestinal, renal failure, re-laparotomy and death.
14. Surgical treatment of relapsed ovarian cancer: Secondary
cytoreduction
Once recurrence is confirmed, the next step is to determine the best treatment approach for
each individual case. Recurrent epithelial ovarian carcinoma is, however, a therapeutic di‐
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lemma for physicians. To date, there is no consensus for optimal treatment strategies. Three
essential options are proposed: surgical resection followed by chemotherapy, chemotherapy
only or enrollment into clinical trials. This dilemma will be fundamentally responded by the
localization of the disease, by the disease free interval (DFI) between the end of standard
front-line chemotherapy (platinum/taxanes-based) and the date of documented disease re‐
currence. This period will divide patients in three groups: platinum sensible with a DFI more
than 6 months; platinum resistant: patients with a DFI less than 6 months; and the group of
platinum refractory: patients who will never respond to front line therapy or who will experi‐
ence progression of disease. The latter represents 20-30% of the patients with FIGO stage III-
IV who underwent surgical cytoreduction followed by carboplatin /paclitaxel.[55],[56] DFI
has been established as the most important predictor factor for response to treatment of the
relapsed disease.[55],[57],[58]
15. Secondary cytoreduction
Surgical resection for ovarian cancer recurrence means secondary cytoreduction. Although
primary cytoreductive surgery is well accepted as the cornerstone of initial management,
the use of cytoreductive surgery in the setting of recurrent disease is defined less clearly.
Benefits of secondary cytoreduction are encountered in several studies.[59] No randomized
studies exist regarding the benefits of surgical resection over chemotherapy in patients with
recurrent disease. The available data is controversial and biased by the decision whether or
not to expose patients to a surgical treatment. In general, studies included patients with
more favorable characteristics such as younger age, fewer medical comorbidity, scarce num‐
ber of lesions, better performance status, absence of ascites at recurrence, early stage at diag‐
nosis, DFI more than 12 months, and optimal primary cytoreduction.[60]-[64] All of the
previous characteristics are favorable prognostic factors and constitute the standard indica‐
tions for secondary surgical resection.[60] A recent meta-analysis studied 2.019 patients en‐
rolled in 40 retrospective and prospective trials who underwent secondary cytoreduction
due to recurrent ovarian cancer. The mean weighted median OS time after recurrence was
30.3 months. Complete cytoreduction was identified as an independent factor for the im‐
proving OS after secondary cytoreduction. In addition, the multivariate analysis showed
that the survival time is increased 3.0 months each 10 % increase in the proportion of pa‐
tients undergoing complete cytoreductive surgery.[65]
The objective of secondary cytoreduction should be to achieve complete debulking. In pa‐
tients who are able to tolerate a major surgical procedure, secondary cytoreduction should
be offered to those with a single site disease regardless of DFI, as well as to all patients with
a DFI of greater than 30 months regardless the amount of disease sites. Patients with carci‐
nomatosis and a DFI of less than 12 months should not be considered for secondary cytore‐
duction. The decisions must be, however, individualized based on each patient’s goals,
performance status, operative risk, and available therapeutic options.[66] (Table 3)
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Multiple site od recurrence – but no
carcinomatosis
Carcinomatosis
6 – 12 months Offer SC Consider SC No SC
12 – 30 months Offer SC Offer SC Consider SC
> 30 months Offer SC Offer SC Offer SC
Table 3. Recommendations for secondary cytoreduction (SC)
16. Specialized gynecologists
Surgical evaluation of a pelvic mass is one of the most common indications for gynecologic
surgery and, therefore, it is unlikely that all patients with adnexal masses will be referred to
a gynecologic oncologist. To assist in the referral process, the Society of Gynecologic Oncolo‐
gy established a guideline for patient referral with suspected ovarian cancer.[67]
It has been demonstrated that patients operated on by gynecologic oncologists are more
likely to undergo an adequate staging procedure in early stage disease[34],[36],[37],[68] and
a better percentage of optimal primary cytoreduction in advanced stage disease can be ach‐
ieved in comparison to general gynecologists or general surgeons.[33]-[38] Moreover, many
studies from several countries around the world have shown over 10 months increased OS
when ovarian cancer patients were initially operated by a gynecological oncologist rather
than general gynecologist [33],[34],[69]-[71] or general surgeons.[68],[72] Thus, optimal pri‐
mary cytoreductive surgery performed by a surgeon with extended formal training in cytor‐
eductive techniques followed by an appropriate chemotherapy combination is among the
most powerful clinician-driven determinants of survival for women with ovarian cancer.[24]
17. Multidisciplinary team and centralization of treatment
Ovarian cancer is a challenging, complex and multidisciplinary disease. It is not only impor‐
tant how well trained physicians are, but also how many physicians of different specialties
are involved in the management of this malignancy. The holistic conception of patient care
and the intrinsic complexity of ovarian cancer require the involvement of different special‐
ties to optimize the quality of care. The concept of multidisciplinary team approach in ovari‐
an cancer is not restricted to the operating room settings. Multidisciplinary approach is
crucial from the diagnosis to the demise of disease.
Results of different studies consistently show that patients with ovarian cancer treated at re‐
ferral teaching high-volume hospitals receive better quality of care as accomplished by bet‐
ter surgical staging, better optimal cytoreduction[35],[39],[69],[73]-[75] and better
chemotherapy administration rate and schemes.[69],[75]-[78] Treating patients at referral
hospitals was independently associated with 10%-20% increased probability of survival at 5
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years after first treatment.[69],[72],[73],[75],[79] In absolute numbers, this translates in an ex‐
tension of survival of more than 10 months.[79]
Despite the consensus and the advantages explained above, population-based studies indi‐
cate that access to specialist care in gynecologic oncology for women with suspected ovarian
cancer has been less than universal.[35],[36],[70] Reports from countries such as USA,[80]
and UK[35],[81] have consistently shown that the majority of patients were treated in low-
volume hospitals by low-volume surgeons. For example, the accessibility of patients with
ovarian cancer to a specialized center was reported in 18% of patients in The Nether‐
lands[74], 35% in Canada[72] and 40% in Maryland, USA.[82]
In summary, the configuration of health-care delivery systems to facilitate quick and consis‐
tent centralized referral will be necessary to ensure widespread access for women with sus‐
pected ovarian cancer to such health-care providers. Only through such efforts will
contemporary patterns of surgical practice conform to the definition of high-quality cancer
care.[83]
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1. Introduction
Epithelial ovarian cancer causes more deaths than any other cancer of the female reproductive
system and it is the leading cause of death from gynecologic cancer. There is no universally
accepted consensus on the surveillance of ovarian cancer, but if we review the main clinical
guidelines, we can find similar recommendations for follow-up for patients with ovarian
cancer after chemotherapy treatment.
Approximately 60% of patients will experience a relapse after the standard first-line treatment
including cytoreductive surgery and adjuvant chemotherapy [1]. At this time, when relapse
occurs, the chance of cure decreases drastically and treatment is solely palliative. This makes
the increase in overall survival and the quality of life the primary endpoints. Surgery is not
sufficiently validated due to the lack of phase III clinical trials, and there are no approved
targeted therapies in relapsed ovarian cancer. Therefore, chemotherapy is the only option to
achieve these objectives. We will review the role of chemotherapy in recurrent ovarian cancer
in this chapter.
2. Diagnosis of epithelial ovarian cancer relapse
In stages I, II, III and IV complete responders, American guidelines recommend that, after
completing primary surgery and adjuvant chemotherapy, follow-up visits should include a
physical examination with a pelvic exam every 2 to 4 months for the first two years, then every
3 to 6 months until the fifth year, and then annually after the fifth year. Periodic monitoring
of CA 125 and other tumor markers (e.g., CA 19.9, CEA) are also recommended if the markers
were elevated previously. The rest of the examination, which ranges from performing
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Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) or Positron Emission
Tomography/Computerized Tomography (PET/CT), will be performed as clinically indicated
such as weight loss, fatigue, bloating, pelvic pain or bowel occlusion [2].
European clinical guidelines recommend a physical exam and routine measurement of CA 125
every 3 months for 2 years, every 4 months during the third year and every 6 months during
years 4 and 5. CT scan will be performed if the CA 125 is elevated or if there is clinical evidence
of relapse [3].
A physical examination to detect recurrent ovarian cancer has limited value and detects
abnormalities that indicate a recurrence only in 3.8 to 4.6% of patients [4, 5]. CT has a sensitivi‐
ty of 40 - 93%, depending on the presence of peritoneal disease, tumor location and the pres‐
ence of ascites. The sensitivity of MRI ranges from 62 to 91%, depending on the location of the
tumor and tumor size. MRI facilitates the detection of disease on the peritoneal and intestinal
surface [6].
We can define the relapse of ovarian cancer with the RECIST (Response Evaluation Criteria in
Solid Tumors) criteria. However, relapse can also be defined as a doubling from the upper
limit of normal value of CA 125 (30 U/mL) in patients who normalized their value after
finishing their treatment, or doubling this value from the nadir (minimum value) in patients
who never had normalized values [7-9]. It is estimated that this rise in the CA 125 level precedes
the clinical detection of recurrence by about three months [10], and this may have implications
at the beginning of the second-line treatment.
3. Classification of relapse
There are several classifications of patients with relapsed ovarian cancer based on the plati‐
num-free interval (Table 1).
Markman suggested that the probability of response in the re-treatment with platinum-based
chemotherapy depends on the platinum-free interval. In a retrospective analysis conducted at
the Memorial Sloan-Kettering Cancer Center (New York, United States of America), these
authors found a subgroup of patients with a higher likelihood of response to platinum salts.
They selected 82 patients who received initial chemotherapeutic treatment with a cisplatin-
based regimen and second-line treatment with a cisplatin- or carboplatin-based regimen, with
a platinum-free interval of more than 4 months. The response rate to second-line treatment in
the three groups according to the platinum-free interval at 5 to 12 months, 13 to 24 months and
more than 24 months, was 27%, 33% and 59%, respectively [11]. They proposed to classify
patients into different groups according to their previous response to platinum-based treat‐
ment and platinum-free interval: primary platinum-resistant (patients who progressed before
the completion of the planned treatment), secondary platinum-resistant (patients who
responded to a platinum regimen and did not respond to a second platinum-based treatment),
and potentially platinum-sensitive (all patients who respond to a platinum-based treatment,
subdivided into patients with platinum-free intervals of less than 6, 6 to 12 months and more
than 12 months) [12].
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In 1993, Thigpen defined two subgroups of patients with relapsed ovarian carcinoma based
on the volume of relapse and the time to relapse after the end of treatment with platinum.
Patients with small-volume disease confined to the peritoneal cavity have a far better chance
of achieving a response to second-line chemotherapy with subsequent prolonged survival than
those with bulky disease or disease outside the abdomen. Thus, we can classify the patients
into those who are still "clinically sensitive" to the platinum-based regimens (initial response
to platinum-based therapy and relapse more than 6 months after cessation of treatment) and
those with "clinically resistant" disease (defined as progression disease during or within 6
months of first-line treatment platinum-based therapy). We should choose a platinum-
containing regimen for relapse for those patients classified as clinically sensitive and an
alternative treatment without platinum salts for those with clinically resistant disease [13].
Until recently, this was the most utilized and simplest classification.
Author Best response to platinum Platinum Free
Interval
Classification
Markman [11,12] Progression ----- Primary Platinum-resistant
No response Any Primary Platinum-resistant
Response < 6 months Potentially platinum-sensitive
Response > 6 months Potentially platinum-sensitive
Thigpen [13] Progression ---- Platinum-resistant
No response Any Platinum-resistant
Response < 6 months Platinum-resistant





No response Any Platinum-refractory
Response < 4 months Platinum-refractory
Response > 4 - 12 months Intermediate platinum-sensitive
Response > 12 months Platinum-sensitive
NICE 2005 [15] Progression ---- Platinum-refractory
No response Any Platinum-refractory
2010 GCIG Consensus
[16]
Response < 6 months Platinum-resistant
Response > 6 - 12 months Partially platinum-sensitive
Response > 12 months Platinum-sensitive
Table 1. Classification of relapsed ovarian cancer
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The International Workshop Consensus established a different classification in 1998 and
stratified patients into platinum-refractory (progression during or within 4 months), inter‐
mediate platinum-sensitive (initial response but relapse 4 -12 months) and platinum-sensitive
(relapse after 12 months) [14].
More recently, the National Institute for Health and Clinical Excellence (NICE) in 2005 [15]
and the Gynecologic Cancer InterGroup (GCIG) in 2010 [16] have developed new classifica‐
tions, including partially platinum-sensitive patients (those who relapse between 6 and 12
months after completion of initial platinum-based chemotherapy).
4. Treatment of platinum-sensitive disease
Until the early 2000s, monotherapy with platinum salts was the standard treatment for patients
with platinum-sensitive disease because clinical trials attempting to prove the superiority of
polychemotherapy were negative.
More recent clinical trials have demonstrated the superiority of polychemotherapy versus
monotherapy, making this strategy the standard treatment in patients with platinum-sensitive
disease. We discuss the main previous studies in this section.
4.1. Carboplatin versus carboplatin/paclitaxel (ICON4/AGO-OVAR 2.2)
In parallel, two pragmatic clinical trials were designed to determine whether the combination
of carboplatin and paclitaxel should be used at first relapse after platinum-based chemother‐
apy [the International Collaborative Ovarian Neoplasm 4 (ICON4), coordinated by the
Instituto Mario Negri, Milan, Italy (IRFMN) and the Medical Research Council's Clinical Trials
Unit, London, United Kingdom (MRC CTU), and Arbeitsgemeinschaft Gynaekologische
Onkologie (AGO) OVAR 2.2 coordinated by AGO, Karlsruhe, Germany] [17].
They randomized 802 patients with relapsed epithelial ovarian cancer who previously received
platinum-based chemotherapy and had a platinum-free interval of more than 6 months (more
than 12 months in the ICON4 group) to receive a conventional platinum-based chemotherapy
(the majority of patients (71%) received carboplatin alone) or a combined treatment with
paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin AUC 5 – 6 every 3 weeks for at
least 6 cycles. The primary endpoint was overall survival (OS), and secondary endpoints were
progression-free survival (PFS) and quality of life. The platinum-free interval was greater than
12 months in 75% of patients.
Patients in the AGO protocol must have previously received cisplatin or carboplatin plus
paclitaxel, patients in the MRC CTU protocol trial were permitted to have had more than one
line of previous chemotherapy and patients randomized into the Italian protocol required
measurable disease.
With a median follow-up of 42 months, OS was increased by 5 months (24 versus 29 months),
with an absolute difference in 2-year survival of 7% in favor of paclitaxel plus platinum-based
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chemotherapy (57% versus 50%; Hazard Ratio (HR): 0.82; 95% CI 0.69 - 0.97; p = 0.02). For PFS,
there was a HR: 0.76 (95% CI 0.66 - 0.89; p = 0.0004) in favor of paclitaxel plus platinum-based
chemotherapy, which translates into an absolute difference in median PFS of 3 months in favor
of the combination regimen (9 versus 12 months). The response rate (RR) seemed to be higher
in the combination arm (66%) compared to the conventional chemotherapy arm (p = 0.06).
There were no differences between the quality of life measures in both groups. The results
showed no difference between different subgroups (randomization group, time to relapse,
number of previous lines of chemotherapy, type of prior chemotherapy, age and performance
status).
Paclitaxel plus platinum-based chemotherapy was generally more toxic than conventional
platinum-based chemotherapy, causing more alopecia and neurotoxicity (20% of patients),
while conventional platinum-based chemotherapy was associated with more hematological
toxic effects than paclitaxel plus platinum chemotherapy.
The ICON4/AGO-OVAR 2.2 trial was the first large clinical trial that showed the superiority
of polychemotherapy versus monotherapy in platinum-sensitive ovarian cancer.
Similar results were found in a Spanish randomized phase II clinical trial conducted by GEICO
(Grupo Español de Investigación en Cáncer de Ovario) [18]. In this trial, 81 patients with
platinum-sensitive recurrent ovarian carcinoma were randomized to carboplatin or carbopla‐
tin plus paclitaxel. The primary endpoint was objective response and secondary endpoints
were time to progression, overall survival, tolerability and quality of life. The platinum-free
interval was greater than 12 months in 57.7% of patients. In the intent-to-treat analysis, they
reported a higher response rate in the group treated with carboplatin plus paclitaxel than in
the carboplatin group (75.6% versus 50%; p = 0.017). The median time to progression (49.1
versus 33.7 weeks; p = 0.021) and overall survival (not reached versus 72.7 weeks; p = 0.0021)
were also better in the group treated with the combination therapy. There were no differences
in the quality of life. As in the ICON4/AGO-OVAR 2.2 trial, alopecia (86.8%) and neurotoxicity
(23.7%) were more frequent in patients treated with paclitaxel. Stomatitis (18.4%) and myal‐
gias/arthralgias (36.8%) were also more frequent in this group. In the ICON4/AGO OVAR 2.2
trial, only 40% of patients received paclitaxel as part of a previous treatment, which could affect
the superiority of the paclitaxel arm following the relapse. In the Spanish trial, 87.2% of patients
received paclitaxel previously, so it was suggested that carboplatin plus paclitaxel could be
administered at relapse in patients who received this treatment as first-line therapy.
4.2. Carboplatin versus carboplatin/gemcitabine (AGO-OVAR 2.5)
Neurotoxicity is the main drawback for the re-treatment with carboplatin plus paclitaxel
because, among other factors, co-administration of paclitaxel and platinum compounds can
increase  the  development  of  neurotoxicity  [19].  Neurotoxicity  is  a  cumulative  dose-
dependent toxicity; 715 mg/m2 is the mean cumulative dose to onset of grade 2 or greater
neurotoxicity [20].
In the ICON4-AGO OVAR 2.2 study, moderate or severe neurological effects were observed
in 20% of patients in the combination arm, and the majority of patients experienced grades 1
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to 4 neurotoxicity (75% to 83%) with the combination of carboplatin–paclitaxel and cisplatin-
paclitaxel.
For these reasons, an alternative combination with carboplatin and gemcitabine was designed
to avoid toxic effects, such as neurotoxicity, derived from the combination of carboplatin or
cisplatin and paclitaxel.
In the AGO-OVAR 2.5 [21] clinical trial, the AGO-OVAR investigators, in collaboration with
the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the European
Organization for Research and Treatment of Cancer Gynecological Cancer Group (EORTC
GCG), randomized 356 patients with platinum-sensitive recurrent ovarian cancer to receive
either carboplatin alone (AUC 5) every 21 days or carboplatin AUC 4 on day 1 plus gemcitabine
1000 mg/m2 on days 1 and 8, every 21 days. Patients could receive 6 to 10 cycles in both arms.
The primary objective was progression-free survival, and secondary objectives included the
response rate, duration of response, overall survival, quality of life and toxicity. Both groups
were well balanced: 70.8% of patients had received platinum-based plus taxane as first-line
therapy, and 59.8% of patients had a platinum-free interval greater than 12 months. The study
was not powered to detect differences in OS.
With a median follow-up of 17 months, the median PFS in the combination arm and the
single-agent arm were 8.6 months (95% CI, 7.9 - 9.7) and 5.8 months (95% CI, 5.2 - 7.1),
respectively,  with a 28% reduction in the progression-free event rate (HR: 0.72;  95% CI,
0.58 - 0.90; p = 0.0031). On the other hand, the RR was significantly higher in the gemcita‐
bine plus carboplatin arm than in the carboplatin arm (47.2% versus 30.9%; p = 0.0016).
The HR for overall survival was 0.96 (95% CI, 0.75 - 1.23; p = 0.7349). There was no difference
in OS, which was 18 months for patients treated with carboplatin and gemcitabine versus
17.3 for patients treated with carboplatin alone. Furthermore,  there was no difference in
the quality of life between treatment arms.
A significant increase in serious (grade 3 to 4) hematologic adverse events was documented
in both arms, including neutropenia (71% versus 12%), thrombocytopenia (35% versus 11%)
and anemia (27% versus 8%). These adverse events appeared more commonly in the combi‐
nation arm. The use of granulocyte colony-stimulating factor was more frequent in patients
treated with carboplatin and gemcitabine (24% versus 10%).
The results of the AGO-OVAR 2.5 trial confirmed the superiority of platinum-based polyche‐
motherapy over platinum salts in monotherapy.
The results of this clinical trial provide a treatment alternative to carboplatin/paclitaxel, with
a different profile of toxicity, including less alopecia and neurotoxicity, which can affect the
quality of life for women with ovarian cancer.
4.3. Carboplatin/paclitaxel versus carboplatin/Pegylated Liposomal Doxorubicin (PLD)
(CALYPSO)
In an attempt to establish a new second-line treatment with improved tolerance and equal or
greater efficacy than the standard treatment with carboplatin and paclitaxel, the CALYPSO
clinical trial was designed [22].
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In  this  trial,  a  total  of  976  patients  with  histologically  confirmed  ovarian  cancer  with
recurrence  more  than  6  months  after  first-  or  second-line  platinum-  and  taxane-based
therapies were randomly assigned to receive carboplatin AUC 5 on day 1 plus pegylated
liposomal doxorubicin (PLD) 30 mg/m2 on day 1, every 28 days, or carboplatin AUC 5 on
day 1 plus paclitaxel 175 mg/m2 on day 1 at 3-week intervals for at least 6 cycles (in case
of stabilization of disease or if partial response was achieved after 6 courses, the patients
were allowed to receive therapy until progression). The platinum-free interval was greater
than 12 months in 63.9% of patients.
The study was designed as a non-inferiority trial. The primary endpoint was progression-free
survival, and secondary endpoints were toxicity, quality of life, and overall survival.
With a median follow-up of 22 months, PFS was statistically superior for patients treated with
carboplatin/PLD than patients in the carboplatin/paclitaxel arm (11.3 versus 9.4 months with
HR: 0.821; 95% CI, 0.72 to 0.94; p = 0.005).
Severe  non-hematologic  toxicity  (grades  3  to  4)  was  more  frequent  in  patients  in  the
carboplatin/paclitaxel  arm  than  in  patients  treated  with  carboplatin/PLD  (36.8%  versus
28.4%; p = 0.001). Grade 2 or greater palmar-plantar erythrodisestesia (12% versus 2.2%),
nausea (35.2% versus 24.2%), vomiting (22.5% versus 15.6%) and mucositis (13.9% versus
7%) occurred more commonly in the carboplatin/PLD arm. Grade 2 or greater neurotoxic‐
ity (4.9% versus 26.9%), complete hair loss (7% versus 83.6%) and allergic/hypersensitivi‐
ty reactions (5.6% versus 18.8%) were more frequent in patients treated with carboplatin
and paclitaxel. The allergic/hypersensitivity reactions were mainly secondary to carbopla‐
tin administration and was the reason for significantly lower rates of  early discontinua‐
tion of one or both drugs in the paclitaxel arm compared with the PLD arm (1% versus
6%; p > 0.001). Fewer patients discontinued treatment early for toxicity in the carboplatin/
PLD arm (6% versus 15%; p < 0.001).
Regarding hematologic toxicities, they were generally similar between the treatment groups,
although grades 3 to 4 neutropenia was more frequent in patients treated with carboplatin/
paclitaxel (35.2% versus 45.7%) and grades 3 to 4 thrombocytopenia was more frequent in
patients treated with carboplatin/PLD (15.9% versus 6.2%). There were no differences in febrile
neutropenia or the use of supportive treatment (e.g., transfusion, granulocyte colony-stimu‐
lating factor).
Recently, data on the final OS were reported. With a median follow-up of 49 months, no
statistically significant difference in OS was observed between the two arms (HR: 0.99; 95%
CI: 0.85 - 1.16; p = 0.94). The median OS was 30.7 months in patients treated with carbopla‐
tin  and  PLD and 33.0  months  for  patients  treated  with  carboplatin  and  paclitaxel.  The
authors rationalize this fact with an imbalanced post-study cross-over between arms, with
a greater proportion of patients randomized to carboplatin/paclitaxel receiving post-study
PLD (68%) than patients in the carboplatin/PLD arm receiving post-study paclitaxel (43%;
p < 0.001) [23].
The improved disease-related outcomes achieved with carboplatin/PLD treatment were not
at the expense of quality of life [24].
The Role of Chemotherapy in Recurrent Ovarian Cancer
http://dx.doi.org/10.5772/54171
189
to 4 neurotoxicity (75% to 83%) with the combination of carboplatin–paclitaxel and cisplatin-
paclitaxel.
For these reasons, an alternative combination with carboplatin and gemcitabine was designed
to avoid toxic effects, such as neurotoxicity, derived from the combination of carboplatin or
cisplatin and paclitaxel.
In the AGO-OVAR 2.5 [21] clinical trial, the AGO-OVAR investigators, in collaboration with
the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the European
Organization for Research and Treatment of Cancer Gynecological Cancer Group (EORTC
GCG), randomized 356 patients with platinum-sensitive recurrent ovarian cancer to receive
either carboplatin alone (AUC 5) every 21 days or carboplatin AUC 4 on day 1 plus gemcitabine
1000 mg/m2 on days 1 and 8, every 21 days. Patients could receive 6 to 10 cycles in both arms.
The primary objective was progression-free survival, and secondary objectives included the
response rate, duration of response, overall survival, quality of life and toxicity. Both groups
were well balanced: 70.8% of patients had received platinum-based plus taxane as first-line
therapy, and 59.8% of patients had a platinum-free interval greater than 12 months. The study
was not powered to detect differences in OS.
With a median follow-up of 17 months, the median PFS in the combination arm and the
single-agent arm were 8.6 months (95% CI, 7.9 - 9.7) and 5.8 months (95% CI, 5.2 - 7.1),
respectively,  with a 28% reduction in the progression-free event rate (HR: 0.72;  95% CI,
0.58 - 0.90; p = 0.0031). On the other hand, the RR was significantly higher in the gemcita‐
bine plus carboplatin arm than in the carboplatin arm (47.2% versus 30.9%; p = 0.0016).
The HR for overall survival was 0.96 (95% CI, 0.75 - 1.23; p = 0.7349). There was no difference
in OS, which was 18 months for patients treated with carboplatin and gemcitabine versus
17.3 for patients treated with carboplatin alone. Furthermore,  there was no difference in
the quality of life between treatment arms.
A significant increase in serious (grade 3 to 4) hematologic adverse events was documented
in both arms, including neutropenia (71% versus 12%), thrombocytopenia (35% versus 11%)
and anemia (27% versus 8%). These adverse events appeared more commonly in the combi‐
nation arm. The use of granulocyte colony-stimulating factor was more frequent in patients
treated with carboplatin and gemcitabine (24% versus 10%).
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This study provides an optional scheme of treatment for patients with platinum-sensitive
ovarian cancer, with a reduction in severe toxicities, including carboplatin hypersensitivity
reactions and peripheral neurotoxicity, both of which can be a reason for limiting the dose.
Carboplatin/PLD also induced far less alopecia, one of the most feared adverse effects of
chemotherapy for the majority of women.
4.4. Carboplatin/gemcitabine versus carboplatin/gemcitabine/bevacizumab (OCEANS)
In ovarian cancer, as in other tumors, the addition of new treatments is required for improved
outcomes.
In a phase III clinical trial, 484 patients with relapsed platinum-sensitive ovarian cancer were
randomly assigned to receive Carboplatin AUC 4 on day 1 and Gemcitabine 1000 mg/m2 on
days 1 and 8, every 21 days with placebo, or bevacizumab 15 mg/kg on day 1, every 21 days
[25]. After 6 to 10 cycles of chemotherapy, bevacizumab or placebo were continued until
toxicity or progression. The primary endpoint was progression-free survival, and secondary
endpoints were overall response rate, overall survival and the duration of response.
With a median follow-up of 24 months, the analysis showed an increase in PFS (12.4 versus
8.4 months with a HR of 0.484; 95% CI 0.388 to 0.605; p < 0.0001) and in the RR (78.5%
versus 57.4%, p < 0.0001) for bevacizumab. The duration of response was also significant‐
ly increased with the addition of bevacizumab (10.4 versus 7.4 months; HR: 0.534; 95% CI:
0.408 - 0.698). With the number of events for the final analysis not yet reached, the OS was
35.2 months in the placebo arm versus 33.3 months in the bevacizumab arm. This could
be related to subsequent therapy, including patients receiving bevacizumab in the place‐
bo arm (31%).
The bevacizumab arm had a higher incidence of grade 3 or higher hypertension (17.4% versus
1%) and proteinuria (8.5% versus < 1%). There was no gastrointestinal perforation in any group.
This is the first positive phase III trial evaluating the addition of a targeting therapy to a
standard platinum-based chemotherapy regimen for recurrent ovarian cancer.
4.5. New perspectives in the treatment of platinum-sensitive disease
The poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are a family of enzymes
that play a role in the repair of DNA damage by repairing base excisions. The tumor-suppressor
proteins BRCA1 and BRCA2 are components of the DNA repair pathway, and it is known that
a germ-line mutation in BRCA1 or BRCA2 is associated with a high risk of the development
of some cancers, including breast, prostate and ovarian cancer. Olaparib (AZD2281) is an oral
PARP inhibitor that has shown activity in cancers associated with BRCA1 or BRCA2 mutations
with an acceptable side-effect profile [26].
A randomized phase II clinical trial was designed to compare the efficacy of olaparib and PLD
in patients with confirmed germ-line BRCA1 or BRCA2 mutations and recurrent or progressed
ovarian cancer within 12 months of the most recent platinum-based chemotherapy regimen
[27]. The primary endpoint was the progression-free survival by RECIST criteria, and secon‐
Ovarian Cancer - A Clinical and Translational Update190
dary endpoints included the overall response rate, duration of treatment response, overall
survival, safety and tolerability, and health-related quality of life. Ninety-seven patients were
randomly assigned (1:1:1 ratio) to receive olaparib 200 mg twice per day, 400 mg twice per day
continuously or PLD 50 mg/m2 every 28 days. Patients were stratified by BRCA1 or BRCA2
status and platinum sensitivity (sensitive or resistant). There was no statistically significant
difference in PFS between the olaparib 200 mg, olaparib 400 mg and PLD groups (6.5 months,
8.8 months and 7.1 months, respectively). The overall response rate was 25%, 31% and 18%,
respectively, with no statistically significant difference. A similar duration of response was
also observed (6.0, 6.8 and 5.5 months). There was no difference among groups in the OS or
the health-related quality of life. Nausea, vomiting, fatigue and anemia were the most common
adverse events related to olaparib; the adverse events related to PLD were stomatitis and
palmo-plantar erythrodysesthesia.
In a second randomized phase II study, olaparib was evaluated in the maintenance treatment
for patients with platinum-sensitive relapsed high-grade (grades 2 or 3) ovarian cancer who
responded to their most recent platinum-based chemotherapy [28]. A total of 265 patients were
randomized to receive olaparib 400 mg twice daily or placebo after completion of their last
dose of platinum-based chemotherapy. The primary endpoint was progression-free survival;
it was significantly longer in the olaparib group (8.4 months) than in the placebo group (4.8
months), with a hazard ratio for progression or death of 0.35 (95% CI 0.25 to 0.49; p < 0.001).
Secondary efficacy endpoints were time to progression, objective response rate and overall
survival. The time to progression was also significantly longer in patients treated with olaparib
(8.3 versus 3.7 months; HR: 0.35; 95% CI 0.25 to 0.47; p < 0.001). According to the RECIST
criteria, there was no difference in the response rate (12% versus 4%; p = 0.12) or in the overall
survival in the interim analysis at 38% maturity (29.7 versus 29.9 months; p = 0.75). Nausea,
vomiting, fatigue and anemia were the adverse events, with an incidence of at least 10% or
higher in the olaparib group; the majority of them were grade 1 or 2.
The results of these two trials underline the necessity of further exploring the role of olaparib
and other PARP inhibitors in the treatment of women with recurrent ovarian cancer. It may
well be that their use has to be restricted to BRCA mutated patients, but a better definition of
BRCAness should then be standardized. [29]
5. Treatment of platinum-resistant disease
Patients with platinum-resistant disease have a worse prognosis than patients with platinum-
sensitive disease and a poorer response rate to cytostatic treatment. Although there is no clear
recommendation for the standard treatment in these patients, there is a long list of drugs that
have shown activity in phase II clinical trials in this situation: pegylated liposomal doxorubicin,
topotecan, gemcitabine, paclitaxel, docetaxel, trabectedin, vinorelbine, ifosfamide, etoposide,
and pemetrexed (Table 2).
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Drug Response rate Main toxicity
Pegylated liposomal doxorubicin 20% Hand-foot syndrome, mucositis
Topotecan 6 - 20% Hematologic, alopecia
Gemcitabine 9 - 16% Hematologic
Paclitaxel 13 - 17% Neurotoxicity, alopecia
Docetaxel 23% Hematologic
Trabectedin 6% Hematologic
Vinorelbine 3 - 21% Neutropenia
Ifosfamide 12% Hematologic, central nervous toxicity
Etoposide 27% Neutropenia
Pemetrexed 9 - 21% Neutropenia, asthenia
Table 2. Response rate and toxicity for platinum-resistant disease
The comparisons between some of these drugs in phase III clinical trials do not yield superior
results for any of the drugs in terms of overall or progression-free survival.
As explained, the response rate to platinum compounds is too low in patients with platinum-
resistant disease, so monotherapy with a non-platinum drug is usually preferred because
studies with doublets have not demonstrated superiority in platinum-resistant patients or
either have presented greater toxicity [30 - 37].
Despite its frequent use in clinical practice, endocrine treatment (e.g., Tamoxifen, Letrozole)
is not approved, and there is no good evidence supporting its use. Data on tamoxifen were
obtained from observational studies, not comparative ones, and do not allow us to make any
evidence-based recommendations [38]. In a phase II trial with letrozol carried out in 44 patients
(half of them with platinum-resistant disease) who had primary tumors that expressed the
estrogen receptor, a 9% overall response and 42% stabilization at 12 weeks was obtained in 33
patients with radiologically measurable disease, with a minimal toxicity [39]. In any case, there
are worse data in the literature on the impact of endocrine therapy versus chemotherapy on
progression-free survival [40]. Unfortunately, there are no phase III trials to make any
recommendations about the use of hormone treatment in relapsed ovarian cancer.
The main phase III clinical trials comparing different agents in platinum-resistant relapsed
ovarian cancer are shown below.
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5.1. Topotecan versus paclitaxel
Topotecan and paclitaxel are active in platinum-resistant relapsed ovarian cancer. To compare
the activity of these two drugs in this setting, a phase III clinical trial was conducted in patients
who had progressed during or after platinum-based therapy [41, 42]. A total of 226 patients
were randomized to receive chemotherapy with topotecan 1.5 mg/m2/24 h on 5 consecutive
days, every 21 days (112 patients), or paclitaxel 175 mg/m2, every 21 days (114 patients). The
duration of treatment was dependent on response. Patients with a complete or partial response
continued treatment until progression or for 6 months past the maximal response. Patients
who progressed were removed from the study and patients with stable disease after six courses
were removed from the study or switched to the alternate regimen (the study allowed
crossover of the arms). None of the patients had previously received topotecan or paclitaxel
(not included in standard first-line therapy as of now). Patients were stratified as platinum-
resistant or as early, interim and late relapse groups. In the study, 53% of the patients did not
respond to platinum-based treatment or had progression within 6 months; they had platinum-
resistant disease (55% in the topotecan group and 52% in the paclitaxel group).
The primary efficacy parameters were the response rate, duration of response and time to
progression. The secondary criteria for efficacy were the time to response and survival.
In the whole group of patients in the study, no differences in the response rates (topotecan
20.5% versus paclitaxel 13.2%; p = 0.138) or in the median survival (63 weeks for topotecan
versus 53 weeks for paclitaxel, p = 0.44) were achieved. The duration of response was 32.1
weeks in patients treated with topotecan and 19.7 weeks in patients treated with paclitaxel (p
= 0.222). There was no statistically significant difference in the time to progression after therapy
(18.9 weeks for topotecan versus 14.7 weeks for paclitaxel; p = 0.08). The median time to
documented radiologic response was inferior in the paclitaxel group (6 weeks) than in the
topotecan group (9 weeks; p = 0.041).
Among platinum-resistant patients, the response rates were superior in the topotecan group
than in the paclitaxel group (13.1 versus 6.7%, p = 0.303), and the median overall survival was
28.4 weeks in the topotecan group and 39.7 weeks in patients treated with paclitaxel.
Patients who had no ascites, better performance status and a smaller tumor burden had higher
response rates.
The results of questionnaires on the quality of life, including pain, anorexia, diarrhea, fatigue,
nausea and vomiting, dyspnea, constipation and insomnia, were similar in both groups.
Different toxicities were observed in the two groups. Hematologic toxicity was more frequent
in the topotecan group, including grade 4 neutropenia (79% versus 23% in paclitaxel group; p
< 0.01) and grade 4 thrombocytopenia (25% versus 2% in paclitaxel group; p < 0.01). Other
toxicities more frequent in patients treated with topotecan were fatigue, nausea and vomiting
(generally grades 1 – 2). Patients in the paclitaxel group experienced more alopecia, arthralgia,
myalgia and neurotoxicity.
Patients who received topotecan after paclitaxel in their third-line treatment had an overall
response rate of 13%, compared to 10% (p = 0.638) in patients who received paclitaxel after
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days, every 21 days (112 patients), or paclitaxel 175 mg/m2, every 21 days (114 patients). The
duration of treatment was dependent on response. Patients with a complete or partial response
continued treatment until progression or for 6 months past the maximal response. Patients
who progressed were removed from the study and patients with stable disease after six courses
were removed from the study or switched to the alternate regimen (the study allowed
crossover of the arms). None of the patients had previously received topotecan or paclitaxel
(not included in standard first-line therapy as of now). Patients were stratified as platinum-
resistant or as early, interim and late relapse groups. In the study, 53% of the patients did not
respond to platinum-based treatment or had progression within 6 months; they had platinum-
resistant disease (55% in the topotecan group and 52% in the paclitaxel group).
The primary efficacy parameters were the response rate, duration of response and time to
progression. The secondary criteria for efficacy were the time to response and survival.
In the whole group of patients in the study, no differences in the response rates (topotecan
20.5% versus paclitaxel 13.2%; p = 0.138) or in the median survival (63 weeks for topotecan
versus 53 weeks for paclitaxel, p = 0.44) were achieved. The duration of response was 32.1
weeks in patients treated with topotecan and 19.7 weeks in patients treated with paclitaxel (p
= 0.222). There was no statistically significant difference in the time to progression after therapy
(18.9 weeks for topotecan versus 14.7 weeks for paclitaxel; p = 0.08). The median time to
documented radiologic response was inferior in the paclitaxel group (6 weeks) than in the
topotecan group (9 weeks; p = 0.041).
Among platinum-resistant patients, the response rates were superior in the topotecan group
than in the paclitaxel group (13.1 versus 6.7%, p = 0.303), and the median overall survival was
28.4 weeks in the topotecan group and 39.7 weeks in patients treated with paclitaxel.
Patients who had no ascites, better performance status and a smaller tumor burden had higher
response rates.
The results of questionnaires on the quality of life, including pain, anorexia, diarrhea, fatigue,
nausea and vomiting, dyspnea, constipation and insomnia, were similar in both groups.
Different toxicities were observed in the two groups. Hematologic toxicity was more frequent
in the topotecan group, including grade 4 neutropenia (79% versus 23% in paclitaxel group; p
< 0.01) and grade 4 thrombocytopenia (25% versus 2% in paclitaxel group; p < 0.01). Other
toxicities more frequent in patients treated with topotecan were fatigue, nausea and vomiting
(generally grades 1 – 2). Patients in the paclitaxel group experienced more alopecia, arthralgia,
myalgia and neurotoxicity.
Patients who received topotecan after paclitaxel in their third-line treatment had an overall
response rate of 13%, compared to 10% (p = 0.638) in patients who received paclitaxel after
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topotecan. The data analysis for those patients receiving the other drug (paclitaxel or topote‐
can) in the third-line therapy showed that there was a degree of non-cross-resistance between
them [43]. Therefore, the use of paclitaxel in first-line therapy does not prevent the adminis‐
tration of topotecan in relapsed epithelial ovarian cancer.
5.2. Paclitaxel versus pegylated liposomal doxorubicin
One study compared PLD 50 mg/m2 every 4 weeks versus paclitaxel 175 mg/m2 every 3 weeks
in 214 patients with relapsed epithelial ovarian cancer [44].
There were no differences in the response rates among patients who received pegylated
liposomal doxorubicin and patients who received paclitaxel (17.8% versus 22.4%; p = 0.034).
There was also no difference in the PFS (21.7 weeks versus 22.4 weeks; p = 0.15) or OS (45.7
weeks versus 56.1 weeks; p = 0.44).
There were no observed differences in the PFS or OS in platinum-resistant or platinum-
sensitive patients.
In the PLD group, hand-foot syndrome, stomatitis, nausea, and vomiting were more frequent.
Conversely, alopecia, myalgia, arthralgia, and paresthesia were more frequent in the paclitaxel
group.
5.3. Pegylated liposomal doxorubicin versus topotecan
To compare the efficacy and safety of PLD and topotecan in relapsed ovarian cancer after
chemotherapy with platinum and taxanes, a phase III clinical trial was carried out in 474
patients [45, 46].
Patients were randomized to receive treatment with PLD 50 mg/m2 every 28 days (239
patients), or topotecan 1.5 mg/m2/24 h on 5 consecutive days, every 21 days (235 patients). The
primary endpoint was time to progression, and the secondary endpoints included overall
survival, response rate, time to response, duration of response and toxicity. The trial included
54% of the platinum-resistant patients in the PLD group and 53% of such patients in the
topotecan group.
There was no difference in the rate of response between the two groups (19.7% in patients
treated with PLD versus 17% in patients treated with topotecan; p = 0.390). A reduction in the
risk of death by 18% was achieved in the group of patients treated with PLD compared to
topotecan (HR = 1.216: 95% CI 1.000 to 1.478, p = 0.050). The median survival was 62.7 weeks
in the PLD group versus 59.7 weeks in the topotecan group.
In the platinum-sensitive population, there were benefits in survival among patients treated
with PLD, with a reduced risk of death by 30% (HR 1.432, 95% CI 1.066 to 1.923, p = 0.017) and
a median survival of 107.9 weeks in the PLD group compared to 70.1 weeks in the topotecan
group. The progression-free survival was 28.9 weeks for the PLD group and 23.3 weeks for
the topotecan group (p =0.037), although the response rate was similar between the two groups
(28.4% in the PLD group versus 28.8% in the topotecan group, p = 0.964).
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In the subgroup of platinum-resistant patients, (54% of the population of the study; 255
patients) there were no statistically significant differences in the response rate (12.3% for PLD
and 6.5% for topotecan, p = 0.118), the PFS (9.1 weeks in patients who received PLD compared
to 13.6 weeks in the topotecan group, p = 0.733), or OS (35.6 weeks for the PLD group and 41.3
for the topotecan group, p = 0.455, with a HR = 1.069, 95% CI 0.823 to 1.387, p = 0.618).
The toxicity profiles of the two drugs were different. The main toxicities in patients treated
with PLD were hand-foot syndrome (49%) and stomatitis (40%). The main toxicities in patients
treated with topotecan were hematological toxicity, so they were more likely to receive
granulocyte colony-stimulating factor (29.1%), erythropoietin (23.1%) and transfusions
(57.8%). Moreover, the toxicity caused by PLD was usually mild to moderate, while the toxicity
caused by topotecan was more severe. Despite this difference, there was no difference in the
health-related quality of life questionnaire at 12 weeks.
5.4. Gemcitabine versus pegylated liposomal doxorubicin
Two randomized phase III trials compared gemcitabine with PLD in patients with platinum-
resistant disease.
The first trial [47] was carried out in 195 patients with platinum-resistant ovarian cancer who
were randomly assigned to receive gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days,
or PLD 50 mg/m2 every 28 days until the progression of disease or unacceptable toxicity. Cross-
over treatment was administered at progression. The primary endpoint was progression-free
survival, and secondary endpoints were response rate, time to treatment failure, survival and
quality of life.
The response rate was similar in both groups (9.2% for gemcitabine versus 11.7% for PLD, p =
0.772). There was no difference in the progression-free survival between patients treated with
gemcitabine and patients treated with PLD (3.6 months versus 3.1 months, p = 0.870). The
overall survival was similar in patients treated with gemcitabine followed by PLD and patients
who received the inverse sequence (12.7 months versus 13.5 months, p = 0.997).
The toxicity profiles were different, with more hand-foot syndrome and stomatitis in the PLD
arm and increased constipation, nausea and vomiting, fatigue and neutropenia in the gemci‐
tabine arm. During the cross-over treatment, toxicity was similar to those observed during the
initial treatment phase.
In a second study [48], 153 patients previously treated with platinum/paclitaxel who had
relapsed or progressed within 12 months (53% within 6 months) were randomized to receive
gemcitabine 1000 mg/m2 on days 1, 8 and 15, every 28 days, or PLD 40 mg/m2 every 28 days.
There were no differences in the response rate (29% for gemcitabine versus 16% for PLD, p =
0.066) or time to progression (20 weeks in gemcitabine group versus 16 weeks in PLD group,
p = 0.411). Although the overall survival was higher in the PLD arm (51 weeks versus 56 weeks,
p = 0.048), this difference was not detected in the platinum-resistant subgroup (relapse or
progression < 6 months). The toxicity profile was similar to the previous study. Health-related
quality of life favored the PLD arm.
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can) in the third-line therapy showed that there was a degree of non-cross-resistance between
them [43]. Therefore, the use of paclitaxel in first-line therapy does not prevent the adminis‐
tration of topotecan in relapsed epithelial ovarian cancer.
5.2. Paclitaxel versus pegylated liposomal doxorubicin
One study compared PLD 50 mg/m2 every 4 weeks versus paclitaxel 175 mg/m2 every 3 weeks
in 214 patients with relapsed epithelial ovarian cancer [44].
There were no differences in the response rates among patients who received pegylated
liposomal doxorubicin and patients who received paclitaxel (17.8% versus 22.4%; p = 0.034).
There was also no difference in the PFS (21.7 weeks versus 22.4 weeks; p = 0.15) or OS (45.7
weeks versus 56.1 weeks; p = 0.44).
There were no observed differences in the PFS or OS in platinum-resistant or platinum-
sensitive patients.
In the PLD group, hand-foot syndrome, stomatitis, nausea, and vomiting were more frequent.
Conversely, alopecia, myalgia, arthralgia, and paresthesia were more frequent in the paclitaxel
group.
5.3. Pegylated liposomal doxorubicin versus topotecan
To compare the efficacy and safety of PLD and topotecan in relapsed ovarian cancer after
chemotherapy with platinum and taxanes, a phase III clinical trial was carried out in 474
patients [45, 46].
Patients were randomized to receive treatment with PLD 50 mg/m2 every 28 days (239
patients), or topotecan 1.5 mg/m2/24 h on 5 consecutive days, every 21 days (235 patients). The
primary endpoint was time to progression, and the secondary endpoints included overall
survival, response rate, time to response, duration of response and toxicity. The trial included
54% of the platinum-resistant patients in the PLD group and 53% of such patients in the
topotecan group.
There was no difference in the rate of response between the two groups (19.7% in patients
treated with PLD versus 17% in patients treated with topotecan; p = 0.390). A reduction in the
risk of death by 18% was achieved in the group of patients treated with PLD compared to
topotecan (HR = 1.216: 95% CI 1.000 to 1.478, p = 0.050). The median survival was 62.7 weeks
in the PLD group versus 59.7 weeks in the topotecan group.
In the platinum-sensitive population, there were benefits in survival among patients treated
with PLD, with a reduced risk of death by 30% (HR 1.432, 95% CI 1.066 to 1.923, p = 0.017) and
a median survival of 107.9 weeks in the PLD group compared to 70.1 weeks in the topotecan
group. The progression-free survival was 28.9 weeks for the PLD group and 23.3 weeks for
the topotecan group (p =0.037), although the response rate was similar between the two groups
(28.4% in the PLD group versus 28.8% in the topotecan group, p = 0.964).
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In the subgroup of platinum-resistant patients, (54% of the population of the study; 255
patients) there were no statistically significant differences in the response rate (12.3% for PLD
and 6.5% for topotecan, p = 0.118), the PFS (9.1 weeks in patients who received PLD compared
to 13.6 weeks in the topotecan group, p = 0.733), or OS (35.6 weeks for the PLD group and 41.3
for the topotecan group, p = 0.455, with a HR = 1.069, 95% CI 0.823 to 1.387, p = 0.618).
The toxicity profiles of the two drugs were different. The main toxicities in patients treated
with PLD were hand-foot syndrome (49%) and stomatitis (40%). The main toxicities in patients
treated with topotecan were hematological toxicity, so they were more likely to receive
granulocyte colony-stimulating factor (29.1%), erythropoietin (23.1%) and transfusions
(57.8%). Moreover, the toxicity caused by PLD was usually mild to moderate, while the toxicity
caused by topotecan was more severe. Despite this difference, there was no difference in the
health-related quality of life questionnaire at 12 weeks.
5.4. Gemcitabine versus pegylated liposomal doxorubicin
Two randomized phase III trials compared gemcitabine with PLD in patients with platinum-
resistant disease.
The first trial [47] was carried out in 195 patients with platinum-resistant ovarian cancer who
were randomly assigned to receive gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days,
or PLD 50 mg/m2 every 28 days until the progression of disease or unacceptable toxicity. Cross-
over treatment was administered at progression. The primary endpoint was progression-free
survival, and secondary endpoints were response rate, time to treatment failure, survival and
quality of life.
The response rate was similar in both groups (9.2% for gemcitabine versus 11.7% for PLD, p =
0.772). There was no difference in the progression-free survival between patients treated with
gemcitabine and patients treated with PLD (3.6 months versus 3.1 months, p = 0.870). The
overall survival was similar in patients treated with gemcitabine followed by PLD and patients
who received the inverse sequence (12.7 months versus 13.5 months, p = 0.997).
The toxicity profiles were different, with more hand-foot syndrome and stomatitis in the PLD
arm and increased constipation, nausea and vomiting, fatigue and neutropenia in the gemci‐
tabine arm. During the cross-over treatment, toxicity was similar to those observed during the
initial treatment phase.
In a second study [48], 153 patients previously treated with platinum/paclitaxel who had
relapsed or progressed within 12 months (53% within 6 months) were randomized to receive
gemcitabine 1000 mg/m2 on days 1, 8 and 15, every 28 days, or PLD 40 mg/m2 every 28 days.
There were no differences in the response rate (29% for gemcitabine versus 16% for PLD, p =
0.066) or time to progression (20 weeks in gemcitabine group versus 16 weeks in PLD group,
p = 0.411). Although the overall survival was higher in the PLD arm (51 weeks versus 56 weeks,
p = 0.048), this difference was not detected in the platinum-resistant subgroup (relapse or
progression < 6 months). The toxicity profile was similar to the previous study. Health-related
quality of life favored the PLD arm.
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5.5. Canfosfamide versus pegylated liposomal doxorubicin or topotecan
A phase III clinical trial (ASSIST-1) was designed to attempt to demonstrate superiority in
the  overall  survival  (primary  endpoint)  and  progression-free  survival  (secondary  end‐
point)  with  canfosfamide  versus  PLD  or  topotecan  in  patients  who  progressed  despite
second-line  treatment  with  either  topotecan  or  PLD  in  platinum-refractory  or  -resistant
patients [49].
The study included 461 patients randomized to an active control arm (PLD 50 mg/m2 every 28
days or topotecan 1.5 mg/m2 on days 1 – 5, every 21 days, based on the prior therapy) or
canfosfamide 1000 mg/m2 every 21 days.
The median overall survival was 8.5 months with canfosfamide and 13.5 months in the control
arm (p < 0.01). The median OS was similar between PLD and topotecan (14.2 versus 10.8
months; p = 0.1695). The progression-free survival was longer for patients treated in the control
group than for patients in the canfosfamide group (4.3 versus 2.3 months; p < 0.01). Hemato‐
logic adverse events were more frequent in the control arm, and non-hematologic adverse
events were similar in both arms.
6. Extending the platinum-free interval
The cells of ovarian cancer could have intrinsic or acquired resistance to platinum compounds,
which is a large clinical obstacle in the treatment of women with relapsed ovarian cancer. There
are several mechanisms by which tumor cells can develop resistance to platinum, including
increased efflux, enhanced DNA repair of damage caused by chemotherapy and defective cell
death pathways. Some of these mechanisms may be reversible with time. It has been hypothe‐
sized that artificially extending the platinum-free interval with non-cross-resistant chemo‐
therapy may improve the likelihood of responding to platinum salts subsequently
administered and prolong the overall survival [35, 50, 51].
Recently, the OVA-301 trial [35] randomized 672 women with recurrent ovarian cancer to
receive trabectedin 1.1 mg/m2 plus PLD 30 mg/m2 every 21 days, or PLD 50 mg/m2 every 28
days. The primary endpoint was progression-free survival, and secondary endpoints included
overall survival and safety. The PFS was higher in the combination group in the overall
population of the study (7.3 versus 5.8 months; HR = 0.79, p = 0.0190) and in the platinum-
sensitive patients (9.2 versus 7.5 months; HR = 0.73, p = 0.0170). The most common adverse
effects were hand-foot syndrome in the PLD group and neutropenia and a transient ALT
increase in the PLD/trabectedin group. After a median follow-up of 47.4 months, no difference
in overall survival was observed (22.2 months in the combination group versus 18.9 months
in the PLD group; HR = 0.86, p = 0.0835). Despite stratification based on platinum sensitivity,
the authors detected an imbalance in the mean platinum-free interval, which favored the PLD
group (13.3 versus 10.6 months; p = 0.009) [36].
Furthermore, the data reported in patients with a platinum-free interval of 6 - 12 months are
especially interesting. These are the patients who can obtain the most benefit from an extension
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in the platinum-free interval. In this population, the median PFS was 7.4 months in the PLD/
trabectedin group versus 5.5 months in the PLD group (HR = 0.65; p = 0.0152) [52]. The median
OS was 22.4 months in the PLD/trabectedin group versus 16.4 months in the monotherapy arm
(HR = 0.64; p = 0.0027) [36].
In the OVA-301 study, similar proportions of patients received subsequent therapy in each
arm (77% and 76%), with 56% and 57% receiving platinum-based therapies in the 6 - 12 months
subgroup. In this subgroup, the time from randomization to subsequent platinum-based
therapy was significantly longer for patients treated with PLD/trabectedin (9.8 versus 7.9
months; p = 0.0167). Patients randomized to the combination group experienced significantly
longer survival after the initiation of subsequent platinum-based therapy (13.3 versus 9.8
months; HR = 0.63, p = 0.0357) [52]. These data support the hypothesis that the enhanced
survival benefits may be due to an artificial extension of the platinum-free interval. In any case,
this hypothesis should be confirmed in prospective randomized trials.
When the data on patients who received platinum-based therapy as the first subsequent
treatment after PLD/trabectedin or PLD in the 6 - 12 months subset were analyzed, platinum
was delayed 4 months (11.5 versus 7.5 months; HR: 0.61, p = 0.0203) and the overall survival
from the first platinum treatment was significantly extended by a median of 8.7 months (18.6
versus 9.9 months; HR = 0.54, p = 0.0169) [53].
The delay in platinum re-treatment could promote the recovery from toxicities, such as
polyneuropathy or alopecia.
7. Discussion
As previously shown, a longer platinum-free interval is the most important factor associated
with a higher likelihood of response and prolongation of progression-free survival. Therefore,
patients who relapse after six months of completion of chemotherapy and are responders are
candidates for re-treatment with platinum salts.
The considerations in the choice of a second and subsequent line of chemotherapy in recurrent
ovarian cancer may also include assessment of efficacy, cumulative toxicities and the optimal
sequencing of available agents.
Currently, in patients with platinum-sensitive disease, it is preferred to administer a combi‐
nation regimen including a platinum compound and a second active drug (Table 3). The
platinum compound most commonly used is carboplatin, due to its better toxicity profile.
These treatments provide a high response rate and significant improvements in the quality of
life and progression-free survival compared to platinum monotherapy. However, the ideal
platinum combination is unknown, and several regimens are available. Recently, schemes
without platinum, such as PLD/trabectedin, have been developed and can be useful. Never‐
theless, there are no data comparing these regimens to platinum-based schemes, so we must
be prudent.
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point)  with  canfosfamide  versus  PLD  or  topotecan  in  patients  who  progressed  despite
second-line  treatment  with  either  topotecan  or  PLD  in  platinum-refractory  or  -resistant
patients [49].
The study included 461 patients randomized to an active control arm (PLD 50 mg/m2 every 28
days or topotecan 1.5 mg/m2 on days 1 – 5, every 21 days, based on the prior therapy) or
canfosfamide 1000 mg/m2 every 21 days.
The median overall survival was 8.5 months with canfosfamide and 13.5 months in the control
arm (p < 0.01). The median OS was similar between PLD and topotecan (14.2 versus 10.8
months; p = 0.1695). The progression-free survival was longer for patients treated in the control
group than for patients in the canfosfamide group (4.3 versus 2.3 months; p < 0.01). Hemato‐
logic adverse events were more frequent in the control arm, and non-hematologic adverse
events were similar in both arms.
6. Extending the platinum-free interval
The cells of ovarian cancer could have intrinsic or acquired resistance to platinum compounds,
which is a large clinical obstacle in the treatment of women with relapsed ovarian cancer. There
are several mechanisms by which tumor cells can develop resistance to platinum, including
increased efflux, enhanced DNA repair of damage caused by chemotherapy and defective cell
death pathways. Some of these mechanisms may be reversible with time. It has been hypothe‐
sized that artificially extending the platinum-free interval with non-cross-resistant chemo‐
therapy may improve the likelihood of responding to platinum salts subsequently
administered and prolong the overall survival [35, 50, 51].
Recently, the OVA-301 trial [35] randomized 672 women with recurrent ovarian cancer to
receive trabectedin 1.1 mg/m2 plus PLD 30 mg/m2 every 21 days, or PLD 50 mg/m2 every 28
days. The primary endpoint was progression-free survival, and secondary endpoints included
overall survival and safety. The PFS was higher in the combination group in the overall
population of the study (7.3 versus 5.8 months; HR = 0.79, p = 0.0190) and in the platinum-
sensitive patients (9.2 versus 7.5 months; HR = 0.73, p = 0.0170). The most common adverse
effects were hand-foot syndrome in the PLD group and neutropenia and a transient ALT
increase in the PLD/trabectedin group. After a median follow-up of 47.4 months, no difference
in overall survival was observed (22.2 months in the combination group versus 18.9 months
in the PLD group; HR = 0.86, p = 0.0835). Despite stratification based on platinum sensitivity,
the authors detected an imbalance in the mean platinum-free interval, which favored the PLD
group (13.3 versus 10.6 months; p = 0.009) [36].
Furthermore, the data reported in patients with a platinum-free interval of 6 - 12 months are
especially interesting. These are the patients who can obtain the most benefit from an extension
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trabectedin group versus 5.5 months in the PLD group (HR = 0.65; p = 0.0152) [52]. The median
OS was 22.4 months in the PLD/trabectedin group versus 16.4 months in the monotherapy arm
(HR = 0.64; p = 0.0027) [36].
In the OVA-301 study, similar proportions of patients received subsequent therapy in each
arm (77% and 76%), with 56% and 57% receiving platinum-based therapies in the 6 - 12 months
subgroup. In this subgroup, the time from randomization to subsequent platinum-based
therapy was significantly longer for patients treated with PLD/trabectedin (9.8 versus 7.9
months; p = 0.0167). Patients randomized to the combination group experienced significantly
longer survival after the initiation of subsequent platinum-based therapy (13.3 versus 9.8
months; HR = 0.63, p = 0.0357) [52]. These data support the hypothesis that the enhanced
survival benefits may be due to an artificial extension of the platinum-free interval. In any case,
this hypothesis should be confirmed in prospective randomized trials.
When the data on patients who received platinum-based therapy as the first subsequent
treatment after PLD/trabectedin or PLD in the 6 - 12 months subset were analyzed, platinum
was delayed 4 months (11.5 versus 7.5 months; HR: 0.61, p = 0.0203) and the overall survival
from the first platinum treatment was significantly extended by a median of 8.7 months (18.6
versus 9.9 months; HR = 0.54, p = 0.0169) [53].
The delay in platinum re-treatment could promote the recovery from toxicities, such as
polyneuropathy or alopecia.
7. Discussion
As previously shown, a longer platinum-free interval is the most important factor associated
with a higher likelihood of response and prolongation of progression-free survival. Therefore,
patients who relapse after six months of completion of chemotherapy and are responders are
candidates for re-treatment with platinum salts.
The considerations in the choice of a second and subsequent line of chemotherapy in recurrent
ovarian cancer may also include assessment of efficacy, cumulative toxicities and the optimal
sequencing of available agents.
Currently, in patients with platinum-sensitive disease, it is preferred to administer a combi‐
nation regimen including a platinum compound and a second active drug (Table 3). The
platinum compound most commonly used is carboplatin, due to its better toxicity profile.
These treatments provide a high response rate and significant improvements in the quality of
life and progression-free survival compared to platinum monotherapy. However, the ideal
platinum combination is unknown, and several regimens are available. Recently, schemes
without platinum, such as PLD/trabectedin, have been developed and can be useful. Never‐
theless, there are no data comparing these regimens to platinum-based schemes, so we must
be prudent.
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Clinical Trial Scheme Patients RR PFS OS
ICON4/AGO-OVAR
2.2 [20]
C vs. C/P n = 802 54% vs. 66% 9 vs. 12 m 24 vs. 29 m
AGO-OVAR 2.5 [24] C vs. C/Gem n = 356 30.9 vs. 47.2% 5.8 vs. 8.6 m 18 vs. 17.3 m







8.4 vs. 12.4 m 35.2 vs. 33.3 m
Abbreviations: RR: response rate. PFS: progression-free survival. OS: overall survival. C: carboplatin. P: paclitaxel. Gem:
gemcitabine. PLD: pegylated liposomal doxorubicin, m: months.
Table 3. Main phase III clinical trials in platinum-sensitive relapsed ovarian cancer
The ICON4/AGO-OVAR 2.2 trial was the first clinical trial that showed the superiority of
polychemotherapy to monotherapy in patients with platinum-sensitive relapsed ovarian
cancer. The combination of carboplatin and paclitaxel may be used in patients who have no
residual neurotoxicity, especially if the platinum-free interval is greater than one year.
A valid alternative is the administration of carboplatin plus PLD (CALYPSO), which has
demonstrated similar efficacy to carboplatin/paclitaxel and a more favorable toxicity profile,
with less alopecia, neurotoxicity and allergic/hypersensitivity reactions. Perhaps this is the
most commonly used scheme by oncologists worldwide, now conditioned by a globally
limited availability of PLD.
Although no survival benefit was achieved in the AGO-OVAR 2.5 trial with carboplatin and
gemcitabine, the results of this clinical trial allow us to recommend this chemotherapy scheme
as an alternative to carboplatin/paclitaxel, due to its different, and perhaps more favorable,
toxicity profile. This scheme is especially useful for patients with risk factors for neurotoxicity
development. The addition of an anti-angiogenic drug, such as bevacizumab (OCEANS), can
improve outcomes without a significant increase in toxicity.
The incorporation of new active drugs into the treatment of patients with platinum-sensitive
ovarian cancer is also important. Thus, we must be aware of the results of the phase III clinical
trial, HECTOR (ClinicalTrials.gov Identifier: NCT00437307), which compares the combination
of carboplatin plus topotecan with the current standard of care (carboplatin/paclitaxel,
carboplatin/gemcitabine or carboplatin/PLD). The trial may be completed in 2013.
Because the response rate to platinum salts is too low in patients with platinum-resistant
disease, monotherapy with a non-platinum drug is usually the choice in this setting. Compar‐
isons of the efficacy of different active drugs in phase III clinical trials show no superiority of
any of them, and there is no clear recommendation for the standard treatment in these patients.
Therefore, the selection of treatment for platinum-resistant patients will be based on other
criteria, such as toxicity, patient preferences and physician experience. Whenever possible,
patients with platinum-resistant disease should be considered for treatment in clinical trials.
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Recurrent platinum-resistant ovarian cancer has limited treatment options and is generally
treated sequentially with multiple single-agent regimens consisting of non-platinum and non-
taxane chemotherapy.
The most common options are PLD, topotecan and gemcitabine. These options have been
compared in several phase III clinical trials (Table 4), but none of the options have proven
superior. PLD and gemcitabine could be used in patients who do not desire alopecia. Addi‐
tionally, PLD is dosed less frequently than topotecan and gemcitabine, which results in
improved convenience for the patient and a reduction in the use of resources.
Subsequent lines of treatment will be made with available drugs.





n = 226 13.1% vs.
6.7%**
23.1 vs. 14 w* 28.4 vs.
39.7 w**
O'Byrne KJ, 2002 Paclitaxel vs. PLD n = 214 22.4% vs.
17.8%*
22.4 vs. 21.7 w* 56.1 vs.
45.7 w*
Gordon AN, 2004 PLD vs. Topotecan n = 474 12.3% vs.
6.5%**
9.1 vs. 13.6 w** 35.6 vs.
41.3 w**
Mutch DG, 2007 Gemcitabine vs. PLD n = 195 9.2% vs.
11.7%**




Gemcitabine vs. PLD n = 153 29% vs. 16%* 20 vs. 16 w* 51 vs.
56 w*
*Data from the whole group
**Data from platinum-resistant patients
Abbreviations: RR: response rate, PFS: progression-free survival, OS: overall survival, PLD: pegylated liposomal doxoru‐
bicin, w: weeks, m: months.
Table 4. Main phase III clinical trials including platinum-resistant relapsed ovarian cancer
Recently, the use of non-platinum agents in relapsed ovarian cancer to extend the platinum-
free interval has gained interest. The answer to the question of whether the prolongation of
the platinum-free interval increases overall survival after the reintroduction of platinum
should be revealed by two phase III trials currently in progress. The MITO-8 (ClinicalTrials.gov
Identifier: NCT00657878) trial compares carboplatin/paclitaxel followed by PLD versus the
reverse sequence (PLD followed by carboplatin/paclitaxel), and the INOVATYON trial
(ClinicalTrial.gov identifier: NCT01379989) compares the administration of carboplatin/PLD
followed by treatment at the discretion of the investigator versus PLD/trabectedin followed
by a platinum-based.
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Clinical Trial Scheme Patients RR PFS OS
ICON4/AGO-OVAR
2.2 [20]
C vs. C/P n = 802 54% vs. 66% 9 vs. 12 m 24 vs. 29 m
AGO-OVAR 2.5 [24] C vs. C/Gem n = 356 30.9 vs. 47.2% 5.8 vs. 8.6 m 18 vs. 17.3 m







8.4 vs. 12.4 m 35.2 vs. 33.3 m
Abbreviations: RR: response rate. PFS: progression-free survival. OS: overall survival. C: carboplatin. P: paclitaxel. Gem:
gemcitabine. PLD: pegylated liposomal doxorubicin, m: months.
Table 3. Main phase III clinical trials in platinum-sensitive relapsed ovarian cancer
The ICON4/AGO-OVAR 2.2 trial was the first clinical trial that showed the superiority of
polychemotherapy to monotherapy in patients with platinum-sensitive relapsed ovarian
cancer. The combination of carboplatin and paclitaxel may be used in patients who have no
residual neurotoxicity, especially if the platinum-free interval is greater than one year.
A valid alternative is the administration of carboplatin plus PLD (CALYPSO), which has
demonstrated similar efficacy to carboplatin/paclitaxel and a more favorable toxicity profile,
with less alopecia, neurotoxicity and allergic/hypersensitivity reactions. Perhaps this is the
most commonly used scheme by oncologists worldwide, now conditioned by a globally
limited availability of PLD.
Although no survival benefit was achieved in the AGO-OVAR 2.5 trial with carboplatin and
gemcitabine, the results of this clinical trial allow us to recommend this chemotherapy scheme
as an alternative to carboplatin/paclitaxel, due to its different, and perhaps more favorable,
toxicity profile. This scheme is especially useful for patients with risk factors for neurotoxicity
development. The addition of an anti-angiogenic drug, such as bevacizumab (OCEANS), can
improve outcomes without a significant increase in toxicity.
The incorporation of new active drugs into the treatment of patients with platinum-sensitive
ovarian cancer is also important. Thus, we must be aware of the results of the phase III clinical
trial, HECTOR (ClinicalTrials.gov Identifier: NCT00437307), which compares the combination
of carboplatin plus topotecan with the current standard of care (carboplatin/paclitaxel,
carboplatin/gemcitabine or carboplatin/PLD). The trial may be completed in 2013.
Because the response rate to platinum salts is too low in patients with platinum-resistant
disease, monotherapy with a non-platinum drug is usually the choice in this setting. Compar‐
isons of the efficacy of different active drugs in phase III clinical trials show no superiority of
any of them, and there is no clear recommendation for the standard treatment in these patients.
Therefore, the selection of treatment for platinum-resistant patients will be based on other
criteria, such as toxicity, patient preferences and physician experience. Whenever possible,
patients with platinum-resistant disease should be considered for treatment in clinical trials.
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Recurrent platinum-resistant ovarian cancer has limited treatment options and is generally
treated sequentially with multiple single-agent regimens consisting of non-platinum and non-
taxane chemotherapy.
The most common options are PLD, topotecan and gemcitabine. These options have been
compared in several phase III clinical trials (Table 4), but none of the options have proven
superior. PLD and gemcitabine could be used in patients who do not desire alopecia. Addi‐
tionally, PLD is dosed less frequently than topotecan and gemcitabine, which results in
improved convenience for the patient and a reduction in the use of resources.
Subsequent lines of treatment will be made with available drugs.
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bicin, w: weeks, m: months.
Table 4. Main phase III clinical trials including platinum-resistant relapsed ovarian cancer
Recently, the use of non-platinum agents in relapsed ovarian cancer to extend the platinum-
free interval has gained interest. The answer to the question of whether the prolongation of
the platinum-free interval increases overall survival after the reintroduction of platinum
should be revealed by two phase III trials currently in progress. The MITO-8 (ClinicalTrials.gov
Identifier: NCT00657878) trial compares carboplatin/paclitaxel followed by PLD versus the
reverse sequence (PLD followed by carboplatin/paclitaxel), and the INOVATYON trial
(ClinicalTrial.gov identifier: NCT01379989) compares the administration of carboplatin/PLD
followed by treatment at the discretion of the investigator versus PLD/trabectedin followed
by a platinum-based.
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1. Introduction
In 2012, approximately 22,280 women will be diagnosed with ovarian carcinoma in the United
States and roughly 15,500 will die from this disease, ranked the most common cause of death
among gynecologic malignancies in developed countries [1]. Most women with epithelial
ovarian cancer (EOC) present with advanced disease (stage III or IV) at the time of diagnosis.
This phenomenon is mainly due to the lack of specific symptoms until disease has spread
beyond the ovaries, at which time the chance of cure is dramatically reduced [2]. Current
standard treatment of ovarian cancer, in both early and advanced stages, consists of complete
cytoreductive surgery followed by chemotherapy, usually based on a platinum and a taxane
doublet [3,4,5]. Initial response rate (RR) is high (70%-80%); but the majority of patients with
advanced disease relapse within two years. Recurrent ovarian cancer is not curable, due to the
development of chemoresistance [6,7]. The Gynecologic Oncology Group (GOG) adopted the
definition of sensitivity to chemotherapy (or sensitivity to platinum) in EOC based on clinical
criteria from retrospective case series [8]. When patients were re-challenged with a platinum
compound the longer the interval from the last dose of platinum patients had received the
better the response (and outcome) was. This clinical observation set the base for the current
classification of platinum resistance in relapsed EOC (Figure 1), and allowed the commonly
used stratification criteria in clinical trials of recurrent EOC. Platinum-resistant disease is also
characterized by resistance to other cytotoxic agents, and not necessarily only resistant to
platinum. However, current treatment for platinum-resistant EOC consists of chemotherapy
agents whose mechanism of action is somewhat different from that of platinum compounds [9].
Since platinum compounds are the backbone in the systemic treatment of EOC, there is great
interest in elucidate the molecular mechanisms contributing to platinum resistance in this
disease. The present chapter will provide a comprehensive basic and translational update with
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regards to biological pathways implicated in the development of platinum resistance, focusing
on ovarian cancer therapeutics.
2. Cisplatin: Mechanism of action
Once introduced actively into the cell mediated by a copper transporter (CTR1), the molecule
is activated through a series of aquation reactions, in which one of the chloride ligands is slowly
displaced by water. Aquated cisplatin avidly binds DNA, with a predilection for nucleophilic
N7-sites on purine bases [10]. The first step of the reaction involves the formation of monoad‐
ducts. These monoadducts may then react further to form intra-strand and inter-strand
crosslinks. The cytotoxic activity of platinum compounds has been related to binding with
DNA and the production of intra-strand and inter-strand crosslinks, as well as the formation
of adducts that cause conformational DNA changes, impeding the separation of both DNA
strands, which subsequently impairs replication and inhibits DNA synthesis [11]. Intra-strand
cross-links are the most abundant products of the interaction with DNA (around 70% of all
platinum-DNA linking products). These lesions cause significant distortions in the DNA that
can be recognized by one or more DNA binding proteins. These proteins can either initiate
DNA damage repair or signal for apoptosis. Platinum-mediated programmed cell death is
caused by cell cycle arrest in the G2-phase, although the pathways from platinum–DNA
binding to apoptosis are not completely understood [12].
Figure 1. Platinum-resistance definition by the Gynecologic Oncology Group (GOG). Platinum sensitivity is classified as
resistant, partially sensitive, or sensitive, according to the time relapsed since finishing first-line treatment. Probability
of re-treatment response is shown for each group of patients.
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Other proposed mechanisms of cisplatin cytotoxicity include mitochondrial damage, de‐
creased ATPase activity, and altered cellular transport mechanisms. Mitochondria seem to
play a role in the cell death. This is believed to be mediated by their interaction with nuclear
DNA [13]. Additionally, mitochondria are thought to be a major target of cisplatin and
mitochondrial DNA is heavily damaged by cisplatin leading to mitochondrial loss of energy
production and decreasing the ATPase activity [14,15]. Another proposed mechanism of action
is the transporter-mediated uptake. Entering the cells is the first step for cisplatin to exert its
toxic effects. In recent years there has been increasing evidence that the cellular uptake of
cisplatin is mediated, at least in part, by transport proteins. Several transporters, which are
expressed on the cell membranes, have been associated with cisplatin transport across the
plasma membrane and across the cell: the copper transporter 1 (Ctr1), the copper transporter
2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B [16,17].
3. Platinum analogues and ovarian cancer therapeutics
Despite the clear advantage in OS and PFS obtained with cisplatin–paclitaxel, it was immedi‐
ately noted that this regimen carries a significant toxicity, namely peripheral neurotoxicity and
nephrotoxicity [18]. Another important limitation of cisplatin–paclitaxel chemotherapy is the
difficulty in administering it as an outpatient regimen. Prior to the introduction of paclitaxel,
several studies had established that cisplatin and carboplatin are therapeutically equivalent in
women with advanced epithelial ovarian cancer. Furthermore, carboplatin is associated with
significantly lower neurotoxicity and renal toxicity and that the combination of carboplatin
and 3-h infusion paclitaxel can be given as an outpatient schedule. This was also demonstrated
in a Cochrane meta-analysis [19].
Three trials have investigated the equivalence of carboplatin and cisplatin in combination with
paclitaxel in the first-line setting [20,21,22]. Given the evidence of a more favorable toxicity
profile and ease of delivery, the carboplatin–paclitaxel combination has become an almost
universal choice in the management of ovarian cancer, and is the standard comparator in all
the recent trials performed in this disease.
4. Mechanisms of cellular resistance to platinum agents
Even though initial responsiveness to platinum-based therapy is high in ovarian cancer, the
majority of patients relapse. Several mechanisms of cellular resistance to platinum compounds
have been described. These mechanisms can be classified in two groups: 1) those that the limit
the formation of cytotoxic platinum-DNA adducts, and 2) those that prevent cell death
occurring after platinum-DNA adduct formation [11,23]. A better understanding of the
molecular basis of cisplatin resistance may lead to new antitumor strategies that will sensitize
unresponsive ovarian cancers to cisplatin-based chemotherapy.
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4.1. Reduced intracellular drug accumulation
Decreased cellular uptake of cisplatin by resistant cells is one of the major mechanisms of
resistance described in vitro. The mechanism responsible for reduced cisplatin accumulation
in resistant cells may be ascribed to either an inhibition in drug uptake, an increase in drug
efflux, or both. Cisplatin and its analogues may accumulate within cells by passive diffusion
or facilitated transport. The copper transporter-1 (CTR1) regulates the influx of cisplatin and
its analogues into the cell. This is supported by the evidence in cell lines of deletion of the yeast
CTR1 gene, which encodes a high-affinity copper transporter, results in increased cisplatin
resistance and reduced intracellular accumulation of cisplatin in various cell lines including
ovarian cancer [24,25]. In human ovarian cancer cell lines it has been demonstrated that copper
and cisplatin are competitive inhibitors for the transport of each other into the cell and cause
a rapid down-regulation of CTR1 expression mediated by internalization of this transporter
from the plasma membrane and subsequent [26]. Two copper exporters, ATP7A and ATP7B,
have also been proposed to be involved in cellular resistance to cisplatin [27]. ATP7A is thought
to sequester platinum agents in intracellular compartments, preventing their reaction with
nuclear DNA. ATP7A is over-expressed in some cisplatin-resistant ovarian carcinoma cell
lines. Additionally, ovarian cancer patients with ATP7A expression have a lower survival rate
than patients with undetectable levels of expression, as determined by ATP7A immunostain‐
ing [28]. Over-expression of ATP7B in primary ovarian carcinomas and ovarian carcinoma cell
lines resulted in resistance to cisplatin, with only 60% of the cisplatin accumulation present in
ATP7B-expressing cells compared to vector control [29].
MRP-related transport proteins are involved in the active efflux of platinum drugs. MRP is
a member of the ABC (adenosine triphosphate-binding cassette) family of transport pro‐
teins that participates in the efflux of anticancer drugs from cells. Thus, it has been speculat‐
ed that deregulation of some of the MRP components may influence platinum resistance [30].
The MRP gene family is composed of at least seven members (MRP1–7) but recent reports
reinforced  the  notion  that  MRP2  expression  levels  can  be  important  in  predicting  the
sensitivity  of  tumors  to  platinum-based  therapies  [31,32].  MDR1  encodes  an  integral
membrane protein named P-glycoprotein (Pgp) or an ATP-binding cassette subfamily B,
member 1, which acts as a drug efflux pump [33]. This protein is a transmembrane transport‐
er  that  resides  in  the  plasma  membrane  of  many  cells,  including  cancer  cells  that  are
multidrug resistant. Pgp recognizes a wide range of anticancer drugs and was shown to
reduce intracellular concentrations of a variety of cytotoxic drugs, including platinum agents.
Pgp activity  results  in  blunted  chemotherapy-induced cytotoxicity  in  vitro  and in  vivo.
Moreover, anticancer drugs were found to induce MDR1 gene. Since Pgp alone can medi‐
ate resistance to a whole array of drugs through drug efflux, it is an attractive target for the
improvement of anticancer therapy. In theory, co-administration of transporter inhibitors
with Pgp-substrate anticancer drugs could reverse MDR and improve treatment outcome.
Clinical trials aimed at specifically inhibiting the function of Pgp have given mixed results,
but in at least some cases this inhibition has resulted in improved tumor shrinkage and
increased  patient  survival.  Unfortunately,  Pgp  inhibitors  such  as  PSC-833  (Valspodar)
induced pharmacokinetic interactions that limited drug clearance and metabolism of the
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concomitantly administered chemotherapy, thereby elevating plasma concentrations beyond
acceptable toxicity [34]. It is thus clear that the Pgp overexpression can be a cause of failure
of anticancer chemotherapy and be associated with worse prognosis in patients with ovarian
and breast cancers, sarcomas and other malignancies [29,35,36].
4.2. Intracellular cisplatin inactivation
Glutathione (gamma-glutamylcysteinylglycine: GSH), the most abundant intracellular thiol,
contributes (along with methionine, metallothionein and other cysteine-rich proteins) to
detoxify many cellular toxins, including cisplatin and its analogues. Part of the cytoplasmic
cisplatin reacts with DNA, which ultimately lead to the activation of the apoptosis cascade in
response to DNA damage. However, a major fraction of intracellular cisplatin can be converted
into cisplatin-thiol conjugates by GSH-S-transferase π, and these conjugates are ultimately
inactivated. Both GSTπ and γ-glutamylcysteine synthetase (γ- GCS), the latter being the
enzyme involved in GSH synthesis, have been associated with cisplatin resistance in ovarian,
cervical and lung cancer cell lines [37,38,39].
Thus, reducing intracellular glutathione levels would seem a rational strategy to overcome
platinum resistance. To that end, a novel glutathione analog prodrug, canfosfamide, initiated
clinical development in ovarian cancer. Canfosfamide (TLK286) works by targeting tumors
that over-express glutathione S-transferase (GST) P1-1, increasing the sensitivity of those
tumors to the cytotoxic effects of canfosfamide. Following activation, the apoptotic activity of
canfosfamide is mediated through the stress response pathway, resulting in the induction of
cellular apoptosis. Human cancer cells exposed to canfosfamide demonstrate activation of
mitogen- activated protein (MAP) kinase MKK4, p38 kinase, jun-N-terminal kinase (JNK) and
caspase 3. The cytotoxic activity of canfosfamide has been demonstrated in vitro and in vivo
against a variety of human cancer cell lines, including ovarian cancer cells (OVCAR3).
A phase II trial involving 34 patients with platinum-refractory or platinum-resistant ovarian
cancer reported that 15% of patients had an objective response and 50% of patients had disease
stabilization [40]. Three phase III trials in platinum-resistant ovarian cancer were undertaken
in an attempt to define the potential role of canfosfamide in ovarian cancer therapeutics:
TLK286 versus liposomal doxorubicin or topotecan (ASSIST-1,41); TLK286 plus carboplatin
versus liposomal doxorubicin (ASSIST-3,42) and TLK286 plus liposomal doxorubicin versus
liposomal doxorubicin alone (ASSIST-5,43). Unfortunately, none of these studies showed
superior efficacy of canfosfamide compared to standard treatment.
4.3. Increased DNA repair
The cytotoxicity of cisplatin is attributed to the formation of cisplatin-DNA adducts, and to
the induction of DNA damage. The balance between DNA damage to DNA repair dictates
tumor cell death or survival after cisplatin therapy. Depending on the type of damage inflicted
on the DNA structure, different DNA repair mechanisms have the ability to restore these
lesions and remove the platinum-DNA adducts from the tumor DNA [44]. The major pathway
in the repair of DNA damage is the nucleotide excision repair (NER) system. NER is one of
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TLK286 versus liposomal doxorubicin or topotecan (ASSIST-1,41); TLK286 plus carboplatin
versus liposomal doxorubicin (ASSIST-3,42) and TLK286 plus liposomal doxorubicin versus
liposomal doxorubicin alone (ASSIST-5,43). Unfortunately, none of these studies showed
superior efficacy of canfosfamide compared to standard treatment.
4.3. Increased DNA repair
The cytotoxicity of cisplatin is attributed to the formation of cisplatin-DNA adducts, and to
the induction of DNA damage. The balance between DNA damage to DNA repair dictates
tumor cell death or survival after cisplatin therapy. Depending on the type of damage inflicted
on the DNA structure, different DNA repair mechanisms have the ability to restore these
lesions and remove the platinum-DNA adducts from the tumor DNA [44]. The major pathway
in the repair of DNA damage is the nucleotide excision repair (NER) system. NER is one of
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five separate DNA repair mechanisms that also include mismatch repair (MMR), homologous
recombination repair (HR), base excision repair (BER) and translesion synthesis. The prepon‐
derance of one repair mechanism over another may also change in different tumor types.
4.3.1. Nucleotide Excision Repair (NER)
The nucleotide excision repair (NER) pathway is predominantly responsible for repairing
platinum-DNA adducts in cellular DNA. Several proteins interact in a coordinated fashion
to recognize damage and further repair of the DNA (Figure 2).  One of these proteins is
excision  repair  cross-complementation  group  1  (ERCC1).  This  33-kD  protein,  mainly
coupled with XPF (Xeroderma Pigmentosum-F protein)  acts  in  the  rate-limiting incision
step that cleaves the DNA strand before DNA polymerases and ligases act to reconstitute
double-strand integrity. Different studies with ovarian cancer cell lines have demonstrat‐
ed that high ERCC1 mRNA expression is correlated with increased capacity of cells to repair
cisplatin-induced DNA damage, thus conferring resistance to the drug. Further, transfec‐
tion experiments using ERCC1 antisense vectors in both cell lines and mice have shown
increased sensitivity to platinum [45,46,47].
There is growing interest in evaluating the potential role of ERCC1 as a biomarker of platinum
resistance in ovarian cancer. However, despite multiple studies evaluating the association
between ERCC1 protein expression or even single nucleotide polymorphisms and clinical
outcome, no definitive conclusion has yet been reached regarding the predictive and/or
prognostic role of ERRCC1 in the management of EOC [48,49].
4.3.2. DNA mismatch repair
The mismatch repair (MMR) system is a strand-specific DNA repair mechanism involved in
the post-replicative repair of the errors made by DNA polymerases and in charge of eliminat‐
ing single-base mismatches and insertion-deletion loops that have escaped the proofreading
back-up mechanisms.
Loss of function of the cellular mismatch repair system (MMR) can partially contribute to
develop  DNA  damage  tolerance.  Unaltered,  MMR  scans  newly  synthesized  DNA  and
removes mismatches that result  from nucleotide incorporation errors made by the DNA
polymerases. The repair process consists of 3 steps—initiation, excision, and re-synthesis—
that involve several proteins: MLH1, MSH2, MSH3, MSH6, and PMS2. Inactivation of MMR
leads to the occurrence of unrepaired deletions in mononucleotide and dinucleotide repeats,
resulting  in  variable  length  repeats.  This  phenomenon is  called  microsatellite  instability
(MSI), which can be caused by genetic or epigenetic inactivation and has been postulated
as a potential marker for MMR deficiency. DNA methylation changes in plasma have been
suggested  as  another  rationale  of  chemotherapy  resistance  in  OEC  after  treatment  (ac‐
quired MLH1 methylation) [50].
MMR deficient human cancer cell lines tolerate cytotoxic drugs, suggesting that loss of MMR
could cause platinum resistance [51]. Most MMR-deficient cancers have mutations in MLH1
or MSH2. Samimi et al [52] investigated MLH1 and MSH2 expression in paired ovarian tumor
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Figure 2. Schematic Representation of the Mismatch Repair Pathway (Adapted with permission from Diaz-Padilla I, Po‐
veda A. Clin Ovarian Cancer Other Gynecol Malig 2010, 3(1):29-35.) Base-base mismatches are the most frequent errors
associated with microsatellites (repetitive sequences of mononucleotide, dinucleotide, or higher-order nucleotide re‐
peats distributed throughout the human genome). The mismatch repair system is responsible for the surveillance and
correction of errors introduced in microsatellites. Mismatch repair proteins: MLH1, MSH2, MSH3, MSH6, PMS2. Exo 1,
exonuclease; DNA Pol, DNA polymerase δ; PCNA, proliferating cell nuclear antigen.
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tion experiments using ERCC1 antisense vectors in both cell lines and mice have shown
increased sensitivity to platinum [45,46,47].
There is growing interest in evaluating the potential role of ERCC1 as a biomarker of platinum
resistance in ovarian cancer. However, despite multiple studies evaluating the association
between ERCC1 protein expression or even single nucleotide polymorphisms and clinical
outcome, no definitive conclusion has yet been reached regarding the predictive and/or
prognostic role of ERRCC1 in the management of EOC [48,49].
4.3.2. DNA mismatch repair
The mismatch repair (MMR) system is a strand-specific DNA repair mechanism involved in
the post-replicative repair of the errors made by DNA polymerases and in charge of eliminat‐
ing single-base mismatches and insertion-deletion loops that have escaped the proofreading
back-up mechanisms.
Loss of function of the cellular mismatch repair system (MMR) can partially contribute to
develop  DNA  damage  tolerance.  Unaltered,  MMR  scans  newly  synthesized  DNA  and
removes mismatches that result  from nucleotide incorporation errors made by the DNA
polymerases. The repair process consists of 3 steps—initiation, excision, and re-synthesis—
that involve several proteins: MLH1, MSH2, MSH3, MSH6, and PMS2. Inactivation of MMR
leads to the occurrence of unrepaired deletions in mononucleotide and dinucleotide repeats,
resulting  in  variable  length  repeats.  This  phenomenon is  called  microsatellite  instability
(MSI), which can be caused by genetic or epigenetic inactivation and has been postulated
as a potential marker for MMR deficiency. DNA methylation changes in plasma have been
suggested  as  another  rationale  of  chemotherapy  resistance  in  OEC  after  treatment  (ac‐
quired MLH1 methylation) [50].
MMR deficient human cancer cell lines tolerate cytotoxic drugs, suggesting that loss of MMR
could cause platinum resistance [51]. Most MMR-deficient cancers have mutations in MLH1
or MSH2. Samimi et al [52] investigated MLH1 and MSH2 expression in paired ovarian tumor
Ovarian Cancer - A Clinical and Translational Update210
Figure 2. Schematic Representation of the Mismatch Repair Pathway (Adapted with permission from Diaz-Padilla I, Po‐
veda A. Clin Ovarian Cancer Other Gynecol Malig 2010, 3(1):29-35.) Base-base mismatches are the most frequent errors
associated with microsatellites (repetitive sequences of mononucleotide, dinucleotide, or higher-order nucleotide re‐
peats distributed throughout the human genome). The mismatch repair system is responsible for the surveillance and
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sections from 54 ovarian cancer patients before and after platinum-based therapy by using
immunohistochemical staining techniques. These authors demonstrated associations between
MLH1 and MSH2 protein expression and clinical parameters known to be of prognostic
significance as well as response to treatment and overall survival. MLH1 and MSH2 staining
decreased significantly after platinum-based therapy. Hypermethylation of the MLH1
promoter has also been identified as a casual event in sporadic MMR-deficient malignant
tumors. In ovarian cancer, it is estimated that about 10% of cases are related to this molecular
pathway [53], although the methodology and definitions when assessing MSI in ovarian cancer
are heterogeneous and not prospectively validated. The frequency of MMR dysfunction seems
to vary depending on the histological subtype, being higher in endometrioid (19%) and
mucinous (17%) subtypes. It is an assumption that MMR deficiency might be a tumor-initiating
phenomenon in ovarian cancer, similar to colorectal and endometrial tumors. However, MMR
deficient ovarian cancers have been only poorly characterized to date with respect to their
epidemiological, molecular and clinical features.
Only a few studies have found a consistent relationship between MMR inactivation and
platinum-based chemotherapy resistance (primarily down-regulation or mutations in MMR
genes MLH1, MSH2 or MSH1) [50, 54,55,56].
This resistance to cisplatin can be circumvented using a DNA demethylating agent such as 2′-
deoxy-5-azacytidine (decitabine; Dacoge, MGI Pharma) in combination with cisplatin or
carboplatin to reverse this resistance mechanism [57]. Two phase II clinical trials have tested
the combination of carboplatin and decitabine in recurrent Platinum-resistant OC patients with
different conclusions [58,59].
4.3.3. Homologous recombination repair pathway
Platinum-based chemotherapy causes inter-strand DNA cross-linking which cause DNA
double-strand breaks (DSBs) during DNA replication. DSBs are one of the most toxic lesions
to DNA. This is because it affects both strands of the duplex, thus no intact complimentary
strand is available as a template for repair. When such lesions are not repaired the cell
undergoes apoptosis. If the reparation is not done appropriately, secondary lesions can occur,
such as mutations and/or deletions. Cells have evolved two major pathways for the repair of
DSBs: non-homologous end-joining (NHEJ) and homologous recombination (HR). The HR
system is the preferred system by cells when it comes to repair DSBs. It is a highly conserved
system, generally regarded as error-free, that requires an intact sister chromatid to act as
template for correct repair of the break without loss of sequence information. As such, HR
takes place in G2 and S phases of the cell cycle.
The BRCA1 gene is located on chromosome 17q21. The BRCA1 protein is a component of a
number of supercomplexes, each of which plays a role in DNA damage response activation,
cell cycle checkpoint activation and/or DSB repair. Some of the key components of this repair
process are proteins such as BRCA2, RAD51 and PALB2. Actually, the interaction between
specific domains of BRCA1 and PALB2 is key in the reparation of DBSs. Thus, mutations in
domains of BRCA1 can potentially abolish its PALB2-binding activity, resulting in compro‐
mised HR function. These mutations have been found in BRCA1-mutated tumors, implying
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that loss of this specific BRCA1 function in DSB repair is source of the genomic instability and
tumorigenesis observed in this subset of BRCA1 mutation carriers.
The BRCA2 gene is located on chromosome 13q. The BRCA2 protein has its primary function
in HR and its based upon its ability to bind to the strand invasion recombinase, RAD51. In fact,
recruitment of RAD51 to sites of DNA damage requires BRCA2, and BRCA2-deficient cells
exhibit genomic instability.
Despite only 5-10% of epithelial ovarian cancer has an inherited background, more than 90%
of hereditary ovarian tumors bear BRCA1/2 mutations. It has been described that these tumors
are generally of serous histology, and high-grade. They usually present at younger ages, and
more recently, it has been described that BRCA-mutated tumors have better prognosis.
[60,61,62]. It is relevant to note that up to 55% of sporadic epithelial ovarian tumors have some
sort of BRCA dysfunction. This has been named as BRCAness, and it may have important
clinical consequences. One of the reasons behind this better outcome relies on a higher
sensitivity to platinum compounds [63,64]. However, BRCA1/2-mutated also develop plati‐
num resistance. One possible explanation is in relation with the production of secondary
intragenic mutations in BRCA1/2 that restore these genetic expressions and HR function
correcting the open reading frames of mutated BRCA1/2 [65,66,67]. However BRCA1/2
restoration does not explain all cases of cisplatin resistance so investigations in other mecha‐
nisms of chemo-resistance in BRCA-deficient ovarian cancer cells are needed.
Recently, PARP inhibitors have been developed as an important novel strategy for the
treatment of BRCA mutation-associated ovarian and breast cancer. The rationale for this
approach is that by inhibiting BER, these agents can prevent repair that occurs after cytotoxic
chemotherapy that causes single-strand DNA breaks, and also they can work by creating
“synthetic lethality” in cells which have lost one mechanism of DNA repair. In the absence of
HR, inhibition of PARP results in poor repair of these lesions and apoptosis, increasing around
1000-fold the sensitivity in cells that are BRCA1 or BRCA2 deficient [68,69,70]. Although
olaparib and veliparib are the most widely studied in ovarian cancer [71,72,73,74,75], other
PARP inhibitors are in development such as BSI-201, AG014699, CEP9722, MK4827, E7016,
LT673, to name just a few.
5. Conclusion and future directions
Chemotherapy resistance is the ultimate reason for tumor recurrence. Relapsed ovarian cancer
is an incurable disease where chemotherapy plays a major therapeutic role. Platinum agents,
likely in conjunction with taxanes, are the most active cytotoxic drugs in ovarian cancer.
Traditionally, ovarian cancer recurrence has been classified according to the time elapsed from
the last dose of platinum. Thus, relapses occurring more than six months from the last dose of
platinum are generally re-treated with a platinum combination. Responses to a platinum
rechallenge tend to be similar to the initial response, and the longer the platinum-free interval
is the better the responses are. The so-called “platinum-sensitive” patients have better
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sections from 54 ovarian cancer patients before and after platinum-based therapy by using
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decreased significantly after platinum-based therapy. Hypermethylation of the MLH1
promoter has also been identified as a casual event in sporadic MMR-deficient malignant
tumors. In ovarian cancer, it is estimated that about 10% of cases are related to this molecular
pathway [53], although the methodology and definitions when assessing MSI in ovarian cancer
are heterogeneous and not prospectively validated. The frequency of MMR dysfunction seems
to vary depending on the histological subtype, being higher in endometrioid (19%) and
mucinous (17%) subtypes. It is an assumption that MMR deficiency might be a tumor-initiating
phenomenon in ovarian cancer, similar to colorectal and endometrial tumors. However, MMR
deficient ovarian cancers have been only poorly characterized to date with respect to their
epidemiological, molecular and clinical features.
Only a few studies have found a consistent relationship between MMR inactivation and
platinum-based chemotherapy resistance (primarily down-regulation or mutations in MMR
genes MLH1, MSH2 or MSH1) [50, 54,55,56].
This resistance to cisplatin can be circumvented using a DNA demethylating agent such as 2′-
deoxy-5-azacytidine (decitabine; Dacoge, MGI Pharma) in combination with cisplatin or
carboplatin to reverse this resistance mechanism [57]. Two phase II clinical trials have tested
the combination of carboplatin and decitabine in recurrent Platinum-resistant OC patients with
different conclusions [58,59].
4.3.3. Homologous recombination repair pathway
Platinum-based chemotherapy causes inter-strand DNA cross-linking which cause DNA
double-strand breaks (DSBs) during DNA replication. DSBs are one of the most toxic lesions
to DNA. This is because it affects both strands of the duplex, thus no intact complimentary
strand is available as a template for repair. When such lesions are not repaired the cell
undergoes apoptosis. If the reparation is not done appropriately, secondary lesions can occur,
such as mutations and/or deletions. Cells have evolved two major pathways for the repair of
DSBs: non-homologous end-joining (NHEJ) and homologous recombination (HR). The HR
system is the preferred system by cells when it comes to repair DSBs. It is a highly conserved
system, generally regarded as error-free, that requires an intact sister chromatid to act as
template for correct repair of the break without loss of sequence information. As such, HR
takes place in G2 and S phases of the cell cycle.
The BRCA1 gene is located on chromosome 17q21. The BRCA1 protein is a component of a
number of supercomplexes, each of which plays a role in DNA damage response activation,
cell cycle checkpoint activation and/or DSB repair. Some of the key components of this repair
process are proteins such as BRCA2, RAD51 and PALB2. Actually, the interaction between
specific domains of BRCA1 and PALB2 is key in the reparation of DBSs. Thus, mutations in
domains of BRCA1 can potentially abolish its PALB2-binding activity, resulting in compro‐
mised HR function. These mutations have been found in BRCA1-mutated tumors, implying
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tumorigenesis observed in this subset of BRCA1 mutation carriers.
The BRCA2 gene is located on chromosome 13q. The BRCA2 protein has its primary function
in HR and its based upon its ability to bind to the strand invasion recombinase, RAD51. In fact,
recruitment of RAD51 to sites of DNA damage requires BRCA2, and BRCA2-deficient cells
exhibit genomic instability.
Despite only 5-10% of epithelial ovarian cancer has an inherited background, more than 90%
of hereditary ovarian tumors bear BRCA1/2 mutations. It has been described that these tumors
are generally of serous histology, and high-grade. They usually present at younger ages, and
more recently, it has been described that BRCA-mutated tumors have better prognosis.
[60,61,62]. It is relevant to note that up to 55% of sporadic epithelial ovarian tumors have some
sort of BRCA dysfunction. This has been named as BRCAness, and it may have important
clinical consequences. One of the reasons behind this better outcome relies on a higher
sensitivity to platinum compounds [63,64]. However, BRCA1/2-mutated also develop plati‐
num resistance. One possible explanation is in relation with the production of secondary
intragenic mutations in BRCA1/2 that restore these genetic expressions and HR function
correcting the open reading frames of mutated BRCA1/2 [65,66,67]. However BRCA1/2
restoration does not explain all cases of cisplatin resistance so investigations in other mecha‐
nisms of chemo-resistance in BRCA-deficient ovarian cancer cells are needed.
Recently, PARP inhibitors have been developed as an important novel strategy for the
treatment of BRCA mutation-associated ovarian and breast cancer. The rationale for this
approach is that by inhibiting BER, these agents can prevent repair that occurs after cytotoxic
chemotherapy that causes single-strand DNA breaks, and also they can work by creating
“synthetic lethality” in cells which have lost one mechanism of DNA repair. In the absence of
HR, inhibition of PARP results in poor repair of these lesions and apoptosis, increasing around
1000-fold the sensitivity in cells that are BRCA1 or BRCA2 deficient [68,69,70]. Although
olaparib and veliparib are the most widely studied in ovarian cancer [71,72,73,74,75], other
PARP inhibitors are in development such as BSI-201, AG014699, CEP9722, MK4827, E7016,
LT673, to name just a few.
5. Conclusion and future directions
Chemotherapy resistance is the ultimate reason for tumor recurrence. Relapsed ovarian cancer
is an incurable disease where chemotherapy plays a major therapeutic role. Platinum agents,
likely in conjunction with taxanes, are the most active cytotoxic drugs in ovarian cancer.
Traditionally, ovarian cancer recurrence has been classified according to the time elapsed from
the last dose of platinum. Thus, relapses occurring more than six months from the last dose of
platinum are generally re-treated with a platinum combination. Responses to a platinum
rechallenge tend to be similar to the initial response, and the longer the platinum-free interval
is the better the responses are. The so-called “platinum-sensitive” patients have better
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prognosis than women whose relapse is shorter than six months. For this group of patients
therapeutic options are limited and usually consist in non-platinum agents.
The development of platinum resistance is a multifactorial and complex molecular process.
Understanding the molecular basis of this mechanism would help potentially in selecting
patients  who  are  likely  to  have  platinum-resistance  tumors  for  alternate  non-platinum
containing  regimens.  This  would  spare  women  from  unnecessary  toxic  effects  and
ineffective treatments. One potential scenario where the application of a molecular selection
of patients by platinum sensitivity would be at initial presentation. A substantial number
of advanced ovarian cancer patients undergo neoadjuvant chemotherapy prior to debulk‐
ing surgery. Such chemotherapy consists of platinum and a taxane doublet. Despite most
patients  do  have  a  major  response  to  primary  chemotherapy,  about  20-30%  fail  to  re‐
spond or progress.
The development of platinum resistance seems a dynamic process. Patients who initially
respond to platinum-based chemotherapy end up becoming resistant.  This suggests that
we may need to investigate the mechanisms at several time points of the disease course.
It  is  likely  that  primary  platinum resistance  is  a  molecular  phenomenon different  from
secondary  (and  subsequent)  platinum  resistance.  At  this  point,  it  is  key  that  reliable
biomarkers can be identified to better  define platinum resistance.  The quest  for  a  bona-
fide biomarker of platinum resistance in ovarian cancer has been so far disappointing. It
may  well  be  the  case  that  several  markers  need  to  be  jointly  studied,  since  platinum
resistance is not a one-step molecular event. Further validation in large (ideally prospec‐
tive)  cohorts  and in  randomized phase  III  trials  will  be  still  needed.  It  will  be  difficult
though to extrapolate results of platinum sensitivity when other agents are given concom‐
itantly.  It  is  not  possible  to  rule  out  the  potential  influence  of  cytotoxics  with  similar
mechanisms of action or biologics with the potential of modifying the tumor microenviron‐
ment.  Unraveling  the  mechanisms  of  resistance  to  platinum  (and  other  chemotherapy
agents) in ovarian cancer is a very difficult task. However, its potential clinical benefits are
worth such tremendous joint basic and clinical research effort.
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agents) in ovarian cancer is a very difficult task. However, its potential clinical benefits are
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1. Introduction
An apoptotic program is present in almost all cell types. Functional characterization of the
apoptotic cascade has revealed how the apoptotic program is activated in response to di‐
verse stresses such as DNA damage, signaling imbalance provoked by oncogene activation,
survival factors insufficiency or hypoxia. One of the hallmarks of tumor cells is their ability
to resist apoptosis. The concept that apoptosis serves as a barrier to cancer development has
been well established (Evan and Littlewood, 1998; Hengartner, 2000; Lowe et al., 2004;
Adams and Cory, 2007). This is especially relevant for ovarian cancer (OC) where most pa‐
tients presenting with advanced OC (most commonly high grade serous OC) will respond to
the initial chemotherapy treatment suggesting that most tumor cells present are sensitive to
chemotherapy. However, only 10-15% of these patients maintain a complete response to the
initial therapy implying that a fraction of the tumor cells escaped apoptosis induced by che‐
motherapeutic drugs. Thus, one of the main obstacles to an effective treatment in OC is the
failure of the initial chemotherapy to eradicate a sufficient number of tumor cells to prevent
disease recurrence. Attenuation of apoptosis in those tumor cells contributes to the resist‐
ance to subsequent therapy and likely plays an important role in OC progression.
This chapter focuses on the molecular pathways that lead to apoptotic resistance and the
need to move towards new targeted treatment in OC. Particular attention will be given to
the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling cascade.
TRAIL is a cytokine that triggers apoptosis in a wide variety of tumor cells with apparent
little effect on normal cells. We will discuss the various mechanisms that OC cells may de‐
velop to suppress TRAIL cytotoxicity. Furthermore, we will review the emerging TRAIL-tar‐
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geting strategies for treating OC and provide information about the latest clinical studies of
TRAIL agonists that are being conducted for the treatment of OC.
2. Treatment for ovarian cancer
Because of the limited efficacy of current treatments for advanced OC, novel and more effec‐
tive therapies are being investigated. An emerging option for the treatment of OC is the tar‐
geting of the TRAIL signaling cascade. Because of its unique ability to trigger apoptosis in
cancer cells and spare normal cells, in contrast to other cytokines such as FasL and TNFα,
TRAIL is an attractive and promising treatment for cancer therapy. Preclinical studies in
mice provided the first evidence that the soluble recombinant TRAIL suppresses the growth
of human tumor xenografts with no apparent systemic toxicity (Walczak et al., 1999; Ashke‐
nazi et al., 1999). More recently, recombinant TRAIL has entered clinical trials for the treat‐
ment of various malignancies (Ashkenazi, 2008; Ashkenazi et al., 2008; Abdulghani and El-
Deiry, 2010; Hellwig and Rehm, 2012). In addition to soluble TRAIL, several agonistic
antibodies targeting TRAIL R1 or TRAIL R2 death receptors have been developed and en‐
tered into clinical trials that included OC patients (Ashkenazi et al., 2008; Hellwig and
Rehm, 2012). As for standard chemotherapy, tumor cells have developed various mecha‐
nisms to escape the apoptosis induced by TRAIL. This underscores the need to understand
the mechanisms of TRAIL resistance, and based on this knowledge, identify and validate
novel combinations that could be used with TRAIL to potentiate its therapeutic efficacy. For
example, TRAIL resistance has been often associated with overexpression of anti-apoptotic
proteins. Therefore, the identification of combination treatments that abrogate anti-apoptotic
protein function is promising.
3. Apoptosis overview
Deregulation of the apoptotic cascade not only plays a key role in the pathogenesis and pro‐
gression of cancer, but also leads to resistance to chemotherapy. There are two major cellular
death pathways that transduce the effects of various death inducers: the extrinsic and the
intrinsic pathway (Figure 1). The extrinsic pathway is triggered when TRAIL binds to
TRAIL R1 or TRAIL R2. Receptor trimerization, along with the subsequent oligomerization
and clustering of the receptors, leads to the recruitment of the adaptor protein Fas-associat‐
ed protein with death domain (FADD). FADD allows the recruitment of the inactive pro-
caspase-8 or –caspase-10 via a shared death effector domain (DED) leading to the formation
of the death-inducing signaling complex (DISC). Depending on the cell type, apoptosis acti‐
vation through the extrinsic pathways may or may not depend on the intrinsic pathway. For
example, in type I cells, upon DISC activation, sufficient caspase-8 is activated and, in turn,
directly activates the effector caspases (caspase-3, -6, -7) leading to the execution of apopto‐
sis (Abdulghani and El-Deiry, 2010). FLICE-inhibitory protein (c-FLIP) shares structural ho‐
mology with pro-caspase-8 and possesses a death effector domain that lacks protease
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activity. In specific conditions, its structure allows c-FLIP to be recruited to the DISC where
it inhibits the processing and activation of pro-caspase-8. Although many isoforms of c-FLIP
have been identified, only three are expressed in human cells (Djerbi et al., 2001). They con‐
sist of two short variants, c-FLIPS and c-FLIPR, and a long splice variant, c-FLIPL. Both c-
FLIPL and c-FLIPS contain two DEDs and compete with pro-caspase-8 for association with
FADD (Bagnoli et al., 2010). Depending on the level of c-FLIPL expression, its function at the
DISC will vary. When present in high amounts, c-FLIPL will exert an anti-apoptotic effect at
the DISC (Krueger et al., 2001). When present in low amounts, it may heterodimerize with
caspase-8 at the DISC and promotes apoptosis (Chang et al., 2002). c-FLIP is thus seen as a
major inhibitor of the extrinsic pathway of apoptosis. In so-called type II cells, less caspase-8
is activated at the DISC and efficient apoptosis requires further signal amplification via the
intrinsic or mitochondrial pathway. This is achieved by caspase-8-mediated Bid cleavage to
generate a truncated form of Bid (tBid) which subsequently engages Bax/Bak to activate the
mitochondria.
The intrinsic pathway is usually triggered in response to DNA damage, hypoxia or onco‐
gene overexpression. As a sensor of cellular stress, p53 is a critical initiator of the intrinsic
pathway. In response to cellular damage, p53 translocates from the cytoplasm to the nucleus
where it promotes the transcription of pro-apoptotic members of the Bcl-2 family. Pro-apop‐
totic Bcl-2 family members Bax and Bak form pores in the outer mitochondrial membrane
causing the release of cytochrome c and other apoptogenic factors such as apoptosis induc‐
ing factor (AIF) and SMAC/DIABLO into the cytoplasm. The released of cytochrome c,
along with apoptosis protease activating factor-1 (APAF-1) and pro-caspase-9 form the
apoptosome. Within the apoptosome, clustered pro-caspase-9 gets activated and cleaves
downstream effector caspases, leading to the hallmark of apoptosis (Youle and Strasser,
2008; Brunelle and Letai, 2009). The release of SMAC/DIABLO from the mitochondria pro‐
motes apoptosis by binding to and neutralizing members of the family of inhibitor of apop‐
tosis proteins (IAPs), which can block caspase-3 activity through its baculovirus IAP repeat
domains. Although the extrinsic and intrinsic pathways are activated by different mecha‐
nisms, these two pathways are interconnected (Figure 1). In type II cells, activated caspase-8
cleaves pro-apoptotic Bcl-2 family member Bid to form truncated Bid (tBid), which can then
interact with Bax/Bak. This interaction increases the release of cytochrome c from the mito‐
chondria. Thus, Bid provides a connection between extrinsic and intrinsic pathways (so
called mitochondrial amplification loop). The reasons that determine whether tumor cells re‐
ly on type I or II signaling are not well understood but resistance has been attributed to dys‐
function of different steps in the TRAIL-induced apoptosis pathway and/or elevation of
survival signals (Zhang and Fang, 2005). In particular, it has been proposed that the levels of
c-FLIP and XIAP relative to caspase-8 and SMAC/DIABLO might be important determi‐
nants (Kim et al., 2000).
Bcl-2 family proteins are involved in the regulation of apoptosis by controlling mitochondri‐
al membrane permeability. Several studies have demonstrated that these proteins can inter‐
act with each other and these interactions can neutralize their pro- or anti-apoptotic
functions. The balance between anti- and pro-apoptotic members dictates the fate of cell sur‐
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geting strategies for treating OC and provide information about the latest clinical studies of
TRAIL agonists that are being conducted for the treatment of OC.
2. Treatment for ovarian cancer
Because of the limited efficacy of current treatments for advanced OC, novel and more effec‐
tive therapies are being investigated. An emerging option for the treatment of OC is the tar‐
geting of the TRAIL signaling cascade. Because of its unique ability to trigger apoptosis in
cancer cells and spare normal cells, in contrast to other cytokines such as FasL and TNFα,
TRAIL is an attractive and promising treatment for cancer therapy. Preclinical studies in
mice provided the first evidence that the soluble recombinant TRAIL suppresses the growth
of human tumor xenografts with no apparent systemic toxicity (Walczak et al., 1999; Ashke‐
nazi et al., 1999). More recently, recombinant TRAIL has entered clinical trials for the treat‐
ment of various malignancies (Ashkenazi, 2008; Ashkenazi et al., 2008; Abdulghani and El-
Deiry, 2010; Hellwig and Rehm, 2012). In addition to soluble TRAIL, several agonistic
antibodies targeting TRAIL R1 or TRAIL R2 death receptors have been developed and en‐
tered into clinical trials that included OC patients (Ashkenazi et al., 2008; Hellwig and
Rehm, 2012). As for standard chemotherapy, tumor cells have developed various mecha‐
nisms to escape the apoptosis induced by TRAIL. This underscores the need to understand
the mechanisms of TRAIL resistance, and based on this knowledge, identify and validate
novel combinations that could be used with TRAIL to potentiate its therapeutic efficacy. For
example, TRAIL resistance has been often associated with overexpression of anti-apoptotic
proteins. Therefore, the identification of combination treatments that abrogate anti-apoptotic
protein function is promising.
3. Apoptosis overview
Deregulation of the apoptotic cascade not only plays a key role in the pathogenesis and pro‐
gression of cancer, but also leads to resistance to chemotherapy. There are two major cellular
death pathways that transduce the effects of various death inducers: the extrinsic and the
intrinsic pathway (Figure 1). The extrinsic pathway is triggered when TRAIL binds to
TRAIL R1 or TRAIL R2. Receptor trimerization, along with the subsequent oligomerization
and clustering of the receptors, leads to the recruitment of the adaptor protein Fas-associat‐
ed protein with death domain (FADD). FADD allows the recruitment of the inactive pro-
caspase-8 or –caspase-10 via a shared death effector domain (DED) leading to the formation
of the death-inducing signaling complex (DISC). Depending on the cell type, apoptosis acti‐
vation through the extrinsic pathways may or may not depend on the intrinsic pathway. For
example, in type I cells, upon DISC activation, sufficient caspase-8 is activated and, in turn,
directly activates the effector caspases (caspase-3, -6, -7) leading to the execution of apopto‐
sis (Abdulghani and El-Deiry, 2010). FLICE-inhibitory protein (c-FLIP) shares structural ho‐
mology with pro-caspase-8 and possesses a death effector domain that lacks protease
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activity. In specific conditions, its structure allows c-FLIP to be recruited to the DISC where
it inhibits the processing and activation of pro-caspase-8. Although many isoforms of c-FLIP
have been identified, only three are expressed in human cells (Djerbi et al., 2001). They con‐
sist of two short variants, c-FLIPS and c-FLIPR, and a long splice variant, c-FLIPL. Both c-
FLIPL and c-FLIPS contain two DEDs and compete with pro-caspase-8 for association with
FADD (Bagnoli et al., 2010). Depending on the level of c-FLIPL expression, its function at the
DISC will vary. When present in high amounts, c-FLIPL will exert an anti-apoptotic effect at
the DISC (Krueger et al., 2001). When present in low amounts, it may heterodimerize with
caspase-8 at the DISC and promotes apoptosis (Chang et al., 2002). c-FLIP is thus seen as a
major inhibitor of the extrinsic pathway of apoptosis. In so-called type II cells, less caspase-8
is activated at the DISC and efficient apoptosis requires further signal amplification via the
intrinsic or mitochondrial pathway. This is achieved by caspase-8-mediated Bid cleavage to
generate a truncated form of Bid (tBid) which subsequently engages Bax/Bak to activate the
mitochondria.
The intrinsic pathway is usually triggered in response to DNA damage, hypoxia or onco‐
gene overexpression. As a sensor of cellular stress, p53 is a critical initiator of the intrinsic
pathway. In response to cellular damage, p53 translocates from the cytoplasm to the nucleus
where it promotes the transcription of pro-apoptotic members of the Bcl-2 family. Pro-apop‐
totic Bcl-2 family members Bax and Bak form pores in the outer mitochondrial membrane
causing the release of cytochrome c and other apoptogenic factors such as apoptosis induc‐
ing factor (AIF) and SMAC/DIABLO into the cytoplasm. The released of cytochrome c,
along with apoptosis protease activating factor-1 (APAF-1) and pro-caspase-9 form the
apoptosome. Within the apoptosome, clustered pro-caspase-9 gets activated and cleaves
downstream effector caspases, leading to the hallmark of apoptosis (Youle and Strasser,
2008; Brunelle and Letai, 2009). The release of SMAC/DIABLO from the mitochondria pro‐
motes apoptosis by binding to and neutralizing members of the family of inhibitor of apop‐
tosis proteins (IAPs), which can block caspase-3 activity through its baculovirus IAP repeat
domains. Although the extrinsic and intrinsic pathways are activated by different mecha‐
nisms, these two pathways are interconnected (Figure 1). In type II cells, activated caspase-8
cleaves pro-apoptotic Bcl-2 family member Bid to form truncated Bid (tBid), which can then
interact with Bax/Bak. This interaction increases the release of cytochrome c from the mito‐
chondria. Thus, Bid provides a connection between extrinsic and intrinsic pathways (so
called mitochondrial amplification loop). The reasons that determine whether tumor cells re‐
ly on type I or II signaling are not well understood but resistance has been attributed to dys‐
function of different steps in the TRAIL-induced apoptosis pathway and/or elevation of
survival signals (Zhang and Fang, 2005). In particular, it has been proposed that the levels of
c-FLIP and XIAP relative to caspase-8 and SMAC/DIABLO might be important determi‐
nants (Kim et al., 2000).
Bcl-2 family proteins are involved in the regulation of apoptosis by controlling mitochondri‐
al membrane permeability. Several studies have demonstrated that these proteins can inter‐
act with each other and these interactions can neutralize their pro- or anti-apoptotic
functions. The balance between anti- and pro-apoptotic members dictates the fate of cell sur‐
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vival or death. Pro-apoptotic Bcl-2 members can be divided into 2 groups according to their
function and the number of BH domains that they possess. Proteins containing BH domains
1-3 are known as multidomain pro-apoptotic proteins such as Bax, Bak and Bok (Youle and
Strasser, 2008). BH-3-only pro-apoptotic proteins such as Bik, Bid, Bad, Bim, Bmf, Noxa, Pu‐
ma and others can form heterodimers with the multidomain proteins Bax and Bak leading to
the activation of the mitochondria. Anti-apoptotic proteins such as Bcl-2, Bcl-XL and Mcl-1
can also form hetero-dimeric interactions with Bax and Bak, thereby neutralizing their pro-
apoptotic activity. Anti-apoptotic proteins can form hetero-dimers with BH-3-only proteins
and this interaction neutralizes the pro-survival function of anti-apoptotic proteins.
4. TRAIL and its receptors
TRAIL is a member of the TNF ligand superfamily of cytokines and is a type II transmem‐
brane protein, which is anchored to the plasma membrane and presented to the cell surface.
The extracellular domain of TRAIL can be shed from the cell surface by cysteine proteases to
produce soluble TRAIL. Both the soluble and the membrane-bounded TRAIL can trigger
apoptosis by interacting with its cognate death receptors expressed by target cells. Of the
five human TRAIL receptors that have been identified, both TRAIL R1 (DR4) and TRAIL R2
(DR5) contain a functional death domain in their intracellular portion, unlike decoy recep‐
tors TRAIL R3 (DcR1) and TRAIL R4 (DcR2), which lack a functional death domain and are
thus incapable of transmitting an apoptotic signal (Pan et al., 1997a; Pan et al., 1997b; Sheri‐
dan et al., 1997; Marsters et al., 1997). Soluble TRAIL also binds with low affinity to soluble
osteoprotegerin (OPG), which is a decoy receptor for RANKL that blocks the RANK-
RANKL interaction (Hofbauer et al., 2000). OPG negatively regulates osteoclastogenesis and
soluble OPG can act as a scavenger for soluble TRAIL and therefore inhibits TRAIL-induced
apoptosis (Vitovski et al., 2007).
5. Expression of apoptosis-related proteins in ovarian cancer
Because the susceptibility of tumor cells to apoptosis appears to be determined, at least in
part, by the ratio between pro- and anti-apoptotic proteins, the expression pattern of anti-
apoptotic proteins, Bcl-2, Bcl-XL and Mcl-1 has been assessed in OC tissues. For example,
higher Bcl-2 expression has been generally associated with a favorable outcome in OC (Hen‐
riksen et al., 1995; Herod et al., 1996; Marx et al., 1997; Marone et al., 1998). This apparent
paradox may be explained by the observation that high Bcl-2 expression delays cell cycle
progression by promoting accumulation of cells in S phases without affecting the rate of
apoptosis in OC cells (Bélanger et al., 2005). Bcl-XL expression is generally higher in OC tis‐
sues when compared to normal tissues (Marone et al., 1998) but has not been consistently
associated with worse outcome (Shigemasa et al., 2002; Williams et al., 2005). This could be
related to the observation that the ability of Bcl-XL to attenuate apoptosis appears to be cell
context-dependent in OC (Dodier and Piché, 2006). In at least one study, increased Mcl-1 ex‐
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pression has been correlated with poor prognostic for patients with OC (Shigemasa et al.,
2002). Elevated expression of c-FLIPL has been reported in a substantial percentage of OC
tissues from patients with advanced diseases (Mezzanzanica et al., 2004; Horak et al., 2005a)
and has been associated with adverse outcome in some studies (Ouellet et al, 2007; Bagnoli
et al., 2009) whereas others have found no such association (Duiker et al., 2010).
In patients with OC, high TRAIL expression in either tumor or stromal cells is a predictor of
overall survival (Lancaster et al., 2003; Horak et al., 2005a). Interestingly in Horak’s study,
almost 50% of the tumor analyzed expressed elevated level of c-FLIPL and about 80% of tu‐
mors displayed low expression of TRAIL R1 and/or TRAIL R2, which could contribute to
protect OC cells from TRAIL-induced apoptosis. Loss of TRAIL expression has been associ‐
ated with worse outcome (Duiker et al., 2010). Furthermore, this group reported that epige‐
netic silencing of TRAIL R1 occurred in 8% to 27% OC tumor samples (Horak et al., 2005b).
Higher expression of TRAIL receptors in OC cells has been associated with a worse outcome
(Ouellet et al., 2007; Dong et al., 2008) but other studies have found no correlation between
TRAIL R1 or TRAIL R2 expression and survival (Duiker et al., 2010).
6. Resistance in OC cells
The mechanisms of resistance to TRAIL can be divided into three categories based on their
mode of acquisition: intrinsic resistance, acquired resistance and environment-mediated re‐
sistance (Goncharenko-Khaider et al., 2012). Each of them will be discussed separately.
6.1. Intrinsic resistance
Intrinsic resistance is observed when tumor cells are resistant to a specific drug without pre‐
vious exposure to this drug. The incidence of intrinsic resistance to TRAIL among patients
presenting with OC is not known but intrinsic TRAIL resistance among OC cell lines and
primary OC cells is roughly 50% (Cuello et al., 2001a; Vignati et al., 2002; Siervo-Sassi et al.,
2003; Lane et al., 2004). Multiple mechanisms have been described for intrinsic TRAIL resist‐
ance in OC cells because the susceptibility to TRAIL-induced apoptosis can be regulated at
multiple levels in the apoptotic signaling cascade. The loss of TRAIL R1 expression by epi‐
genetic silencing correlated with resistance to TRAIL-induced apoptosis in OC cells (Horak
et al., 2005b). Aberrant methylation of TRAIL receptors has been reported in up to 40% of
OC tumors (Shivapurkar et al., 2004). Despite these observations in OC tissues, the levels of
TRAIL receptors or decoy receptors do not usually correlate with sensitivity or resistance to
TRAIL in OC cell lines (Cuello et al., 2001a; Vignati et al., 2002; Lane et al., 2004). However,
the modulation of TRAIL receptors expression may sensitize tumor cells to TRAIL. For ex‐
ample, celestrol-induced upregulation of TRAIL R1 and TRAIL R2 enhances TRAIL-induced
apoptosis (Zhu et al., 2010).
As mentioned earlier, c-FLIP is an important modulator of TRAIL sensitivity. Therefore, it is
not surprising that c-FLIP overexpression has been associated with intrinsic TRAIL resist‐
ance in OC cells. A number of studies have demonstrated that the down-regulation of c-
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vival or death. Pro-apoptotic Bcl-2 members can be divided into 2 groups according to their
function and the number of BH domains that they possess. Proteins containing BH domains
1-3 are known as multidomain pro-apoptotic proteins such as Bax, Bak and Bok (Youle and
Strasser, 2008). BH-3-only pro-apoptotic proteins such as Bik, Bid, Bad, Bim, Bmf, Noxa, Pu‐
ma and others can form heterodimers with the multidomain proteins Bax and Bak leading to
the activation of the mitochondria. Anti-apoptotic proteins such as Bcl-2, Bcl-XL and Mcl-1
can also form hetero-dimeric interactions with Bax and Bak, thereby neutralizing their pro-
apoptotic activity. Anti-apoptotic proteins can form hetero-dimers with BH-3-only proteins
and this interaction neutralizes the pro-survival function of anti-apoptotic proteins.
4. TRAIL and its receptors
TRAIL is a member of the TNF ligand superfamily of cytokines and is a type II transmem‐
brane protein, which is anchored to the plasma membrane and presented to the cell surface.
The extracellular domain of TRAIL can be shed from the cell surface by cysteine proteases to
produce soluble TRAIL. Both the soluble and the membrane-bounded TRAIL can trigger
apoptosis by interacting with its cognate death receptors expressed by target cells. Of the
five human TRAIL receptors that have been identified, both TRAIL R1 (DR4) and TRAIL R2
(DR5) contain a functional death domain in their intracellular portion, unlike decoy recep‐
tors TRAIL R3 (DcR1) and TRAIL R4 (DcR2), which lack a functional death domain and are
thus incapable of transmitting an apoptotic signal (Pan et al., 1997a; Pan et al., 1997b; Sheri‐
dan et al., 1997; Marsters et al., 1997). Soluble TRAIL also binds with low affinity to soluble
osteoprotegerin (OPG), which is a decoy receptor for RANKL that blocks the RANK-
RANKL interaction (Hofbauer et al., 2000). OPG negatively regulates osteoclastogenesis and
soluble OPG can act as a scavenger for soluble TRAIL and therefore inhibits TRAIL-induced
apoptosis (Vitovski et al., 2007).
5. Expression of apoptosis-related proteins in ovarian cancer
Because the susceptibility of tumor cells to apoptosis appears to be determined, at least in
part, by the ratio between pro- and anti-apoptotic proteins, the expression pattern of anti-
apoptotic proteins, Bcl-2, Bcl-XL and Mcl-1 has been assessed in OC tissues. For example,
higher Bcl-2 expression has been generally associated with a favorable outcome in OC (Hen‐
riksen et al., 1995; Herod et al., 1996; Marx et al., 1997; Marone et al., 1998). This apparent
paradox may be explained by the observation that high Bcl-2 expression delays cell cycle
progression by promoting accumulation of cells in S phases without affecting the rate of
apoptosis in OC cells (Bélanger et al., 2005). Bcl-XL expression is generally higher in OC tis‐
sues when compared to normal tissues (Marone et al., 1998) but has not been consistently
associated with worse outcome (Shigemasa et al., 2002; Williams et al., 2005). This could be
related to the observation that the ability of Bcl-XL to attenuate apoptosis appears to be cell
context-dependent in OC (Dodier and Piché, 2006). In at least one study, increased Mcl-1 ex‐
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pression has been correlated with poor prognostic for patients with OC (Shigemasa et al.,
2002). Elevated expression of c-FLIPL has been reported in a substantial percentage of OC
tissues from patients with advanced diseases (Mezzanzanica et al., 2004; Horak et al., 2005a)
and has been associated with adverse outcome in some studies (Ouellet et al, 2007; Bagnoli
et al., 2009) whereas others have found no such association (Duiker et al., 2010).
In patients with OC, high TRAIL expression in either tumor or stromal cells is a predictor of
overall survival (Lancaster et al., 2003; Horak et al., 2005a). Interestingly in Horak’s study,
almost 50% of the tumor analyzed expressed elevated level of c-FLIPL and about 80% of tu‐
mors displayed low expression of TRAIL R1 and/or TRAIL R2, which could contribute to
protect OC cells from TRAIL-induced apoptosis. Loss of TRAIL expression has been associ‐
ated with worse outcome (Duiker et al., 2010). Furthermore, this group reported that epige‐
netic silencing of TRAIL R1 occurred in 8% to 27% OC tumor samples (Horak et al., 2005b).
Higher expression of TRAIL receptors in OC cells has been associated with a worse outcome
(Ouellet et al., 2007; Dong et al., 2008) but other studies have found no correlation between
TRAIL R1 or TRAIL R2 expression and survival (Duiker et al., 2010).
6. Resistance in OC cells
The mechanisms of resistance to TRAIL can be divided into three categories based on their
mode of acquisition: intrinsic resistance, acquired resistance and environment-mediated re‐
sistance (Goncharenko-Khaider et al., 2012). Each of them will be discussed separately.
6.1. Intrinsic resistance
Intrinsic resistance is observed when tumor cells are resistant to a specific drug without pre‐
vious exposure to this drug. The incidence of intrinsic resistance to TRAIL among patients
presenting with OC is not known but intrinsic TRAIL resistance among OC cell lines and
primary OC cells is roughly 50% (Cuello et al., 2001a; Vignati et al., 2002; Siervo-Sassi et al.,
2003; Lane et al., 2004). Multiple mechanisms have been described for intrinsic TRAIL resist‐
ance in OC cells because the susceptibility to TRAIL-induced apoptosis can be regulated at
multiple levels in the apoptotic signaling cascade. The loss of TRAIL R1 expression by epi‐
genetic silencing correlated with resistance to TRAIL-induced apoptosis in OC cells (Horak
et al., 2005b). Aberrant methylation of TRAIL receptors has been reported in up to 40% of
OC tumors (Shivapurkar et al., 2004). Despite these observations in OC tissues, the levels of
TRAIL receptors or decoy receptors do not usually correlate with sensitivity or resistance to
TRAIL in OC cell lines (Cuello et al., 2001a; Vignati et al., 2002; Lane et al., 2004). However,
the modulation of TRAIL receptors expression may sensitize tumor cells to TRAIL. For ex‐
ample, celestrol-induced upregulation of TRAIL R1 and TRAIL R2 enhances TRAIL-induced
apoptosis (Zhu et al., 2010).
As mentioned earlier, c-FLIP is an important modulator of TRAIL sensitivity. Therefore, it is
not surprising that c-FLIP overexpression has been associated with intrinsic TRAIL resist‐
ance in OC cells. A number of studies have demonstrated that the down-regulation of c-
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FLIPL (through different means) enhances TRAIL-induced apoptosis in resistant OC cells
(Lane et al., 2004; Clarke et al., 2007; Syed et al. 2007; Park et al., 2009). In addition, the
knockdown of c-FLIPL inhibited human OC cell lines migratory phenotype in a TRAIL-de‐
pendent manner in vitro and inhibited the invasion of tumor cells into the peritoneal cavity
(El-Gazzar et al., 2010a).
Activation of the PI3K/Akt promotes cell survival and resistance to chemotherapy in OC
cells (Fraser et al., 2008; Abedini et al., 2010). The constitutive activation of Akt in OC cell
lines and primary tumor cells also promotes resistance to TRAIL (Goncharenko-Khaider et
al., 2010). There is a close correlation between the activation of Akt in OC cells and the de‐
gree of resistance to TRAIL (Goncharenko-Khaider et al., 2010; Lane et al., 2010). The inhibi‐
tion of Akt phosphorylation reversed cellular resistance to TRAIL whereas the transfection
of Akt in tumor cells with low Akt basal activity enhanced TRAIL resistance (Goncharenko-
Khaider et al., 2010). Akt confers resistance, in part, by modulating TRAIL-induced Bid
cleavage (Goncharenko-Khaider et al., 2010). The role of Akt in TRAIL resistance among OC
cells is also supported by the observation that the inhibition of Akt activation by trastuzu‐
mab (Cuello et al., 2001b), an ErbB2 receptor inhibitor, or by a small molecule that inhibits
hPEBP4 (Qiu et al., 2010), enhanced TRAIL-induced apoptosis.
TRAIL triggers changes in mitochondrial membrane permeability which results in the re‐
lease of pro-apoptotic proteins such as cytochrome c and SMAC/DIABLO from the mito‐
chondria. In a cohort of 75 patients, Mao et al. demonstrated decreased expression of SMAC/
DIABLO and increased expression of XIAP in OC compared to normal ovarian tissues (Mao
et al., 2007). However, they observed no difference in SMAC/DIABLO and XIAP expression
between TRAIL sensitive and resistant cell lines. To assess the biological relevance of these
observations, they stably transfected TRAIL resistant OC cell lines with a SMAC/DIABLO
expression vector and showed enhanced TRAIL-induced apoptosis in transfected cells. Simi‐
larly, the treatment of TRAIL resistant OC cells with a small molecule SMAC/DIABLO mim‐
ic enhanced TRAIL- and TRAIL R1 or R2 agonist-induced apoptosis (Petrucci et al., 2007).
Others have found a lack of correlation between XIAP protein expression and TRAIL sensi‐
tivity (Goncharenko-Khaider et al., 2010). Furthermore, down-regulation of XIAP in TRAIL
resistant OC cells failed to enhance TRAIL-induced apoptosis (Goncharenko-Khaider et al.,
2010) suggesting that XIAP is not a major factor contributing to TRAIL resistance in OC.
In summary, intrinsic TRAIL resistance appears to be multi-factorial and can be influenced
by the activation of survival pathways such as Akt. In this context, the identification of in‐
formative and validated biomarkers of TRAIL resistance will be important for selecting pa‐
tients and predicting the clinical outcome.
6.2. Acquired resistance
Acquired resistance is a mechanism by which tumor cells that were initially sensitive to a
drug adapted to survive to prolonged exposure to this drug. Acquired drug resistance con‐
stitutes a major problem in the management of OC. This type of resistance is believed to be
caused by sequential genetic alterations in tumor cells often associated with sub-lethal expo‐
sure to apoptosis-inducing drugs that eventually result in a therapy-resistant phenotype.
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For example, in an OC cell line model, resistance to the anti-TRAIL-R2 antibody TRA-8 was
induced by repeated exposure to non-apoptosis-inducing doses of the antibody (Li et al.,
2006). Interestingly, the apoptotic responses induced by TRAIL, a TRAIL-R1 agonist anti‐
body (2E12), and other apoptotic stimuli were not impaired. Lane et al. demonstrated that
TRAIL acquired resistance was due to a rapid degradation of active caspase-3 subunits by
the proteasome in the TRAIL resistant variant OC cells OVCAR3 (Lane et al., 2006). Interest‐
ingly, TRAIL resistant OVCAR3 cells remained sensitive to chemotherapeutic drugs.
One reassuring finding of these studies in OC and other in different tumor types is the fact
that acquired TRAIL resistance does not confer cross-resistance to chemotherapeutic drugs
such as cisplatin. In fact, combining standard chemotherapy with TRAIL treatment appears
to be beneficial because treatment with platinum compounds upregulates the expression of
TRAIL death receptors regardless of the p53 status which leads to increase apoptosis in OC
cells (El-Gazzar et al., 2010b).
6.3. Environment-mediated resistance
Environment-mediated drug resistance (de novo resistance) is a form of resistance by which
tumor cells are transiently protected from drug-induced apoptosis via the induction of sur‐
vival signaling pathways (Meads et al., 2009). Soluble factors in the tumor environment may
engage cell surface receptor to activate survival pathways. Evidence is accumulating that the
tumor environment affects both tumor progression and response to chemotherapy in OC.
The accumulation of peritoneal fluid that develops during OC progression, which contains a
large mass of the tumor cells, represents a unique form of tumor environment. The floating
malignant cells are capable of surviving and proliferating despite lacking immediate prox‐
imity to blood vessels presumably due to the permissive attributes of this environment.
There are several indirect evidences to suggest that ascites alter drug resistance in tumor
cells. Proteomic profiling of tumor cells from ascites before and after chemotherapy showed
an increase in the activation of survival pathways such as Akt pathway (Davidson et al.,
2006). Moreover, OC ascites attenuate TRAIL and drug-induced apoptosis in vitro (Lane et
al., 2007; Lane et al., 2010a; Lane et al., 2010b). OC ascites contains significant levels of bioac‐
tive lipids such as lysophosphatidic acid (LPA), which exceed levels required to activate
LPA receptors (Yamada et al., 2004; Lane et al., 2010a). LPA, one of the ligands of G-protein
coupled receptors, has been shown to induce cell survival signaling pathways through dif‐
ferent mechanisms including PI3K/Akt activation and regulation of DR4 and c-FLIP (Tanyi
et al., 2003; Kang et al., 2004; Ishdorj et al., 2008). Furthermore, LPA inhibits cisplatin-in‐
duced apoptosis (Tanyi et al., 2003). The role of LPA, as a component of ascites, in modulat‐
ing drug resistance in OC cells remains however uncertain. For example, the blockade of
LPA cascade did not altered TRAIL-induced apoptosis in OC cells (Lane et al., 2010a) and
incubation of OC cells with LPA did not protect them from TRAIL-induced apoptosis (Lane
et al., 2010).
A wide variety of cytokines can be measured in OC ascites and interleukin-6 (IL-6) and
interleukin-8 (IL-8) are among the most abundant (Giuntoli et al., 2009; Lane et al., 2011;
Matte et al., 2012). A number of studies have reported an association between serum lev‐
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FLIPL (through different means) enhances TRAIL-induced apoptosis in resistant OC cells
(Lane et al., 2004; Clarke et al., 2007; Syed et al. 2007; Park et al., 2009). In addition, the
knockdown of c-FLIPL inhibited human OC cell lines migratory phenotype in a TRAIL-de‐
pendent manner in vitro and inhibited the invasion of tumor cells into the peritoneal cavity
(El-Gazzar et al., 2010a).
Activation of the PI3K/Akt promotes cell survival and resistance to chemotherapy in OC
cells (Fraser et al., 2008; Abedini et al., 2010). The constitutive activation of Akt in OC cell
lines and primary tumor cells also promotes resistance to TRAIL (Goncharenko-Khaider et
al., 2010). There is a close correlation between the activation of Akt in OC cells and the de‐
gree of resistance to TRAIL (Goncharenko-Khaider et al., 2010; Lane et al., 2010). The inhibi‐
tion of Akt phosphorylation reversed cellular resistance to TRAIL whereas the transfection
of Akt in tumor cells with low Akt basal activity enhanced TRAIL resistance (Goncharenko-
Khaider et al., 2010). Akt confers resistance, in part, by modulating TRAIL-induced Bid
cleavage (Goncharenko-Khaider et al., 2010). The role of Akt in TRAIL resistance among OC
cells is also supported by the observation that the inhibition of Akt activation by trastuzu‐
mab (Cuello et al., 2001b), an ErbB2 receptor inhibitor, or by a small molecule that inhibits
hPEBP4 (Qiu et al., 2010), enhanced TRAIL-induced apoptosis.
TRAIL triggers changes in mitochondrial membrane permeability which results in the re‐
lease of pro-apoptotic proteins such as cytochrome c and SMAC/DIABLO from the mito‐
chondria. In a cohort of 75 patients, Mao et al. demonstrated decreased expression of SMAC/
DIABLO and increased expression of XIAP in OC compared to normal ovarian tissues (Mao
et al., 2007). However, they observed no difference in SMAC/DIABLO and XIAP expression
between TRAIL sensitive and resistant cell lines. To assess the biological relevance of these
observations, they stably transfected TRAIL resistant OC cell lines with a SMAC/DIABLO
expression vector and showed enhanced TRAIL-induced apoptosis in transfected cells. Simi‐
larly, the treatment of TRAIL resistant OC cells with a small molecule SMAC/DIABLO mim‐
ic enhanced TRAIL- and TRAIL R1 or R2 agonist-induced apoptosis (Petrucci et al., 2007).
Others have found a lack of correlation between XIAP protein expression and TRAIL sensi‐
tivity (Goncharenko-Khaider et al., 2010). Furthermore, down-regulation of XIAP in TRAIL
resistant OC cells failed to enhance TRAIL-induced apoptosis (Goncharenko-Khaider et al.,
2010) suggesting that XIAP is not a major factor contributing to TRAIL resistance in OC.
In summary, intrinsic TRAIL resistance appears to be multi-factorial and can be influenced
by the activation of survival pathways such as Akt. In this context, the identification of in‐
formative and validated biomarkers of TRAIL resistance will be important for selecting pa‐
tients and predicting the clinical outcome.
6.2. Acquired resistance
Acquired resistance is a mechanism by which tumor cells that were initially sensitive to a
drug adapted to survive to prolonged exposure to this drug. Acquired drug resistance con‐
stitutes a major problem in the management of OC. This type of resistance is believed to be
caused by sequential genetic alterations in tumor cells often associated with sub-lethal expo‐
sure to apoptosis-inducing drugs that eventually result in a therapy-resistant phenotype.
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For example, in an OC cell line model, resistance to the anti-TRAIL-R2 antibody TRA-8 was
induced by repeated exposure to non-apoptosis-inducing doses of the antibody (Li et al.,
2006). Interestingly, the apoptotic responses induced by TRAIL, a TRAIL-R1 agonist anti‐
body (2E12), and other apoptotic stimuli were not impaired. Lane et al. demonstrated that
TRAIL acquired resistance was due to a rapid degradation of active caspase-3 subunits by
the proteasome in the TRAIL resistant variant OC cells OVCAR3 (Lane et al., 2006). Interest‐
ingly, TRAIL resistant OVCAR3 cells remained sensitive to chemotherapeutic drugs.
One reassuring finding of these studies in OC and other in different tumor types is the fact
that acquired TRAIL resistance does not confer cross-resistance to chemotherapeutic drugs
such as cisplatin. In fact, combining standard chemotherapy with TRAIL treatment appears
to be beneficial because treatment with platinum compounds upregulates the expression of
TRAIL death receptors regardless of the p53 status which leads to increase apoptosis in OC
cells (El-Gazzar et al., 2010b).
6.3. Environment-mediated resistance
Environment-mediated drug resistance (de novo resistance) is a form of resistance by which
tumor cells are transiently protected from drug-induced apoptosis via the induction of sur‐
vival signaling pathways (Meads et al., 2009). Soluble factors in the tumor environment may
engage cell surface receptor to activate survival pathways. Evidence is accumulating that the
tumor environment affects both tumor progression and response to chemotherapy in OC.
The accumulation of peritoneal fluid that develops during OC progression, which contains a
large mass of the tumor cells, represents a unique form of tumor environment. The floating
malignant cells are capable of surviving and proliferating despite lacking immediate prox‐
imity to blood vessels presumably due to the permissive attributes of this environment.
There are several indirect evidences to suggest that ascites alter drug resistance in tumor
cells. Proteomic profiling of tumor cells from ascites before and after chemotherapy showed
an increase in the activation of survival pathways such as Akt pathway (Davidson et al.,
2006). Moreover, OC ascites attenuate TRAIL and drug-induced apoptosis in vitro (Lane et
al., 2007; Lane et al., 2010a; Lane et al., 2010b). OC ascites contains significant levels of bioac‐
tive lipids such as lysophosphatidic acid (LPA), which exceed levels required to activate
LPA receptors (Yamada et al., 2004; Lane et al., 2010a). LPA, one of the ligands of G-protein
coupled receptors, has been shown to induce cell survival signaling pathways through dif‐
ferent mechanisms including PI3K/Akt activation and regulation of DR4 and c-FLIP (Tanyi
et al., 2003; Kang et al., 2004; Ishdorj et al., 2008). Furthermore, LPA inhibits cisplatin-in‐
duced apoptosis (Tanyi et al., 2003). The role of LPA, as a component of ascites, in modulat‐
ing drug resistance in OC cells remains however uncertain. For example, the blockade of
LPA cascade did not altered TRAIL-induced apoptosis in OC cells (Lane et al., 2010a) and
incubation of OC cells with LPA did not protect them from TRAIL-induced apoptosis (Lane
et al., 2010).
A wide variety of cytokines can be measured in OC ascites and interleukin-6 (IL-6) and
interleukin-8 (IL-8) are among the most abundant (Giuntoli et al., 2009; Lane et al., 2011;
Matte et al., 2012). A number of studies have reported an association between serum lev‐
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els of  IL-6 and prognosis,  where elevated levels correlated with a poor relapse-free and
overall survival (Plante et al., 1994; Scambia et al., 1995; Tempfer et al., 1997). Interesting‐
ly, it was recently shown that elevated ascites levels of IL-6, but not IL-8, were an inde‐
pendent predictor of shorter progression-free survival (Lane et al., 2011). Whether IL-6 is
a critical soluble factor in ascites-mediated TRAIL resistance is unclear but a recent study
suggests that IL-6 may indeed be an important component of the tumor environment that
support tumor growth (Kulbe et al., 2012). Recently, high levels of IL-10, OPG and leptin
in ascites  were found to correlate  with shorter  PFS (Matte  et  al.,  2012).  Furthermore,  in
this study, Il-10 neutralizing antibodies attenuated the protective effect of ascites against
TRAIL-induced apoptosis  suggesting that  IL-10 is  one of  the factors  in  ascites  that  pro‐
mote ascites-induced TRAIL resistance.
The role of integrins in mediating cell proliferation, migration and survival in ovarian can‐
cer is well established (Carreiras et al., 1999; Cruet-Hennequart et al., 2003; Lane et al., 2008).
Integrins transmit signals directly through ligation-dependent recruitment of non-receptor
tyrosine kinases from the focal adhesion kinase (FAK) leading to the activation of several
cell signaling pathways including the PI3K/Akt pathway (Stupack and Cheresh, 2002). Re‐
cently, it has been shown that the PI3K/Akt cascade is activated by OC ascites (Lane et al.,
2010a). The ability of different ascites to induce Akt phosphorylation in tumor cells strongly
correlates with their ability to inhibit TRAIL-induced apoptosis. The PI3K/Akt pathway
most likely couples signals from ascites-activated cell surface receptors which regulate the
expression and/or phosphorylation of apoptosis-regulating targets. Ascites-induced activa‐
tion of αvβ5 integrins leads to focal adhesion kinase (FAK) phosphorylation and FAK indu‐
ces the activation of Akt (Lane et al., 2010a). This leads to Akt-mediated up-regulation of c-
FLIPs expression in ovarian cancer cells (Lane et al., 2007).
Collectively, these data support the role of ascites to promote resistance to TRAIL-induced
apoptosis, at least in vitro. Whether this is relevant in vivo remains unclear for the moment.
However, the prosurvival activity of ascites against TRAIL-induced apoptosis has been as‐
sociated with shorter PFS in women with OC suggesting that ascites-mediated resistance
might be clinically relevant (Lane et al., 2010b).
7. TRAIL targeting agents
Different strategies have been used to activate the TRAIL signaling pathway in cancer thera‐
py. A variety of recombinant forms of soluble TRAIL have been developed and fused with
different tags (Pitti et al., 1996; Schneider et al., 2000; Ganten et al., 2006). Major limitations
however of recombinant soluble TRAIL (rsTRAIL) include the short half-life in vivo and rela‐
tive lack of specificity as rsTRAIL can also bind decoy receptors TRAIL R3 and TRAIL R4.
Despite these potential limitations, rsTRAIL (dulanermin) has entered phase I and phase II
clinical trials. Alternatively, various humanized TRAIL receptor agonist antibodies have
been developed which target TRAIL R1 (Mapatumumab) or TRAIL R2 (Apomab, Conatu‐
mumab, Lexatumumab, Tigatuzumab and LBY-135), and are currently being evaluated clin‐
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ically (Table 1). These antibodies have a significantly increased half-life and consequently
their bioavailability is increased at the tumor site.
Name Targets Compagny Clinical stage
development
Apomab/Drozitumab (PRO95780)
(human monoclonal antibody agonist)
TRAIL R2 Genetech Phase II
Conatumumab (AMG 655)
(human monoclonal antibody agonist)








TRAIL R2 Human Genome
Sciences
Phase I




(humanized monoclonal antibody agonist)
TRAIL R2 Daiichi Sankyo Phase I/II
LBY-135
(humanized monoclonal antibody agonist)
TRAIL R2 Novartis Phase I
Table 1. TRAIL-targeting agents
8. Therapeutic potential of TRAIL agonistic agents in ovarian cancer:
Preclinical studies
8.1. Monotherapy
The anti-tumor activity of dulanermin has been extensively evaluated in preclinical models
(Ashkenazi et al., 1999; Hylander et al., 2005; Pollack et al., 2001). Furthermore, preclinical in
vitro studies have demonstrated that OC cell lines displayed variable sensitivity to recombi‐
nant human TRAIL (Cuello et al., 2001; Vignati et al., 2002; Siervo-Sassi et al., 2003; Lane et
al., 2004). TRAIL-resistant cell lines usually remain sensitive to chemotherapy and converse‐
ly, cisplatin-resistant cell lines may be sensitive to TRAIL. Collectively, these results suggest
that both platinum-sensitive and platinum-resistant OC are candidates for TRAIL-targeting
therapy (Tomek et al., 2004). To increase cancer cell-directed toxicity of TRAIL, fusion pro‐
teins of rsTRAIL with target moiety to epidermal growth factor receptor (EGFR) have been
developed and were shown to have superior pro-apoptotic activity compared to soluble
TRAIL in tumor cells that expressed high levels of EGFR such as the OC cell line OVCAR3
(Bremer et al., 2008).
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Several studies demonstrated that the combination of TRAIL with cisplatin was more effi‐
cient than either molecule alone in various OC cell lines in vitro (Cuello et al., 2001; Vignati
et al., 2002; Siervo-Sassi et al., 2003; Tomek et al., 2004; Liu et al., 2006). In a mouse model of
OC, treatment with rhTRAIL-DR5 or rhTRAIL in combination with cisplatin significantly re‐
duced tumor growth compared to rhTRAIL-DR5 alone (97% and 85% reduction in the com‐
bination arms versus 63% reduction in the rhTRAIL-DR5 arm alone) (Duiker et al., 2009). In
this study, the beneficial effect of combined treatment was related to the observation that
cisplatin strongly enhanced TRAIL R2 surface expression. Similar to cisplatin, proteasome
inhibitors and nelfinavir, an HIV protease inhibitor, up-regulate TRAIL R2 and enhance the
sensitivity of ovarian cancer cells and tissue explants to an apoptosis-inducing TRAIL recep‐
tor antibody (Saulle et al., 2007; Brüning et al., 2008; Brüning et al., 2009; Pasquini et al.,
2010). For example, mapatumumab (TRAIL R1 agonist) and lexatumumab (TRAIL R2 ago‐
nist) were more efficient than TRAIL to induce apoptosis in primary OC cells and enhanced
apoptosis induced by the proteasome inhibitor bortezomid (Pasquini et al., 2010). Using a
model of acquired cisplatin resistant cell lines, Duiker et al. showed that cisplatin enhances
TRAIL-induced apoptosis in cisplatin-resistant ovarian cancer cells, and induction of cas‐
pase-8 protein expression is the key factor of TRAIL sensitization (Duiker et al., 2011). Estes
et al. evaluated the cytotoxicity of TRAIL R2 agonist (TRA-8) in nineteen chemotherapy-na‐
ive primary ovarian tumor samples (stage III/IV) (Estes et al., 2007). Using a similar ex vivo
model, increased cytotoxicity was observed when TRA-8 was used in combination with che‐
motherapeutic drugs (Frederick et al., 2009). The potential of TRA-8 was further evaluated
in a xenograft mouse model of OC (Bevis et al., 2011). When used alone, TRA-8 produced
only a modest benefit in terms of tumor growth inhibition. However, animals treated with
the combination of carboplatin, docetaxel and TRA-8 demonstrated a better outcome when
compared to carboplatin and docetaxel only.
Because TRAIL cytotoxicity in OC cells relies on the activation of both the extrinsic and the
intrinsic apoptosis pathways, the combination of TRAIL with pro-apoptotic proteins is of in‐
terest. For example, SMAC/DIABLO or LBW242, a SMAC/DIABLO mimic, sensitizes OC
cell lines to the antitumor effects of TRAIL and anticancer drugs commonly used in clinic
(Mao et al., 2007; Petrucci et al., 2007; Petrucci et al., 2012). These observations suggest that
the LBW242 could be of value for the development of experimental strategies for treatment
of ovarian cancer. Radicicol, an Hsp90 inhibitor, potentiate the apoptotic effect of TRAIL on
ovarian carcinoma cell lines by increasing the activation of the caspase-8- and Bid-depend‐
ent pathway and the mitochondria-mediated apoptotic pathway, leading to caspase activa‐
tion (Kim et al., 2012).
The enhanced efficacy of TRAIL in combination with other agents in preclinical models is
encouraging and suggests that combination therapies with TRAIL probably represent the
best clinical option at this point. Because TRAIL resistance in OC can be induced by various
pathways, a combination of molecules that targets critical steps in the TRAIL signaling cas‐
cade is likely to be the most efficient approach.
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9. Clinical trials with TRAIL targeting agents in OC patients
A large number of phase I/II clinical trials have been undertaken with TRAIL targeting
agents either as monotherapy or in combination with chemotherapeutic drugs in a wide
range of solid and haematological malignancies (Table 2). For the purpose of this discussion,







A study of PRO95780 in patients with previously
untreated, advanced-stage NSCLC
Completed Phase II NCT00480831
A study of PRO95780 in combination with Rituximab in
patients with NHL that has progressed following previous
Rituximab therapy
Completed Phase II NCT00517049
A study of PRO95780 in combination with Cetuximab
and Irinotecan chemotherapy or the FOLFIRI regimen
with Bevacizumab in patients with previously treated
metastatic colorectal cancer
Completed Phase I NCT00497497
A study of PRO95780 administered in combination with
the FOLFOX regimen and Bevacizumab in patients with
previously untreated, locally advanced, recurrent, and
metastatic colorectal Cancer
Completed Phase I NCT00851136
Conatumumab
Phase I/II study of Conatumumab and Gemcitabine
Hydrochloride followed by Conatumumab, Capecitabine,
and 3-dimensional conformal radiotherapy in patients




A phase 1b/2 study of AMG 655 in combination with
Paclitaxel and Carboplatin for the first-line treatment of
advanced NSCLC
Completed Phase I/II NCT00534027
Phase 1b/2 study of AMG 655 with mFOLFOX6 and
Bevacizumab for first-line metastatic colorectal cancer
Completed Phase I/II NCT00625651
Phase 1b/2 study of AMG 655 with Doxorubicin for the
first-line treatment of unresectable soft tissue sarcoma
Completed Phase I/II NCT00626704
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Paclitaxel and Carboplatin for the first-line treatment of
advanced NSCLC
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Phase 1b/2 study of AMG 655 with mFOLFOX6 and
Bevacizumab for first-line metastatic colorectal cancer
Completed Phase I/II NCT00625651
Phase 1b/2 study of AMG 655 with Doxorubicin for the
first-line treatment of unresectable soft tissue sarcoma
Completed Phase I/II NCT00626704







A study of AMG 655 or AMG 479 in combination with
Gemcitabine for treatment of metastatic pancreatic
cancer
Completed Phase I/II NCT00630552
AMG655/Panitumumab combination in metastatic
colorectal cancer study
Completed Phase I/II NCT00630786
AMG 655 in combination with AMG 479 in advanced,
refractory solid tumors
Completed Phase I/II NCT00819169
Phase 2 safety & efficacy of FOLFIRI in combination with
AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant
metastatic colorectal carcinoma
Completed Phase II NCT00813605
Phase 1b Lymphoma Study of AMG 655 in Combination
With Bortezomib or Vorinostat
Completed Phase I NCT00791011
Dulanermin
A study of AMG 951 [rhApo2L/TRAIL] in subjects with
previously untreated NSCLC treated with chemotherapy
+/- Bevacizumab
Completed Phase II NCT00508625
A study of Dulanermin administered in combination with
Camptosar®/Erbitux® chemotherapy or FOLFIRI (with or
without Bevacizumab) in subjects with previously treated
metastatic colorectal cancer
Completed Phase I NCT00671372
A study of Dulanermin administered in combination with
the FOLFOX regimen and Bevacizumab in patients with
previously untreated, locally advanced, recurrent, or
metastatic colorectal cancer
Completed Phase I NCT00873756
Lexatumumab
Phase I study of Lexatumumab with or without
recombinant interferon gamma in pediatric patients with
relapsed or refractory solid tumors or lymphoma
Completed Phase I NCT00428272
Mapatumumab
Mapatumumab, Cisplatin and radiotherapy for advanced
cervical cancer
Active Phase I/II NCT01088347
Study of TRM-1 (TRAIL-R1 monoclonal antibody) in
subject with relapsed or refractory NSCLC
Completed Phase II NCT00092924
Study of TRM-1 (TRAIL-R1 monoclonal antibody) in
subjects with relapsed or refractory NHL
Completed Phase II NCT00094848





Study of Mapatumumab in combination with Bortezomib
(Velcade) and Bortezomib alone in subjects with relapsed
or refractory multiple myeloma
Completed Phase II NCT00315757
A Study of Mapatumumab in combination with Paclitaxel
and Carboplatin in Subjects With NSCLC
Completed Phase II NCT00583830
Study of Mapatumumab in combination with Sorafenib
in subjects with advanced hepatocellular carcinoma
Completed Phase II NCT01258608
Tigatuzumab
An imaging and pharmacodynamic trial of CS-1008 in
patients with metastatic colorectal cancer
Active Phase I NCT01220999
Open-label study of CS1008 for subjects with untreated
and unresectable pancreatic cancer
Completed Phase II NCT00521404
Combination chemotherapy with CS-1008 to treat
ovarian cancer
Completed Phase II NCT00945191
CS-1008 with Carboplatin/Paclitaxel in chemotherapy
naive subjects with metastatic or unresectable NSCLC
Completed Phase II NCT00991796
CS1008- in combination with Sorafenib compared to
Sorafenib alone in subjects with advanced liver cancer
Completed Phase II NCT01033240
Abraxane with or without Tigatuzumab in patients with
metastatic, triple negative breast cancer
Completed Phase II NCT01307891
Study of CS-1008 in patients with advanced solid
malignancies and lymphomas (without leukemic
component)
Completed Phase I NCT00320827
Study of CS-1008 in combination with FOLFIRI in patients
who have failed other treatments
Completed Phase I NCT01124630
Abbreviations: NHL, non Hodgkin lymphoma; NSCLC, non-small cell lung cancer
Table 2. Active or completed clinical trials with TRAIL targeting agents
TRAIL-based treatment strategies that entered clinical studies have included dulanermin. In
a phase I study involving 71 patients with advanced or metastatic solid tumors or non-
Hodgkin lymphoma (NHL), dulanermin appeared safe and well tolerated (Herbst et al.,
2010). Partial response and stable disease were observed in 3% and 53% of patients respec‐
tively in this study. Additonal clinical studies with dulanermin in combination with other
drugs have been performed most often in patients with lung cancer (Soria et al., 2010; Soria
et al., 2011).
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Completed Phase I/II NCT00630786
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A study of Dulanermin administered in combination with
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Completed Phase I NCT00873756
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Mapatumumab
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cervical cancer
Active Phase I/II NCT01088347
Study of TRM-1 (TRAIL-R1 monoclonal antibody) in
subject with relapsed or refractory NSCLC
Completed Phase II NCT00092924
Study of TRM-1 (TRAIL-R1 monoclonal antibody) in
subjects with relapsed or refractory NHL
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Study of Mapatumumab in combination with Bortezomib
(Velcade) and Bortezomib alone in subjects with relapsed
or refractory multiple myeloma
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and Carboplatin in Subjects With NSCLC
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Study of Mapatumumab in combination with Sorafenib
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An imaging and pharmacodynamic trial of CS-1008 in
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Completed Phase II NCT00991796
CS1008- in combination with Sorafenib compared to
Sorafenib alone in subjects with advanced liver cancer
Completed Phase II NCT01033240
Abraxane with or without Tigatuzumab in patients with
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who have failed other treatments
Completed Phase I NCT01124630
Abbreviations: NHL, non Hodgkin lymphoma; NSCLC, non-small cell lung cancer
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drugs have been performed most often in patients with lung cancer (Soria et al., 2010; Soria
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Although there have been several published early-phase trials with antibody targeting
TRAIL-R1 or TRAIL-R2, only two have included patients with OC. The feasibility of intrave‐
nous mapatumumab administration, as a single-agent, has been examined in a phase I phar‐
macokinetic and biological correlative study in patients with advanced solid malignancies
refractory to standard therapy (Tolcher et al., 2007). Of the 49 patients enrolled in the study,
two had advanced OC. Mapatumumab dosing ranged from 0.01 to 10 mg/kg and was ad‐
ministered every 2-4 weeks. Overall, mapatumumab was well tolerated and toxicity was
generally limited to grade 1-2 events. No objective response was observed for mapatumu‐
mab in this unselected phase I study. Hotte et al. evaluated the safety and tolerability of ma‐
patumumab in a phase I clinical trial involving 41 patients with malignant solid tumors
refractory to conventional therapy in which 22% of the patients had OC (Hotte et al., 2008).
Mapatumumab was administered intravenously every 4 weeks and patients received a me‐
dian of 2 cycles (range, 1-33) with mapatumumab doses ranging from 0.01 to 20 mg/kg. The
patient that received 33 cycles of mapatumumab had a diagnosis of borderline OC. She ex‐
perienced no cumulative toxicity. Indeed, mapatumumab was generally well tolerated and
common adverse events included fatigue, hypotension, nausea and fever. No objective re‐
sponse was observed. Conatumumab (AMG 655), a TRAIL R2-specific antibody is currently
being evaluated in patients with advanced refractory solid tumors that includes ovarian tu‐
mors in combination with ganitumab, a fully human monoclonal antibody against insulin-
like growth factor receptor 1 (National Cancer Institute (NCI) Clinical Trials Identifier
Number : NCT00819169).
Of the two studies published with mapatumumab in combination with chemotherapy, one
included a patient with OC (primary peritoneal carcinoma) (Leong et al., 2009). A phase II
using tigatuzumab (CS-1008), a humanized TRAIL-R2 antibody, in combination with pacli‐
taxel and carboplatin is underway (NCI Clinical Trials Identifier Number: NCT00945191).
10. Conclusions and future directions
The inherent properties of TRAIL or its agonists offer a new targeted therapy for OC. Pre‐
clinical studies using TRAIL or its agonists have demonstrated the therapeutic potential of
these molecules and formed the basis of ongoing phase I/II clinical trials. Although these
treatments appear to be clinically well tolerated so far, intrinsic, acquired and environment-
mediated resistance may limit the effectiveness of these approaches. However, the develop‐
ment of combination treatments appears to be capable of overcoming, at least in part, some
of these limitations. As the search for more effective treatment for OC continues, the mor‐
bidity and mortality will hopefully improve. TRAIL treatment strategies have been used so
far in the context of salvage treatment and the optimal patient population that will mostly
benefit from these treatments remains to be defined. Although significant progress has been
made in our understanding of the molecular basis of TRAIL resistance in OC, efforts should
continue to further improve this knowledge as this will likely lead to the development of
specific biomarkers of resistance and more efficient targeted therapies.
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Figure 1. Apoptotic pathways. Binding of TRAIL to death receptors (TRAIL R1, TRAIL R2) leads to the recruitment of
the adaptor molecule, FADD. Pro-caspase-8 binds to FADD leading to DISC formation and resulting in its activation.
Activated caspase-8 directly activates executioner caspases (caspase-3, -6, and -7) (type I cells) or cleaves Bid (type II
cells). Translocation of the truncated Bid (tBid) to the mitochondria promotes the assembly of Bax-Bak oligomers and
mitochondria outer membrane permeability changes. Cytochrome c is released into cytosol resulting in apoptosome
assembly. Active caspase-9 then propagates a proteolytic cascade of effector caspases activation that leads to mor‐
phological hallmarks of apoptosis. Further cleavage of pro-caspase-8 by effector caspases generates a mitochondrial
amplification loop that further enhances apoptosis. When FLIP levels are elevated in cells, caspase-8 preferentially re‐
cruits FLIP to form a caspase-8-FLIP heterodimer which does not trigger apoptosis. Chemotherapeutic drugs such as
cisplatin cause DNA damage which is sensed by the ataxia telangiectasia mutated homolog (ATM) leading to the acti‐
vation of p53 dependent activation of genes such as PUMA and Noxa which can bind to anti-apoptotic proteins Bcl-2/
Bcl-XL thereby opposing their effect. This leads to mitochondrial permeabilization and activation.
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bidity and mortality will hopefully improve. TRAIL treatment strategies have been used so
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benefit from these treatments remains to be defined. Although significant progress has been
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continue to further improve this knowledge as this will likely lead to the development of
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1. Introduction
Platinum-based drugs such as cisplatin (cis-diammine-dichloro-platinum, also commonly
known as CDDP) have dominated the drug therapy of ovarian cancer during the past three
decades [1]. Cisplatin interacts with DNA to form intrastrand crosslink adducts, and its mo‐
lecular mechanism involves regulation of p53 and the mitogen-activated protein kinase
(MAPK) signaling pathway [2]. The phosphatidylinositol-3-kinase (PI3K)/Akt signaling
pathway is crucial for regulation of survival and for progression and chemoresistance in
ovarian cancer, leading to the development of new chemotherapeutic inhibitors targeting
the PI3K/Akt pathway and the downstream serine/threonine protein kinase mTOR. [3]. In‐
hibition of PI3K pathway signaling using PI3K or mTOR inhibitors has been shown to sensi‐
tize ovarian cancer cell lines to the apoptosis-inducing effect of platinum compounds [4, 5].
In addition, activation of the PI3K/Akt/mTOR pathway in ovarian cancer cell lines contrib‐
utes to cisplatin resistance [6]. The anti-apoptotic, pro-angiogenic effects of PI3K/Akt/mTOR
may be mediated, at least in part, through a downstream signaling pathway involving en‐
dogenous endothelial-form nitric oxide synthase (eNOS, also called NOS3), and subsequent‐
ly soluble guanylyl cyclase (sGC) and protein kinase G (PKG). Studies have shown that Akt
activates eNOS by phosphorylating human eNOS at Ser1177 (equivalent to bovine eNOS at
Ser1179), leading to an increase in nitric oxide (NO) production in endothelial cells [7, 8]. In
the cases of vascular endothelial growth factor (VEGF) [9, 10], sphingosine 1-phosphate [11,
12], and estrogen [13, 14], there are vast evidences suggesting PI3K-activation of Akt is re‐
sponsible for regulating the phosphorylation and activation of eNOS. In bovine aortic endo‐
thelial cells, eNOS co-immunoprecipitates with Akt, indicating that the two enzymes
associate in vivo, and Akt directly activates eNOS, increasing eNOS activity by 15-20 fold
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1. Introduction
Platinum-based drugs such as cisplatin (cis-diammine-dichloro-platinum, also commonly
known as CDDP) have dominated the drug therapy of ovarian cancer during the past three
decades [1]. Cisplatin interacts with DNA to form intrastrand crosslink adducts, and its mo‐
lecular mechanism involves regulation of p53 and the mitogen-activated protein kinase
(MAPK) signaling pathway [2]. The phosphatidylinositol-3-kinase (PI3K)/Akt signaling
pathway is crucial for regulation of survival and for progression and chemoresistance in
ovarian cancer, leading to the development of new chemotherapeutic inhibitors targeting
the PI3K/Akt pathway and the downstream serine/threonine protein kinase mTOR. [3]. In‐
hibition of PI3K pathway signaling using PI3K or mTOR inhibitors has been shown to sensi‐
tize ovarian cancer cell lines to the apoptosis-inducing effect of platinum compounds [4, 5].
In addition, activation of the PI3K/Akt/mTOR pathway in ovarian cancer cell lines contrib‐
utes to cisplatin resistance [6]. The anti-apoptotic, pro-angiogenic effects of PI3K/Akt/mTOR
may be mediated, at least in part, through a downstream signaling pathway involving en‐
dogenous endothelial-form nitric oxide synthase (eNOS, also called NOS3), and subsequent‐
ly soluble guanylyl cyclase (sGC) and protein kinase G (PKG). Studies have shown that Akt
activates eNOS by phosphorylating human eNOS at Ser1177 (equivalent to bovine eNOS at
Ser1179), leading to an increase in nitric oxide (NO) production in endothelial cells [7, 8]. In
the cases of vascular endothelial growth factor (VEGF) [9, 10], sphingosine 1-phosphate [11,
12], and estrogen [13, 14], there are vast evidences suggesting PI3K-activation of Akt is re‐
sponsible for regulating the phosphorylation and activation of eNOS. In bovine aortic endo‐
thelial cells, eNOS co-immunoprecipitates with Akt, indicating that the two enzymes
associate in vivo, and Akt directly activates eNOS, increasing eNOS activity by 15-20 fold
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[15]. This signaling pathway has been shown to play an essential role in promoting angio‐
genesis or tumor vascularization [16]. In a very recent study, microgravity stimulated tube
formation and migration in human umbilical vein endothelial cells (HUVEC), and the proc‐
ess was mediated through the PI3K-Akt-eNOS signal pathway [17].
Our early studies of the NO/cyclic GMP (cGMP)/PKG signaling pathway have identified
PKG as a key mediator of  vasodilation and anti-hypertensive effects  induced by NO as
well as atrial natriuretic peptide (ANP) [18-21].  Recent studies from our laboratory have
shown that  the  PKG-Iα splice  variant  of  PKG,  at  basal  or  moderately  elevated activity,
plays an important cytoprotective role in preventing spontaneous apoptosis and promot‐
ing  cell  proliferation  in  many  types  of  mammalian  cells,  including  neural  cells  [22-27],
human  ovarian  cancer  cells  [28-30],  primary  murine  vascular  smooth  muscle  cells  [31]
and murine bone marrow mesenchymal (stromal) stem cells [32]. Evidence from our lab‐
oratory suggested that  basal  activation of  PKG-Iα leads to increased attachment of  cells
to the extracellular matrix and increased cell  migration,  shown in bone marrow-derived
mesenchymal  (stromal)  stem cells  [32].  We have  identified  certain  intracellular  proteins
that are directly phosphorylated and functionally regulated by PKG-Iα,  including 1)  the
apoptosis-regulating protein BAD [26],  2)  vasodilator-stimulated phosphoprotein (VASP)
[28, 31, 32], 3) the oncogenic tyrosine kinase c-Src [28, 33] and 4) the transcription factor
cAMP responsive element binding protein (CREB) [24,  34],  which may contribute to the
exaggerated proliferation, enhanced chemoresistance and increased cell migration and in‐
vasion  in  ovarian  cancer  cells  (Figure  1).  Our  recent  studies  have  shown that  cisplatin
regulates the endogenous expression of nitric oxide synthases (NOSs) in human ovarian
cancer  cells,  upregulating  inducible  nitric  oxide  synthase  (iNOS,  also  called  NOS2)  ex‐
pression but dramatically downregulating the expression of eNOS and neural-form nitric
oxide synthase (nNOS, also called NOS1), which is involved in determining cisplatin re‐
sistance in ovarian cancer cells [30].  Our studies show that the chemoresistance/cytopro‐
tective  effects  of  endogenous  eNOS  involve  hyperactivation  of  PKG-Iα  in  the  ovarian
cancer cells [28].
Studies from our laboratory suggest that PKG-Iα promotes proliferation in ovarian cancer
cells, which involves the enhancement of the tyrosine kinase activity of c-Src [28], an onco‐
genic protein often overexpressed and/or hyperactivated in many types of cancer cells. We
showed that PKG-Iα plays a key role in activating c-Src and promoting cell proliferation, us‐
ing the short interfering RNA (siRNA) or RNA interference (RNAi) technique, to knock‐
down the expression of PKG-Iα in ovarian cancer cells [28]. We found that epidermal
growth factor (EGF)-induced activation of c-Src tyrosine kinase activity causes tyrosine
phosphorylation of PKG-Iα, increasing the serine/threonine kinase activity of PKG-Iα and
its growth-promoting effects in ovarian cancer cells [28]. Later, we have found that PKG-Iα
directly phosphorylates c-Src at Ser17, which enhances the tyrosine kinase activity of c-Src in
both in vitro and intact-cell experiments [33]. This novel interaction between PKG-Iα and c-
Src causes reciprocal phosphorylation, which means PKG-Iα and c-Src phosphorylate each
other, potentially setting up an “oncogenic reinforcement” resulting in exaggerated DNA
synthesis and cell proliferation (Figure 1).
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Figure 1. Model of the biological role of PKG-Iα in ovarian cancer cells illustrating the effects of growth factors (e.g.
EGF), which stimulates both the PI3K/Akt pathway, enhancing eNOS activity and low-level NO generation and the ac‐
tivation of c-Src. The low, physiological levels of NO activate sGC, elevating cGMP levels that enhance the activation of
PKG-Iα. PKG-Iα is further activated (hyperactivated) by the combined effects of cGMP allosteric stimulation and the
tyrosine phosphorylation by c-Src. PKG-Iα phosphorylates several downstream proteins, including c-Src, Bad, CREB and
VASP, leading to enhanced cell proliferation and cytoprotection, contributing to chemoresistance in ovarian cancer
cells and increased cell migration and invasion.
2. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP)
at Ser239 as a useful indicator of endogeneous PKG kinase activity
Vasodilator-stimulated phosphoprotein (VASP) was first described in 1987 as a protein
phosphorylated in platelets in response to vasodilators such as sodium nitroprusside, nitro‐
glycerin and various prostaglandins that elevate cAMP and cGMP [35]. VASP belongs to the
Ena/VASP family which includes VASP, Mena (mammalian enabled) and EVL (Ena VASP-
like). The Ena/VASP family proteins function as anti-capping proteins [36, 37], regulating
the actin cytoskeleton dynamics [38-42] and are therefore important for actin-based adhe‐
sion [43, 44], migration [45-47] and cell–cell interaction [48-50]. Many studies from others
have suggested the involvement of VASP in invasion, angiogenesis and tumorigenesis. In an
in vitro model of capillary morphogenesis using human umbilical vein endothelial cells
(HUVECs) in three-dimensional collagen gels, the differentiated endothelial cells showed 2
to 3-fold increase in migration with increased VASP mRNA and protein expression [51]. A
study on human placenta development showed that VASP may participate in vasculogene‐
sis and endothelial sprouting during placental vasculogenesis, and VASP expression was
stimulated by vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) [52].
NIH-3T3 fibroblast deficient in VASP showed loss of contact inhibition, and continued cell
division past confluence, while overproduction of VASP by transfection in NIH-3T3 fibro‐
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formation and migration in human umbilical vein endothelial cells (HUVEC), and the proc‐
ess was mediated through the PI3K-Akt-eNOS signal pathway [17].
Our early studies of the NO/cyclic GMP (cGMP)/PKG signaling pathway have identified
PKG as a key mediator of  vasodilation and anti-hypertensive effects  induced by NO as
well as atrial natriuretic peptide (ANP) [18-21].  Recent studies from our laboratory have
shown that  the  PKG-Iα splice  variant  of  PKG,  at  basal  or  moderately  elevated activity,
plays an important cytoprotective role in preventing spontaneous apoptosis and promot‐
ing  cell  proliferation  in  many  types  of  mammalian  cells,  including  neural  cells  [22-27],
human  ovarian  cancer  cells  [28-30],  primary  murine  vascular  smooth  muscle  cells  [31]
and murine bone marrow mesenchymal (stromal) stem cells [32]. Evidence from our lab‐
oratory suggested that  basal  activation of  PKG-Iα leads to increased attachment of  cells
to the extracellular matrix and increased cell  migration,  shown in bone marrow-derived
mesenchymal  (stromal)  stem cells  [32].  We have  identified  certain  intracellular  proteins
that are directly phosphorylated and functionally regulated by PKG-Iα,  including 1)  the
apoptosis-regulating protein BAD [26],  2)  vasodilator-stimulated phosphoprotein (VASP)
[28, 31, 32], 3) the oncogenic tyrosine kinase c-Src [28, 33] and 4) the transcription factor
cAMP responsive element binding protein (CREB) [24,  34],  which may contribute to the
exaggerated proliferation, enhanced chemoresistance and increased cell migration and in‐
vasion  in  ovarian  cancer  cells  (Figure  1).  Our  recent  studies  have  shown that  cisplatin
regulates the endogenous expression of nitric oxide synthases (NOSs) in human ovarian
cancer  cells,  upregulating  inducible  nitric  oxide  synthase  (iNOS,  also  called  NOS2)  ex‐
pression but dramatically downregulating the expression of eNOS and neural-form nitric
oxide synthase (nNOS, also called NOS1), which is involved in determining cisplatin re‐
sistance in ovarian cancer cells [30].  Our studies show that the chemoresistance/cytopro‐
tective  effects  of  endogenous  eNOS  involve  hyperactivation  of  PKG-Iα  in  the  ovarian
cancer cells [28].
Studies from our laboratory suggest that PKG-Iα promotes proliferation in ovarian cancer
cells, which involves the enhancement of the tyrosine kinase activity of c-Src [28], an onco‐
genic protein often overexpressed and/or hyperactivated in many types of cancer cells. We
showed that PKG-Iα plays a key role in activating c-Src and promoting cell proliferation, us‐
ing the short interfering RNA (siRNA) or RNA interference (RNAi) technique, to knock‐
down the expression of PKG-Iα in ovarian cancer cells [28]. We found that epidermal
growth factor (EGF)-induced activation of c-Src tyrosine kinase activity causes tyrosine
phosphorylation of PKG-Iα, increasing the serine/threonine kinase activity of PKG-Iα and
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Figure 1. Model of the biological role of PKG-Iα in ovarian cancer cells illustrating the effects of growth factors (e.g.
EGF), which stimulates both the PI3K/Akt pathway, enhancing eNOS activity and low-level NO generation and the ac‐
tivation of c-Src. The low, physiological levels of NO activate sGC, elevating cGMP levels that enhance the activation of
PKG-Iα. PKG-Iα is further activated (hyperactivated) by the combined effects of cGMP allosteric stimulation and the
tyrosine phosphorylation by c-Src. PKG-Iα phosphorylates several downstream proteins, including c-Src, Bad, CREB and
VASP, leading to enhanced cell proliferation and cytoprotection, contributing to chemoresistance in ovarian cancer
cells and increased cell migration and invasion.
2. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP)
at Ser239 as a useful indicator of endogeneous PKG kinase activity
Vasodilator-stimulated phosphoprotein (VASP) was first described in 1987 as a protein
phosphorylated in platelets in response to vasodilators such as sodium nitroprusside, nitro‐
glycerin and various prostaglandins that elevate cAMP and cGMP [35]. VASP belongs to the
Ena/VASP family which includes VASP, Mena (mammalian enabled) and EVL (Ena VASP-
like). The Ena/VASP family proteins function as anti-capping proteins [36, 37], regulating
the actin cytoskeleton dynamics [38-42] and are therefore important for actin-based adhe‐
sion [43, 44], migration [45-47] and cell–cell interaction [48-50]. Many studies from others
have suggested the involvement of VASP in invasion, angiogenesis and tumorigenesis. In an
in vitro model of capillary morphogenesis using human umbilical vein endothelial cells
(HUVECs) in three-dimensional collagen gels, the differentiated endothelial cells showed 2
to 3-fold increase in migration with increased VASP mRNA and protein expression [51]. A
study on human placenta development showed that VASP may participate in vasculogene‐
sis and endothelial sprouting during placental vasculogenesis, and VASP expression was
stimulated by vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) [52].
NIH-3T3 fibroblast deficient in VASP showed loss of contact inhibition, and continued cell
division past confluence, while overproduction of VASP by transfection in NIH-3T3 fibro‐
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blasts resulted in neoplastic transformation, suggesting a role of VASP in tumorigenesis
and/or cancer progression [53]. In human osteocarcinoma specimans, higher VASP expres‐
sion was associated with metastasis and increased migration, and VASP expression was
regulated by Rac1 [54]. In lung adenocarcinomas tissues, VASP expression was increased
compared to normal lung tissues, and was significantly increased with more advanced tu‐
mor stage [55]. Elevated VASP expression was also reported in human breast cancer tissues
[56] and was implicated on invasion and migration in breast cancer cells involving the Rac1
pathway [57]. Moreover, it was shown that in mice lacking VASP, melanoma growth was
greatly impaired [58]. In gastric cancer cells, VASP was upregulated by epidermal growth
factor (EGF) and promoted migration and invasion. Using microRNA (miRNA) expression
profiling of the paired normal/tumor gastric tissues, the same group identified miR-610 as a
novel miRNA regulated by EGF that targets VASP in gastric cancer cells [59].
VASP has been reported to be phosphorylated by cAMP-dependent protein kinase (PKA) and
cGMP-dependent protein kinase (PKG) [35, 60]. VASP was found to be primarily present as a
46 kDa membrane-associated protein in its dephosphorylated form in platelets, and VASP is
converted to an apparent 50 kDa phosphoprotein upon phosphorylation, as observed on West‐
ern blot [61, 62]. VASP contains three phosphorylation sites, Ser157, Ser239 and Thr274, all of
which can be phosphorylated by either PKA or PKG [63]. Ser157 is the preferred site of phos‐
phorylation for PKA, Ser239 is the preferred site for PKG, and Ser157 was the site responsible
for the phosphorylation-induced mobility shift of VASP on Western blots [63]. Because it was
well-characterized that VASP at Ser239 is the preferred phosphorylation site for PKG in vitro
and in mammalian cells, VASP phosphorylation at Ser239 has been proposed to be a useful in‐
dicator of endogenous PKG kinase activity [61, 63, 64]. In fact, VASP at Ser239 was shown to be
a functional biomarker of endothelial nitric oxide/cyclic GMP signaling [65], and could be used
to indicate defective nitric oxide/cGMP signaling and endothelial dysfunction [66]. In colon
cancer cells, VASP Ser239 phosphorylation was used as a biomarker for the action of the anti-
cancer drug Exisulind, an inhibitor of type-5 phosphodiesterase (PDE-5) that elevates cGMP
and stimulates PKG activation, and that constitutively activated mutants of PKG resulted in di‐
rect in vivo phosphorylation of VASP Ser239 [67].
We had shown that the endogenous NO/cGMP signaling pathway in ovarian cancer cells caus‐
es a constitutive downregulation of p53 protein expression, which likely contributes to the che‐
moresistance and exaggerated cell proliferation in these cells [29].  Furthermore, we have
previously identified that PKG-Iα is the predominant isoform of PKG in both OV2008 (cispla‐
tin-sensitive, wild-type p53) and A2780cp (cisplatin-resistant, mutated p53) ovarian cancer
cells as determined by Western blot analysis as well as using the new, ultrasensitive Nano‐
Pro100 capillary electrophoresis-based nano-fluidic protein analysis system [28, 68, 69]. Our
more recent data now show that the chemoresistance and exaggerated cell proliferation are
likely mediated by the constitutive hyperactivation of PKG-Iα (reflected in the high levels of
VASP phosphorylation at Ser239) in ovarian cancer cells, and that the PKG-Iα is already acti‐
vated to approximately 90% of maximal activity, described in our previous book chapter [68].
In our recent study, epidermal growth factor (EGF)-induced activation of Src family kinase
(SFK) was found to tyrosine-phosphorylate PKG-Iα increasing its serine/threonine kinase ac‐
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tivity in ovarian cancer cells. The EGF-stimulated increase in PKG-Iα kinase activity (indicated
by VASP Ser239 phosphorylation) was blocked by both SKI-1 and SU6656 (SFK inhibitors). Us‐
ing the specific PKG-Iα kinase inhibitor DT-2 and small interfering RNA (siRNA) PKG-Iα gene
knockdown, we showed that the inhibition of endogenous PKG-Iα kinase activity reduced
VASP Ser239 phosphorylation and DNA synthesis rate in ovarian cancer cells [28]. New data
from our laboratory show that the knockdown of PKG-Iα expression inhibits the EGF-stimu‐
lated increases in VASP Ser239 phosphorylation and Src/SFK autophosphorylation at the
equivalent of Tyr416 (the phosphorylation site for activating the tyrosine kinase activity) in
A2780cp (cisplatin-resistant, mutated p53) ovarian cancer cells (see Figure 2 below).
Figure 2. A, EGF (10 ng/mL) elevated VASP Ser239 phosphorylation and Src Tyr416 phosphorylation in A2780cp cells,
assessed by Western blot analysis. Gene knockdown of PKG-Iα by PKG-Iα-siRNA partially inhibited the basal VASP
phosphorylation and Src/SFK autophosphorylation and completely inhibited the EGF-stimulated increases in VASP
phosphorylation and Src/SFK autophosphorylation. The Western blot shown is representative of four experiments. B,
Quantification of the relative levels of VASP and Src phosphorylation from Western blot. Bar graphs show mean ± SEM
from four independent experiments. *, P< 0.05, compared with no EGF control; #, P<0.05; ##, P<0.01; ###, P < 0.001,
compared with negative control.
3. Role of PKG in invasion/migration in A2780cp ovarian cancer cells
The role of NO/cGMP/PKG pathway in invasion/migration in cancer cells is largely unknown.
However, a significant number of reports have shown that the NO/cGMP/PKG pathway plays a
key role in endothelial cell migration and angiogenesis, involving the downstream activation of
the mitogen-activated protein kinase (MAPK) family. It has been shown that NO promotes endo‐
thelial cell migration and neovascularization by activating the PI3K/Akt signaling pathway in a
PKG-dependent manner [70]. Activation of the NO/cGMP/PKG pathway also promoted endo‐
thelial cell angiogenesis and increased extracellular signal regulated kinase 1/2 (ERK1/2) and p38
phosphorylation [71, 72], which were blocked by soluble guanylyl cyclase (sGC) inhibitor, 1H-
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to indicate defective nitric oxide/cGMP signaling and endothelial dysfunction [66]. In colon
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cancer drug Exisulind, an inhibitor of type-5 phosphodiesterase (PDE-5) that elevates cGMP
and stimulates PKG activation, and that constitutively activated mutants of PKG resulted in di‐
rect in vivo phosphorylation of VASP Ser239 [67].
We had shown that the endogenous NO/cGMP signaling pathway in ovarian cancer cells caus‐
es a constitutive downregulation of p53 protein expression, which likely contributes to the che‐
moresistance and exaggerated cell proliferation in these cells [29].  Furthermore, we have
previously identified that PKG-Iα is the predominant isoform of PKG in both OV2008 (cispla‐
tin-sensitive, wild-type p53) and A2780cp (cisplatin-resistant, mutated p53) ovarian cancer
cells as determined by Western blot analysis as well as using the new, ultrasensitive Nano‐
Pro100 capillary electrophoresis-based nano-fluidic protein analysis system [28, 68, 69]. Our
more recent data now show that the chemoresistance and exaggerated cell proliferation are
likely mediated by the constitutive hyperactivation of PKG-Iα (reflected in the high levels of
VASP phosphorylation at Ser239) in ovarian cancer cells, and that the PKG-Iα is already acti‐
vated to approximately 90% of maximal activity, described in our previous book chapter [68].
In our recent study, epidermal growth factor (EGF)-induced activation of Src family kinase
(SFK) was found to tyrosine-phosphorylate PKG-Iα increasing its serine/threonine kinase ac‐
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tivity in ovarian cancer cells. The EGF-stimulated increase in PKG-Iα kinase activity (indicated
by VASP Ser239 phosphorylation) was blocked by both SKI-1 and SU6656 (SFK inhibitors). Us‐
ing the specific PKG-Iα kinase inhibitor DT-2 and small interfering RNA (siRNA) PKG-Iα gene
knockdown, we showed that the inhibition of endogenous PKG-Iα kinase activity reduced
VASP Ser239 phosphorylation and DNA synthesis rate in ovarian cancer cells [28]. New data
from our laboratory show that the knockdown of PKG-Iα expression inhibits the EGF-stimu‐
lated increases in VASP Ser239 phosphorylation and Src/SFK autophosphorylation at the
equivalent of Tyr416 (the phosphorylation site for activating the tyrosine kinase activity) in
A2780cp (cisplatin-resistant, mutated p53) ovarian cancer cells (see Figure 2 below).
Figure 2. A, EGF (10 ng/mL) elevated VASP Ser239 phosphorylation and Src Tyr416 phosphorylation in A2780cp cells,
assessed by Western blot analysis. Gene knockdown of PKG-Iα by PKG-Iα-siRNA partially inhibited the basal VASP
phosphorylation and Src/SFK autophosphorylation and completely inhibited the EGF-stimulated increases in VASP
phosphorylation and Src/SFK autophosphorylation. The Western blot shown is representative of four experiments. B,
Quantification of the relative levels of VASP and Src phosphorylation from Western blot. Bar graphs show mean ± SEM
from four independent experiments. *, P< 0.05, compared with no EGF control; #, P<0.05; ##, P<0.01; ###, P < 0.001,
compared with negative control.
3. Role of PKG in invasion/migration in A2780cp ovarian cancer cells
The role of NO/cGMP/PKG pathway in invasion/migration in cancer cells is largely unknown.
However, a significant number of reports have shown that the NO/cGMP/PKG pathway plays a
key role in endothelial cell migration and angiogenesis, involving the downstream activation of
the mitogen-activated protein kinase (MAPK) family. It has been shown that NO promotes endo‐
thelial cell migration and neovascularization by activating the PI3K/Akt signaling pathway in a
PKG-dependent manner [70]. Activation of the NO/cGMP/PKG pathway also promoted endo‐
thelial cell angiogenesis and increased extracellular signal regulated kinase 1/2 (ERK1/2) and p38
phosphorylation [71, 72], which were blocked by soluble guanylyl cyclase (sGC) inhibitor, 1H-
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[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), or PKG inhibitor DT-3 [73-75]. Moreover, the
mitogenic effect of vascular endothelial growth factor (VEGF) on endothelial cells appears to be
mediated by endogenous NO (from eNOS) and cGMP, which results in PKG activation and PKG-
mediated downstream stimulation of MEK and ERK [76, 77]. Although it has not yet been report‐
ed which isoform of PKG is involved in the multiple pro-angiogenesis responses of endothelial
cells, our recent studies suggest that endothelial cells express predominantly the PKG-Iα isoform
(unpublished observations by J.C. Wong and R.R. Fiscus), which likely mediates the stimulation
of downstream growth-promoting and pro-angiogenesis pathways in endothelial cells.
Interestingly, in colon cancer cells, recent studies showed that activation of PKG inhibited cell mi‐
gration [78], and cGMP-dependent VASP phosphorylation suppressed the number and length
of locomotory (filopodia) and invasive (invadopodia) actin-based organelles [79], suggesting a
role of VASP Ser239 in invasion and migration. Our studies suggest that the opposite roles of PKG
in regulating apoptosis, proliferation and migration reported by others are likely dependent on
cell type, growth conditions (presence of different growth factors), as well as the differential ex‐
pression of PKG-Iα and PKG-Iβ isoforms. The two splice variants of PKG-I, PKG-Iα and PKG-Iβ,
are activated by different concentration ranges of NO and are localized to different subcellular lo‐
cations within cells. Therefore, the two PKG-I isoforms can phosphorylate different sets of down‐
stream target proteins and can mediate completely different biological responses. The very
different biological roles of the two PKG-I isoforms are reviewed in further detail elsewhere in an‐
other recent book chapter from our laboratory [68]. For example, PKG-Iα (Kact = 0.1 µM by cGMP
allosteric activation) is activated at low, physiological levels of NO, whereas PKG-Iβ is activated
at higher, pathological levels of NO and requires at least 10-times higher levels of cGMP for acti‐
vation (Kact = 1 µM) [68, 72, 80, 81].
In our hypothesis, the PKG-Iα and PKG-Iβ isoforms mediate opposite biological effects on cell
proliferation and apoptosis, based on observations in two types of cells that express one isoform
of PKG-I or the other. Our studies have shown that human ovarian cancer cells express predomi‐
nantly the PKG-Iα isoform, and that the activation of this kinase by endogenous low-level NO
(0.01 – 1 nM), generated by endogenous eNOS and nNOS, would selectively activate the PKG-Iα
isoform within ovarian cancer cells from our laboratory, promoting DNA synthesis/cell prolifer‐
ation and suppressing apoptosis, thus contributing to chemoresistance [28, 30, 68]. Studies in our
laboratory, using both normal and malignant cells, including vascular smooth muscle cells, bone
marrow-derived mesenchymal (stromal) stem cells and neuroblastoma cells, have suggested
that a major role of the low-level-NO/cGMP/PKG-Iα signaling pathway is to protect these cells
against the toxic/pro-apoptotic effects of high-level NO, as might occur during inflammation and
exposure of cells to pro-inflammatory cytokines [22, 24, 25, 31, 32]. In contrast, based in part on
published data from the laboratories of Weinstein and Thompson, it appears that when PKG-Iβ is
activated by the higher levels of NO, the growth-inhibitory and pro-apoptotic effects of PKG-Iβ
predominate over the growth-stimulatory and anti-apoptotic effects mediated by PKG-Iα. Their
laboratories have shown that in colon cancer cells, PKG-Iβ is the predominant PKG-I isoform ex‐
pressed. Upon activation, PKG-Iβ phosphorylates two downstream target proteins, β-catenin
and MEKK1, resulting in inhibition of cell proliferation and induction of apoptosis [78, 82, 83].
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As stated above, we have previously determined that PKG-Iα is the predominant isoform in
A2780cp ovarian cancer cells [30, 68, 69]. To study whether PKG-Iα plays a role in cell mi‐
gration/invasion in ovarian cancer cells, we performed experiments using small interfering
RNA (siRNA) gene knockdown against PKG-Iα in transwell migration studies. Figure 3
shows that siRNA gene knockdown of PKG-Iα dramatically decreases no EGF as well as
EGF-stimulated cell migration (as reflected by the quantity of migrated cells at the bottom of
the transwell, stained with crystal violet) in A2780cp cisplatin-resistant ovarian cancer cells.
These data confirm the role of endogenous PKG-Iα activity, potentially via VASP Ser239
phosphorylation, in promoting cell migration/invasion in ovarian cancer.
Figure 3. PKG-Iα siRNA gene knockdown in A2780cp cells decreased both basal and EGF-stimulated cell migration as‐
sessed by in vitro cell migration (invasion) assay. Migration of cells was assessed using transwells (Corning) with 8 µM pore
polycarbonated inserts, coated with growth factor-reduced matrigel (BD Bioscience). The upper chamber contained 4 x
104 cells and the lower chamber contained 0.6 ml of complete medium with or without EGF. Migration through the mem‐
brane was determined after 24 h of incubation at 37°C. Cells remaining on the topside of the transwell membrane were re‐
moved using a cotton swab, and cells migrated to bottom were stained with 0.5% crystal violet.
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4. Inhibition of the PKG-Iα signaling pathway enhances sensitivity of
ovarian cancer cells to cisplatin-induced apoptosis – Potential
involvement of cAMP-response-element-binding protein (CREB) and
inhibitor of apoptosis proteins (IAPs)
Platinum-based drugs such as cisplatin have dominated the drug therapy of ovarian cancer
during the past three decades [1]. Cisplatin interacts with DNA to form intrastrand crosslink
adducts, and its molecular mechanism involves regulation of p53 and the mitogen-activated
protein kinase (MAPK) signaling pathway [2]. It has been shown that inhibition of ERK1/2
activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor
PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53
protein during exposure to cisplatin [84]. Our data have shown that human ovarian cancer
cells express all of the key components of the NO/cGMP/PKG signaling pathway, including
all three isoforms of NOSs, thus providing an endogenous source of NO [30]. Furthermore,
ovarian cancer cells continuously produce NO at low physiological levels, activating the
heme-dependent soluble guanylyl cyclase (sGC) [29], elevating cGMP levels sufficiently
enough to cause continuous high-level activation of PKG [28]. Our data suggested that such
basal sGC/cGMP activity regulates p53 expression, and promotes cell survival in part
through regulation of caspase-3 [29] (now thought to be mediated by downstream hyperac‐
tivation of PKG-Iα).
Cisplatin is also widely employed in chemotherapy on treating solid tumors such as lung
cancer. Recently, we showed that, in NCI-H460 and A549 non-small cell lung cancer
(NSCLC) cells, PKG-Iα phosphorylates cAMP-response-element-binding protein (CREB) at
Ser133 [34]. CREB was first shown to be phosphorylated by PKG in vitro by Colbran et al.,
which showed that PKG effectively phosphorylates CREB at Ser133, although at a slower
rate compared to PKA [85]. Interestingly, NO was shown to regulate the c-fos promoter in‐
volving soluble guanylyl cyclase (sGC) and PKG [86] in a CREB-dependent manner [87].
They also showed that transfection of PKG in baby hamster kidney (BHK) cells activated the
c-fos promoter [88], which required nuclear translocation of PKG and phosphorylation of
CREB at Ser133 by PKG [87, 89, 90]. In our recent study, inhibition of the sGC/PKG-Iα sig‐
naling pathway by ODQ (sGC inhibitor), DT-2 (PKG-Iα kinase inhibitor) and PKG-Iα-siR‐
NA gene knockdown showed that PKG-Iα kinase activity is necessary for maintaining
higher levels of CREB phosphorylation at Ser133 and the protein expression of certain inhib‐
itor of apoptosis proteins (IAPs), specifically c-IAP1, livin and survivin, as well as the anti-
apoptotic Bcl-2 family member Mcl-1, preventing spontaneous apoptosis and promoting
colony formation [34]. In the same study, we discovered that DT-2 and cisplatin have a syn‐
ergistic effect on the induction of apoptosis, with DT-2 dramatically enhancing the pro-
apoptotic effects of cisplatin in A549 cells (a NSCLC cell line that requires higher levels of
cisplatin to induce apoptosis). We also showed that prior activation of PKG-Iα by 8-bromo-
cGMP (8-Br-GMP), a cell-permeable cGMP analog that directly activates PKG [22, 24], has
cytoprotective effects against cisplatin. PKG-Iα activity stimulated by 8-Br-cGMP was re‐
flected by increased VASP phosphorylation at Ser239. Pretreatment of A549 cells with 8-Br-
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cGMP caused significant protection against cisplatin-induced apoptosis, even at higher
concentrations of cisplatin. Interestingly, when the same treatments were used on PKG-Iα
knockdown cells, the cytoprotective effects of 8-Br-cGMP against cisplatin-induced apopto‐
sis was completely abolished, confirming that the cytoprotection (chemoresistance) was
mediated by PKG-Iα [34].
To investigate whether such synergism occurs in ovarian cancer cells, we tested the com‐
bined treatment of the specific PKG-Iα kinase inhibitor, DT-2, and cisplatin in the A2780cp
cisplatin-resistant ovarian cancer cell line. Our new preliminary data presented in this book
chapter (illustrated in Figure 4) verified the synergistic effects of DT-2 and cisplatin. Figure 4
shows the level of apoptosis in A2780cp cells after a 24-hr co-treatment of DT-2 (5 or 10 µM)
and cisplatin (2 µM). The Cell Death Detection ELISAPLUS assay (Roche Applied Science),
based on quantitative sandwich-enzyme-immunoassay-principle with monoclonal antibod‐
ies directed against DNA and histones, were used to quantify apoptotic fragments. DT-2 (5
µM) or cisplatin (2 µM) alone did not cause significant increase in apoptosis. However, com‐
bined treatment of DT-2 (5 or 10 µM) and cisplatin (2 µM) significantly (###P<0.001) in‐
creased apoptosis, showing a synergistic effect.
Figure 4. Synergistic effect of DT-2 with cisplatin in A2780cp human ovarian cancer cells. Combined treatment of
DT-2 (5 or 10 µM) and cisplatin (2 µM) significantly (###P<0.001) increased apoptosis, compared to cisplatin (2 µM)
alone. **P<0.01, ***P<0.001, compared to no DT-2 control. Statistical analysis was performed by one-way ANOVA, fol‐
lowed by Newman-Keuls Multiple Comparison Test using GraphPad (PRISM software). Results were expressed as the
mean ± SEM of at least six different samples.
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during the past three decades [1]. Cisplatin interacts with DNA to form intrastrand crosslink
adducts, and its molecular mechanism involves regulation of p53 and the mitogen-activated
protein kinase (MAPK) signaling pathway [2]. It has been shown that inhibition of ERK1/2
activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor
PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53
protein during exposure to cisplatin [84]. Our data have shown that human ovarian cancer
cells express all of the key components of the NO/cGMP/PKG signaling pathway, including
all three isoforms of NOSs, thus providing an endogenous source of NO [30]. Furthermore,
ovarian cancer cells continuously produce NO at low physiological levels, activating the
heme-dependent soluble guanylyl cyclase (sGC) [29], elevating cGMP levels sufficiently
enough to cause continuous high-level activation of PKG [28]. Our data suggested that such
basal sGC/cGMP activity regulates p53 expression, and promotes cell survival in part
through regulation of caspase-3 [29] (now thought to be mediated by downstream hyperac‐
tivation of PKG-Iα).
Cisplatin is also widely employed in chemotherapy on treating solid tumors such as lung
cancer. Recently, we showed that, in NCI-H460 and A549 non-small cell lung cancer
(NSCLC) cells, PKG-Iα phosphorylates cAMP-response-element-binding protein (CREB) at
Ser133 [34]. CREB was first shown to be phosphorylated by PKG in vitro by Colbran et al.,
which showed that PKG effectively phosphorylates CREB at Ser133, although at a slower
rate compared to PKA [85]. Interestingly, NO was shown to regulate the c-fos promoter in‐
volving soluble guanylyl cyclase (sGC) and PKG [86] in a CREB-dependent manner [87].
They also showed that transfection of PKG in baby hamster kidney (BHK) cells activated the
c-fos promoter [88], which required nuclear translocation of PKG and phosphorylation of
CREB at Ser133 by PKG [87, 89, 90]. In our recent study, inhibition of the sGC/PKG-Iα sig‐
naling pathway by ODQ (sGC inhibitor), DT-2 (PKG-Iα kinase inhibitor) and PKG-Iα-siR‐
NA gene knockdown showed that PKG-Iα kinase activity is necessary for maintaining
higher levels of CREB phosphorylation at Ser133 and the protein expression of certain inhib‐
itor of apoptosis proteins (IAPs), specifically c-IAP1, livin and survivin, as well as the anti-
apoptotic Bcl-2 family member Mcl-1, preventing spontaneous apoptosis and promoting
colony formation [34]. In the same study, we discovered that DT-2 and cisplatin have a syn‐
ergistic effect on the induction of apoptosis, with DT-2 dramatically enhancing the pro-
apoptotic effects of cisplatin in A549 cells (a NSCLC cell line that requires higher levels of
cisplatin to induce apoptosis). We also showed that prior activation of PKG-Iα by 8-bromo-
cGMP (8-Br-GMP), a cell-permeable cGMP analog that directly activates PKG [22, 24], has
cytoprotective effects against cisplatin. PKG-Iα activity stimulated by 8-Br-cGMP was re‐
flected by increased VASP phosphorylation at Ser239. Pretreatment of A549 cells with 8-Br-
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cGMP caused significant protection against cisplatin-induced apoptosis, even at higher
concentrations of cisplatin. Interestingly, when the same treatments were used on PKG-Iα
knockdown cells, the cytoprotective effects of 8-Br-cGMP against cisplatin-induced apopto‐
sis was completely abolished, confirming that the cytoprotection (chemoresistance) was
mediated by PKG-Iα [34].
To investigate whether such synergism occurs in ovarian cancer cells, we tested the com‐
bined treatment of the specific PKG-Iα kinase inhibitor, DT-2, and cisplatin in the A2780cp
cisplatin-resistant ovarian cancer cell line. Our new preliminary data presented in this book
chapter (illustrated in Figure 4) verified the synergistic effects of DT-2 and cisplatin. Figure 4
shows the level of apoptosis in A2780cp cells after a 24-hr co-treatment of DT-2 (5 or 10 µM)
and cisplatin (2 µM). The Cell Death Detection ELISAPLUS assay (Roche Applied Science),
based on quantitative sandwich-enzyme-immunoassay-principle with monoclonal antibod‐
ies directed against DNA and histones, were used to quantify apoptotic fragments. DT-2 (5
µM) or cisplatin (2 µM) alone did not cause significant increase in apoptosis. However, com‐
bined treatment of DT-2 (5 or 10 µM) and cisplatin (2 µM) significantly (###P<0.001) in‐
creased apoptosis, showing a synergistic effect.
Figure 4. Synergistic effect of DT-2 with cisplatin in A2780cp human ovarian cancer cells. Combined treatment of
DT-2 (5 or 10 µM) and cisplatin (2 µM) significantly (###P<0.001) increased apoptosis, compared to cisplatin (2 µM)
alone. **P<0.01, ***P<0.001, compared to no DT-2 control. Statistical analysis was performed by one-way ANOVA, fol‐
lowed by Newman-Keuls Multiple Comparison Test using GraphPad (PRISM software). Results were expressed as the
mean ± SEM of at least six different samples.
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Based on our study of the roles of sGC/PKG-Iα/CREB/IAPs in cisplatin resistant non-small
lung cancer cells, we have proposed the anti-apoptotic role of PKG-Iα observed in A2780cp
cells is likely mediated through PKG-Iα downstream phosphorylation of CREB at Ser133
and activation of certain IAPs. IAPs have been shown to regulate apoptosis and tumorigene‐
sis [91]. Although how CREB regulates apoptosis through IAPs is largely unknown, it was
shown that CREB phosphorylation is a key event in the induction of certain IAPs, c-IAP2
and livin, via multiple protein kinases, PKA, ERK1/2 and p38 MAPK, in colon cancer cells
[92, 93]. In ovarian cancer cells, X-linked inhibitor of apoptosis protein (XIAP) has been
shown to control ovarian tumor growth and regulate Akt activity and caspase-3 in cisplatin-
induced apoptosis [94-96], and the ability of cisplatin to down-regulate XIAP may be an im‐
portant determinant of chemosensitivity [97]. Down-regulation of XIAP sensitized cells to
cisplatin in the presence of wild-type p53, and both XIAP and Akt modulated cisplatin sen‐
sitivity individually but that XIAP required Akt for its full function [98]. Inhibition of
PI3K/Akt/mTOR signaling has been shown to activate apoptosis and inhibit migration and
invasion in ovarian cancer cells [3, 4, 99-104]. Furthermore, inhibition of PI3K pathway sig‐
naling using PI3K or mTOR inhibitors has been shown to sensitize ovarian cancer cell lines
to induction of apoptosis by platinum compounds [4, 5]. Several recent evidences have sug‐
gested that such effects involve the matrix-metalloproteinases (MMPs) [105-107], which are
zinc-dependent endopeptidases capable of degradation of extracellular matrix proteins.
5. Overall model of NO/cGMP/PKG-Iα signaling pathway in ovarian
cancer
Figure 5 illustrates our overall model showing the involvement of the NO/cGMP/PKG-Iα
pathway in promoting cell proliferation and suppressing apoptosis in human ovarian cancer
cells, which would contribute to enhanced tumor growth and chemoresistance. Our early
studies of the NO/cGMP/PKG pathway have identified PKG as a key mediator of vasodila‐
tion and anti-hypertensive effects induced by NO as well as atrial natriuretic peptide (ANP)
[18-21]. Recent studies from our laboratory have shown that basal or moderately elevated
PKG-Iα activity plays a cytoprotective role in preventing spontaneous apoptosis and pro‐
moting cell proliferation in many types of mammalian cells, including neural cells [22-27],
human ovarian cancer cells [28-30], primary murine vascular smooth muscle cells [31] and
murine bone marrow stromal cells [32]. We found that murine bone marrow-derived mesen‐
chymal (stromal) stem cells endogenously produced ANP and that basal NO/cGMP/PKG-Iα
activity and autocrine ANP/cGMP/PKG-Iα activity are necessary for preserving cell survival
and promoting cell proliferation and migration in the OP9 bone marrow stromal cell line
[32]. Recently, we have identified certain intracellular proteins phosphorylated by PKG-Iα,
including BAD [26], vasodilator-stimulated phosphoprotein (VASP) [28, 31, 32], c-Src [28]
and cAMP responsive element binding protein (CREB) [34]. We have recently shown that
PKG-Iα directly phosphorylates BAD at Ser155, using in vitro experiments, and have further
shown that a large part of the Ser155 phosphorylation of BAD within neuroblastoma cells is
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dependent on endogenous PKG-Iα kinase activity, contributing to decreased caspase-3 ac‐
tivity and inhibition of apoptosis [26].
Figure 5. Cellular model of the involvement of the NO/cGMP/PKG-Iα signaling pathway in promoting chemoresist‐
ance, tumor growth and angiogenesis in ovarian cancer. A special role of VASP phosphorylation at Ser239 may con‐
tribute to enhanced ovarian cancer cell migration and invasion.
As illustrated in the model of Figure 5, we have also identified an important role of c-Src/PKG-
Iα interaction in promoting DNA synthesis and cell proliferation in human ovarian cancer
cells. Previous studies have shown that PKG-I binds Raf-1 and promotes downstream activa‐
tion of MEK and ERK1/2 in endothelial cells [76]. In ovarian cancer cells, we proposed that
PKG-Iα binds to Raf-1 at the internal surface of the plasma membrane, bringing PKG-Iα in
close proximity to one of its downstream target proteins c-Src. This leads to downstream acti‐
vation of the Raf-1/MEK/ERK signaling pathway, promoting cell proliferation. We found that
PKG-Iα directly phosphorylates c-Src at Ser17, which enhances the tyrosine kinase activity of c-
Src in both in vitro and intact-cell experiments [33]. Our recent studies have shown a clear role
of the PKG-Iα-mediated phosphorylation of c-Src at Ser17 in preventing apoptosis and pro‐
moting proliferation, attachment and migration in the mesothelioma and NSCLC cells. It is
very likely that a similar PKG-Iα catalyzed phosphorylation of c-Src at Ser17 occurs in human
ovarian cancer cells, which can explain the dependence of the c-Src activation by EGF on the
presence of PKG-Iα [28]. Epidermal growth factor (EGF)-induced activation of c-Src tyrosine
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cells. Previous studies have shown that PKG-I binds Raf-1 and promotes downstream activa‐
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PKG-Iα binds to Raf-1 at the internal surface of the plasma membrane, bringing PKG-Iα in
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vation of the Raf-1/MEK/ERK signaling pathway, promoting cell proliferation. We found that
PKG-Iα directly phosphorylates c-Src at Ser17, which enhances the tyrosine kinase activity of c-
Src in both in vitro and intact-cell experiments [33]. Our recent studies have shown a clear role
of the PKG-Iα-mediated phosphorylation of c-Src at Ser17 in preventing apoptosis and pro‐
moting proliferation, attachment and migration in the mesothelioma and NSCLC cells. It is
very likely that a similar PKG-Iα catalyzed phosphorylation of c-Src at Ser17 occurs in human
ovarian cancer cells, which can explain the dependence of the c-Src activation by EGF on the
presence of PKG-Iα [28]. Epidermal growth factor (EGF)-induced activation of c-Src tyrosine
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kinase activity was found to cause tyrosine phosphorylation of PKG-Iα, increasing the serine/
threonine kinase activity of PKG-Iα (indicated by phosphorylation of the PKG substrate VASP
at Ser239) and its growth-promoting effects in ovarian cancer cells [28]. In human ovarian can‐
cer cells, the c-Src-mediated tyrosine-phosphorylation of the EGF receptor was found to be
highly dependent on PKG-Iα kinase activity [28].
We hypothesized in ovarian cancer cells, as reported in the lung cancer cells in our recent
study [34], that PKG-Iα phosphorylated CREB at Ser133, and the cGMP/PKG-Iα signaling
pathway maintains the expression of certain IAPs such as c-IAP1, livin and survivin as well
as the anti-apoptotic Bcl-2 family member Mcl-1, leading to decreased activity of caspase-3
and promoting cell survival. In ovarian cancer cells where PKG-Iα is hyperactivated, in‐
creased downstream phosphorylation of CREB at Ser133 and increased IAPs expression
may explain the development of resistance to cisplatin-induced apoptosis. Moreover, PKG-
Iα siRNA gene knockdown also decreased both basal and EGF-stimulated cell migration in
A2780cp ovarian cancer cells, as shown in Figure 3.
VASP phosphorylation at Ser239 has been shown to be a useful indicator of endogenous
PKG kinase activity, both in our recent studies [28, 31, 32] and reports from others [61, 63,
64]. In the current study in this book chapter, we show that siRNA gene knockdown of
PKG-Iα expression inhibited EGF-stimulated increases in VASP Ser239 phosphorylation and
Src/SFK autophosphorylation in A2780cp (cisplatin-resistant, mutated p53) ovarian cancer
cells. Therefore, VASP Ser239 phosphorylation may be a useful biomarker in ovarian cancer
cells, and hyperactivation of the unique NO/sGC/PKG-Iα signaling pathway may be a novel
therapeutic target for regulation of cancer cell migration/invasion.
Also shown in the model of Figure 5 is the role of endothelial cells, which would provide an
additional source of endogenous NO within the growing tumor, potentially contributing to
the “angiogenic switch”, i.e. the increased tumor growth that occurs after the invasion of en‐
dothelial cells into the tumor. Endothelial cells also play another important role in tumor
growth by providing new blood vessels needed for the vascularization and blood perfusion
of the growing tumor. In endothelial cells, heat shock protein 90 (HSP90) and Akt activate
eNOS involving the formation of a HSP90-Akt-Calmodulin (CaM)-eNOS complex, leading
to an increase in NO production [108-111]. Interestingly, HSP90 activation of eNOS can be
Ca2+-dependent [112] or Ca2+-independent [109, 113].
6. Future experiments
Our future studies will need to determine: 1) whether PKG-Iα is the only isoform of PKG
expressed in other human ovarian cancer cell lines as well as in tumor samples of ovarian
cancer patients, 2) the subcellular localization of PKG-Iα (and possibly PKG-Iβ), for exam‐
ple, membrane, nuclear, and/or cytosolic localization, 3) the roles of PKG-Iα, its downstream
phosphorylation of CREB at Ser133 (and other transcription factors), expression of the IAPs
and anti-apoptotic Bcl-2 family proteins in ovarian cancer cells.
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7. Conclusions
The NO/cGMP/PKG-Iα pathway and the downstream phosphorylation of the actin-fila‐
ment/focal-adhesion-regulating protein VASP at Ser239 appear to promote migration/inva‐
sion and the downstream phosphorylation of BAD at ser155, CREB at ser133 and c-Src at
ser17 appear to promote DNA synthesis, cell proliferation and platinum resistance in ovari‐
an cancer cells. The unique features of this signaling pathway in ovarian cancer cells may
provide a novel therapeutic target for disrupting tumor growth and the metastasis and sec‐
ondary tumor formation during ovarian cancer progression.
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1. Introduction
Ovarian cancer is the most lethal cause of gynecological cancer deaths in the developing
world and typically presents at an advanced stage when optimal debulking and platinum
based-chemotherapy remain the cornerstone of management. Unfortunately, despite fre‐
quent initial responses to chemotherapy, these tumors almost invariably relapse. Thanks to
recent large scale molecular profiling studies in ovarian cancer, such as the integrated ge‐
nomic analyses performed by the Cancer Genome Atlas (TCGA) network, significant head‐
way has been made in our understanding of the molecular pathogenesis of ovarian cancer1.
However these advances have failed to translate into meaningful clinical benefit for patients.
The only approved novel ‘targeted’ therapy to date in ovarian cancer is the anti-angiogenic
antibody, bevacizumab, for which reliable predictive markers still elude us.
With the possible exception of the p53 signaling network, the PI3K/Akt/mTOR cascade is
probably the most frequently altered signaling pathway in cancer, including ovarian cancer.
First generation inhibitors of mTOR have demonstrated anti-tumor activity and are current‐
ly approved for the treatment of renal, pancreatic, breast and some brain cancers. In addi‐
tion, a huge number of PI3K, Akt and second generation mTOR inhibitors are in early
clinical trials.
We propose to provide a brief overview of the PI3K/Akt/mTOR signaling network and dis‐
cuss the rationale for targeting this pathway in ovarian cancer. Preclinical data and results of
recent clinical trials will be presented. In addition, some of the challenges facing the devel‐
opment of these inhibitors in ovarian cancer will be discussed, such as the need for predic‐
tive markers and quality tumor samples, drug resistance, managing toxicity, as well as trial
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1. Introduction
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design considerations in order to optimize the development of novel therapies against the
PI3K pathway in ovarian cancer.
2. The PI3K/Akt/mTOR signaling pathway
The phophatidylinositol 3 Kinase (PI3K) pathway is a complex signaling network coordinat‐
ing a number of direct upstream inputs from growth factors (EGF, heregulin, TGF, and oth‐
ers), tyrosine kinase receptors (IGF1R, EGFR, HER2…) or other membrane receptors such as
Met as well as cross-talk with the Ras-Raf-Mek-Erk pathway via indirect input from Ras
(Figure 1). PI3K is composed of a p110 catalytic subunit and a p85 regulatory subunit. The
p110 subunit of PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to the ac‐
tive second messenger, PIP3 which recruits Akt to the plasma membrane, and results in a
conformational change and activation of PDK1 and Akt proteins. Akt is a serine threonine
kinase that regulates a huge number of downstream targets [2],[3], while the phosphatase
and tensin (PTEN) analog protein acts as an endogenous pathway repressor by de-phos‐
phorylating PIP3 back to PIP2. Akt controls critical cellular survival and metabolic processes
by influencing some of the following:
1. Via downstream regulation of p53, NFκΒ (nuclear factor κΒ) or CREB (cAMP response
element-binding protein), Akt promotes the transcription of genes involved in anti-
apoptotic and proliferative responses such as XIAP (X-linked inhibitor of apoptosis pro‐
tein), the apoptosis regulating protein Bcl-2, survivin and others[4].
2. Akt also phosphorylates proteins involved in cell cycle regulation and apoptosis thus
promoting cell cycle progression and survival:
a. Phosphorylation of GSK3 inhibits proteosomic degradation of cyclin D1,
b. Phosphorylation of the cyclin-dependent kinase (CDK) inhibitors p21 and p27 commits
them to nuclear export and removes their inhibitory effect on cyclin D and cyclin E,
c. Downregulation of the apoptotic effector, caspase 9.
3. In addition downstream signaling via mammalian target of rapamycin (mTOR) acti‐
vates two key substrates 4EBP1 and p70S6K resulting in increased translation of target
genes involved in angiogenesis (VEGF), or cell cycle progression (cyclin D1, c-Myc)[5].
In addition to activation via upstream input, the PI3K pathway can be ‘intrinsically’ activat‐
ed due to i) gain of function mutations or amplifications in the p110 subunit of PI3K
(PIK3CA), ii) mutations in the p85 subunit (PIK3R), iii) mutations or amplifications in one of
the Akt isoforms (AKT1, AKT2, AKT3), or iv) due to loss of its negative regulator, PTEN via
inactivating mutations, copy number loss or homozygous deletions.
While mTOR is probably the best described direct target of Akt, the mTOR complex is actually
composed of two components, the mTORC1-Raptor complex primary coordinator of transla‐
tional control via 4EBP1 and p70S6K[6]; and the mTORC2-Rictor complex whose function is
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less well described but likely regulates cell proliferation and survival in part by Akt activation
via phosphorylation at Serine 473[7]. Importantly mTORC1 is sensitive to inhibition by rapa‐
mycin, while mTORC2 is not. In the presence of selective mTORC1 inhibition, mTORC2 can ex‐
ert a positive feedback on Akt[8]. As discussed later, this positive feedback loop may have
important implications regarding the emergence of resistance to first generation mTOR inhibi‐
tors (rapalogs) that exclusively target mTORC1, with no effect on mTORC2.
Figure 1. The PI3K/Akt/mTOR signaling pathway. This pathway is up-regulated in a significant proportion of ovari‐
an cancers via either (i) direct upstream stimulation (growth factor receptors and their ligands), (ii) indirect activation
via cross-talk with the Ras pathway, or (iii) intrinsically via activating genetic alterations in PI3K or Akt, or via loss of
function in the tumor suppressor, PTEN.
3. Relevance of PI3K/Akt/mTOR signaling in ovarian cancer
The PI3K/Akt/mTOR pathway is frequently deregulated in ovarian cancer. Array Compara‐
tive Genomic Hybridization (aCGH) studies on 93 ovarian tumors have identified this path‐
way as the most frequently altered in ovarian cancer [9]. Copy gains in the genes encoding
both the p110α (PIK3CA) and p110β (PIK3CB) subunits of PI3K were associated with a poor
prognosis in patients with ovarian cancer. Expression levels of both p110α and pAkt were
analyzed in over 500 ovarian cancer tumors and associated with decreased survival. Activa‐
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tion of the pathway as measured by Akt or mTOR phosphorylation levels is almost ubiqui‐
tous in ovarian cancer and an independent negative prognostic marker [10-12].
Interestingly, the type of PI3K/Akt/mTOR molecular alteration appears to be histological
subtype specific (Table 1). There is mounting evidence that ovarian cancer is a highly hetero‐
geneous disease with marked differences in molecular profile, histology, prognosis and che‐
mosensitivity depending on the subtype [1],[13],[14]. The most common subtype (70%) high
grade serous ovarian cancer (HGSOC) is characterized by almost universal p53 mutations
(95-97% of cases) and marked genomic instability resulting in frequent somatic copy num‐
ber alterations (amplifications or deletions)[13]. In HGSOC, oncogenic mutations are rare,
but amplifications of the p110 subunit of PI3K (PIK3CA) have been described in 20% of cas‐
es, amplifications of one of the AKT isoforms (AKT 1, AKT2 or AKT3) occur in 15% to 20%,
while PTEN deletions have been described in 5%[15],[16] (Table 1). Finally RICTOR or RAP‐
TOR amplifications have also been reported [1]. Rare but potentially relevant mutations in
HGSOC include activating PIK3CA mutations (3%), or loss of function PTEN mutations (1%)
[17]. Mutations have also been described in the p85α subunit of PI3K (PIK3R1, 4%), resulting
in loss of its negative regulation on the p110 subunit and constitutive kinase activity[18]. In
summary, 40 to 50% of HGSOC may have constitutive PI3K signaling. In a significant pro‐
portion of HGSOC, hyperactive PI3K/Akt/mTOR pathway may also be attributable to up‐
stream deregulations in receptor tyrosine kinases (RTKs) or cross-talk with the
Ras/Mek/Mek/Erk pathway. Indeed, amplifications or mutations in RTKs such as ERBB3,
ERBB2, EGFR or IGF1R have been described with frequencies of 1% to 9% [1],[17]. Similarly,
the ras pathway is often altered in HGSOC by amplifications in KRAS (11%), MAPK (20%),
loss of the tumor suppressor NF1 (8%), or less frequent mutations in KRAS, NRAS, or BRAF.
Whereas individual mutations remain an infrequent event in HGSOC, they are much more
prevalent in the rarer subtypes such as low grade serous, mucinous, endometrioid or clear
cell ovarian cancer. For example, 20% of endometrioid and 35% of clear cell ovarian tumors
display PIK3CA mutations[19],[20]. In addition, while PTEN loss of function mutations are
rare in ovarian cancer in general, they are well documented in up to 20% of endometrioid
tumors and PTEN deletion occurs in 20% of endometrioid and clear cell ovarian cancers[21].
Low grade mucinous and serous subtypes do not tend to demonstrate intrinsic activation of
PI3K effectors, however they frequently exhibit KRAS mutations, or amplifications/muta‐
tions in ERBB2[22],[23].
Importantly intrinsic activation of the pathway (via PIK3CA mutations and PTEN loss) has
been shown to initiate ovarian tumors in mice and inhibition of PI3K/mTOR in these models
delayed tumor growth and prolonged survival, thus providing critical proof of concept for
the pathologic relevance of this pathway in OC and its potential as a therapeutic target[24],
[25]. Whether amplifications of pathway members actually activate PI3K signaling and con‐
fer comparable sensitivity to pathway inhibitors remains to be established. Similarly, while
cross-talk with Ras may result in PI3K activation, it is unlikely that this also results in PI3K
pathway dependence, however as discussed later, alterations in KRAS may be relevant with
regards to predicting benefit from dual PI3K-Ras inhibition.
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High grade serous ovarian cancer is exquisitely chemosensitive, with response rates to first-
line platinum-based chemotherapy of 75%, but almost invariably relapses with acquired re‐
sistance. The rarer subtypes tend to respond poorly to platinum chemotherapy with
response rates of only 15% to 30%. Thus both acquired and de novo chemotherapy resist‐
ance remains a significant clinical challenge in ovarian cancer. Increased phosphorylation of
mTOR has been described in cell lines with acquired cisplatin resistance, and Akt signaling
has been implicated in primary platinum resistance[12]. Inhibitors of Akt or mTOR were
shown to restore chemo-sensitivity in vitro and in xenograft models [26],[27]. These data
suggest a potential role for inhibitors of the PI3K pathway in modulating chemotherapy sen‐
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4. Results of clinical trials targeting the PI3K/Akt/mTOR pathway in
ovarian cancer
The frequent PI3K/Akt alterations demonstrated in vivo in tumors from patients with ovari‐
an cancer, combined with the evidence for dependence on this oncogenic pathway in pre‐
clinical models provide a robust biological rationale for investigating the benefit of targeting
PI3K, Akt or mTOR in ovarian cancer. However as detailed throughout this chapter, the in‐
trinsic complexity of this signaling network may limit the anti-tumor potential of inhibiting
a single effector along the pathway.
4.1. mTOR inhibitor monotherapy in ovarian cancer (Table 2)
The first inhibitors of the pathway to enter the clinic were rapamycin analogs that bind to the
FK506 binding protein-12 of the MTORC1 complex and prevent mTOR activity. Rapamycin
was used for years as an immunosuppressant to prevent rejection in solid organ transplants
and hematological malignancies; its toxicity profile is therefore well described with main side
effects consisting of edema, hypertension, renal toxicity, hematologic toxicity, and hypertrigly‐
ceridemia and hypercholesterolemia. In addition, rarer but potentially more concerning side
effects included interstitial lung disease, risk of secondary lymphoma, and reactivation of la‐
tent infections[28]. Rapamycin analogs with less immunosuppressive properties, such as tem‐
sirolimus, everolimus and ridaforolimus have shown activity in a number of tumor types.
A phase II trial of temsirolimus at a flat dose of 25mg IV weekly in patients with ovarian cancer
progressing after 1-3 previous regimens met its first stage response and PFS criteria at interim
analysis with three responses and seven PFS at 6 months and pursued accrual through the sec‐
ond stage[29]. At final analysis, with 54 evaluable patients, grade 3-4 toxicities were as expect‐
ed for mTOR inhibitors, mainly gastrointestinal (10%), metabolic (15%), and study drug was
discontinued in 6% for interstitial pneumonitis. Unfortunately, objective responses were only
seen in 9.3% (5/54) and 6 months PFS was 24% thus the study failed to meet its efficacy end‐
point. Exploratory analyses were conducted in order to identify potential predictive markers.
Phosphorylated-Akt, p-mTOR, p-p70-S6K, and cyclinD1 were measured in archival tumor
samples as surrogates for activation of the PI3K pathway; only cyclinD1 levels were weakly
correlated with PFS>6 months (r=0.28). The authors concluded that observed activity was in‐
sufficient to justify a phase III trial of temsirolimus in unselected patients with ovarian cancer.
As discussed later in the chapter; these negative results may be explained by i) the lack of pa‐
tient selection, ii) the cytostatic rather than cytotoxic effect of mTOR inhibitors (mTORi) and iii)
the fact that these agents may require combinations with chemotherapy or other targeted
agents to achieve a robust anti-tumor effect. The trial just fell short of its PFS efficacy endpoint
(>24% PFS at 6 months), had the study limited enrollment to clear cell and endometrioid histol‐
ogies known to show frequent PI3K alterations, the results may have been different.
4.2. mTOR inhibitors in combination with chemotherapy in ovarian cancer (Table 2)
Given the implication of mTOR and Akt in chemo-resistance and the preclinical studies sug‐
gesting an additive benefit with chemotherapy, studies have investigated mTORi-cytotoxic
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combinations. A phase I study of weekly topotecan (1mg/m2 days 1, 8 and 15) and temsiroli‐
mus 25mg days 1, 8, 15 and 22 on a 28 day schedule was conducted in 15 patients with gyne‐
cological malignancies including 7 patients with ovarian cancer. Dose limiting toxicities
were myelosuppression and although efficacy was not a primary objective, 8 of 11 patients
had stable disease at first evaluation and one patient with clear cell histology was still pro‐
gression free at 6 months[30].
A phase Ib dose escalation study of temsirolimus (T) and pegylated liposomal doxorubicin
(PLD) in advanced breast and gynaecological malignancies identified T 15mg and PLD
40mg/m2 as the maximum tolerated dose (MTD)[31]. The most frequent grade 3-4 adverse
events were fatigue (5%), nausea (16%), mucositis (21%), rash (11%) and hand-foot syn‐
drome (21%). The mean PFS was 4.9 months and the authors concluded that the combina‐
tion warranted further study.
Two other phase I studies of rapalogs in combination with chemotherapy (temsirolimus
plus carboplatin/paclitaxel[32] and everolimus plus weekly paclitaxel[33]) have been con‐
ducted with grade 3-4 neutropenia being the major DLT (at 89% and 56%, respectively) as
well as fatigue and mucositis. These studies included a small number of patients with ad‐
vanced ovarian cancer and responses were described (3 of 6 patients with ovarian cancer
had a PR to temsirolimus plus carboplatin and paclitaxel). However given the small num‐
bers and the combination with chemotherapy, no robust conclusions may be drawn regard‐
ing the added value of the mTOR inhibitor.
These early studies have begun to establish the feasibility and safety of mTORi-cytotoxic
combinations, randomized trials will be required to investigate efficacy. In the interim, a
number of non-randomized phase I and II studies are ongoing (Table 4). Given the heteroge‐
neity of ovarian cancer, non-randomized phase II studies may require a degree of patient se‐
lection by molecular alteration or even histology in order to enrich the trial for potential
responders and make the patient population more uniform with regards to natural disease
course and chemosensitivity. Indeed studies recruiting patients with both high and low
grade tumors with marked differences in tumor growth rates and responsiveness to chemo‐
therapy may mask any benefit from the addition of the mTOR inhibitor. For example, a
phase II trial of temsirolimus plus carboplatin and paclitaxel as adjuvant treatment is ongo‐
ing for patients with stage III or IV clear cell ovarian cancer (NCT01196429).
4.3. mTOR inhibitors in combination with anti-angiogenics in ovarian cancer (Table 2)
Finally, given the activity of VEGF inhibitors in ovarian cancer and the fact that downstream
mTOR targets include angiogenic genes, there is A biological rationale for using mTOR and
VEGF inhibitors in combination. A phase II trial of temsirolimus and bevacizumab in ovari‐
an cancer has been conducted[34]. Thirty one (31) patients were evaluable for toxicity and 25
for efficacy. Adverse events included fatigue, mucositis, hypertension and neutropenia. In
addition one grade 4 rash and 6% colonic perforations (2/31) were reported. While the con‐
firmed PR rate is only 12% in the first 25 evaluable patients (all in platinum-resistant pa‐
tients), the 6 months PFS rate of 56% (14/25) met efficacy criteria to justify progression to
second stage accrual. Updated results are awaited. It is noteworthy that the study only en‐
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rolled patients who had not been exposed to anti-angiogenics; the previously reported RR of
15-21% in early trials of bevacizumab monotherapy among heavily pretreated patients with
ovarian cancer raises the possibility that temsirolimus may be adding little anti-tumor effect
to bevacizumab alone[35],[36]. A randomized phase II study is ongoing comparing bevaci‐
zumab alone to bevacizumab and everolimus in patients with recurrent ovarian cancer
(NCT00886691, Table 4). Patients will be stratified according to their platinum-free interval
or prior treatment with bevacizumab. This study should provide valuable insight into the
potential additive benefit of this combinatorial strategy.
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While the evidence for clinical activity of mTOR inhibitors in ovarian cancer remains quite lim‐
ited, especially compared to endometrial cancer where efficacy has been more encouraging, a
number of phase II trials of mTOR inhibitors alone or in combination with conventional cyto‐
toxics or targeted therapies are currently ongoing. These should help clarify the role mTOR in‐
hibitors may have in the management of patients with ovarian cancer (Table 4).
4.4. Akt inhibitors
Targeting Akt upstream from mTOR may produce a more effective knock-down of signal
transduction and a number of Akt inhibitors have therefore been generated. These include
ATP-competitive inhibitors, allosteric inhibitors, peptide-based inhibitors and lipid-based
inhibitors (reviewed in Stronach et al[37]). Akt inhibitors are still in early stages of clinical
development and two compounds have been specifically tested in ovarian cancer (Table 3).
The most mature inhibitor in clinical development is the lipid-based inhibitor, perifosine, it
interferes with the cell membrane recruitment of Akt (thus preventing activation). However
early data in phase I and II trials in other tumor types were disappointing with frequent gas‐
trointestinal toxicity and a lack of meaningful activity[38]-[41]. Given the suggestion that the
narrow therapeutic window of perifosine may limit its clinical usefulness, combination trials
with conventional cytotoxics have been conducted in order to improve the therapeutic in‐
dex. Preclinical studies have shown that perifosine inhibited ovarian cancer cell prolifera‐
tion, motility and angiogenesis and potentiated paclitaxel sensitivity in vitro and in vivo[42],
[43]. On this basis, a phase I trial of perifosine and docetaxel in platinum and taxane resist‐
ant ovarian cancer was conducted[42]. Perifosine was given at a loading dose of 100mg ev‐
ery 6 hours for 4 doses followed by a daily dose according to dose level (50, 100 or 150mg
daily) in combination with docetaxel 75mg/m2 day 1 every 3 weeks. Twenty one patients
were enrolled including 11 at the MTD level of perifosine 150mg. No DLTs were observed,
frequent adverse events included nausea, vomiting, anorexia, constipation and fatigue. With
regards to efficacy at the MTD (N=11), there was one PR in an endometrioid ovarian cancer
with a loss of function PTEN mutation (R130Q) and one SD maintained for 4 months in a
PI3K mutated clear cell tumor. Two other patients without apparent PI3K alterations ach‐
ieved SD while two patients with KRAS mutations progressed quickly. The investigators al‐
so performed pharmacodynamic studies using reverse phase protein array (RPPA) to detect
changes in total and phosphorylated markers in pre-treatment versus day 7 tumor biopsies
and functional imaging studies using FDG-PET scans. Bcl2 and ERK2 levels were increased
by treatment suggesting that the low response rate may be in part explained by perifosine
induced increases in alternate signalling pathways. However FDG-PET responses at one
week correlated with inhibition of S6 phosphorylation raising the possibility that FDG-PET
may serve as an early surrogate indicator of Akt inhibition.
GSK795 is an oral ATP-competitive pan-Akt inhibitor in early stages of development and a
small phase I pharmacodynamic and pharmacokinetic study was conducted in order to
characterize the relationship between AKT inhibition by GSK795 and downstream effects in
patients with advanced platinum resistant ovarian cancer[44]. Twelve patients were enrol‐
led. The only toxicities were grade 2 anorexia (18%) and vomiting (18%). FDG metabolism
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induced increases in alternate signalling pathways. However FDG-PET responses at one
week correlated with inhibition of S6 phosphorylation raising the possibility that FDG-PET
may serve as an early surrogate indicator of Akt inhibition.
GSK795 is an oral ATP-competitive pan-Akt inhibitor in early stages of development and a
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decreased in the majority of tumors but there was no dose response relationship. Among 5
patients treated at the higher dose levels, paired pre- and post-treatment tumor biopsies
demonstrated downregulation in pAkt and in the tumor proliferative marker, Ki67. Two pa‐
tients have achieved >6 months PFS with objective tumor regressions of 26% and 11%, re‐
spectively.
In  addition  to  the  aforementioned  inhibitors,  Akt  isoform  specific  inhibitors  are  being
developed,  however  the  distinct  functions  of  each  of  these  isoforms  and  their  rele‐
vance  to  different  tumor  types  or  individual  tumor  genetic  background  is  still  poorly
understood.  Studies  of  AKT isoform knockouts  provide  some insight  into  their  relative
roles:  AKT1  loss  is  associated  with  impaired  fetal  development  and  increased  fetal
mortality;  AKT2 loss  leads  to  diabetes  and AKT3 loss  results  in  defective  central  nerv‐
ous system development[45].
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Table 3. Completed clinical trials of Akt inhibitors in ovarian cancer
4.5. PI3K inhibitors
The PI3K inhibitors, LY290002 and wortmannin have been used for years as tools in preclin‐
ical experiments to demonstrate the biological relevance of PI3K and explore its potential as
a therapeutic target in cancer. However, the micromolar IC50 (50% inhibitory concentration)
and off-target effects of these agents have limited their clinical applicability. Less toxic PI3K
inhibitors are just entering phase II stages of clinical development (reviewed in Kurtz et
al[46]). BKM120 is an oral selective PI3K inhibitor with an IC50 for the PI3K kinase of 35nM.
A dose escalation phase I trial has shown that the drug is well tolerated at the MTD of
100mg once a day with rash, hyperglycemia, diarrhea and mood alterations in over a third
of patients[47]. BKM120 demonstrated dose dependent inhibition of FDG activity and
downregulation in p-S6 in skin biopsies. The only response was in a KRAS mutated breast
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cancer patient, and 7 patients had stable disease for more than 8 months. Five of these 7 pa‐
tients had either PTEN loss or PI3K mutation. GDC0941 is an oral selective class I PI3K in‐
hibitor that showed evidence of clinical activity in 3 patients enrolled in a phase I trial,
including one ovarian cancer (PTEN negative) patient who remained on study for 5 months
with a FDG-PET response, >50% decrease in pS6 staining in paired biopsies, and 80% de‐
crease in CA-125[48]. XL147 is another selective PI3K inhibitor which was well tolerated in a
phase I trial with rash as the main DLT. An associated trial of XL147 in combination with
carboplatin and paclitaxel demonstrated that the combination was feasible with no evidence
of PK interactions or overlapping toxicities and dose expansion cohorts are ongoing in ovar‐
ian cancer[49].
5. Challenges of PI3K/Akt/mTOR pathway inhibitors
Despite a strong preclinical rationale, clinical trials of novel agents targeting the PI3K/Akt/
mTOR pathway in ovarian cancer have been disappointing. Given the complexity and re‐
dundancy of the PI3K signaling network, combined targeting may be required. The fact that
all the trials conducted to date enrolled an unselected patient population may have diluted
objective activity in a subset. It is therefore crucial that efforts are made to uncover resist‐
ance mechanisms, develop rationale combinatorial strategies, identify predictive biomark‐
ers, and explore novel trial designs.
5.1. Resistance
5.1.1. Feedback loops via MTORC2 or IRS1
Compensatory feedback loops may allow escape from blockade of a single effector of the
pathway. Early on, paradoxical increases in pAkt were identified in preclinical models and
in tumors from patients treated with mTOR inhibitors8. As illustrated in Figure 2, rapalogs
suppress MTORC1 but do not affect the other subunit of mTOR, MTORC2. MTORC2 is a
positive regulator of Akt, and selective inhibition of MTORC1 results in compensatory in‐
crease in Akt phosphorylation at Serine 473[50]. Rapalog-induced rebound Akt activation
has been proposed as one of the mechanisms accounting for resistance to first generation in‐
hibitors in the clinic. In addition, although the function and downstream effectors of
MTORC2 are less well described, it is reasonable to expect that complete abrogation of the
whole mTOR complex may be required to achieve a robust anti-tumor effect. As a result,
mTORC1/mTORC2 dual inhibitors have been developed such as DS3078a, INK128,
AZD8055, OSI027 and AZD2014 (reviewed in [51]).
Another postulated compensatory escape route from mTOR inhibition is via insulin growth
factor 1 receptor (IGF1R, see Figure 2)[52]. Insulin receptor substrate-1 is normally under
basal negative regulation via phosphorylation by mTOR; mTOR inhibition prevents IRS-1
phosphorylation thus allowing IRS-1 to complex with IGF1R and promote Akt signaling[53]
thereby generating another positive feedback loop accounting for resistance.
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Figure 2. Proposed mechanisms accounting for resistance to inhibitors of the PI3K pathway. (1) Selective block‐
ade of MTORC1 by rapalogs increases MTORC2 and results in positive feedback activation of pAkt. (2) Inhibition of
mTOR removes the basal inhibition of IRS1, now free to bind to and activate IGF1R and promote PI£K activation. (3) In
the presence of constitutive activation of KRAS, abrogation of the PI3K pathway alone does not inhibit cancer cell
growth. (4) A dysfunctional apoptotic pathway (high bcl2, high survivin...) may lead to resistance to the pro-apoptotic
effects of PI3K apthway inhibitors. (5) One downstream effect of Akt inhibition is cell cyle arrest via increase in the cdk
inhibitors, p21 or p27; p27 low tumors may be resistant to PI3K pathway inhibitor induced cell cycles arrest.
5.1.2. The Ras pathway: KRAS/BRAF mutations and compensatory increases in Erk signaling
Interactions with parallel pathways may also allow escape from PI3K inhibition. Akt has
been shown to be phosphorylated via cross-talk with Ras. Thus, in KRAS mutant tumors
primarily driven by a constitutively upregulated Ras pathway, PI3k pathway inhibitors
alone are unlikely to be effective. This hypothesis is supported by studies demonstrating
that KRAS or BRAF mutated tumors are insensitive to mTOR inhibitors. Using a panel of
cell lines including ovarian cancer, PI3K mutated tumors were shown to be sensitive, while
dual PI3K and KRAS or BRAF mutated tumors were resistant to everolimus[54]. Important‐
ly, they also demonstrated that knock-down of the KRAS mutation in these cells restored ev‐
erolimus sensitivity in vitro and in vivo. In the presence of KRAS or BRAF mutations,
tumors may exhibit ‘oncogenic addiction’ to an alternate survival pathway, e.g. Ras-Raf-
Mek-Erk. This illustrates the fact that sensitivity to PI3K transduction inhibitors may require
not only pathway activation but also demonstration of pathway dependence.
In addition to reactivating Akt, rapalogs have been reported to cause treatment induced in‐
creases in Mek/Erk signalling. In mice models and human tumors, everolimus increased
Erk1/2 activation in post treatment tumor samples, suggesting the existence of crosstalk be‐
tween the PI3K/mTOR and Mek/Erk signal transduction cascades[55]. Selective targeting of
one pathway may simply result in compensatory upregulation in the other, and vice versa.
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5.1.3. Dysfunctional apoptotic machinery
Even in tumor types such as renal cell or pancreatic neuroendocrine cancers where mTOR
inhibitors have demonstrated sufficient clinical benefit to justify FDA approval, objective tu‐
mor responses are sporadic[56]. Some researchers have hypothesized that tumor shrinkage
in response to mTOR inhibitors requires a functional apoptotic machinery. Majumder et al
demonstrated that rapamycin-resistant SKOV3 ovarian cells have an activated PI3K path‐
way but upregulated levels of the anti-apoptotic protein, bcl2, and bcl2 knock-down using
siRNA restored rapamycin sensitivity[57]. In line with this preclinical data, the Phase I trial
of the Akt inhibitor perifosine reported compensatory increases in bcl2 in post treatment tu‐
mor biopsies[42].
5.1.4. Cell cycle dependent kinase (cdk) inhibitors
One of the major anti-tumor effects of PI3K blockade is to activate the cdk inhibitors p27 and
p21, allow their nuclear translocation where they interact with, and inhibit cdks, thereby
promoting cell cycle arrest. p27-null cells are resistant to rapamycin in vitro, some therefore
postulate that tumors that have very low levels of p27 may therefore be less responsive to
PI3K/Akt inhibition[58].
5.2. Combinatorial strategies
Given the presence of redundant pathways and the adaptive capacity of cancer cells, drug
combinations are increasingly being investigated in an effort to abrogate both primary and
acquired resistance to PI3K pathway inhibitors. Different approaches include targeting the
same pathway at different levels (vertical combinations) or aiming for different pathways
(horizontal combinations).
5.2.1. Vertical combinations
With membrane growth factor receptor inhibitors
Activation of the PI3K pathway can be attributable to upstream activation via membrane re‐
ceptor kinases, and preclinical data suggest that concurrent inhibition of mTOR and EGFR
may result in synergistic anti-tumor effect. Studies are investigating the benefit of dual
mTOR/EGFR blockade[59]. A completed phase I trial showed that the combination of evero‐
limus, bevacizumab and panitumumab was well tolerated, and three patients with ovarian
cancer achieved prolonged disease control for 11 to >40 months[59]. In addition, mTOR in‐
hibition may induce IRS1 expression and promote Akt activation via IGF1R thus attenuating
the anti-tumor effects of rapalogs[60]. The addition of IFG1R antibodies to mTOR inhibitors
has been shown to improve growth inhibition in vitro[52]. Studies investigating concurrent
IGF1R/mTOR targeting have shown that treatment is feasible with an acceptable toxicity
profile and encouraging activity in other tumor types[61] and studies using this approach
are ongoing in ovarian cancer (Table 4).
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Dual MTORC1 and MTORC2 inhibitors have therefore been developed and shown to result
in greater anti-tumor activity than rapalogs in preclinical studies[62]. Another strategy in‐
volves co-targeting mTOR as well as upstream PI3K in order to overcome the positive feed‐
back loops via Akt. In addition, simultaneous targeting of several effectors of the PI3K
pathway may improve the likelihood of completely shutting down the signaling cascade. A
combination of everolimus and the PI3K inhibitor, PI-103 blocked rebound rapalog induced
Akt activation and resulted in greater cell cycle arrest than either treatment alone in ovarian
cancer cells[63]. NVP-BEZ235 is a novel agent that is both an ATP-competitive PI3K inhibi‐
tor and an inhibitor of both mTORC1 and mTORC2. Studies in ovarian cancer cell lines and
mouse models have suggested that this drug caused cell cycle arrest and apoptosis, and pro‐
longed survival of mice with established ovarian tumors[64]. A phase I trial of ridaforolimus
with the Akt inhibitor MK2206 is ongoing and a dose expansion cohort in ovarian cancer is
planned (NCT01295632). Other studies are exploring the benefit of inhibiting further down‐
stream effectors such as p70S6 in combination with everolimus (NCT01115803).
5.2.2. Horizontal combinations
With Mek inhibitors
Given the evidence that oncogenic activation of the ras pathway may be associated with re‐
sistance to mTOR inhibitors even in the presence of PI3K oncogenic mutations, targeting
both PI3K and Ras pathways simultaneously is worthy of investigation. In a mouse model
of ovarian cancer driven by PTEN loss and KRAS mutation, simultaneous blockade of both
PI3K and Mek signalling using pharmacological inhibitors resulted in significant tumor re‐
gressions and prolonged survival compared to monotherapy[65]. A phase I study compar‐
ing the tolerability and efficacy of dual PI3K and Mek targeting to either treatment alone
showed that the combination significantly increased the risk of Grade 3-4 toxicity from 18%
to 54% (p=0.001), but all patients with alterations in the PI3K pathway and a KRAS or BRAF
mutation had tumor regressions with dual targeting[66].
With chemotherapy
One of the earliest explored strategy has been the combination of novel inhibitors with che‐
motherapy. There has been the theoretical concern that the cytostatic effects of these drugs
may in fact antagonize the cell cycle dependent effects of chemotherapy. Preclinical studies
in ovarian cancer have indeed suggested that PI3K inhibitor-induced G1 arrest undermined
the cytotoxic effects of agents such as cisplatin, paclitaxel, gemcitabine and topotecan that
are primarily effective in the S or G2 phase of the cell cycle[67]. However preliminary data
from non-randomized studies of mTOR inhibitors in combination with chemotherapy have
reported objective response rates comparable to those expected for chemotherapy alone,
thus providing indirect evidence for a lack of antagonism. Randomized studies will be re‐
quired to rule out any antagonism between PI3K inhibitors and conventional cytotoxics.
With anti-angiogenics
Pro-angiogenic factors such as HIF1α and VEGF are downregulated by inhibition of PI3K
signaling. This may explain the activity of mTOR inhibitors in HIF1α-driven clear cell renal
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cancer. Given the putative anti-angiogenic effects of PI3K pathway inhibitors and the known
activity of the VEGF antibody, bevacizumab in ovarian cancer, there is a rationale for target‐
ing multiple angiogenic regulators at once in an effort to shut down angiogenesis complete‐
ly. In fact, clear cell ovarian cancers with their reported angiogenic signature and increased
HIF1α signaling[68] may be particularly suited to a therapeutic strategy combining tradi‐
tional anti-angiogenics with PI3K pathway inhibitors.
5.3. Biomarkers
In light of the heterogeneity of ovarian cancer, predictive as well as pharmacodynamic
(demonstrating target downregulation) biomarkers are desperately needed in order to select
patients most likely to respond. In addition biomarkers would be useful to identify the sub‐
set of patients who may benefit from specific combinations. One question is whether sensi‐
tivity can be predicted on the basis of activation status of pathway members.
5.3.1. Constitutive PI3K activity: PIK3CA mutations and PTEN loss of function
The main intrinsic effectors of the pathway that have been studied in preclinical and clinical
models have been PTEN loss, and PIK3CA activating mutations. Early studies in cell lines
including ovarian cancer demonstrated greater anti-proliferative activity of PI3K pathway
inhibitors in PTEN-null or PIK3CA mutated cells[69]-[71], Di Nicolantonio et al, showed in
cell lines and in 43 patient tumor samples that PIK3CA mutations sensitized cancer cells to
everolimus, but co-existing KRAS or BRAF mutations predicted resistance[54]. More recent
clinical and preclinical studies have reported contradictory correlations between PI3K muta‐
tions or PTEN loss and response to inhibitors[72],[73]; in particular, a significant number of
PI3K mutated tumors fail to respond, while a proportion of tumors lacking PI3K and PTEN
alterations respond. This is in contrast to the much stronger association between activating
mutations and response to other targeted agents such as EGFR, BRAF or ALK inhibitors.
Studies in tumor types with frequent PTEN mutations, such as melanoma have not demon‐
strated significant responses to mTOR inhibitors suggesting that patient selection on the ba‐
sis of PTEN loss alone may not identify responders[74]. In a pooled analysis of 3 trials of
mTOR inhibitors in endometrial cancers, MacKay et al found no correlation between
PIK3CA mutation or PTEN loss and response[75]. However a recent report by Janku and
colleagues suggested that PI3K mutations did preferentially identify responders[76]. They
conducted mutational analyses on 140 patients with breast and gynecological malignancies
(including 60 with ovarian cancer) enrolled in phase I trials of PI3K/Akt/mTOR inhibitors.
They demonstrated that the response rate was higher among patients with PIK3CA mutated
tumors (RR=30% versus 10%). However these results should be interpreted in light of the
fact that all responders were included in a trial of temsirolimus, bevacizumab and liposomal
doxorubicin. Given the known activity of bevacizumab and liposomal doxorubicin in ovari‐
an cancer and the fact that half the responding patients had never been previously exposed
to liposomal doxorubicin, mutations may simply correlate with prognosis, or with an im‐
proved response to treatment in general.
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planned (NCT01295632). Other studies are exploring the benefit of inhibiting further down‐
stream effectors such as p70S6 in combination with everolimus (NCT01115803).
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Given the evidence that oncogenic activation of the ras pathway may be associated with re‐
sistance to mTOR inhibitors even in the presence of PI3K oncogenic mutations, targeting
both PI3K and Ras pathways simultaneously is worthy of investigation. In a mouse model
of ovarian cancer driven by PTEN loss and KRAS mutation, simultaneous blockade of both
PI3K and Mek signalling using pharmacological inhibitors resulted in significant tumor re‐
gressions and prolonged survival compared to monotherapy[65]. A phase I study compar‐
ing the tolerability and efficacy of dual PI3K and Mek targeting to either treatment alone
showed that the combination significantly increased the risk of Grade 3-4 toxicity from 18%
to 54% (p=0.001), but all patients with alterations in the PI3K pathway and a KRAS or BRAF
mutation had tumor regressions with dual targeting[66].
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One of the earliest explored strategy has been the combination of novel inhibitors with che‐
motherapy. There has been the theoretical concern that the cytostatic effects of these drugs
may in fact antagonize the cell cycle dependent effects of chemotherapy. Preclinical studies
in ovarian cancer have indeed suggested that PI3K inhibitor-induced G1 arrest undermined
the cytotoxic effects of agents such as cisplatin, paclitaxel, gemcitabine and topotecan that
are primarily effective in the S or G2 phase of the cell cycle[67]. However preliminary data
from non-randomized studies of mTOR inhibitors in combination with chemotherapy have
reported objective response rates comparable to those expected for chemotherapy alone,
thus providing indirect evidence for a lack of antagonism. Randomized studies will be re‐
quired to rule out any antagonism between PI3K inhibitors and conventional cytotoxics.
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Pro-angiogenic factors such as HIF1α and VEGF are downregulated by inhibition of PI3K
signaling. This may explain the activity of mTOR inhibitors in HIF1α-driven clear cell renal
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ly. In fact, clear cell ovarian cancers with their reported angiogenic signature and increased
HIF1α signaling[68] may be particularly suited to a therapeutic strategy combining tradi‐
tional anti-angiogenics with PI3K pathway inhibitors.
5.3. Biomarkers
In light of the heterogeneity of ovarian cancer, predictive as well as pharmacodynamic
(demonstrating target downregulation) biomarkers are desperately needed in order to select
patients most likely to respond. In addition biomarkers would be useful to identify the sub‐
set of patients who may benefit from specific combinations. One question is whether sensi‐
tivity can be predicted on the basis of activation status of pathway members.
5.3.1. Constitutive PI3K activity: PIK3CA mutations and PTEN loss of function
The main intrinsic effectors of the pathway that have been studied in preclinical and clinical
models have been PTEN loss, and PIK3CA activating mutations. Early studies in cell lines
including ovarian cancer demonstrated greater anti-proliferative activity of PI3K pathway
inhibitors in PTEN-null or PIK3CA mutated cells[69]-[71], Di Nicolantonio et al, showed in
cell lines and in 43 patient tumor samples that PIK3CA mutations sensitized cancer cells to
everolimus, but co-existing KRAS or BRAF mutations predicted resistance[54]. More recent
clinical and preclinical studies have reported contradictory correlations between PI3K muta‐
tions or PTEN loss and response to inhibitors[72],[73]; in particular, a significant number of
PI3K mutated tumors fail to respond, while a proportion of tumors lacking PI3K and PTEN
alterations respond. This is in contrast to the much stronger association between activating
mutations and response to other targeted agents such as EGFR, BRAF or ALK inhibitors.
Studies in tumor types with frequent PTEN mutations, such as melanoma have not demon‐
strated significant responses to mTOR inhibitors suggesting that patient selection on the ba‐
sis of PTEN loss alone may not identify responders[74]. In a pooled analysis of 3 trials of
mTOR inhibitors in endometrial cancers, MacKay et al found no correlation between
PIK3CA mutation or PTEN loss and response[75]. However a recent report by Janku and
colleagues suggested that PI3K mutations did preferentially identify responders[76]. They
conducted mutational analyses on 140 patients with breast and gynecological malignancies
(including 60 with ovarian cancer) enrolled in phase I trials of PI3K/Akt/mTOR inhibitors.
They demonstrated that the response rate was higher among patients with PIK3CA mutated
tumors (RR=30% versus 10%). However these results should be interpreted in light of the
fact that all responders were included in a trial of temsirolimus, bevacizumab and liposomal
doxorubicin. Given the known activity of bevacizumab and liposomal doxorubicin in ovari‐
an cancer and the fact that half the responding patients had never been previously exposed
to liposomal doxorubicin, mutations may simply correlate with prognosis, or with an im‐
proved response to treatment in general.
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In conclusion, if trials of PI3K/mTOR inhibitors had limited enrolment to PTEN null or PI3K
mutated tumors a significant proportion of responding patients would have been missed. In
light of the imperfect association between PI3K mutations or PTEN loss and response to
PI3K pathway inhibitors, most ongoing trials are enrolling an unselected patient population;
unfortunately, most of these studies do not appear to be collecting archival tumor samples
for detailed molecular analyses (Table 4).
5.3.2. pAkt and stathmin
The level of phosphorylated Akt has been identified as a read-out for activation of the PI3K
pathway and thus a potential biomarker for responsiveness to PI3K inhibitors. An in vitro
and in silico study using a panel of cell lines and xenograft models treated with PI3K path‐
way inhibitors showed that pAkt correlated with efficacy, and KRAS or BRAF mutations
with resistance; neither PTEN loss nor PIK3CA mutations correlated with response[77].
Udai et al analyzed PI3K signaling output in patient tumor samples by measuring phos‐
phorylation of 3 effectors downstream of PI3K, ie pAkt, p p70S6K and pGSK3beta[78]. No
correlation was found between the presence of genomic alterations in PI3K or PTEN and ac‐
tivation of the pathway as measured by phosphorylated downstream targets. In a study of
17 well-characterized ovarian cancer cell lines, the majority failed to respond to Akt inhibi‐
tors despite Akt phosphorylation[79]. A high level of pAkt may not only reflect PI3K path‐
way intrinsic activation, but also result from cross-talk with Ras or other upstream signals.
In addition to being a non-specific measure of PI3K signal transduction, pAkt is a labile
phosphorylated tumor marker, its stability is affected by pre-analytical factors such as tissue
acquisition, ischemic time and fixation method[80],[81], In an effort to identify more stable
biomarkers, Saal et al developed a gene expression signature of PI3K pathway activation
and Stathmin, a regulator of microtubule dynamics was an accurate marker of the gene sig‐
nature. Stathmin can be easily measured by immunohistochemistry and is increasingly be‐
ing used as a surrogate marker for activation of the PI3K pathway[82].
5.3.3. KRAS/BRAF
As previously discussed a number of preclinical studies have demonstrated that KRAS and
BRAF mutations confer resistance to inhibitors of the PI3K pathway[54],[77]. Intringingly, in
a pooled molecular analysis of patients treated with PI3K/Akt/mTOR inhibitors in phase I
trials, Janku et al reported 2 objective responses in patients with co-existing PI3K and KRAS
or BRAF mutation[76]. Genomic analyses of tumors and cell lines has established that a sub‐
set of ovarian cancers have co-existing Ras and PI3K/Akt amplifications or mutations. This
easily identifiable subset may benefit from coordinated inhibition of both pathways, and a
trial combining a Mek inhibitor with a PI3K/mTOR inhibitor in ovarian cancer patients har‐
boring KRAS/BRAF and PI3K/Akt genomic alterations is warranted.
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6. Practical issues: Samples and trial design
6.1. Access to quality ovarian cancer samples
As the data to date suggest that there is insufficient evidence to select patients for trials
of PI3K inhibitors on the basis  of  specific  molecular alterations,  it  is  imperative that fu‐
ture  trials  enrolling  unselected patient  populations  include parallel  biological  studies  in
an  effort  to  uncover  candidate  biomarkers.  Biological  assays  must  be  reproducible,  ro‐
bust and require access to high quality tumor samples.  As such, pre-analytical  variables
must be controlled for as much as possible by following standardized sample collection,
fixation,  processing  and  storage  procedures.  When  dealing  with  paraffin-embedded  tis‐
sue,  markers  of  the  PI3K  Akt  pathway  may  be  particularly  susceptible  to  artefactual
loss[80]. In fact,  the optimal fixative for in depth genomic analyses is unlikely to be for‐
malin, and may therefore require a shift in routine practice from paraffin to fresh frozen
or RNAlater for sample storage.
6.2. Access to post-treatment samples
6.2.1. At relapse
It  is  likely that  clonal  evolution and treatment selection pressure will  lead to important
genomic and/or phenotypic modifications in the tumor in the interval between diagnosis
and relapse.  An increasing number of  phase I  and II  trials  are  therefore  requesting op‐
tional biopsies of metastatic disease and the vast majority of patients are willing to con‐
sent  this  procedure.  A  study  of  patients  enrolled  in  phase  I  trials  at  our  institution
revealed that  84% of  patients  who were proposed optional  tumor biopsies consented to
the procedure,  including sequential  pre-  and post-treatment biopsies[85].  All  procedures
were  performed  using  an  18-gauge  needle  under  ultrasound  or  computed  tomography
scanning and were associated with low minor complication rates (9/145 tumor biopsies).
In  70%  of  the  cases  the  biopsy  met  quality  criteria  for  ancillary  molecular  (RNA  and
DNA) analyses. Access to samples from relapsed disease is likely to be particularly rele‐
vant to high grade ovarian cancer, where the initial disease is exquisitely chemosensitive
and repeat  profiling of  the chemoresistant  recurrence may reveal  a  completely different
molecular profile.
6.2.2. Residual disease post-chemotherapy
The  molecular  characterization  of  ovarian  cancer  clones  surviving  after  chemotherapy
could identify targets for novel agents designed to eradicate chemoresistant residual dis‐
ease. As discussed above, the combination of PI3K/Akt/mTOR inhibitors with chemother‐
apy  may  not  be  optimal  because  of  the  risk  of  cumulative  toxicities  as  well  as  the
theoretical  risk that these inhibitors may antagonize the cytotoxic effects  of  chemothera‐
py. A more attractive approach may be sequential, where primarily chemosensitive ovar‐
ian cancer is  treated with chemotherapy followed by PI3K inhibitors if  indicated by the
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unfortunately, most of these studies do not appear to be collecting archival tumor samples
for detailed molecular analyses (Table 4).
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The level of phosphorylated Akt has been identified as a read-out for activation of the PI3K
pathway and thus a potential biomarker for responsiveness to PI3K inhibitors. An in vitro
and in silico study using a panel of cell lines and xenograft models treated with PI3K path‐
way inhibitors showed that pAkt correlated with efficacy, and KRAS or BRAF mutations
with resistance; neither PTEN loss nor PIK3CA mutations correlated with response[77].
Udai et al analyzed PI3K signaling output in patient tumor samples by measuring phos‐
phorylation of 3 effectors downstream of PI3K, ie pAkt, p p70S6K and pGSK3beta[78]. No
correlation was found between the presence of genomic alterations in PI3K or PTEN and ac‐
tivation of the pathway as measured by phosphorylated downstream targets. In a study of
17 well-characterized ovarian cancer cell lines, the majority failed to respond to Akt inhibi‐
tors despite Akt phosphorylation[79]. A high level of pAkt may not only reflect PI3K path‐
way intrinsic activation, but also result from cross-talk with Ras or other upstream signals.
In addition to being a non-specific measure of PI3K signal transduction, pAkt is a labile
phosphorylated tumor marker, its stability is affected by pre-analytical factors such as tissue
acquisition, ischemic time and fixation method[80],[81], In an effort to identify more stable
biomarkers, Saal et al developed a gene expression signature of PI3K pathway activation
and Stathmin, a regulator of microtubule dynamics was an accurate marker of the gene sig‐
nature. Stathmin can be easily measured by immunohistochemistry and is increasingly be‐
ing used as a surrogate marker for activation of the PI3K pathway[82].
5.3.3. KRAS/BRAF
As previously discussed a number of preclinical studies have demonstrated that KRAS and
BRAF mutations confer resistance to inhibitors of the PI3K pathway[54],[77]. Intringingly, in
a pooled molecular analysis of patients treated with PI3K/Akt/mTOR inhibitors in phase I
trials, Janku et al reported 2 objective responses in patients with co-existing PI3K and KRAS
or BRAF mutation[76]. Genomic analyses of tumors and cell lines has established that a sub‐
set of ovarian cancers have co-existing Ras and PI3K/Akt amplifications or mutations. This
easily identifiable subset may benefit from coordinated inhibition of both pathways, and a
trial combining a Mek inhibitor with a PI3K/mTOR inhibitor in ovarian cancer patients har‐
boring KRAS/BRAF and PI3K/Akt genomic alterations is warranted.
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vant to high grade ovarian cancer, where the initial disease is exquisitely chemosensitive
and repeat  profiling of  the chemoresistant  recurrence may reveal  a  completely different
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could identify targets for novel agents designed to eradicate chemoresistant residual dis‐
ease. As discussed above, the combination of PI3K/Akt/mTOR inhibitors with chemother‐
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theoretical  risk that these inhibitors may antagonize the cytotoxic effects  of  chemothera‐
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molecular  profile  of  the  residual  resistant  clones.  Although  recent  trials  using  such  an
approach with erlotinib or olaparib after response to platinum based treatment were dis‐
appointing, neither trial selected the maintenance treatment on the basis of the profile of
residual disease.
6.3. Surrogate tissue
Any effort to sample relapsed disease in ovarian cancer patients invariably faces the chal‐
lenge of access to tumor. Recurrences tend to be limited to the abdominal cavity with diffuse
carcinomatosis which can be difficult to biopsy safely. This is a critical need for more easily
accessible surrogate tumor samples which would allow for serial tumor sampling through‐
out the disease course, to identify both predictive and pharmacodynamic markers. Possibili‐
ties include circulating tumor cells, ascites and circulating DNA.
Serial sampling of circulating tumor cells (CTCs) has been shown to provide useful prognos‐
tic and/or predictive information in a number of tumor types such as breast and prostate
cancer[86],[87]. In the temsirolimus trial, CTCs were detected in 45% of patients before cycle
1 and found to correlate weakly with progressive disease, however no significant change in
CTC levels were observed with treatment[29].
Udai et al demonstrated the feasibility of profiling the PI3K pathway from ascites in patients
with advanced ovarian cancer: they successfully measured PI3K and PTEN mutations, am‐
plifications and losses as well as PI3K signaling output in ascitic samples by ELISA for phos‐
phorylated proteins[78]. Finally, cancer mutations have been identified by deep sequencing
of circulating plasma DNA from patients with advanced ovarian cancer, providing another
example of a non-invasive “liquid biopsy”[88].
1) Standardized quality ovarian cancer sample collection protocols at diagnosis and surgery optimized for
comprehensive molecular studies.
2) Sequential biopsies for post-treatment/resistant tumor molecular profiling.
3) Studies investigating the feasibility and translational research value of surrogate tissue samples: ascites, circulating
tumor cells, circulating DNA
Table 5. Sample-related considerations to enhance the development of PI3K pathway inhibitors in ovarian cancer
6.4. Novel trial designs
Conventional endpoints such as RECIST response may not be appropriate for inhibitors of
the PI3K pathway that may result in disease stabilization rather than objective tumor shrink‐
age. Single arm phase II trials offer little data regarding activity of a novel drug: patient
numbers are small, heterogeneous and comparisons with historical controls are intrinsically
unreliable. A number of subtle deviations from traditional trial designs could help improve
the likelihood that novel PI3K inhibitors make a successful transition from preclinical testing
through early and late phase trials. Various strategies are outlined in table 6.
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∙ Randomized placebo controlled phase II trials instead of single arm phase II.
∙ Randomized discontinuation design: After an initial run-in phase where all patients receive the experimental agent,
patients with stable disease are randomized to placebo versus continued drug. This model may be particularly suited
to slower growing Type I ovarian cancers where the distinction between treatment induced disease stabilization and
natural disease course may be difficult to make.
∙ When evaluating tumor response on imaging, percentage tumor shrinkage as a continuous variable could be used,
rather than categorical RECIST where an arbitrary cut-off of 30% decrease to define response may be more suited to
conventional cytotoxics.
∙ Metabolic response on functional imaging by FDG/PET.
∙ Using each patient as internal control for evidence of drug activity: the ratio of time to progression (TTP) on
experimental drug to TTP on last treatment (TTPn+1/TTPn), where TTPn+1/TTPn ≥1.3 would suggest drug activity[89];
Table 6. Suggested modifications to the traditional trial design adapted to testing PI3K pathway inhibitors and other
novel therapies
7. Conclusion
The PI3K pathway is  emerging as an important  and viable therapeutic  target.  However
evidence  for  efficacy  in  ovarian  cancer  remains  limited  and  predictive  biomarkers  to
identify  the  patients  most  likely  to  benefit  from  this  approach  are  desperately  needed.
Given the complexicity of the PI3K pathway and its  cross-talk with other signaling net‐
works, inhibiting a single member of the pathway may be insufficient to abrogate onco‐
genic  signaling  and  result  in  meaningful  tumor  control.  A  number  of  resistance
mechanisms to PI3K pathway inhibitors have been identified. Primary resistance may be
attributable to co-existing KRAS or BRAF mutations; therefore concurrent PI3K and Mek
inhibition in dual PI3K/KRAS mutated ovarian cancer may be worthy of investigation. In
addition,  treatment  induced  compensatory  increases  in  alternate  pathways  (via  IGF1R,
MTORC2/Akt  and  others)  may  allow  escape  from  selective  mTOR  targeting;  response
could be improved by appropriately designed combinatorial strategies. This suggests that
abrogating adaptive escape pathways will  require truly individualized treatment,  select‐
ed on the basis of on-treatment tumor biopsies to identify the culprit compensatory path‐
ways.  A  number  of  trials  are  ongoing  exploring  the  benefit  of  combinations,
unfortunately few are including correlative biological studies. Finally, for decades, ovari‐
an cancer was treated as a uniform disease, a greater understanding of the biology of ep‐
ithelial  ovarian  tumors  has  encouraged  the  initiation  of  a  few  histology-specific  trials.
The successful transition of novel PI3K pathway inhibitors from bench to the bedside of
patients with ovarian cancer will  depend on a greater integration of translation research
in trial development. Efforts must be made to include comprehensive molecular profiling
both at  baseline  and sequentially  throughout  the  disease  course,  and studies  investigat‐
ing the usefulness of novel surrogate tumor markers such as ascites or circulating DNA
will likely be essential.
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molecular  profile  of  the  residual  resistant  clones.  Although  recent  trials  using  such  an
approach with erlotinib or olaparib after response to platinum based treatment were dis‐
appointing, neither trial selected the maintenance treatment on the basis of the profile of
residual disease.
6.3. Surrogate tissue
Any effort to sample relapsed disease in ovarian cancer patients invariably faces the chal‐
lenge of access to tumor. Recurrences tend to be limited to the abdominal cavity with diffuse
carcinomatosis which can be difficult to biopsy safely. This is a critical need for more easily
accessible surrogate tumor samples which would allow for serial tumor sampling through‐
out the disease course, to identify both predictive and pharmacodynamic markers. Possibili‐
ties include circulating tumor cells, ascites and circulating DNA.
Serial sampling of circulating tumor cells (CTCs) has been shown to provide useful prognos‐
tic and/or predictive information in a number of tumor types such as breast and prostate
cancer[86],[87]. In the temsirolimus trial, CTCs were detected in 45% of patients before cycle
1 and found to correlate weakly with progressive disease, however no significant change in
CTC levels were observed with treatment[29].
Udai et al demonstrated the feasibility of profiling the PI3K pathway from ascites in patients
with advanced ovarian cancer: they successfully measured PI3K and PTEN mutations, am‐
plifications and losses as well as PI3K signaling output in ascitic samples by ELISA for phos‐
phorylated proteins[78]. Finally, cancer mutations have been identified by deep sequencing
of circulating plasma DNA from patients with advanced ovarian cancer, providing another
example of a non-invasive “liquid biopsy”[88].
1) Standardized quality ovarian cancer sample collection protocols at diagnosis and surgery optimized for
comprehensive molecular studies.
2) Sequential biopsies for post-treatment/resistant tumor molecular profiling.
3) Studies investigating the feasibility and translational research value of surrogate tissue samples: ascites, circulating
tumor cells, circulating DNA
Table 5. Sample-related considerations to enhance the development of PI3K pathway inhibitors in ovarian cancer
6.4. Novel trial designs
Conventional endpoints such as RECIST response may not be appropriate for inhibitors of
the PI3K pathway that may result in disease stabilization rather than objective tumor shrink‐
age. Single arm phase II trials offer little data regarding activity of a novel drug: patient
numbers are small, heterogeneous and comparisons with historical controls are intrinsically
unreliable. A number of subtle deviations from traditional trial designs could help improve
the likelihood that novel PI3K inhibitors make a successful transition from preclinical testing
through early and late phase trials. Various strategies are outlined in table 6.
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∙ Randomized placebo controlled phase II trials instead of single arm phase II.
∙ Randomized discontinuation design: After an initial run-in phase where all patients receive the experimental agent,
patients with stable disease are randomized to placebo versus continued drug. This model may be particularly suited
to slower growing Type I ovarian cancers where the distinction between treatment induced disease stabilization and
natural disease course may be difficult to make.
∙ When evaluating tumor response on imaging, percentage tumor shrinkage as a continuous variable could be used,
rather than categorical RECIST where an arbitrary cut-off of 30% decrease to define response may be more suited to
conventional cytotoxics.
∙ Metabolic response on functional imaging by FDG/PET.
∙ Using each patient as internal control for evidence of drug activity: the ratio of time to progression (TTP) on
experimental drug to TTP on last treatment (TTPn+1/TTPn), where TTPn+1/TTPn ≥1.3 would suggest drug activity[89];
Table 6. Suggested modifications to the traditional trial design adapted to testing PI3K pathway inhibitors and other
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The PI3K pathway is  emerging as an important  and viable therapeutic  target.  However
evidence  for  efficacy  in  ovarian  cancer  remains  limited  and  predictive  biomarkers  to
identify  the  patients  most  likely  to  benefit  from  this  approach  are  desperately  needed.
Given the complexicity of the PI3K pathway and its  cross-talk with other signaling net‐
works, inhibiting a single member of the pathway may be insufficient to abrogate onco‐
genic  signaling  and  result  in  meaningful  tumor  control.  A  number  of  resistance
mechanisms to PI3K pathway inhibitors have been identified. Primary resistance may be
attributable to co-existing KRAS or BRAF mutations; therefore concurrent PI3K and Mek
inhibition in dual PI3K/KRAS mutated ovarian cancer may be worthy of investigation. In
addition,  treatment  induced  compensatory  increases  in  alternate  pathways  (via  IGF1R,
MTORC2/Akt  and  others)  may  allow  escape  from  selective  mTOR  targeting;  response
could be improved by appropriately designed combinatorial strategies. This suggests that
abrogating adaptive escape pathways will  require truly individualized treatment,  select‐
ed on the basis of on-treatment tumor biopsies to identify the culprit compensatory path‐
ways.  A  number  of  trials  are  ongoing  exploring  the  benefit  of  combinations,
unfortunately few are including correlative biological studies. Finally, for decades, ovari‐
an cancer was treated as a uniform disease, a greater understanding of the biology of ep‐
ithelial  ovarian  tumors  has  encouraged  the  initiation  of  a  few  histology-specific  trials.
The successful transition of novel PI3K pathway inhibitors from bench to the bedside of
patients with ovarian cancer will  depend on a greater integration of translation research
in trial development. Efforts must be made to include comprehensive molecular profiling
both at  baseline  and sequentially  throughout  the  disease  course,  and studies  investigat‐
ing the usefulness of novel surrogate tumor markers such as ascites or circulating DNA
will likely be essential.
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1. Introduction
Targeted therapy in cancer has led to intensive searches for the molecular pathways of ma‐
lignant transformation [1]. In gynecologic malignancies, BRCA 1 and BRCA 2 gene muta‐
tions on chromosomes 17 and 13 respectively were identified in the 1990s [2]. Since then,
intensive investigation of the pathways for these genes has led to a wealth of information
about molecular pathways [3]. The understanding of these molecular pathways has led in
turn to the development of novel targeted therapies for women with identified gene muta‐
tions [4]. This review reviews the current knowledge of the subset of women with BRCA
gene mutations. The characteristics of BRCA deficiency including genetic background and
current chemotherapeutic options including mechanisms of resistance are discussed as well.
Finally, the data on emerging targeted therapeutic strategies with poly-ADP-ribose-poly‐
merase (PARP) inhibitors and specific PARP clinical trials are reviewed.
2. BRCA genetic background
Hereditary Breast and Ovarian Cancer Syndrome (HBOCS) is characterized by a few distinct
features: earlier age of cancer onset, higher incidence of bilateral disease, higher incidence of
other cancers, and inheritance in an autosomal dominant pattern [5]. A number of genes, as
well as associated syndromes, have been implicated in HBOCS, but none more so than the
BRCA genes. Individuals with impaired BRCA protein function have a 50-85% lifetime risk
of developing breast cancer and 10-40% lifetime risk of developing ovarian cancer [6]. Al‐
though deleterious mutations in either of the 2 BRCA genes significantly increases one’s risk
for breast and ovarian cancer, mutations in these genes account for only about 5-10% of all
breast and ovarian cancer cases [7]. Because of genetic testing, the families of the subset of
women with BRCA associated cancers can be tested and early intervention is a possibility
[8]. These include tamoxifen therapy, bilateral prophylactic oophorectomy, prophylactic
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contralateral mastectomy and combinations of these strategies. Such interventions have
been shown to offer substantial life expectancy gain for young women with BRCA associat‐
ed early stage cancer. Currently, treatment of BRCA-associated breast and/or ovarian cancer
is no different than that for the general population. Survival data of BRCA positive patients
with ovarian cancer suggests that they have prolonged disease free intervals and overall
longer survival than their wild-type counterparts [9].
The Breast Cancer Susceptibility genes (BRCA 1 and 2) are considered tumor suppressors,
whose job it is to maintain appropriate cell growth, ultimately by upholding genomic stability
[10]. No single unified theory exists regarding the action of the BRCA genes. While disruption
of either of the BRCA genes demonstrates similar pathophysiological manifestations, they are
indeed unique. They lie on 2 separate chromosomes, each have unique primary sequences, and
ultimately carry out their responsibilities via discrete (proposed) mechanisms. Furthermore,
their unique mechanisms of action give them distinct characteristics that coincide with dis‐
tinct risks and prognoses with gene disturbance. Both BRCA genes share a relationship with
the gene RAD51, which encodes a protein responsible for assisting in repair of DNA double
strand breaks via homologous recombination. When there is a double strand break in the ge‐
netic sequence,  sequenceX  of  a specific chromatid,  homologous recombination provides a
means for the exchange of the same genetic sequence, sequenceX, from the healthy homolo‐
gous sister chromatid to the damaged one. Rad51 is one of the most important players in HRR.
It assists in the search for homology and strand pairing, and its responsibilities are ultimately
complemented by the proteins encoded by the 2 BRCA genes [11]. Studies suggest that BRCA2
regulates the intracellular transport and function of RAD51, as well as the enzymatic activity of
the RAD51 protein [12]. The relationship between BRCA1 and RAD51 is less clear. There is evi‐
dence that BRCA1 physically associates with proteins other than RAD51, creating a complex
likely responsible for the creation of resected single-stranded DNA at double strand repair
sites [13]. Further data supports BRCA1’s role in activation of DNA damage checkpoints.
There is also evidence that supports BRCA1’s role in altering chromatin structure upon DNA
damage to allow easier access for repair.
Figure 1. Role of BRCA proteins in Homologous Recombination Repair
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(See Figure 1) 1) DNA damage triggers activation of the ataxia-telangiectasia mutated ser‐
ine-protein kinase as well as the ataxia-telangiectasia and Rad3 related protein kinase [14]. 2)
Once activated, these enzymes phosphorylate and activate a number of intracellular items,
including the BRCA1 protein, Checkpoint kinase 2 (which also activates BRCA1), BRCA2,
the Fanconi anemia protein complex, H2AX histones involved in forming nuclear foci cru‐
cial for DNA repair, and a few others [15]. 3) The H2AX histones co-localize and join with
other proteins to form nuclear foci at the sites of DNA damage. These other proteins include
a tumor binding protein 53BP1, the nuclear factor with BRCT domains protein 1 NFBD1,
checkpoint kinase 2, and Nijmegen breakage syndrome 1 protein Nibrin. 4) Nibrin is part of
the MRN complex, which also includes Rad50 and MreII. The MRN complex is important in
initial processing of double stranded DNA breaks. It directs the cellular process to continue
via homologous recombination or non-homologous end joining. BRCA1 plays a part in reg‐
ulating the MRN complex by inhibiting MreII [16]. This action depresses the NHEJ pathway
and stimulates the Rad51 pathway favoring homologous recombination. 5) BRCA1 also acti‐
vates BRCA1 interacting protein C-terminal helicase 1 (BRIP1), which unwinds DNA
strands near sites of damage allowing other repair machinery to access the damaged sites.
The gene that encodes BRIP1 may also act as an oncogene in ovarian cancer. 6) Activation of
Rad51 allows it to form a complex with BRCA2 and Fanconi anemia complementation
group D2 protein, FANCD2 [17]. This complex is a key player in homologous recombination
repair as it is involved in searching for homology as well as strand pairing, while causing S-
phase and G2 arrest [18]. 7) Certain homologous recombination repair (HRR) promoting ac‐
tivities of BRCA1 are amplified when it forms a complex with BRCA1 associated RING
domain protein 1, BARD1 [19]. This complex may also play a role in mismatch repair via
downstream action [20].
3. Associated breast and ovarian cancer
Inheritance of a damaging mutation in either BRCA gene can cause disruption of the
smoothly regulated replication process of the body’s cells, potentially leading to cancer.
Though the mechanism is poorly understood, mutations in the BRCA genes show preferen‐
tial deleterious consequences in breast and ovarian tissues. In the general population, the
lifetime prevalence of breast cancer is 12% and ovarian cancer 1.4% [21]. A mutation in the
BRCA1 gene puts an individual at a 50-85% lifetime risk of developing breast cancer and a
15-40% risk of developing ovarian cancer. BRCA2 mutation carriers have a 50-85% lifetime
risk of developing breast cancer and a 10-20% risk of developing epithelial ovarian cancer.
In addition, BRCA mutations are associated with bilateral disease, cancer at a younger age
(BRCA1), autosomal dominant inheritance pattern, increased risk of male breast cancer
(BRCA2), and increased risk of cancer in other organs [22,23]. Specifically, BRCA positive in‐
dividuals are at increased risk of epithelial ovarian cancer (EOC), which behaves differently
than EOC seen in the general population. Both BRCA1 and 2 carriers have an improved
prognosis when compared to their wild-type counterparts. A pooled analysis of 26 observa‐
tional studies on the survival of women with ovarian cancer, including 1213 EOC cases
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The gene that encodes BRIP1 may also act as an oncogene in ovarian cancer. 6) Activation of
Rad51 allows it to form a complex with BRCA2 and Fanconi anemia complementation
group D2 protein, FANCD2 [17]. This complex is a key player in homologous recombination
repair as it is involved in searching for homology as well as strand pairing, while causing S-
phase and G2 arrest [18]. 7) Certain homologous recombination repair (HRR) promoting ac‐
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domain protein 1, BARD1 [19]. This complex may also play a role in mismatch repair via
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Inheritance of a damaging mutation in either BRCA gene can cause disruption of the
smoothly regulated replication process of the body’s cells, potentially leading to cancer.
Though the mechanism is poorly understood, mutations in the BRCA genes show preferen‐
tial deleterious consequences in breast and ovarian tissues. In the general population, the
lifetime prevalence of breast cancer is 12% and ovarian cancer 1.4% [21]. A mutation in the
BRCA1 gene puts an individual at a 50-85% lifetime risk of developing breast cancer and a
15-40% risk of developing ovarian cancer. BRCA2 mutation carriers have a 50-85% lifetime
risk of developing breast cancer and a 10-20% risk of developing epithelial ovarian cancer.
In addition, BRCA mutations are associated with bilateral disease, cancer at a younger age
(BRCA1), autosomal dominant inheritance pattern, increased risk of male breast cancer
(BRCA2), and increased risk of cancer in other organs [22,23]. Specifically, BRCA positive in‐
dividuals are at increased risk of epithelial ovarian cancer (EOC), which behaves differently
than EOC seen in the general population. Both BRCA1 and 2 carriers have an improved
prognosis when compared to their wild-type counterparts. A pooled analysis of 26 observa‐
tional studies on the survival of women with ovarian cancer, including 1213 EOC cases
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showed that among patients with invasive EOC, having a BRCA mutation was associated
with improved 5-year overall survival, with BRCA2 carriers having the best prognosis [9].
See Table 1.
BRCA 1 carriers BRCA 2 carriers Non-Carriers
Inheritance Auto-Dominant Auto-Dominant Sporadic
Prevalence of EOC 39% 22% 1.4%
Mean age of onset 54 62 63
Tumor: Stage @ surgery Advanced Advanced Advanced
Histolology Serous Serous Serous
Differentiation Mod-Poor Mod-Poor Mod-poor
Treatment Surgery + Chemo Surgery + Chemo Surgery + Chemo
Recurrence-Free interval 14 months 14 months 7 months
5-year Survival 44% 52% 36%








Table 1. Characteristics of BRCA 1/2 associated Epithelial Ovarian Cancer (EOC) [9,24,25]
BRCA1 associated breast cancers tend to be of the triple-negative type which is significant
because it lacks the 3 biomarkers most commonly implicated in breast cancer, the estrogen
and progesterone receptors and the human epidermal growth factor receptor 2 (Her2/neu)
[26]. The presence of these biomarkers helps in the guidance of treatment options. Estrogen/
progesterone positive breast cancers are typically treated with hormonal therapy (in con‐
junction with surgery/radiation), and Her2/neu positive breast cancers are treated with an
agent that specifically targets the Her2 receptor, such as Herceptin. When these 3 biomark‐
ers are negative in a newly diagnosed breast cancer, the treatment approach becomes more
complicated and prognosisis poor. On the other hand, BRCA2 associated breast cancer is
typically hormonal in nature [22]. Current evidence suggests no difference in overall prog‐
nosis of breast cancers in BRCA carriers compared to sporadic breast cancers, but BRCA de‐
ficiency does appear to be predict chemo-sensitivity [27].
4. BRCAness
The term "BRCAness" describes a subset of women with sporadic EOC who display similar
phenotypic characteristics to those with a hereditary BRCA mutation [28]. It is widely ac‐
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cepted that a deleterious BRCA mutation adversely affects homologous recombination.
While the BRCA genes indeed play a very important role in homologous recombination,
they are not the only key players. A defect or hiccup in any of the other genes involved in
homologous recombination would in theory, affect this process. This describes the notion of
BRCAness: Individuals with structurally healthy BRCA genes that are functionally incapa‐
ble of carrying out homologous recombination due to a defect elsewhere that hinders the en‐
tire process. In fact, about 40-50% of ovarian cancer cases have shown to have some defect in
homologous recombination, with a large number of these being associated with BRCA-relat‐
ed defects. See Figure 2.
Figure 2. illustrates the molecular profile of serous ovarian cancer. BRCA1 germline, BRCA2 germline, BRCA1 somatic,
BRCA2 somatic, BRCA1 hypermethylation, EMSY amplification and PTEN loss have all been shown to lead to impaired ho‐
mologous recombination, comprising about half of all cases [29]. Sporadic ovarian cancer mutations that affect homolo‐
gous recombination are clinically significant because they tend to behave like the BRCA cancers. This special sub-group of
epithelial ovarian cancer patients show similar therapeutic response and prognosis as their BRCA mutant counterparts
which includes improved sensitivity to platinum as well as improved 5 year survival [30]. A few studies have attempted to
reveal the mechanism behind BRCAness on a genetic level. There is some data to suggest that transcriptional or post-tran‐
scriptional repression of the BRCA1 gene is responsible for such sporadic tumors. For example, hypermethylation of a pro‐
motor region upstream from BRCA1 gene that leads to inactivation of BRCA1 protein, causes impaired homologous
recombination leading to a sporadic “BRCAness” with an intact yet silenced BRCA1 gene [31].
It should be noted that the specific target of the PARP inhibitor class is not only BRCA mu‐
tant cancers; however, it encompasses all that fall under the umbrella of impaired homolo‐
gous recombination. So in theory, PARP inhibitors should show efficacy in a number of
sporadic cancers as well, specifically those that elicit “BRCAness” characteristics [32].
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5. Mechanisms of resistance
Currently, there is no difference in management of EOC between BRCA positive patients
and BRCA wild type patients. Maximal surgical cytoreduction, with or without neoadjuvant
chemotherapy, is the standard initial approach, excluding individuals who are not good sur‐
gical candidates or whose disease precludes optimal cytoreduction [34]. The typical chemo‐
therapeutic regimen is a taxane/platinum based combination therapy. The standard post-
operative approach would be 6 cycles (21 days each) of IV paclitaxal with carboplatin [35]
The 5-year survival and prognosis for advanced stage ovarian cancer, in BRCA or wild-type
carriers ranges between 10 and 25 percent. Such poor prognosis is due to an incredibly high
recurrence rate of advanced ovarian cancer. The extremely high rate of recurrence is due to
the development of drug resistance [36]. Initially, 75% of patients with advanced disease
show response to chemotherapy, while the remaining 25% show intrinsic resistance. How‐
ever, most of the population with initial chemosensitivity will show relapse within 2 years
of initial treatment. Patients who have a shorter interval from their last course of chemother‐
apy to relapse will show decreased response with future courses [37]. For women who re‐
lapse within 6 months of treatment completion, there is a less than 10% chance of
responding to any future therapies. For women whose disease recurs more than 6 to 12
months after initial therapy, chemotherapy includes platinum-based, multi-agent regimens.
These women are considered partially platinum sensitive (relapse within 6-12 months) or
platinum sensitive (relapse greater than 12 months after initial treatment). For patients who
are platinum resistant (relapse within 6 months) or platinum refractory (no initial response),
sequential single agents, such as pegylated liposomal doxorubicin hydrochloride or topote‐
can are suggested [38]. The slightly superior prognosis of BRCA patients compared to spora‐
dic EOC is likely related to their greater sensitivity to platinum based therapy [33].
However, despite initial chemo-sensitivity of BRCA carriers, they will ultimately develop to
platinum resistant recurrent ovarian cancer.
PARP Inhibitors are not unlike the standard therapies for ovarian cancer, in that they too
have shown evidence of resistance. Theoretically, their maximum potential is seen in cells
with impaired homologous recombination. Researchers have hypothesized that resistance to
PARP Inhibitors is through DNA repair mechanisms that actually correct the homologous
recombination process. Through compensatory mutations, the initial mutational reading
frame is corrected to a reading frame that actually produces a wild type BRCA protein [39].
A restoration in BRCA function would further contribute to platinum resistance and create
PARP inhibitor resistance. This will need further investigations.
6. PARP inhibitors
PARP proteins are involved in a number of cellular processes, including DNA replication,
transcriptional regulation, and DNA damage repair [40].Of the numerous PARP proteins
detected, PARP1 and PARP2, which are associated with DNA stability, have been intensive‐
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ly studied. The PARP enzyme regulates cellular responses to DNA damage, and plays an
important role in the repair of single-stranded breaks by excision repair [41]. See Figure 3.
Figure 3. Role of Poly (ADP-ribose) polymerase in Base Excision Repair
The base excision repair (BER) pathway recognizes and removes damaged or inappropriate
bases [42]. Damage specific glycosylases recognize the presence of a faulty base and imme‐
diately removes it. This leads to the formation of a potentially cytotoxic apurinic or apirimi‐
dinic (AP) site. Such sites are then processed by an AP endonuclease, which creates a strand
break in the DNA. The enzyme Poly (ADP-ribose) polymerase binds to the strand break and
relaxes the chromatin structure to allow for easier access of the BER machinery. Then, PARP
transfers ADP-ribose units from NAD+ to nuclear target proteins, histones, and itself. This
forms long and branched polymers of poly (ADP-ribose) on the PARP enzyme, that act as a
signaling mechanism to recruit the BER machinery, including adaptor factor XECC1, PCNA,
RFC, ligase III and DNA polymerase β. The BER complex assembles at the site of damage
and facilitates repair in a coordinated fashion. Once complete, the complex disperses [43].
When PARP is inhibited, common single-strand breaks are converted into double-stranded
breaks during DNA replication. In normal wild type cells, homologous recombination is the
most common mechanism of repair in these double-stranded breaks which provides a safety
net in maintaining genomic stability. In the presence of a deleterious BRCA gene, homolo‐
gous recombination is impaired. These cells and the tumors that they form have increased
susceptibility to PARP inhibition, which leads to decreased chromosomal stability and, ulti‐
mately, cell death. See Figure 4.
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Figure 4. Synthetic Lethality of PARP Inhibition
PARP inhibitors are also hypothesized to increase cytotoxicity of chemotherapeutic agents.
Cells treated with chemotherapy, especially platinum based agents, ultimately attain resist‐
ance by altering DNA repair processes [44]. It is hypothesized that through PARP inhibition,
cells with faulty BRCA function could be prevented from repairing chemotherapy -induced
DNA damage [45,46]. Clinical trials have examined PARP inhibitors as single agents in pa‐
tients with impaired homologous recombination, as well as in combination with chemo-ra‐
diation therapy.
7. Clinical trials
Table 2 shows a list of PARP inhibitors that are currently in clinical development [4]. A full
list of studies involving all tumor types can be found through the National Institute of
Health website, www.clinicaltrials.gov.
Iniparib is one of the first drugs looked at in the PARP inhibitor class. A phase II trial of inipar‐
ib in women with advanced ovarian or breast cancer compared the chemotherapeutic regi‐
men  carboplatin/gemcitabine  with  and  without  iniparib.  The  iniparib  arm  showed  an
improved rate of clinical benefit (56% vs 34%, P=0.01), increased rate of overall response (52%
vs 32%, P=0.02), prolonged median progression free survival (5.9 movs 3.6 mo, P=0.01), and in‐
creased median overall survival (12.3 mo vs 7.7 mo, P=0.01) [47]. However, a phase III trial of
Iniparib for women with triple negative breast cancer proved to be disappointing [48,49]. This
trial, which randomized 519 women with triple negative breast cancer to carboplatin with
gemcitabine versus carboplatin, gemcitabine plus iniparib demonstrated an increase in pro‐
gression-free survival among the iniparib arm (5.1 vs 4.1 months, with P=0.027), but did not
reach statistical significance. Patients were not stratified based on BRCA status, specific triple
negative breast cancer subtype, or level of expression of PARP proteins. More recent studies
suggest that Iniparib may not actually inhibit the PARP enzyme in vitro. One in particular
compared Iniparib to Olaparib and Veliparib [50]. Olaparib and Veliparib proved to inhibit
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formation of the poly-ADP-ribose polymer in intact cells, but Iniparib exhibited little or no
ability to inhibit poly(ADP-ribose) polymer formation in situ. Other experiments revealed Ini‐
parib’s inability to sensitize cells to cisplatin, gemcitabine and paclitaxel [51]. Iniparib’s actual
role may be modification of cysteine-containing proteins in tumor cells. If this is in fact the case,
failure of the Iniparib phase III trial should not be used to guide further decisions about other
PARP inhibitors. Keeping that in mind, Iniparib is continuing to be studied in a number of
ovarian cancer trials, some showing promise. A phase II trial examining Iniparib in combina‐
tion with gemcitabine/carboplatin in patients with platinum-resistant recurrent ovarian can‐
cer has to date shown a 25% overall response rate consisting of 8 out of 32 confirmed responses
[52]. Progression free survival of 6.4 months (95% CI, 3.0-NE) was demonstrated in an early
analysis. The PFS and ORR are significantly improved when compared to a previous study of
pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer with an ORR
of 11.7% and mean progression free survival of 3.1 months [53]. Once again, these patients
were not stratified based on their BRCA carrier status. A similar study looked at iniparib in
combination with gemcitabine/carboplatin in patients with platinum-sensitive recurrent ovar‐
ian cancer [54]. This study showed an ORR of 65%, consisting of 26 out of 40 patients, as well as
a median progression free survival of 9.5 months. Interestingly, there was no indication of a re‐
lationship between BRCA status and response.
Agent Route of
Administration
Trial Interests Side Effects
Iniparib IV Ovarian cancer, uterine carcinosarcoma, NSCLCFatigue, nausea, diarrhea, dizziness
Olaparib Oral Breast and ovarian cancer, the BRCA
population, other advanced solid tumors
Nausea, vomiting, fatigue, taste-
alteration, anorexia
Veliparib Oral TNBC and BRCA deficient breast and ovarian
cancer
Myelosuppression, fatigue
Rucaparib IV BRCA associated breast cancer, locally
advanced or metastatic breast cancer,
advanced ovarian cancer
Thrombocytopenia and neutropenia
INO-1001 IV Melanoma, p53 deficient cancer cells Myelosuppression, transaminitis






AZD-2461 Oral Single agent for refractory solid tumors
CEP-9722 Oral Single agent for advanced solid tumors
E7016 Oral Advanced solid tumors, melanoma,
glioblastoma
BMN-673 Oral Advanced solid tumors and hematologic
malignancies
Table 2. PARP Inhibitors in Clinical Development
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Olaparib, on the other hand, is a considered a bona-fide PARP inhibitor and has shown
promising results in phase II trials in the treatment of BRCA-deficient advanced ovarian
cancer. A recent study looked at oral Olaparib as a single agent, and its effect on BRCA posi‐
tive vs. BRCA wild-type patients in women with ovarian and breast cancer [55]. Women
with advanced high grade serous and/or undifferentiated ovarian carcinoma or triple-nega‐
tive breast cancer were enrolled and received olaparib 400 mg twice a day. 91 patients were
enrolled in this particular study, 65 with ovarian cancer and 26 with breast cancer. 63 of the
65 ovarian cancer cohorts had target lesions and were evaluable for objective response.
Among these 63 patients, 41% of BRCA carriers showed confirmed objective response (7 out
of 17 with 95% CI) and a surprising 24% of BRCA wild-type patients showed confirmed ob‐
jective response (11 of 46 with 95% CI). The 24% response of BRCA wild type patients sug‐
gests that Olaparib, if not all PARP inhibitors, may provide significant benefit for all patients
with ovarian cancer, and not only those with selective BRCA mutation. As mentioned
above, around 40-50% of ovarian cancers, in the absence of a mutation of the BRCA gene,
can affect the functional aspect of the BRCA proteins and ultimately homologous recombi‐
nation. It is for this reason that PARP inhibition likely shows benefit in not just the BRCA
mutated population, but a larger population that umbrellas deficient homologous repair.
However, for this particular study phase III trials are no longer scheduled to commence be‐
cause the interim analysis of survival did not show the desired benefit in relation to the ben‐
efit in progression free survival. Also, there were no confirmed objective responses reported
in the breast cancer patients.
A very similar 2-part study looked at single agent Olaparib, and compared doses (100mg vs.
400mg) in the treatment of advanced breast and ovarian cancer in BRCA deficient individu‐
als [56,57]. Among the 57 ovarian cancer patients, the overall response rate of olaparib
100mg BID was 12.5% with a clinical benefit rate of 16.7%. For the 400mg BID arm, ORR was
33% with a clinical benefit rate of 57.6%. Further stratification showed a response in both
platinum-sensitive individuals (38% ORR) and platinum-resistant individuals (30%).
Among the 54 breast cancer patients, the overall response of olaparib 100mg BID was 25%
with a progression free survival of 3.8months. For the 400mg BID arm, ORR was 42% with
PFS of 5.7 months.
Olaparib is also being looked at as maintenance therapy. A phase II trial studied Olaparib as
a maintenance therapy in relapsed serous ovarian cancer. The 265 enrolled patients had re‐
ceived at least 2 previous platinum based chemo regimens with eventual relapse [58]. Early
analysis has shown a 65% reduced risk of progression in the Olaparib arm, improving pro‐
gression free survival by 3.6 months (8.4 mo vs. 4.8). Patients were stratified based on BRCA
status, age, race, Jewish ethnicity, prior response to platinum regimen and relapse time, and
each subgroup showed an improved progression free survival in the Olaparib arm. Overall
survival data has not been analyzed.
Another study looking at differences in response to olaparib based on platinum-response
status [59]. This trial looked at oral olaparib as a single agent against advanced ovarian can‐
cer in 50 women with BRCA mutations. Results showed a 61.5% response rate in platinum-
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sensitive patients, a 41.7% response rate in platinum-resistant patients and 15.4% response
rate in platinum-refractory patients.
A randomized phase II trial in BRCA deficient advanced ovarian cancer (platinum interval<12
months) enrolled 97 women and looked at olaparib dosing, 200mg vs 400mg, and compared its
efficacy to pegylated liposomal doxorubicin [60]. Of the 32 low dose olaparib cohorts (200mg
BID), 38 % showed objective response with a median progression free survival of 6.5 months.
Of the 32 high dose (400mg BID) cohorts, 59% showed objective response with a median PFS of
8.8 months. These were compared to 33 women who received the standard pegylated liposo‐
mal doxorubicin, with an objective response of 38% and median PFS of 7.1 months, results that
were not clinically significant. This study, however, does not necessarily rule out Olaparib’s
action in BRCA deficient patients. Recent studies suggest that women with BRCA associated
ovarian cancer may demonstrate increased sensitivity to Doxil than previously reported in un‐
selected cases [61]. One study in particular showed a 57% response rate to PLD among BRCA
deficient patients, compared to 20% response rate among those with sporadic EOC. This re‐
sponse was associated with significantly improved progression-free and overall survival. Fur‐
thermore, the initial study was actually potentially comparing 2 drugs with particular benefit
in BRCA patients and though there is no clinically significant difference among them, they
each may show clinical significance when standing alone.
Another PARP inhibitor under investigation is Veliparib. A phase II trial of Veliparib in
combination with cyclophosphamide compared to single-agent cyclophosphamide is cur‐
rently ongoing [62]. This study examines Veliparib’s activity against advanced solid tumors
and lymphomas. Preliminary results show promising activity in the BRCA subset. Of the 35
patients enrolled, 7 have shown partial response and 6 have stable disease in the veliparib
arm. In another study veliparib with or without carboplatin was evaluated in patients with
stage III and IV BRCA-associated breast cancer [63]. Of the 22 patients enrolled, only 12
were eligible for evaluation. Complete response was seen in 2 patients and partial response
in 6 patients, with a clinical benefit of 75% seen.
A phase I study showed activity of veliparib and temozolomide in combination against
metastatic breast cancer [64]. Of the 41 patients enrolled, complete response was seen in 1
patient, partial response in 2, stable disease in 7 and disease progression in 14. BRCA muta‐
tion analysis is currently underway. Another study is currently looking at veliparib in com‐
bination with doxorubicin and cyclophosphamide for the treatment of breast cancer and
other solid tumors [65]. Of the 18 patients enrolled, 14 have breast cancer (including 5 with
BRCA mutations), 3 have ovarian cancer, and 1 other solid tumor. There has been objective
anti-tumor activity seen in the BRCA mutation carriers. With this particular regimen, dosing
was limited by myelosuppresion. Furthermore, although combination therapy has shown to
enhance chemotherapeutic effects, myelosuppression appears to be enhanced as well. More
than 50 clinical trials examining Veliparib are currently ongoing, looking at gynecologic can‐
cers, solid tumors, lymphomas, brain tumors, GI and prostate cancer. Most of these are cur‐
rently recruiting, with only a few in Stage II. It will be very exciting to see the end results of
these trials, specifically for our purposes, those involving BRCA analysis. Very few updates
have been given, as most of these are in the beginning stages.
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BMN-673 is the newest PARP inhibitor to be developed and is to date the most potent and
selective PARP inhibitor. It has been shown to be up to 700-fold more active in vitro in
BRCA deficient cell lines when compared to olaparib [66]. Phase I trials have yet to begin.
Rucaparib is another new PARP inhibitor being looked into. It is currently the focus of 3 dif‐
ferent clinical trials; examining its activity in combination with several different chemothera‐
peutic regimens, efficacy in BRCA-associated breast cancer, and treatment of patients with
locally advanced or metastatic breast and advanced ovarian cancer [4]. There a few other
PARP inhibitors that are currently being evaluated for efficacy and tolerability, and will
likely acquire more interest in the near future. Table 3 summarizes the findings of the PARP
inhibitors discussed above.
Phase I and II trials demonstrated PARP inhibitor’s favorable side effect profile; potentially
including fatigue, nausea, vomiting, and mood disturbance. Also, myelosuppression has
been noted in higher doses, especially when in combination with chemotherapy. These ad‐
verse effects are generally mild, especially in comparison with current chemotherapeutic
regimens.
8. Conclusion
PARP inhibitors have been increasingly studied. This new group of drugs has been shown
in multiple phase I and II trials to be efficacious with favorable side effect profiles. The pre‐
clinical data which suggested the effect of PARP inhibitors in BRCA deficient cells did not
take into account the much larger population of tumors deficient in homologous recombina‐
tion, with physically healthy yet functionally impaired BRCA genes. This new understand‐
ing has further raised the bar for the potential of this new class. PARP inhibitors have been
shown to increase progression-free-survival and overall response rate in a number of trials.
While there have indeed been some setbacks in the development of these new drugs, some
of the major concerns have been addressed. Though Iniparib’s phase III trial failure was ini‐
tially viewed as a major disappointment, later studies proved that Iniparib does not have
the same efficacy as its counterparts Olaparib/Veliparib, and ultimately may have no role in
PARP inhibition of single-strand break repair. Also, the discovery that Olaparib did not
show a clinically significant difference when compared to pegylated liposomal doxorubicin,
led to the detection of PLD as a particularly potent agent against BRCA deficient cells. So
rather than dismissing Olaparib’s effect as not clinically significant, this particular study en‐
couraged further investigation of PLD in this special population. Furthermore, the efficacy
of PARP inhibition is evident, but the ideal population that could benefit most from this
new class has yet to be determined. Future trials involving PARP inhibitors should undergo
extremely strict stratification, as it is crucial to reveal precisely which population stands to
benefit. Other concerns that need to be further investigated include mechanisms of resist‐
ance, use as frontline vs. maintenance vs. recurrent disease therapy, use in mono-therapy vs.
combination with chemo or combination with other targeted therapies.
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1. Introduction
In this review, we discuss the merit of splicing isoforms as a source of biomarkers for ovari‐
an cancer with a special focus on features that distinguish splice variants from global gene
expression based markers. Key examples demonstrating the usefulness of alternative splic‐
ing (AS) as markers of ovarian cancer are described.
Ovarian cancer is a low incidence cancer with high mortality rate [1]. The asymptomatic na‐
ture of this cancer and the late stage diagnosis of most tumors are the reasons for ineffective
surgery and chemotherapy [2]. In this sense, intensive research aim at increasing overall pa‐
tient survival and quality of life by providing biomarkers for 1) early detection and 2) pre‐
diction of chemotherapy response and/or suggestion of alternative strategies. CA-125 is a
glycoprotein that is usually expressed in a variety of epithelial cells and its serum level rise
up in advance ovarian cancer [3]. However, its use as an early detection marker or as a tool
to screen the general population has not been approved so far [4,5]. CA-125 level is helpful
in treatment-decision making but do not retain the capacity to improve overall survival and
quality of life [6,7]. Clearly, there is still great need for biomarkers or combination of bio‐
markers that could positively identify early ovarian cancer lesions with great certainty or in‐
crease patients’ survival.
Genome-wide mRNA profiling presents an opportunity to rapidly identify RNA markers.
Microarray platform has been applied in numerous occasions to provide gene expression
signature correlating prognosis or indicative of chemotherapy response (review in [8]).
However, the nature of the platform used to carry the experiments and the analysis methods
and sample sets makes inter-laboratory comparison very difficult and finding reliable mark‐
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ers complicated. Indeed, a meta-analysis regrouping 829 samples fails to demonstrate the
predictive power of 16 individual gene expression signatures [9]. Consequently, very few
microarray markers reached the clinic. In contrast, high-throughput protein signature based
on mass spectrometry platform appears to have much more overlap in the peaks found by
different experimental studies [10]. However, the pace by which protein biomarkers are
translated into clinical setting is relatively slow [11]. Clearly, there is a need for novel meth‐
odology to discover ovarian cancer biomarkers that can yield reliable results and produce
tests that could be quickly integrated in normal clinical setting. In this chapter, we discuss
the potential of splice variant annotations as a tool for the discovery of ovarian cancer mark‐
ers and discuss the challenges and promises of this hidden mine.
2. Pre-mRNA splicing mechanism and regulation
Transcription of messenger RNA (mRNA) is the first step of converting the DNA code into
functional proteins. This process was often seen as a linear cascade of events that include
mRNA capping [12], splicing [13], polyadenylation [14], export to the cytoplasm [15] and trans‐
lation [16] to produce a single protein. However, in reality a single pre-mRNA can produce
many mRNAs through the process of AS and this in turn lead to the production of several pro‐
teins from a single gene. Splicing is the process by which the protein coding exons (typically
hundreds of nucleotides in length) are joined together after the removal of large non-coding in‐
trons (typically thousands of nucleotides in length) to form the coding sequence. In some
genes, this process leads to one outcome and thus named constitutive (Fig. 1.) but in most cases
it leads to more than one outcome and thus called alternative (Fig. 2). Both processes are medi‐
ated by the spliceosome, specialized machinery that recognizes consensus RNA sequences
[13,17]. The spliceosome component U1snRNP binds the 5’ splice site (5’ss), the splicing Factor
1 (SF1) binds the branch point site (BPS) adenine, U2 auxiliary factor 65 kDa subunit (U2AF65)
binds the poly-pyrimidine tract (PPT) and U2 auxiliary factor 35 kDa subunits (U2AF35) binds
the 3’ splice site (3’ss) (Fig. 1A). The last two component are further replaced by U2snRNP and
following complex base-paring rearrangements and RNA-protein interactions involving hun‐
dreds of protein, the spliced mRNA, the intron by-product and the spliceosome component are
release [17]. Chemically speaking, the splicing reaction proceeds in two trans-esterification
steps (Fig. 1B). The first step involved the attack by the 2’ hydroxyl of the branch point adenine
on the phosphate at the 5’ss, releasing at the same time the 3’end of the mRNA. The second step
involved the attack by one of the hydroxyl of the terminal phosphate on the phosphate at the
3’ss, liberating the intron in the form of a lariat. This cycle of spliceosome assembly/disassem‐
bly is repeated for every intron of a gene on the nascent RNA transcript [18].
When the splice site for some exons become weak or introns with suboptimal sequence exist
splicing may become less accurate and may depend on the factors that influence the splicing of
competing exons and consequently produce mRNA versions with different exon pairs. AS af‐
fected the majority of multi-exons genes and is believed to be the principal driver of proteome
diversity [19]. As illustrated in figure 2, two 5’ss can compete for a single 3’ss or inversely, two
3’ss can compete for a single 5’ss. These type of alternative splicing events (ASEs) are referred
to alternative 5’ (alt5’, Fig. 2A) and alternative 3’ (alt3’ Fig. 2B), respectively. The most frequent
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type of ASE in human is the full skipping of an exon (cassette exon, Fig. 2C). Some exons are al‐
so skipped as a bloc (multiple cassette exon, Fig. 2D) or mutually exclusive (Fig. 2E). AS could
also be coupled to others regulatory mechanisms such as polyadenylation [14] (Fig. 2F). In this
case, the resulting mRNA exhibits a different 3’ untranslated region (UTR), which is further
subjected to different regulation by small non-coding RNA (e.g. microRNA). In about 1 out of 3
cases, AS decision introduces a sequence containing premature stop codon [20]. In these cases,
the resulting mRNA is flagged to be degraded by the non-sense mediated decay machinery
creating an efficient mechanism that control gene expression post-transcriptionally [21] (Fig.
2G). In some cases, ASE occurs outside the coding region and influence regulatory sequence in
the UTR [22]. These different forms of splicing isoforms should not be confused with those gen‐
erated by alternative transcription start site where a single gene might transcribe from differ‐
ent promoters (Fig. 2H). In this case, and unlike alternative splicing, there is little chance that
the isoform will have different protein sequence unless a new protein-coding exon is added in
frame for translation initiation.
Figure 1. Constitutive splicing. A) Consensus splicing sequences. The 5’ss, BPS, PPT and 3’ss are represented and are
binds by U1 snRNP, SF1, U2AF65 and U2AF35, respectively. B) Splicing reaction. The first step involved the attack by
the 2’ hydroxyl of the branch point adenine on the phosphate at the 5’ss, releasing at the same time the 3’end of the
mRNA. The second step involved the attack by one of the hydroxyl of the terminal phosphate on the phosphate at the
3’ss, liberating the intron in the form of a lariat.
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so skipped as a bloc (multiple cassette exon, Fig. 2D) or mutually exclusive (Fig. 2E). AS could
also be coupled to others regulatory mechanisms such as polyadenylation [14] (Fig. 2F). In this
case, the resulting mRNA exhibits a different 3’ untranslated region (UTR), which is further
subjected to different regulation by small non-coding RNA (e.g. microRNA). In about 1 out of 3
cases, AS decision introduces a sequence containing premature stop codon [20]. In these cases,
the resulting mRNA is flagged to be degraded by the non-sense mediated decay machinery
creating an efficient mechanism that control gene expression post-transcriptionally [21] (Fig.
2G). In some cases, ASE occurs outside the coding region and influence regulatory sequence in
the UTR [22]. These different forms of splicing isoforms should not be confused with those gen‐
erated by alternative transcription start site where a single gene might transcribe from differ‐
ent promoters (Fig. 2H). In this case, and unlike alternative splicing, there is little chance that
the isoform will have different protein sequence unless a new protein-coding exon is added in
frame for translation initiation.
Figure 1. Constitutive splicing. A) Consensus splicing sequences. The 5’ss, BPS, PPT and 3’ss are represented and are
binds by U1 snRNP, SF1, U2AF65 and U2AF35, respectively. B) Splicing reaction. The first step involved the attack by
the 2’ hydroxyl of the branch point adenine on the phosphate at the 5’ss, releasing at the same time the 3’end of the
mRNA. The second step involved the attack by one of the hydroxyl of the terminal phosphate on the phosphate at the
3’ss, liberating the intron in the form of a lariat.
The Merit of Alternative Messenger RNA Splicing as a New Mine for the Next Generation Ovarian Cancer Biomarkers
http://dx.doi.org/10.5772/53976
329
Figure 2. Alternative splicing may take many different forms. A) Alt5’. B) Alt3’. C) Cassette exon. D) Multiple cassette
exons. E) Mutually exclusive exons. F) Coupled to alternative polyadenylation. G) Coupled to NMD. H) Alternative tran‐
scription initiation. Gray boxes = constitutive exons; white boxes = alternative exons; 5’ = 5’ splice site; 3’ = 3’ splice
site; A = polyadenylation site.
ASEs are normally associated with low sequence conservation near the splice site and instead
are usually linked to RNA binding motifs that may enhance or repress exon inclusion [23,24].
Motifs that enhance exon inclusion often recruit splicing factors like the SR protein family,
which in turn interact with the spliceosome via an arginine serine rich domain to increase weak
5’ss and 3’ss recognition [25] (Fig. 3A). On the other hand, splicing motifs that promotes exon
exclusion by binding members of the hnRNP family oligomerized through exon [26], block
UsnRNA recruitment [27] or loop out the alternative exon [28] (Fig. 3B to D). Similarly, se‐
quence motifs in intron may bind to SR or hnRNP proteins to influence splicing, but in this case,
the SR proteins results in exon exclusion and hnRNP in exon inclusion. This is most likely be‐
cause hnRNPs define intronic region and SR protein define exons location. Usually, these dif‐
ferent enhancers and repressor protein families work together to define the final outcome of
any ASEs (Fig. 3E) [29,30]. One of the most conserved intronic motif downstream of alternative
exons is the UGCAUG motif [31,32], which bind the tissue-specific splicing factors family
RBFOX. In general it is suggested that tissues specific splicing factors favor exon inclusion
when bound to introns downstream of alternative exons and exclusion when bound upstream.
This rule is beginning to be appreciated for several splicing factor such as Celf [33], epithelial-
specific regulatory protein [34], Nova [35] and RBFOX [36] (Fig. 3F).
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Figure 3. Schematic representation of the different mechanisms regulating alternative splicing. A) SR protein bind to
exonic splicing enhancer (ESE) and favor exon inclusion by recruting U1snRNP to 5’ss or U2 snRNP to 3’ss. B) HnRNPs
binding to exonic splicing silencer (ESS) and subsequent 3’ to 5’ oligomerization through exon favor exon exclusion by
blocking SR protein access to their exonic splicing enhancer (ESE). C) Intronic splicing enhancer (ISE) binding of hnRNP
interferes with intron definition and favor exon definition. D) HnRNP intron looping out. E) SR protein and hnRNPs
functional antagonism. F) Tissu-specific splicing factor tend to favor exon inclusion when bound to intronic splicing
silencer (ISS) in intron downstream of alternative exon and exclusion when bound upstream. Gray boxes = constitutive
exons; white boxes = alternative exons; 5’ = 5’ splice site; 3’ = 3’ splice site.
3. The advantage of alternative splicing as a source of ovarian cancer
biomarker
Analysis of the ovarian cancer proteome using mass spectrometry is undoubtedly the most di‐
rect approach for the identification of biomarkers that could be readily implemented in the
clinic. However, the difficulty generating specific antibodies for the large number of potential
markers generated via this approach makes marker validation very difficult. In contrast, the
validation of nucleic acid markers generated through microarray or deep-sequencing screen is
fairly simple and is often achieved by polymerase chain reaction (PCR) [34,37]. Furthermore,
the function of these potential markers can easily be verified through the knockdown of gene
expression using RNA interference (RNAi) strategies [38]. However, scoring global changes in
gene expression as markers for ovarian cancer limits the assay to ~25000 genes in the genome,
while it is estimate that the human cells contains at least >100 000 proteins. This limitation is no
longer an issue when we consider the expression of specific splice variants, the number of
which equal or exceeds the number of cellular proteins [39]. In addition, it is much easier to pre‐
dict the function of an alternative splice variant than predicting the function of a peptide mark‐
er. For examples, while the role of the well established markers CA-125 remain unclear after 25
years of research [40], one could easily predict the function of a marker by the protein domain
eliminated or included through AS as is the case of the tyrosine kinase SYK. In this case, exon
skipping remove a nuclear localization domain leading to the accumulation of protein in the
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skipping remove a nuclear localization domain leading to the accumulation of protein in the
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cytoplasm, elegantly explaining the lost of nuclear function associated with cancer [38]. Pre‐
dicting the impact of AS is particularly attractive for biomarkers development when the alter‐
native exon encodes a plasma transmembrane domain or an extracellular protease cleavage
site [41]. In these cases, one would be able to predict whether the cancer associated marker
leads to an increase or decrease in the secretion of membrane anchored protein, an information
that is difficult to obtain using global gene expression profiles.
4. The challenges of detecting splicing isoforms
Examples of alternatively spliced genes are steadily accumulating in the literature for more
than 20 years and the discovery rate was greatly accelerated by recent technological advances
like transcriptome sequencing techniques.  Indeed, while early estimation of alternatively
spliced genes based on Northern-Blots and endpoint RT-PCR were around 5% of the human
genome, transcriptome sequencing revealed ASEs in 95% of the human genes with multiple in‐
trons [39]. Different techniques have different capacity to illustrate the number of ASEs (see Ta‐
ble 1) and detecting splice variants remained difficult to detect for many years, which explains
the reason they are not regularly considered as a source of biomarkers by most clinicians.
Technique Throughput Advantages Limitations
Northern-Blot Low No amplification
Several isoforms can be
detected in a single sample
Labour-intense
Large amount of RNA needed
Restricted by gel resolution
Endpoint RT-PCR Low to medium Considered as the gold
standard for validation
Results easy to analyze




gels are used to separate PCR
products
Low quantitative range
Restricted by gel resolution
Real-time PCR Low to medium Provided already validated
data
Large quantitative range
Accurate data in fixed tissues
Custom primer design
often needed
Microarray medium Some array are commercially
available
Complex analysis
Results need PCR validation
Next generation Sequencing Medium to High Independent of genome
annotation
(Discovery of novel splicing
isoforms)




Results need PCR validation
Table 1. Techniques used for the detection of alternative splicing
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Back in the 1980’s, splicing isoforms were mainly detected by Northern-Blot, which separate
transcripts by size [42] and estimate relative mRNA abundance using internal controls.
However, this method is difficult to adopt in a clinical setting and require a large amount of
RNA (µg), which is difficult to obtain from clinical samples. Later, the discovery of reverse
transcription and PCR amplification greatly facilitated the detection of splice variants [43].
Splicing isoform amplification is achived by using PCR primers that are designed to hybrid‐
ize to constitutive exons flanking the ASE of interest (Fig. 4A). The products are separated in
agarose gels or capillary gel electrophoresis [44] and the ratio of the long and short isoform
quantified and presented as ψ (percent of splicing index): the molarity of the long over the
sum of the long and the short isoforms (Fig. 4A). Even if competitive PCR reaction are limit‐
ed to a narrow range [43,45], endpoint PCR is still the preferred technique to detect splicing
isoforms due to the ease of use and low cost of the experiments.
The gold standard for the mRNA quantification is real-time PCR [46], which unlike stand‐
ard endpoint PCR, detects the amount of products accumulating after each cycle of amplifi‐
cation and permits accurate comparison of different samples. This type of PCR requires the
use of fluorescent probes [47] or dyes [48] that permit detection by specialized sensors. De‐
spite the accuracy of this detection method it is rarely used for the detection of splice var‐
iants due to difficulty in achieving isoform specific amplification [43,49]. Primers required
for the amplification of the short isoform need to bind to a short unique sequence created by
the exon-exon junction, which severely restrict the design (Fig. 4B). However, systematic
evaluation of isoform specific design parameters and the availability of new algorithms for
primer selection greatly facilitated the detection of ASEs from any species [49]. Indeed, uni‐
versal PCR conditions and ease of primer design makes real-time PCR reaches the point
where it can compete with high-throughput detection methods like microarray in term of
ASE coverage [49].
Microarray as a method for genome-wide expression profiling was discovered in 1995 [50],
but the use of this method to detect splice variants was reported only in 2003 [51]. It took 8
years to develop methods that could distinguish between the hybridization patterns of two
closely related transcripts and develop chips with high enough density to accommodate the
thousands of splicing isoforms [51] (Fig. 4C) Early attempts to extract splicing pattern from
expression microarrays generated high false positive rate [52]. Therefore, strategies where
developed to probe exon-exon junction (junction array) [51]. In this case, alternative exons
are defined by very low or very high signals emanating from two consecutive splice junc‐
tions [51]. Another popular strategy is to use exonic probe in addition to exon-exon junction
probe (exon/junction array) [53]. In every case, the high similarity of exon-exon junction to
favor non-specific hybridization and in some analysis procedures the information is restrict‐
ed to splicing isoform “detection” rather than true quantification [54]. The most successful
quantification of splicing isoform by microarray was achieved by relying solely on exonic
probe [54-56]. However, the success of this method was limited by its dependence on a
small set of pre-selected splice variants [53,57]. To allow the discovery of new splicing iso‐
forms, a fourth strategy that consider all putative exons (tiling array) was developed [58].
However, the high number of probe required for this methods restricted coverage to only a
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that is difficult to obtain using global gene expression profiles.
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spliced genes based on Northern-Blots and endpoint RT-PCR were around 5% of the human
genome, transcriptome sequencing revealed ASEs in 95% of the human genes with multiple in‐
trons [39]. Different techniques have different capacity to illustrate the number of ASEs (see Ta‐
ble 1) and detecting splice variants remained difficult to detect for many years, which explains
the reason they are not regularly considered as a source of biomarkers by most clinicians.
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Back in the 1980’s, splicing isoforms were mainly detected by Northern-Blot, which separate
transcripts by size [42] and estimate relative mRNA abundance using internal controls.
However, this method is difficult to adopt in a clinical setting and require a large amount of
RNA (µg), which is difficult to obtain from clinical samples. Later, the discovery of reverse
transcription and PCR amplification greatly facilitated the detection of splice variants [43].
Splicing isoform amplification is achived by using PCR primers that are designed to hybrid‐
ize to constitutive exons flanking the ASE of interest (Fig. 4A). The products are separated in
agarose gels or capillary gel electrophoresis [44] and the ratio of the long and short isoform
quantified and presented as ψ (percent of splicing index): the molarity of the long over the
sum of the long and the short isoforms (Fig. 4A). Even if competitive PCR reaction are limit‐
ed to a narrow range [43,45], endpoint PCR is still the preferred technique to detect splicing
isoforms due to the ease of use and low cost of the experiments.
The gold standard for the mRNA quantification is real-time PCR [46], which unlike stand‐
ard endpoint PCR, detects the amount of products accumulating after each cycle of amplifi‐
cation and permits accurate comparison of different samples. This type of PCR requires the
use of fluorescent probes [47] or dyes [48] that permit detection by specialized sensors. De‐
spite the accuracy of this detection method it is rarely used for the detection of splice var‐
iants due to difficulty in achieving isoform specific amplification [43,49]. Primers required
for the amplification of the short isoform need to bind to a short unique sequence created by
the exon-exon junction, which severely restrict the design (Fig. 4B). However, systematic
evaluation of isoform specific design parameters and the availability of new algorithms for
primer selection greatly facilitated the detection of ASEs from any species [49]. Indeed, uni‐
versal PCR conditions and ease of primer design makes real-time PCR reaches the point
where it can compete with high-throughput detection methods like microarray in term of
ASE coverage [49].
Microarray as a method for genome-wide expression profiling was discovered in 1995 [50],
but the use of this method to detect splice variants was reported only in 2003 [51]. It took 8
years to develop methods that could distinguish between the hybridization patterns of two
closely related transcripts and develop chips with high enough density to accommodate the
thousands of splicing isoforms [51] (Fig. 4C) Early attempts to extract splicing pattern from
expression microarrays generated high false positive rate [52]. Therefore, strategies where
developed to probe exon-exon junction (junction array) [51]. In this case, alternative exons
are defined by very low or very high signals emanating from two consecutive splice junc‐
tions [51]. Another popular strategy is to use exonic probe in addition to exon-exon junction
probe (exon/junction array) [53]. In every case, the high similarity of exon-exon junction to
favor non-specific hybridization and in some analysis procedures the information is restrict‐
ed to splicing isoform “detection” rather than true quantification [54]. The most successful
quantification of splicing isoform by microarray was achieved by relying solely on exonic
probe [54-56]. However, the success of this method was limited by its dependence on a
small set of pre-selected splice variants [53,57]. To allow the discovery of new splicing iso‐
forms, a fourth strategy that consider all putative exons (tiling array) was developed [58].
However, the high number of probe required for this methods restricted coverage to only a
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small fraction of the genome. Not surprisingly, these difficulties hampered the application
of this method for the study of ovarian cancer splicing isforms. Indeed, to date there is no
report of microarray based profiling of ovarian cancer splice variants.
In theory, the most promising approach for the detection of ovarian cancer splicing iso‐
form is the transcriptome sequencing [39]. Next generation sequencing (NGS) technology
provide massively parallel sequencing of nucleotidic sequences in miniaturized microsys‐
tem.  Several  platforms are  commercially  available  and their  unique  technology are  dis‐
cussed  elsewhere  [59,60].  The  specific  application  of  mRNA  quantification  through
sequencing  (RNA-seq)  was  demonstrated  for  different  cancer  types  (e.g.  lung  [61]  and
prostate [62]) but not ovarian cancer thus far. Encouraging development in the refinement
of the analytical pipeline to allow accurate quantification of splicing isoforms was recently
made [37,63,64]. However, the complexity of the analytical pipeline of sequencing data and
the cost of the sequencing read necessary to detect splice variants will reduce the speed by
which this  technique is  applied to the discovery of  splicing dependent biomarkers (Fig.
4D). In addition, secondary techniques like PCR will still be needed to confirm and vali‐
date the accuracy of the data generated and confirm it in a large number of clinical sam‐
ple. Indeed, the majority of the AS information in ovarian cancer are derived from PCR-
based techniques (see Table 2 and 3).
Figure 4. Methodology for splicing isoforms detection. A) Endpoint PCR. B) Real-time PCR. C) Microarray. D) Next Gen‐
eration Sequencing. Red arrows and lines refer to short isoform specific detection. Gray boxes = constitutive exons;
white boxes = alternative exons.
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which this  technique is  applied to the discovery of  splicing dependent biomarkers (Fig.
4D). In addition, secondary techniques like PCR will still be needed to confirm and vali‐
date the accuracy of the data generated and confirm it in a large number of clinical sam‐
ple. Indeed, the majority of the AS information in ovarian cancer are derived from PCR-
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5. Example of alternative splicing based ovarian cancer biomarkers
5.1. Gene specific discovery of splicing markers
PCR-based techniques of specific genes associated with ovarian cancer revealed a number of
ovarian cancer associated splicing events. The most promising of these potential biomarkers
for diagnosis, prognosis, chemoresistance and grade biomarkers are listed in table 2 and are
further described in the text below.
BRCA1/2. The ability of DNA mutation in the hereditary gene BRCA1 and BRCA2
(BRCA1/2) to predict the risk of ovarian and breast cancer is known for decades [65,66].
However, in several instance, the clinical relevance of DNA mutation is unknown, making
the clinical management difficult to establish properly. Furthermore, the role of these muta‐
tions in varying the splicing of BRCA genes was largely ignored despite the fact that any
nucleotide changes in the splice site consensus sequences or in any AS regulatory sequence
could produce aberrant splicing isoforms. Recently, in vitro splicing assay of BRCA1/2 muta‐
tion [67], revealed that many cancer associated variants including those with unsuspected
synonymous mutations have dramatic effect on splicing. Strikingly, six of the most frequent
DNA variants representing 58,5% of BRCA1 families induced aberrant splicing profile [67].
These results, clearly demonstrate the importance of studying cancer associated splicing
since it may in many case help explain mutation that cannot be associated with changes in
protein sequence. However, the fidelity of splicing signature as a diagnostic marker as com‐
pared to DNA sequencing remains to be established.
RUNX1. Runt-related transcription factor 1 is a transcriptional regulator harboring a DNA-
binding runt homology domain (RHD). Several layers of regulation (transcription, splicing
and translation) fine-tune its tissue-specific expression [68]. RUNX1 is also known as Acute
myeloid leukemia (AML) 1 and is often found as oncogenic fusion in leukemia. Nanjundan
M and collaborators [69] report the fortuit discovery of a novel isoform that lack exon 6 as
compared to isoform AML1b during classical cloning procedure. This novel isoform, subse‐
quently named AML1bDel179-242 was found to be the dominant isoform in the majority of the
42 ovarian tumors studied. Functionally speaking, skipping of exon 6 severely abrogated the
transactivation potential of the resulting protein and inhibits its tumor suppressive func‐
tions. Interestingly, AML1bDel179-242 level was either not different from normal cell line (lung
cancer) or significantly decreased (breast cancer), suggesting that it may be an ovarian spe‐
cific marker [69]. Noneoftheless, AML1bDel179-242 expression is inversely proportional to the
survival rate of patient, suggesting is used as a prognosis marker [69]. As attractive as it
sounds, AML1bDel179-242 certainly represent an excellent potential target and marker but re‐
quired further validation in larger cohort and by independent research group.
KLF6. Kruppel-like factor (KLF) 6 is a transcription factor from the well conserved KLF gene
family implicated in differentiation, development and cell growth [70,71]. KLF6 is a suspect‐
ed tumor suppressor gene in several epithelial cancer (see [72] and reference there in). In
ovarian cancer, an increase in KLF6 isoforms was noted and correlates with the aggressivity
of the tumor in tissues (grade). One of these isoform is produced by the use of the more dis‐
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tal alt5’ ss and produce a protein version lacking the characteristic zinc finger binding do‐
main (KLF6 SV1) and act as a dominant-negative [72]. Although the technical challenges of
amplifying specific KLF6 isoforms preclude pinpointing the KLF6 SV1 as the isoform that
correlates with grade tumor, a series of in vitro and in vivo evidence making it likely [72]. It
remains to be established whether or not the full length KLF6 over KLF6 SV1 isoform ratio
could serve as a prognosis or even early marker.
TP53. The tumor suppressor gene TP53 is mutated in several solid tumors and in almost all
of the serous ovarian tumors [73]. Mutations affecting splice site of TP53 are very common
[74] and leads to a complex pattern of splicing isoforms that add up to the already complex
picture of this gatekeeper. Indeed, the point mutation IVS9-2A>G destroys the splice accept‐
or and redirect the splicing to include exon 9c. The resulting p53δ protein isoform is truncat‐
ed in the oligomerization domain and have a new stretch of 27 new residues. In a cohort of
245 ovarian samples, the expression of this isoform is significantly correlated with poor
overall survival in multivariate analyses. Moreover, patient having tumor that express p53δ
have a higher chance of early relapse after first-line chemotherapy [75]. Since isoform p53δ
doesn’t correlate with the debulking status, it suggests that expression of p53δ impair plati‐
num-based chemotherapy [75]. In respect to personalized medicine, it would be very inter‐
esting to sensitize these tumors by targeting p53δ. Thus, p53δ is not only a potential adverse
prognosis marker but could also be a promising target for a subclass of ovarian tumors.
FBLN1. Fibulin (FBLN) 1 is an extracellular matrix (ECM)-associated protein produced by
both stromal cells and epithelial cells [76]. Its presence near sites of epithelial cells locally
invading stromal boundaries suggests its implication in cell adhesion/motility (see [77] and
reference there in). Different C-terminal exons of the FBLN1 gene are alternatively spliced to
generate four isoforms. In ovarian tumors, the ratio fibulin 1C / fibulin 1D is significantly
increased compared to benign ovarian cystic sample [77]. Interestingly, the isoform ratio be‐
tween normal and benign cyst is slightly increased in cystic samples (although not signifi‐
cant). It raises the hypothesis that the ratio fibulin 1C / fibulin 1D could potentially serves as
an early diagnostic marker. Importantly, the sensitivity and specificity of fibulin splicing iso‐
forms remains to be firmly established using a panel of normal and early lesion tissues and
ultimately in patient’s serum.
SPP1. Osteopontin is a member of the small integrin-binding ligand, N-linked glycoprotein
(SIBLING) family of proteins [78]. It is an important component of the ECM that is secreted
by both cancer cells and stromal cells in the tumor microenvironment [79]. Osteopontin in‐
teracts with various integrin receptors [80,81] as well as the CD44 receptor [82] to activate
the angiogenic switch or enhance cancer cell motility [79]. The level of osteopontin is elevat‐
ed in patient’s plasma when compared to healthy controls by enzyme-linked immuno assay
(ELISA) [83]. However, the specificity (80,4%) and sensitivity (80,4%) for the detection of
early stage disease are not convincing [83]. These parameters could be increase if one takes
advantages of AS. A recent report conducted by real-time PCR indicated that the isoform
osteopontin c (excluding exon 4) is absent in normal or benign tissues but always present in
ovarian cancer samples. This is supported by our own data from microdissected normal and
cancerous ovarian cells indicating that the expression of osteopontin c comes specifically
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quently named AML1bDel179-242 was found to be the dominant isoform in the majority of the
42 ovarian tumors studied. Functionally speaking, skipping of exon 6 severely abrogated the
transactivation potential of the resulting protein and inhibits its tumor suppressive func‐
tions. Interestingly, AML1bDel179-242 level was either not different from normal cell line (lung
cancer) or significantly decreased (breast cancer), suggesting that it may be an ovarian spe‐
cific marker [69]. Noneoftheless, AML1bDel179-242 expression is inversely proportional to the
survival rate of patient, suggesting is used as a prognosis marker [69]. As attractive as it
sounds, AML1bDel179-242 certainly represent an excellent potential target and marker but re‐
quired further validation in larger cohort and by independent research group.
KLF6. Kruppel-like factor (KLF) 6 is a transcription factor from the well conserved KLF gene
family implicated in differentiation, development and cell growth [70,71]. KLF6 is a suspect‐
ed tumor suppressor gene in several epithelial cancer (see [72] and reference there in). In
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of the tumor in tissues (grade). One of these isoform is produced by the use of the more dis‐
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could serve as a prognosis or even early marker.
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of the serous ovarian tumors [73]. Mutations affecting splice site of TP53 are very common
[74] and leads to a complex pattern of splicing isoforms that add up to the already complex
picture of this gatekeeper. Indeed, the point mutation IVS9-2A>G destroys the splice accept‐
or and redirect the splicing to include exon 9c. The resulting p53δ protein isoform is truncat‐
ed in the oligomerization domain and have a new stretch of 27 new residues. In a cohort of
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doesn’t correlate with the debulking status, it suggests that expression of p53δ impair plati‐
num-based chemotherapy [75]. In respect to personalized medicine, it would be very inter‐
esting to sensitize these tumors by targeting p53δ. Thus, p53δ is not only a potential adverse
prognosis marker but could also be a promising target for a subclass of ovarian tumors.
FBLN1. Fibulin (FBLN) 1 is an extracellular matrix (ECM)-associated protein produced by
both stromal cells and epithelial cells [76]. Its presence near sites of epithelial cells locally
invading stromal boundaries suggests its implication in cell adhesion/motility (see [77] and
reference there in). Different C-terminal exons of the FBLN1 gene are alternatively spliced to
generate four isoforms. In ovarian tumors, the ratio fibulin 1C / fibulin 1D is significantly
increased compared to benign ovarian cystic sample [77]. Interestingly, the isoform ratio be‐
tween normal and benign cyst is slightly increased in cystic samples (although not signifi‐
cant). It raises the hypothesis that the ratio fibulin 1C / fibulin 1D could potentially serves as
an early diagnostic marker. Importantly, the sensitivity and specificity of fibulin splicing iso‐
forms remains to be firmly established using a panel of normal and early lesion tissues and
ultimately in patient’s serum.
SPP1. Osteopontin is a member of the small integrin-binding ligand, N-linked glycoprotein
(SIBLING) family of proteins [78]. It is an important component of the ECM that is secreted
by both cancer cells and stromal cells in the tumor microenvironment [79]. Osteopontin in‐
teracts with various integrin receptors [80,81] as well as the CD44 receptor [82] to activate
the angiogenic switch or enhance cancer cell motility [79]. The level of osteopontin is elevat‐
ed in patient’s plasma when compared to healthy controls by enzyme-linked immuno assay
(ELISA) [83]. However, the specificity (80,4%) and sensitivity (80,4%) for the detection of
early stage disease are not convincing [83]. These parameters could be increase if one takes
advantages of AS. A recent report conducted by real-time PCR indicated that the isoform
osteopontin c (excluding exon 4) is absent in normal or benign tissues but always present in
ovarian cancer samples. This is supported by our own data from microdissected normal and
cancerous ovarian cells indicating that the expression of osteopontin c comes specifically
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from ovarian epithelial cancer cells [84]. Conditioned medium overexpressing osteopontin c
stimulate proliferation of cancer cells more efficiently than either osteopontin a or b, and this
effect is revert by specific antibodies against osteopontin c [85]. Based on these data, the bio‐
marker capacity of osteopontin in patient’s blood need to be re-established using isoform-
specific methodology. As the secretion of osteopontin might be an early event [86-88], it is
tempting to speculate that osteopontin c could be an early marker.
5.2. Splicing markers generated through genome-wide expression profiling
The advent of splicing sensitive high-throughput technique opens the doors to monitor a
large number of randomly selected ASEs rather than be limited to few candidate genes (see
Table 3). The recent use of high-throughput RT-PCR by coupling PCR reaction in 384 wells
plate to capillary gel electrophoresis in 96 well Caliper station dramatically increased the
number of confirmed ovarian cancer associated splicing events. Initially, exon-exon junc‐
tions were systematically analyzed for a set of 600 cancer related genes in four different
pools of normal and cancer ovarian samples. The resulting ASEs were subsequently validat‐
ed using an independent set of 21 normal ovaries and 25 ovarian cancer samples, yielding 48
ASE markers [44]. Later on, a focus on a collection of 2168 highly curated ASEs (RefSeq
NCBI build 36) subsequently yield 288 ASEs markers using roughly the same sample set
[36]. The relatively high number of ASEs markers found coupled to the fact that several
were related to the epithelial-mesenchymal transition raised the possibility that a large frac‐
tion of the discovered events might result from difference in the cell type compared (normal
ovaries are largely composed of stromal cells where as ovarian tumors have a typical epithe‐
lial content around 75% [36]). This question was answered when 9 ovarian tumors were mi‐
crodissected to isolated the RNA from stromal (tumor microenvironment) and epithelial
cancer cells separately. A real-time PCR-based screening strategy coupled to an update ver‐
sion of RefSeq NCBI build 36 (3313 ASEs) yield a low but unambiguous set of cancer-specif‐
ic splicing isoforms, the cancer epithelial signature (CES) [84]. Surprisingly, the tumor
microenvironment appears to contain promising splicing isoforms RNA markers. Indeed,
this cancer stromal signature (CSS) might be able to diagnosis early ovarian tumors as it
clusters low malignant potential and low-grade tumors within normal ovaries and Fallopian
tube samples, although this study was performed on a low number of tissues [84].
The possibility that ovarian tumor microenvironment may be a source of splicing isoforms
markers raise interesting questions regarding the studies conducted on whole tumors. First,
some of the RNA transcripts detected may actually come from the microenvironment cells.
For exemple, fibulin and fibronectin are two ECM components known to be produced and
secreted by stromal cells. Pinpointing the cell type that produced those splicing deregulated
secreted proteins will certainly help to rationalize the complex autocrine and paracrine path‐
ways implicated in the cell to cell communication that take place into and surrounding the
ovarian tumor. Second, AS is a highly tissue-specific process, some of the splicing pattern
changes might be the reflection of the different proportion of stromal and epithelial cells of
ovarian tumors. Theoretically, those effects would be minimal when ovarian tumors of
equivalent epithelial content (typically 50-75%) are compared but maximal when normal
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ovaries (1% epithelial cells) are used as normal reference. As a consequence, prognosis
marker derived from cancer samples comparison should yield more reliable splicing mark‐
ers than diagnosis marker normalized with normal ovaries.
5.3. Alternative splicing associated protein markers
Interestingly, a number of RNA splicing isoforms markers might be amenable to detection
at the protein level using isoform-specific antibodies. Ultimately, these could serve as diag‐
nostic or prognostic tool to either directly detect the presence of cancer cells or indirectly the
protein in patient’s fluid. Indeed, the product of the genes encoding fibronectin 1, fibulin,
osteopontin, galectin 9, platelet derived growth factor A, extracellular sulfatase 2 and slit ho‐
molog 2 are all secreted in the extracellular matrix. Even some cytosolic proteins such as
utrophin and serine hydroxymethyltransferase 1 were found in patient’s serum [89]. Others
are cell surface protein (amyloid beta A4 protein, stromal interaction molecule 1, CD97, pep‐
tidyl-glycine alpha-amidating monooxygenase and chemokine-like factor) harboring an ASE
that encodes for an extracellular domain. More impressively, the exon encoding the trans‐
membrane domain of betacellulin is preferentially excluded in ovarian tumors [44], leading
to a secreted version of the protein [90]. Thus in every cases, isoform-specific antibodies
could be theoretically raised against the cancer associated isoform to ultimately serve as di‐
agnostic/prognostic tool to either detect cancer cells or detect the protein in patient’s fluid.
Inversely, the splicing isoforms of the cell surface receptor Fas and CD44 were mostly stud‐
ied at the protein level by either immunohistochemistry (IHC) or ELISA. Fas linked extracel‐
lular apoptotic signals that converge to the programmed cell death pathway through
caspase 8 and 10. Differential usage of exon 6, which encodes the single pass transmembrane
domain, results in a soluble version (sFas) and a membrane anchored version (mFas). The
level of sFas is increase in ovarian tumor of higher grade compared to low grade [91,92] and
correlates with worst prognosis for these patient [91]. Although these studies were per‐
formed in small cohort, it elegantly demonstrated that AS can produce isoforms detectable
in patient’s serum.
The glycoprotein CD44 is a cell surface receptor that binds diverse extracellular matrix li‐
gands such as hyaluronic acid, fibronectin, osteopontin, collagen and laminin [93]. The bind‐
ing of low molecular weight hyaluronan polymer promotes the motility and invasion
properties of CD44 (review in [93]). It is encoded as a 20 exons gene that exhibit extensive
AS of the extracellular domain of exons 6 to 15 (also called variable exons 1 to 10). The major
isoform present in normal epithelial [94,95] or stromal [96] ovarian cells is the shorter iso‐
form CD44s lacking all variable exons (CD44s for standard isoform). In contrast, a complex
pattern of splicing isoforms were detected in cancer tissues, including most of ovarian tu‐
mors by mean of RT-PCR [94,97,98] or by IHC using isoform specific antibodies
[95,96,99,100]. One of these splicing isoforms, the inclusion of exon v10, appears to correlate
with prognosis and is indicative of improved survival in a multivariate analysis of a 142 pa‐
tient cohort by IHC [96]. However, these findings contrast the initial study of Schroder who
found no exon v10 expression although it relies on a smaller cohort [100]. Intriguingly, in‐
clusion of exon v10 in metastatic tumors was correlated with decrease survival [96]. This ap‐
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from ovarian epithelial cancer cells [84]. Conditioned medium overexpressing osteopontin c
stimulate proliferation of cancer cells more efficiently than either osteopontin a or b, and this
effect is revert by specific antibodies against osteopontin c [85]. Based on these data, the bio‐
marker capacity of osteopontin in patient’s blood need to be re-established using isoform-
specific methodology. As the secretion of osteopontin might be an early event [86-88], it is
tempting to speculate that osteopontin c could be an early marker.
5.2. Splicing markers generated through genome-wide expression profiling
The advent of splicing sensitive high-throughput technique opens the doors to monitor a
large number of randomly selected ASEs rather than be limited to few candidate genes (see
Table 3). The recent use of high-throughput RT-PCR by coupling PCR reaction in 384 wells
plate to capillary gel electrophoresis in 96 well Caliper station dramatically increased the
number of confirmed ovarian cancer associated splicing events. Initially, exon-exon junc‐
tions were systematically analyzed for a set of 600 cancer related genes in four different
pools of normal and cancer ovarian samples. The resulting ASEs were subsequently validat‐
ed using an independent set of 21 normal ovaries and 25 ovarian cancer samples, yielding 48
ASE markers [44]. Later on, a focus on a collection of 2168 highly curated ASEs (RefSeq
NCBI build 36) subsequently yield 288 ASEs markers using roughly the same sample set
[36]. The relatively high number of ASEs markers found coupled to the fact that several
were related to the epithelial-mesenchymal transition raised the possibility that a large frac‐
tion of the discovered events might result from difference in the cell type compared (normal
ovaries are largely composed of stromal cells where as ovarian tumors have a typical epithe‐
lial content around 75% [36]). This question was answered when 9 ovarian tumors were mi‐
crodissected to isolated the RNA from stromal (tumor microenvironment) and epithelial
cancer cells separately. A real-time PCR-based screening strategy coupled to an update ver‐
sion of RefSeq NCBI build 36 (3313 ASEs) yield a low but unambiguous set of cancer-specif‐
ic splicing isoforms, the cancer epithelial signature (CES) [84]. Surprisingly, the tumor
microenvironment appears to contain promising splicing isoforms RNA markers. Indeed,
this cancer stromal signature (CSS) might be able to diagnosis early ovarian tumors as it
clusters low malignant potential and low-grade tumors within normal ovaries and Fallopian
tube samples, although this study was performed on a low number of tissues [84].
The possibility that ovarian tumor microenvironment may be a source of splicing isoforms
markers raise interesting questions regarding the studies conducted on whole tumors. First,
some of the RNA transcripts detected may actually come from the microenvironment cells.
For exemple, fibulin and fibronectin are two ECM components known to be produced and
secreted by stromal cells. Pinpointing the cell type that produced those splicing deregulated
secreted proteins will certainly help to rationalize the complex autocrine and paracrine path‐
ways implicated in the cell to cell communication that take place into and surrounding the
ovarian tumor. Second, AS is a highly tissue-specific process, some of the splicing pattern
changes might be the reflection of the different proportion of stromal and epithelial cells of
ovarian tumors. Theoretically, those effects would be minimal when ovarian tumors of
equivalent epithelial content (typically 50-75%) are compared but maximal when normal
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ovaries (1% epithelial cells) are used as normal reference. As a consequence, prognosis
marker derived from cancer samples comparison should yield more reliable splicing mark‐
ers than diagnosis marker normalized with normal ovaries.
5.3. Alternative splicing associated protein markers
Interestingly, a number of RNA splicing isoforms markers might be amenable to detection
at the protein level using isoform-specific antibodies. Ultimately, these could serve as diag‐
nostic or prognostic tool to either directly detect the presence of cancer cells or indirectly the
protein in patient’s fluid. Indeed, the product of the genes encoding fibronectin 1, fibulin,
osteopontin, galectin 9, platelet derived growth factor A, extracellular sulfatase 2 and slit ho‐
molog 2 are all secreted in the extracellular matrix. Even some cytosolic proteins such as
utrophin and serine hydroxymethyltransferase 1 were found in patient’s serum [89]. Others
are cell surface protein (amyloid beta A4 protein, stromal interaction molecule 1, CD97, pep‐
tidyl-glycine alpha-amidating monooxygenase and chemokine-like factor) harboring an ASE
that encodes for an extracellular domain. More impressively, the exon encoding the trans‐
membrane domain of betacellulin is preferentially excluded in ovarian tumors [44], leading
to a secreted version of the protein [90]. Thus in every cases, isoform-specific antibodies
could be theoretically raised against the cancer associated isoform to ultimately serve as di‐
agnostic/prognostic tool to either detect cancer cells or detect the protein in patient’s fluid.
Inversely, the splicing isoforms of the cell surface receptor Fas and CD44 were mostly stud‐
ied at the protein level by either immunohistochemistry (IHC) or ELISA. Fas linked extracel‐
lular apoptotic signals that converge to the programmed cell death pathway through
caspase 8 and 10. Differential usage of exon 6, which encodes the single pass transmembrane
domain, results in a soluble version (sFas) and a membrane anchored version (mFas). The
level of sFas is increase in ovarian tumor of higher grade compared to low grade [91,92] and
correlates with worst prognosis for these patient [91]. Although these studies were per‐
formed in small cohort, it elegantly demonstrated that AS can produce isoforms detectable
in patient’s serum.
The glycoprotein CD44 is a cell surface receptor that binds diverse extracellular matrix li‐
gands such as hyaluronic acid, fibronectin, osteopontin, collagen and laminin [93]. The bind‐
ing of low molecular weight hyaluronan polymer promotes the motility and invasion
properties of CD44 (review in [93]). It is encoded as a 20 exons gene that exhibit extensive
AS of the extracellular domain of exons 6 to 15 (also called variable exons 1 to 10). The major
isoform present in normal epithelial [94,95] or stromal [96] ovarian cells is the shorter iso‐
form CD44s lacking all variable exons (CD44s for standard isoform). In contrast, a complex
pattern of splicing isoforms were detected in cancer tissues, including most of ovarian tu‐
mors by mean of RT-PCR [94,97,98] or by IHC using isoform specific antibodies
[95,96,99,100]. One of these splicing isoforms, the inclusion of exon v10, appears to correlate
with prognosis and is indicative of improved survival in a multivariate analysis of a 142 pa‐
tient cohort by IHC [96]. However, these findings contrast the initial study of Schroder who
found no exon v10 expression although it relies on a smaller cohort [100]. Intriguingly, in‐
clusion of exon v10 in metastatic tumors was correlated with decrease survival [96]. This ap‐
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parent discrepancy could be rationalized if the exon v10 inclusion is seen as crucial to
maintain proper cell adhesion and avoid cell detachment [101]. It remains to be determined
if any of the variable exons of CD44 could serve as biomarker at the RNA level.
6. Concluding remarks
AS dramatically increase the diversity of protein expression in human cells and therefore ex‐
ponentially increase the number of potential disease markers. However, the complexity in
detecting AS and the unclear function of the majority of splice variants greatly reduced the
rate of AS based ovarian cancer biomarkers. This trend is likely to change in the next few
years with the explosion of whole transcriptome sequencing efforts and the inevitable iden‐
tification of splice variants as byproducts of next generations’ expression profiles. The real
challenge now is to develop techniques allowing the use of splicing markers in the clinic and
prepare pathologists to this new wave. Clearly, a compelling argument is needed to drive
this drastic change in clinical practice and it will most likely be driven by the success of AS
based screens in rationally predicting secreted protein that may serve as non-invasive ovari‐
an cancer markers.
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parent discrepancy could be rationalized if the exon v10 inclusion is seen as crucial to
maintain proper cell adhesion and avoid cell detachment [101]. It remains to be determined
if any of the variable exons of CD44 could serve as biomarker at the RNA level.
6. Concluding remarks
AS dramatically increase the diversity of protein expression in human cells and therefore ex‐
ponentially increase the number of potential disease markers. However, the complexity in
detecting AS and the unclear function of the majority of splice variants greatly reduced the
rate of AS based ovarian cancer biomarkers. This trend is likely to change in the next few
years with the explosion of whole transcriptome sequencing efforts and the inevitable iden‐
tification of splice variants as byproducts of next generations’ expression profiles. The real
challenge now is to develop techniques allowing the use of splicing markers in the clinic and
prepare pathologists to this new wave. Clearly, a compelling argument is needed to drive
this drastic change in clinical practice and it will most likely be driven by the success of AS
based screens in rationally predicting secreted protein that may serve as non-invasive ovari‐
an cancer markers.
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1. Introduction
The overall mortality of ovarian cancer has remained unchanged despite new chemothera‐
peutic agents that have improved 5-year survival rates. In the United States, ovarian cancer
is among the most lethal malignant gynaecological pathology. Each year, more than 230,000
new cases of ovarian cancer are diagnosed. More than 90% of these cases occur in women
without clearly identifiable risk factors. In the majority of cases, ovarian cancer is first diag‐
nosed as disseminated disease that has a five-year survival rate of less than 30%. Ovarian
cancer, thus, remains a significant health care challenge and the most lethal of women's re‐
productive tract cancers.
Although ovarian cancer is often considered to be a single disease, it is composed of several
related but distinct tumour categories, including: surface epithelial tumours, sex-cord stro‐
mal tumours, germ cell tumours, and metastatic tumours. The most frequent are the epithe‐
lial tumours that are also divided according to their histologic types: serous, mucinous,
endometrioid, clear cell, and transitional. Epithelial tumours may be classified into two fur‐
ther groups, according to their clinical behaviour: either low malignant potential (LMP) or
high malignant potential (HMP). In addition, HMP epithelial tumours are also divided into
type 1 and 2 depending upon whether or not there is a pre-malignant lesion. Considering
this new classification, specific mutations have been isolated depending on the type of tu‐
mour. Furthermore, the primary origin of serous epithelial ovarian cancer has been ques‐
tioned. Crum et al. (2007), proposed that the majority of ovarian carcinomas originate
outside the ovary and are derived from fallopian tube epithelial cells. The identification of
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cells with a molecular phenotype similar to Type 2 ovarian cancer within the fimbria is con‐
sistent with the hypothesis that ovarian cancer may indeed originate from intraepithelial
carcinomas of the fallopian tubule.
Despite significant advances in the development of mathematical modelling and validation
of in vitro diagnostics, to date none have achieved the level of diagnostic performance re‐
quired for implementation as a screening test for asymptomatic women in the general popu‐
lation. In the absence of a screening test, however, it is important for women presenting to
primary care to be diagnosed in the most effective and timely way to ensure that they are
directed to the most appropriate clinical treatment available.
Ongoing studies continue to search for the presence of other biomarkers (in addition to
CA125 and ultrasound imaging) to detect ovarian cancer in its initial stages. Of recent note
has been the identification of tumour-specific exosomes in the blood of women with ovarian
cancer. Other novel diagnosis techniques have been described: intra-fallopian tubule sam‐
pling, uterine washing sampling and the sampling of cervicovaginal swabs. While these ap‐
proaches afford some promise of increasing diagnostic performance for asymptomatic
populations, they await clinical validation.
2. Reclassification of disease type
According to the classification of the World Health Organisation in 2003, from an histopa‐
thological point of view epithelial ovarian tumour are classified in serous (60%), endome‐
trioid (10-20%), clear cell (<10%), transitional (6%), mucinous (5%), and undifferentiated
(<1%) [1,2]. Furthermore, ovarian tumours are also classified, according to behaviour, into
low malignant potential (LMP) and high malignant potential (HMP) depending on the
grade of invasion.[3] High serous malignant tumours are divided into type I and type II [4].
Type I tumours originate from the progressive transformation of low malignant potential
ovarian tumours,  whose behaviour is  considered to be relatively benign.  This  group in‐
clude:  mucinous  carcinoma;  endometrioid  carcinoma;  Brenner  tumours;  and  clear  cell
carcinoma.  Type  II  tumours,  however,  do  not  display  a  defined  pre-malignant  lesion,
and their behaviour is aggressive, and rapidly progressive, metastising in early stages of
diagnosis. Serous carcinomas, sarcocarcinomas and undifferentiated carcinomas belong in
this  group.  Preliminary studies report  that  epithelial  LMP tumours (mucinous,  endome‐
trioid,  and  clear  cell  carcinoma)  could  evolve  from  low  to  mildle  undifferentiated  tu‐
mours becoming HMP ovarian tumours [5].
The  development  of  a  new  classification  of  epithelial  ovarian  tumours  (i.e.  type  1  and
type 2) has led to the identification of specific molecular phenotypes previously unidenti‐
fied  because  of  the  confounding  effects  of  multiple  histopathological  types  of  tumours.
Type I  and type II  tumours display different  characteristics  and activation of  molecular
pathways.  Type  I  tumours  are  associated  with  mutations  in  the  Ras  pathway  (BRAF,
KRAS,  ErbB2)  while,  type  II  tumours  are  frequently  associated  with  mutations  in  the
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TP53 pathway, although there is little information relating to other molecular mutations.
[6,7].  When  stratified  by  type  (i.e.  high-grade  and  low-grade  serous  carcinoma),  it  be‐
came evident that the mutation TP53 is present in almost 100% of type II high-grade se‐
rous  carcinomas  [8].  Taking  into  account  that  TP53  mutation  is  precocious  and
ubiquitous (at least in advance stages) it remains to be proven whether or not this muta‐
tion plays an aetiological role in the development of this phenotype.
Women with mutations in BRCA 1-2 genes have around 30-70% probability of developing
ovarian cancer before reaching old age, in most cases, type II HMP tumours.[9] The BRCA
1-2 genes are crucial components in the DNA repair pathway of homologous recombinant
required to resolve errors in the double-stranded DNA [10]. It is likely that inherited muta‐
tions in BRCA 1-2 genes predispose the epithelial ovarian surface to neoplastic transforma‐
tion secondary to genetic instability 5. The loss of function in the BRCA 1-2 genes is often
lethal to the cell because of the associated apoptotic response with p53.[11] Since the loss of
BRCA gene function is very common in high-grade serous carcinomas, secondary mutations
are expected to be present to ensure the survival of the cells involved 3.
There are undoubtedly many mutations involved in the survival and adaptation of epithe‐
lial ovarian carcinomas that have yet to be studied. Currently, the processes that occur be‐
tween an initial carcinoma and its progression to widely disseminated disease remain
unknown. It is presumed that there are multiple mutations in the tumourigenesis pathways
that allow the tumour to overcome hypoxia, cytokines, the detachment from the basal mem‐
brane and the metabolic demands of many rapidly dividing cells. 7
3. Fallopian tubule involvement in ovarian cancer
Within the advances in histopathological and genetic investigations, recent dogma regard‐
ing the origin of serous ovarian cancer involving pre-cancerous lesions from the ovarian sur‐
face epithelium or intra–ovarian inclusion cysts has been questioned. In women with
BRCA-1 and BRCA-2 germline mutations, tubal intra-epithelial carcinoma in the fimbria has
been identified as a very probable precursor of advanced high-grade serous ovarian cancer
(particularly in Type 2 ovarian cancer) [12]-[14]. This is also validated by the coexistence of
identical TP53 mutations in tubal intra-epithelial carcinoma and in those tumours classified
as ovarian in origin [15].
This evidence is consistent with the idea that the fallopian tube (especially its distal portion:
the fimbria) is an important site for the initiation of high-grade serous ovarian cancer [16].
Crum et al. (2007), further, proposed that most ovarian carcinomas originate outside the
ovary and are derived from fallopian tube epithelial cells. They suggest that fimbrial epithe‐
lial cells detach and implant on the deluded, damaged surface of the ovary resulting in the
formation of inclusion cysts that subsequently give rise to what until now was known as
“ovarian” cancer. The identification of cells with a molecular phenotype similar to Type 2
ovarian cancer within the fimbria is consistent with the hypothesis that ovarian cancer may
indeed originate from intraepithelial carcinomas of the fallopian tubule [17].
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Even though the genesis of this pathology remains unclear, there are some groups that sup‐
port the idea of “endosalpingiosis” as the preliminary event. This means that even when the
primary tumour seems to originate in the ovary, it is possible that the fallopian tube epithe‐
lium provides the originating cell through earlier entrapment in the ovary [16].
These studies potentially have significant impact on clinical practice and raise important
questions, including:
• Should the complete removal of the fallopian tube during hysterectomy and/or oophorec‐
tomy be a general practice? Bowtell et al. and Dietl et al. consider this approach essential
in reducing the risk of high-grade serous cancer [16, 18].
• Is the removal of fallopian tubes a good idea when practicing a prophylactic hysterecto‐
my in women with BRCA mutations? According to Dietl and Wishhusen, a salpingecto‐
my-only for women at increased risk of ovarian cancer would be a proper prophylactic
option [18].
Future research should be oriented towards answering these and many other questions re‐
lated to the development of new surgical and medical techniques in the treatment and pre‐
vention of ovarian cancer.
4. Recent advances in the development of IVDs
Early detection and accurate diagnosis of  ovarian cancer is  a pending issue in gynaeco‐
logic  oncology.  Tools  such as  physical  examination,  transvaginal  ultrasound and serum
markers (e.g.  Ca125) have limited sensitivity. Moreover, genetic counselling is warranted
only  in  high-risk  patients,  such  as  those  with  a  family  history  of  BRCA-1,  BRCA-2  or
Lynch syndrome [19].
Considering the high mortality of this type of cancer, it is necessary to develop new and
more efficient diagnostic strategies. One recent approach to improve diagnostic efficiency
has  been  the  development  of  multivariate  index  assays  (IVDMIA).  IVDMIAs  were  de‐
fined by FDA guidelines  in 2007 as  a  tool  that:  1.  Combines multiple  variables  using a
performance function to obtain a specific  result  for  a  specific  patient;  and 2.  Provides a
result whose derivation is non-transparent and cannot be independently derived or veri‐
fied by the end user.[20] The purpose of the multivariate analysis is to integrate different
biomarkers into a single test,  to optimise the sensitivity and specificity of the diagnostic
through non-lineal functions.[21]
To date, such tests are not methods of screening, but diagnostic tools in the evaluation of
women with pelvic tumours. They help to determine the likelihood of malignancy and thus
the categorisation of urgency at the time of referral to a gynaecological oncologist. [19]
OVA1 (Vermillion, Inc., Austin, TX) is the first ovarian cancer IVDMIA approved by the
FDA, and combines five tests: CA125 II, prealbumin, apolipoprotein A-1, β2-microglobulin,
and transferrin, obtaining a score of 0-10, in which 10 is the highest risk of malignancy. The
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cut-off values to define high probability of malignancy in premenopausal women are 5.0
and 4.4 in postmenopausal women. These tests optimise sensitivity compared to physical
examination in both nongynecologic oncologists (72% to 92%) as in gynecologic oncologists
(78% to 99%), even at 100% stage II in both pre- and postmenopausal women [22]. In addi‐
tion to its association with physical examination, it has a sensitivity of 96%, while physical
examination and CA125 alone have a sensitivity of 75% and 77%, respectively [21].
Even though OVA1 has a high sensitivity, its specificity is low in both nongynecologic on‐
cologists and gynecologic oncologists (being 42% and 26% respectively). Other IVDMIAs
have shown greater specificity, for example OvaSure, a 6 IVDMIA analysing protein bio‐
marker, has a sensitivity of 95.3% and a specificity of 99.4% [23], however, OvaSure has yet
to be approved by the FDA.
In a recent study, Autelitano et al. analysed a unique multianalyte test that integrates
CA125, C-reactive protein, amyloid-A, plasma interleukin-6 and interleukin-8. This test has
a high specificity (92.3%) and a moderate sensitivity (76.4%) for the diagnosis of ovarian
cancer in symptomatic women. The panel performs significantly better than CA125 alone, as
measured by the area under the receiver operator characteristic curve (88.4% and 84.3%, re‐
spectively, p <0.001) [24].
The development of IVDMIAs for ovarian cancer based on known candidate biomarkers of‐
fers promise for improving diagnostic efficiency of not only adrenal masses but also the ear‐
lier detection of ovarian cancer and prognosis.
Optimising preoperative diagnosis and opportune referral to specialists, would not only as‐
sist in the development of a specific management strategy for individual patients, but would
also allow for more accurate determination of perioperative morbidity and chance of surviv‐
al. Further studies, however, are needed to validate not only a comparison with classical
clinical or serological parameters, but also between different IVDMIAs, to determine which
one is the better diagnostic tool.
5. Novel approaches to the diagnosis of ovarian cancer
Ovarian cancer is generally diagnosed in its advanced stages due to the lack of overt symp‐
toms of disease (70% of the cases approximately), resulting in a poor prognosis (rate surviv‐
al around 30%) [25]. Only a small number of ovarian cancers are detected early and these
are the ones that can generally be treated.
The reason ovarian cancer is difficult to diagnose in its initial stage is due to the lack of spe‐
cific and appropriately sensitive serum biomarkers associated with the unspecific symp‐
toms. The most utilised serum biomarker in the diagnosis of ovarian cancer is CA125, but
unfortunately its ability to detect ovarian cancer in a general population is quite low [26, 27].
As a response to this difficult scenario, current investigations include the search for other
serum biomarkers that would improve our ability to detect ovarian cancer in its initial
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stages, possibly in combination with CA125 and ultrasound imaging. The recent identifica‐
tion of tumour-specific nanoparticle (exosomes) in the blood of patients with various diseas‐
es/complications, including ovarian cancer, affords an alternative approach to the
identification of more effective biomarkers.
Exosomes are small (40-100 nm) membrane vesicles that are released following the exocytot‐
ic fusion of multi-vesicular bodies with the cell membrane. They are characterised by: a cup-
shaped form; a buoyant density of 1,13-1,19 g ⁄ ml [28,29] endosomal origin; and the
enrichment of late endosomal membrane markers, including Tsg101, CD63, CD9 and CD81
[30-32]. Exosomes have been identified in plasma under both normal and pathological con‐
ditions, and their concentration has been reported to increase in association with disease se‐
verity and/or progression. While, the process(es) of exosome formation remains to be fully
elucidated, available data support an endosomal origin and formation by the inward bud‐
ding of multi-vesicular bodies [33].
Tumor cells release exosomes into peripheral circulation [34], indeed the first vesicular
structures described in plasma were observed in women with ovarian cancer [35]. In ovarian
cancer, the concentration of exosomes (measured as exosomal protein in peripheral blood)
increases with disease stage and are associated with tumour-specific microRNA [36]. These
results suggest that microRNA profiling of circulating tumor exosomes could potentially be
used as surrogate diagnostic markers and may be of utility for screening asymptomatic pop‐
ulations. Recent data further suggests that the release of exosomes from cells may represent
a normal mechanism for cell-to-cell communication [37] their role in the pathogenesis of
ovarian cancer, however, remain to be established.
Other novel diagnosis techniques have been described: intra-fallopian tubule sampling, the
sampling of uterine washings and the sampling of cervicovaginal swabs. While these ap‐
proaches represent a very promising alternatives for the diagnosis of ovarian cancer, there is
a paucity of data and clinical validation to support their implementation as viable alterna‐
tives to CA125 and ultrasound imaging.
6. Concluding comments
The alignment of metastatic and molecular phenotypes of ovarian cancer is affording new
insights into the aetiology and treatment of this disease cluster.
Recent evidence supports a tubal origin of epithelial ovarian cancer, including the coexi‐
stance of  similar  gene mutations in  the tubal  intraepithelial  carcinoma and those classi‐
fied as  ovarian origin (e.g.  TP53 gene mutation).  On the basis  of  these data,  some have
proposed "endosalpingiosis" as the initial event in ovarian cancer, suggesting that the ep‐
ithelial  cells  of  the  tube migrate  to  the  surface  of  the  ovary constituting ovarian cancer
genesis. If proven to be correct, new opportunities for the management of ovarian cancer
may be  realised,  particularly  for  those  patients  carrying  BRCA-1  and -2  mutations  that
require prophylactic surgery.
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Within the field of gynaecologic oncology, an aspect that has been particularly disappoint‐
ing is the development of early detection tests for ovarian cancer. Classical methods based
on physical examination, images and some serum markers such as CA125, have not resulted
in significant advances in early detection rates. Tests, such as OvaSure and OVA 1, have in‐
tegrated various clinical and serum markers for the diagnosis of cancer with different sensi‐
tivities and specificities, but are aimed at defining malignancy in patients with ovarian
tumours, rather than providing either an earlier diagnosis or a screening test.
A possible answer to the problem is seen with the recognition of specific membrane particles
in ovarian tumors (exosomes), as well as other tissue surfaces. These particles are tissue-spe‐
cific and may allow the identification of specific cell types in preclinical stages of the disease.
The potential detection of these specific exosomes in biofluids also offers new perspectives
in research on the early detection of ovarian cancer. Such ovarian cancer–specific non-parti‐
cles may be present in fallopian tubule fluid, uterine washings or even cervicovaginal fluids.
Further research is needed in this area to assess the utility of such approaches in order to
develop simple and safe methods of detecting ovarian cancer in its early stage.
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1. Introduction
Ovarian  cancer  is  currently  the  fifth  most  lethal  malignancy  of  women  in  Europe  and
the United States  [1,  2].  The prognosis  of  ovarian cancer patients  is  limited due to lack
of specific early symptoms and a high rate of relapse; more than half of all patients will
suffer from disease recurrence, resulting in a poor overall survival [3]. Most cases are di‐
agnosed in advanced stages, and although the initial response to chemotherapy is gener‐
ally good, a significant proportion of patients will  suffer from a relapse despite optimal
cytoreductive surgery [4].  Since treatment strategies are mainly developed to control  lo‐
coregional  cancer  growth,  it  may  be  anticipated  that  more  women  will  die  of  distant
metastatic  disease.  The  identification  of  novel  molecular  markers,  reflecting  current  tu‐
mor activity,  may improve prediction and therapy monitoring and provide valuable in‐
sights into process of carcinogenesis. In this regard, oncologic research have increasingly
focused on disseminated and circulating tumor cells.
The presence of disseminated tumor cell (DTC) in bone marrow (BM) is a phenomenon ob‐
served in almost all solid tumors of epithelial origin. For breast cancer, DTC presence has
been demonstrated as a strong independent prognostic factor (level I evidence) [5]. Availa‐
ble data support the notion that hematogenous tumor cell dissemination may be clinically
relevant in ovarian cancer as well [6-10]. Detection rates of DTC, as a surrogate parameter
for occult hematogenous spread, vary between 30-50% primary ovarian cancer patients.
A provocative hypothesis has been introduced recently with respect to natural history and
progression of ovarian cancer. While the ‘classical’ stochastic model of cancer development
holds that any cell may become source of malignant transformation, emerging evidence sup‐
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ports the view that only a minor subpopulation of cancer cells has the potential to initiate
cancer growth. These cells, called cancer stem cells (CSC), have the ability to self-renew,
propagate tumorigenesis and are usually drug-resistant [11]. Experimental studies on stem
cell biology have given new impetus to the cancer stem cell theory. CSC are assumed to play
important role in development of various tumor entities, such as breast and gastrointestinal
cancer, retinoblastoma and ovarian cancer [12], [13]. Interestingly, ovarian cancer cell lines
feature “side population” cells with potential to differentiate into cancers with different his‐
tologies, suggesting the pluripotent character of stem cells [14]. Whether DTC in extraperito‐
neal sites, such as bone marrow, reflect a stem cell-like sub population of tumor cells,
remains yet to be cleared.
Of all prognostic factors, monitoring of minimal residual disease is the only one available
after the tumor has been removed. Beside monitoring of tumor markers, there is currently a
major effort to identify other biological markers which can be assessed with minimally inva‐
sive methods and persist beyond surgery. We previously reported on a significant correla‐
tion of positive BM status with shortened relapse-free survival in ovarian cancer patients [6].
DTC persistence after completion of platinum-based chemotherapy was also found to be
prognostically relevant [15]. Recently, attempts have been made to target DTC by using anti‐
body-based therapy with the trifunctional antibody catumaxomab. Wimberger et al. report‐
ed a marked decrease in tumor cells in peripheral blood following intraperitoneal
catumaxomab treatment for malignant ascites, indicating a systemic effect of the therapy
[16]. However, in comparison with breast cancer, data on DTC detection in gynecological
malignancies are so far limited [7], [17], [18], [19], [9].
In this chapter we discuss recent advances in ovarian cancer research with respect to disse‐
minated tumor cells and cancer stem cell hypothesis. Data on prognostic and clinical rele‐
vance are presented.
2. Disseminated and circulating tumor cells in ovarian cancer
Detection and characterization of disseminated tumor cells in bone marrow and blood of pa‐
tients with epithelial carcinomas can be accomplished by various techniques. For the detec‐
tion of isolated tumor cells, both antibody-based assays and molecular assays have been
established [20, 21]. Despite advances in this field, no specific antigen or marker gene has
been described for ovarian cancer so far. Therefore, immunocytochemical identification of
these cells based on expression of epithelial markers remains the gold standard (Figure 1).
Commonly targeted antigens are cytokeratin and EpCAM due to relatively constant and
universal expression pattern in cells of epithelial origin [9, 15, 22]. A major difficulty in de‐
tecting and characterizing tumor cells is their relatively low frequency. Most protocols in‐
clude therefore a cell enrichment step (e.g. density gradient centrifugation,
immunomagnetic enrichment). These obstacles highlight the need for optimization of the as‐
say (e.g. by minimizing cell loss, preserving cell morphology and producing reliable immu‐
nophenotypic and genotypic data) as it is essential for detecting, enumerating and
characterizing single tumor cells [21].
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Figure 1. Disseminated tumor cell from ovarian cancer patient with typical cytomorphology and immunophenotype
(positive cytokeratin-staining, large nucleus, high nuclear to cytoplasmic ratio, nucleus partially covered by CK-stain‐
ing, nucleus granular [23].
Detection rates of disseminated tumor cells in ovarian cancer patients stage FIGO I-III reach
20-60% [7, 9, 15, 22]. These results suggest hematogenous spread to be a comparatively fre‐
quent phenomenon in ovarian malignancies and indicate the ability of single tumor cells to
disseminate to bone marrow in a very early stage of disease. DTC are routinely detected in
13-18% FIGO I ovarian cancer patients [6, 19, 22]. Since bone metastases are relatively rare in
ovarian cancer patients, BM seems to serve as a temporary `homing site´ for single tumor
cells, from where they are able to migrate and subsequently cause distant metastasis or local
recurrence [24]. Assuming that DTC may spread by means of blood stream we cannot ex‐
clude that those may also be able to repopulate the peritoneal cavity, an environment which
easily supports ovarian cancer growth [11, 25].
Based on numerous studies,  no significant relationship has been reported between clini‐
copathological  characteristics  of  primary  tumor  and  DTC  detection.  In  our  latest  trial
with  414  ovarian cancer  patients,  DTC status  did not  correlate  with  FIGO stage,  tumor
size, lymph node status, histopathologic grading or resection status [26, 27]. Braun et al.,
in  a  cohort  of  108  primary  ovarian  cancer  patients,  showed  no  concordance  between
classical  prognostic  factors  and DTC positivity.  The only factor  associated with positive
DTC status  was tumor grading (p  =  0.02)  [7].  These  results  could be  also  confirmed in
our earlier study with 112 ovarian cancer patients [6]. Similar findings were obtained by
other investigators [8, 9, 15, 19].
Disseminated Tumor Cells and Cancer Stem Cells in Ovarian Cancer
http://dx.doi.org/10.5772/54391
361
ports the view that only a minor subpopulation of cancer cells has the potential to initiate
cancer growth. These cells, called cancer stem cells (CSC), have the ability to self-renew,
propagate tumorigenesis and are usually drug-resistant [11]. Experimental studies on stem
cell biology have given new impetus to the cancer stem cell theory. CSC are assumed to play
important role in development of various tumor entities, such as breast and gastrointestinal
cancer, retinoblastoma and ovarian cancer [12], [13]. Interestingly, ovarian cancer cell lines
feature “side population” cells with potential to differentiate into cancers with different his‐
tologies, suggesting the pluripotent character of stem cells [14]. Whether DTC in extraperito‐
neal sites, such as bone marrow, reflect a stem cell-like sub population of tumor cells,
remains yet to be cleared.
Of all prognostic factors, monitoring of minimal residual disease is the only one available
after the tumor has been removed. Beside monitoring of tumor markers, there is currently a
major effort to identify other biological markers which can be assessed with minimally inva‐
sive methods and persist beyond surgery. We previously reported on a significant correla‐
tion of positive BM status with shortened relapse-free survival in ovarian cancer patients [6].
DTC persistence after completion of platinum-based chemotherapy was also found to be
prognostically relevant [15]. Recently, attempts have been made to target DTC by using anti‐
body-based therapy with the trifunctional antibody catumaxomab. Wimberger et al. report‐
ed a marked decrease in tumor cells in peripheral blood following intraperitoneal
catumaxomab treatment for malignant ascites, indicating a systemic effect of the therapy
[16]. However, in comparison with breast cancer, data on DTC detection in gynecological
malignancies are so far limited [7], [17], [18], [19], [9].
In this chapter we discuss recent advances in ovarian cancer research with respect to disse‐
minated tumor cells and cancer stem cell hypothesis. Data on prognostic and clinical rele‐
vance are presented.
2. Disseminated and circulating tumor cells in ovarian cancer
Detection and characterization of disseminated tumor cells in bone marrow and blood of pa‐
tients with epithelial carcinomas can be accomplished by various techniques. For the detec‐
tion of isolated tumor cells, both antibody-based assays and molecular assays have been
established [20, 21]. Despite advances in this field, no specific antigen or marker gene has
been described for ovarian cancer so far. Therefore, immunocytochemical identification of
these cells based on expression of epithelial markers remains the gold standard (Figure 1).
Commonly targeted antigens are cytokeratin and EpCAM due to relatively constant and
universal expression pattern in cells of epithelial origin [9, 15, 22]. A major difficulty in de‐
tecting and characterizing tumor cells is their relatively low frequency. Most protocols in‐
clude therefore a cell enrichment step (e.g. density gradient centrifugation,
immunomagnetic enrichment). These obstacles highlight the need for optimization of the as‐
say (e.g. by minimizing cell loss, preserving cell morphology and producing reliable immu‐
nophenotypic and genotypic data) as it is essential for detecting, enumerating and
characterizing single tumor cells [21].
Ovarian Cancer - A Clinical and Translational Update360
Figure 1. Disseminated tumor cell from ovarian cancer patient with typical cytomorphology and immunophenotype
(positive cytokeratin-staining, large nucleus, high nuclear to cytoplasmic ratio, nucleus partially covered by CK-stain‐
ing, nucleus granular [23].
Detection rates of disseminated tumor cells in ovarian cancer patients stage FIGO I-III reach
20-60% [7, 9, 15, 22]. These results suggest hematogenous spread to be a comparatively fre‐
quent phenomenon in ovarian malignancies and indicate the ability of single tumor cells to
disseminate to bone marrow in a very early stage of disease. DTC are routinely detected in
13-18% FIGO I ovarian cancer patients [6, 19, 22]. Since bone metastases are relatively rare in
ovarian cancer patients, BM seems to serve as a temporary `homing site´ for single tumor
cells, from where they are able to migrate and subsequently cause distant metastasis or local
recurrence [24]. Assuming that DTC may spread by means of blood stream we cannot ex‐
clude that those may also be able to repopulate the peritoneal cavity, an environment which
easily supports ovarian cancer growth [11, 25].
Based on numerous studies,  no significant relationship has been reported between clini‐
copathological  characteristics  of  primary  tumor  and  DTC  detection.  In  our  latest  trial
with  414  ovarian cancer  patients,  DTC status  did not  correlate  with  FIGO stage,  tumor
size, lymph node status, histopathologic grading or resection status [26, 27]. Braun et al.,
in  a  cohort  of  108  primary  ovarian  cancer  patients,  showed  no  concordance  between
classical  prognostic  factors  and DTC positivity.  The only factor  associated with positive
DTC status  was tumor grading (p  =  0.02)  [7].  These  results  could be  also  confirmed in
our earlier study with 112 ovarian cancer patients [6]. Similar findings were obtained by
other investigators [8, 9, 15, 19].
Disseminated Tumor Cells and Cancer Stem Cells in Ovarian Cancer
http://dx.doi.org/10.5772/54391
361
2.1. Prognostic relevance of DTC/CTC in ovarian cancer
Detection  of  disseminated  tumor  cells  in  patients  with  primary  ovarian  cancer  was
shown  to  be  of  prognostic  value  (Table  1).  However,  the  currently  available  data  are
sparse.  In  our latest  trial  bone marrow status of  414 ovarian cancer  patients  was corre‐
lated  with  clinical  follow-up  [26].  The  presence  of  DTC  predicted  a  shorter  OS  (p  <
0.001)  and  DFS  (p  =  0.035)  compared  with  BM  negative  patients  [27];  this  association
was highly significant and confirmed in a multivariable Cox regression analysis.  Similar
results  were  found  in  several  smaller  studies.  Braun  et  al.  demonstrated  unfavorable
prognosis  with  regard  to  distant  DFS  in  BM  positive  patients  at  the  time  of  diagnosis
[7].  DTC presence  remained a  strong prognostic  factor  also  in  a  subset  of  64  optimally
debulked  patients  (p  =  0.002),  which  highlights  the  role  of  DTC detection  especially  in
patients who received successful surgical cytoreduction. We previously reported a signif‐
icant correlation of  positive BM status with reduced DFS in a group of  112 stage FIGO
I-III  ovarian  cancer  patients  [6].  Interestingly,  in  some  studies,  the  presence  of  isolated
tumor cells  in  secondary sites,  such as  BM and blood,  was  also  associated with  higher
risk for recurrence [10],  [6].  Therefore,  it  might be speculated that  hematogenous tumor
cell  dissemination may serve as an indicator of a more aggressive phenotype of the pri‐
mary disease that  is  likely to cause local  relapse.  In contrast,  other authors reported no
significant correlation between DTC detection and clinical outcome in ovarian cancer [19,
28].  This  discrepancy might  be  due to  differences  in  study protocols,  e.g.  time point  of
BM sample  collection  (pre-  vs.  postoperative  aspiration).  Hypothetically,  a  transient  in‐
crease in cancer cell dissemination from the primary tumor due to intraoperative manip‐
ulation could contribute to false-positive results and therefore affect further analysis [29].
2.2. Circulating tumor cells
Bone marrow biopsy represents an invasive procedure not well tolerated by many patients.
Therefore, detection of circulating tumor cells (CTC) by simple blood drawing has increas‐
ingly become a focus of translational research. Prognostic significance of CTC in peripheral
blood has been evaluated in breast cancer both in primary and metastatic disease [33, 34].
Two commercially available kits are currently in use for CTC detection in blood of breast
cancer patients: antibody-based CellSearch and RT-PCR-based AdnaTest. Both assays were
modified and validated in ovarian cancer patients (Table 1). Recently published trial by Po‐
veda et al. based on a cohort of 216 patients with recurrent ovarian cancer, represents the
largest study so far on the impact of CTC presence on survival [10]. Using CellSearch test
increased CTC numbers (> 1 cell / 7.5 ml blood) were found in 14% of these patients before
the beginning of treatment. Detection of CTC in peripheral blood was associated with signif‐
icantly impaired prognosis. In the study by Aktas et al., including 86 ovarian cancer pa‐
tients, a modified AdnaTest kit was used to detect cells expressing EpCAM, MUC-1, HER-2
or CA 125-transcripts [8]. CTC positivity rate of 19% observed in this cohort was associated
with significantly shorter survival independent of the time of blood sampling (before sur‐
gery or after chemotherapy). Similar results were obtained by Fan et al. in a trial of 66 pri‐
mary ovarian cancer patients [32]. In contrast, Marth et al. reported a 12% positivity rate
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irrespective of tumor stage but observed no correlation with clinical outcome [19]. Interest‐
ingly, positive finding in the blood was highly associated with DTC detection in bone mar‐








Fehm [26] 414 DTC (ICC) 34 27% OS, DFS 1
Banys [6] 112 DTC (ICC) 12 25% DFS
Braun [7] 108 DTC (ICC) 45 30% DFS
Aktas [8] 95 DTC (ICC) 28 35% n.s.
Schindlbeck [9] 90 DTC (ICC) 28 23% DDFS
Marth [19] 73 DTC (immunobeads) 25 21% n.s.
Wimberger [30] 62 DTC (ICC) 18 54% DFS 2
Poveda [10] 216 CTC (ICC: CellSearch) 3 14% 4 PFS, OS
Sehouli [17] 167 CTC (ICC) 46 n.s.
Marth [19] 90 CTC (immunomagnetic beads) 25 12% n.s.
Aktas [8] 86 CTC (Multiplex-RT-PCR: AdnaTest) 28 19% OS 5







protease and caspase activity
18 - DFS, OS
Abbreviations: DFS – disease-free survival, DDFS – distant disease-free survival, DTC – disseminated tumor cells in bone
marrow, ICC – immunocytochemistry, n.s. – not significant, PFS – progression-free survival
1 Determined by multivariate Cox regression analysis
2 DTC detected after chemotherapy
3 Relapsed ovarian cancer
4 Two or more CTC
5 Both before and after chemotherapy
Table 1. Prognostic relevance of disseminated and circulating tumor cells in ovarian cancer.
2.3. Therapy monitoring
Beyond the prognostic value of DTC/CTC detection, monitoring of minimal residual disease
(MRD) during and after treatment offers the opportunity to assess response to therapy and
evaluate the residual risk of recurrence. Changes in MRD represent the only clinical parame‐
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ter available after surgical removal of the primary tumor. While tumor markers are estab‐
lished tools for the evaluation of treatment efficacy in patients with advanced ovarian
cancer, CA 125 levels fall during adjuvant chemotherapy and remain often below cut-off
values after completion of first line systemic treatment even though significant number of
patients will suffer from relapse within five years. Furthermore, the clinical relevance of se‐
rial CA125 measurements for early detection and treatment of disease recurrence is current‐
ly being controversially discussed [37]. In this regard, the detection of isolated tumor cells in
bone marrow or peripheral blood might serve as a parameter for occult tumor load after
completion of first line therapy. DTC persistence despite adjuvant treatment is so far an in‐
dependent prognostic factor in patients with primary breast cancer [38]. Whether persistent
DTC influence prognosis in ovarian cancer patients, is currently being investigated. In the
study by Wimberger et al. DTC counts before and after the first line systemic treatment were
correlated to clinical course of disease in 30 ovarian cancer patients; 54% of these patients
presented with DTC after first-line chemotherapy. Marked increase in DTC counts was asso‐
ciated with shortened progression free survival [15].
Evaluation of treatment efficacy in ovarian cancer patients after optimal surgical cytoreduc‐
tion and completion of first line systemic therapy is based on clinical, radiological and bio‐
logical (tumor marker CA125) criteria. However, a reliable tool to assess long-term
prognosis has so far not been established. Therefore, a solid therapy monitoring tool could
help to identify a group of high-risk patients who potentially benefit from additional treat‐
ment. New studies are required to evaluate whether persistent DTC indeed predict a worse
prognosis and if these cells may be targeted by secondary adjuvant therapy.
3. Cancer stem cell model
An important hypothesis on tumor initiation and progression has attracted much attention
in the ovarian cancer research in the past decade. In contrast to stochastic model that postu‐
lates every cell as a potential source of malignant transformation, the cancer stem cell model,
a theory introduced over a century ago, proposes that tumors are organized in a cellular hi‐
erarchy, in which cancer stem cell (CSC) are the only cells with tumorigenic potential. Ac‐
cordingly, tumors are initiated in cancer stem cells or their immediate progeny through
imbalance of self-renewal and apoptosis; these tumors contain a cellular subpopulation that
retains key stem cell feature [39]. This small cell group with unlimited proliferative potential
is assumed to play a marked role in initiation and development of several tumor entities like
retinoblastoma, gastrointestinal cancer as well as breast and ovarian cancer [12]. The cancer
stem cell concept has important implications for understanding the process of carcinogene‐
sis as well as for designing new treatment strategies. Due to their long life, CSC are more
likely to acquire transforming mutations; further, they seem more resistant to apoptosis and
DNA damage and are therefore able to persist beyond therapy. New evidence in support of
the cancer stem cell model has arisen due to advances in stem cell biology and the introduc‐
tion of novel animal models to assess self-renewal and challenge the validity of this concept.
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The cancer stem cell hypothesis holds that CSC are responsible for phenomena like drug re‐
sistance, tumor dormancy or minimal residual disease and may persist beyond chemothera‐
py and repopulate the tumor leading to relapse [11]. The stem cell subpopulation, but not
the remaining differentiated cancer cells in the tumor, can sustain tumor formation and
growth due to their high tumor-initiating potential. So far, such cells have been found in
several solid tumors, such as colon [40], breast [41] and ovarian cancer [13, 42, 43]. Indeed, in
accordance with recent studies, ovarian cancer cell lines feature ´side population´ cells (SP)
with potential to differentiate into other morphological entities. Thus, this pluripotent sub‐
clone with stem cell-like features is considered a marker of CSC presence [14]. The detection
of CSC is based on the presence of extracellular markers assumed to be stem cell-specific;
commonly identified markers are CD44, CD133, and CD24, which are found in prostate,
breast, pancreas, and ovarian cancer. It remains under discussion whether these parameters
are universal markers relevant for CSC derived from all tumor types; for ovarian cancer,
multiple markers have been described for the stem cell-like tumor initiating cells.
Owing to aggressive natural course of disease and emergence of multidrug resistance, an es‐
sential role of cancer stem cells has been postulated in ovarian cancer [13, 44]. In the study
by Szotek et al. SP cells have been encountered in ovarian cancer cell lines as well as in pri‐
mary ascites cancer cells [13]. In the trial by Hosonuma et al. in 18 of 28 ovarian cancer pa‐
tients samples side population cells could be detected. SP cells occurred more often in
relapsed and metastatic patients and SP positivity predicted significantly reduced overall
survival [15]. A high proportion of CD44+ stem cells in ovarian cancer was reported to be an
independent predictor of poor progression-free survival [45].
As previously mentioned, CSC are considered responsible for high emergence of drug re‐
sistance in the natural history of ovarian cancer, since standard therapies fail to target pluri‐
potent tumor-initiating cells [13]. Latifi et al. could show in their recently published trial, the
ability of cisplatin chemotherapy to generate residual tumor cells with mesenchymal stem
cell-like characteristics in vitro [46]. Accordingly, new therapeutic strategies have to be de‐
veloped to target these cells by identifying their specific antigens. However, very few tumor
characteristics have been described to target the subset of CSC.
Based on an animal model, Bapat et al. reported the isolation and identification of ovarian
cancer stem cells [42]. In an in vitro model comprised of 19 spontaneously immortalized
clones derived from an advanced-stage patient, the authors demonstrated the ability of two
clones with stem cell-like characteristics to differentiate to grow as spheroids and form xen‐
ografts in an animal model (nude mice). These cells were shown to express CD44, E-cadher‐
in, and the stem cell factors Nestin, Nanong, and Oct-4.
3.1. DTC and cancer stem cell model
A currently discussed theory postulate DTC and CTC, the presumed precursor cells of sys‐
temic metastatic disease, to be in fact cancer stem cells. These observations have been so far
reported in breast cancer studies. Balic et al. analyzed bone marrow specimens from 50 pri‐
mary breast cancer patients; 33-100% of DTC of every patient exhibited stem cell-like pheno‐
type: CD44+ / CD24 low/- [47]. This prevalence is estimated for less than 10% in primary
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tumor suggesting much higher, stem cell like self-renewal and tumorigenic potential in
DTC. Aktas et al. detected stem cells markers on CTC in peripheral blood of metastatic
breast cancer patients [41]. Moreover, Abraham et al. reported that high proportion of stem
cell-like subpopulation in primary breast cancer correlate with a higher prevalence of dis‐
tant metastases [48]. As breast cancer stem cells have been shown to be generally triple-neg‐
ative, basal-like CTC, independent of the phenotype of the primary tumor, support the
cancer stem cell theory [20, 49, 50]. However, this aspect has not been researched in ovarian
cancer so far. Therefore, futher studies have to be performed to evaluate whether isolated
tumor cells in extraperitoneal sites, such as blood and bone marrow, may reflect ovarian
cancer stem cell population.
4. Conclusions
Despite advances in surgical and systemic therapy, ovarian cancer leads to relapse in 60% of
patients within 5 years, resulting in impaired clinical outcome. In the last decades, novel bio‐
markers have been introduced for better prediction and prognostication [51]. Early hema‐
togenous dissemination of single tumor cells is a general phenomenon observed in most
solid tumors of epithelial origin; recent data supports the clinical relevance of disseminated
and circulating tumor cells (DTC/CTC) in ovarian cancer. A currently discussed hypothesis
postulates isolated tumor cells in secondary sites to be not only the presumed precursors of
systemic metastatic disease but in fact pluripotent ‘cancer stem cells’. Future research will
clarify the implications of these findings for clinical management of ovarian cancer patients.
While the published data do not support the use of DTC/CTC detection for early detection
or screening purposes, its role as an important prognostic factor has been confirmed in sev‐
eral studies. One of the most promising applications of DTC detection is their use as a thera‐
py monitoring tool. DTC persistence beyond surgery and adjuvant chemotherapy may help
to identify patients at risk of developing a relapse.
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